---
document_datetime: 2023-09-21 21:52:07
document_pages: 137
document_pathfilename: www.ema.europa.eu/en/documents/variation-report/imfinzi-h-c-4771-ii-0045-epar-assessment-report-variation_en.pdf
document_name: imfinzi-h-c-4771-ii-0045-epar-assessment-report-variation_en.pdf
version: success
processing_time: 219.0576464
conversion_datetime: 2025-12-27 13:34:10.885737
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
<!-- image -->

15 December 2022 EMA/42902/2023 Committee for Medicinal Products for Human Use (CHMP)

## Assessment report

## Imfinzi

International non-proprietary name: durvalumab

Procedure No. EMEA/H/C/004771/II/0045

## Note

Variation assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted.

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Table of contents

| 1. Background information on the procedure                                                                              | .............................................6                                                           |
|-------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------|
| 1.1. Type II variation ................................................................................................ | 6                                                                                                        |
| 1.2. Steps taken for the assessment of the product                                                                      | ....................................................... 7                                                |
| 2. Scientific discussion                                                                                                | ................................................................................8                        |
| 2.1. Introduction                                                                                                       | ...................................................................................................... 8 |
| 2.1.1. Problem statement                                                                                                | .......................................................................................... 8             |
| 2.1.2. About the product .........................................................................................      | 10                                                                                                       |
| 2.1.3. The development programme/compliance with CHMP guidance/scientific advice                                        | ..... 11                                                                                                 |
| 2.1.4. General comments on compliance with GCP                                                                          | ...................................................... 11                                                |
| 2.2. Non-clinical aspects..........................................................................................     | 11                                                                                                       |
| 2.2.1. Ecotoxicity/environmental risk assessment........................................................                | 12                                                                                                       |
| 2.2.2. Discussion and conclusion on non-clinical aspects                                                                | .............................................. 12                                                        |
| 2.3. Clinical aspects                                                                                                   | ................................................................................................ 12      |
| 2.3.1. Introduction .................................................................................................   | 12                                                                                                       |
| 2.3.2. Pharmacokinetics                                                                                                 | .......................................................................................... 20            |
| 2.3.3. Pharmacodynamics........................................................................................         | 29                                                                                                       |
| 2.3.4. Discussion on clinical pharmacology .................................................................            | 39                                                                                                       |
| 2.3.5. Conclusions on clinical pharmacology ...............................................................             | 40                                                                                                       |
| 2.4. Clinical efficacy ................................................................................................ | 40                                                                                                       |
| 2.4.1. Main study                                                                                                       | ................................................................................................... 41   |
| 2.4.2. Discussion on clinical efficacy ..........................................................................       | 92                                                                                                       |
| 2.4.3. Conclusions on the clinical efficacy...................................................................          | 96                                                                                                       |
| 2.5. Clinical safety                                                                                                    | .................................................................................................. 96    |
| 2.5.1. Discussion on clinical safety                                                                                    | ...........................................................................127                           |
| 2.5.2. Conclusions on clinical safety                                                                                   | .........................................................................130                             |
| 2.5.3. PSUR cycle                                                                                                       | ..................................................................................................130    |
| 2.6. Risk management plan.....................................................................................130       |                                                                                                          |
| 2.7. Update of the Product information                                                                                  | .....................................................................130                                 |
| 2.7.1. User consultation..........................................................................................130   |                                                                                                          |
| 2.7.2. Additional monitoring....................................................................................131     |                                                                                                          |
| 3. Benefit-Risk Balance............................................................................131                  |                                                                                                          |
| 3.1. Therapeutic Context                                                                                                | ........................................................................................131              |
| 3.1.1. Disease or condition......................................................................................131    |                                                                                                          |
| 3.1.2. Available therapies and unmet medical need                                                                       | ....................................................131                                                  |
| 3.1.3. Main clinical studies                                                                                            | ......................................................................................132                |
| 3.2. Favourable effects...........................................................................................132   |                                                                                                          |
| 3.3. Uncertainties and limitations about favourable effects                                                             | ..........................................132                                                            |
| 3.4. Unfavourable effects........................................................................................132    |                                                                                                          |
| 3.5. Uncertainties and limitations about unfavourable effects                                                           | .......................................133                                                               |
| 3.6. Effects Table                                                                                                      | ..................................................................................................133    |
| 3.7. Benefit-risk assessment and discussion                                                                             | ..............................................................134                                        |
| 3.7.1. Importance of favourable and unfavourable effects                                                                | ...........................................134                                                           |
| 3.7.2. Balance of benefits and risks..........................................................................135       |                                                                                                          |

<div style=\"page-break-after: always\"></div>

3.7.3. Additional considerations on the benefit-risk balance .........................................  135

3.8. Conclusions  ....................................................................................................  135

4. Recommendations ...............................................................................  135

5. EPAR changes  ......................................................................................  137

<div style=\"page-break-after: always\"></div>

## List of abbreviations

| Abbreviation or special term   | Explanation                                                                                     |
|--------------------------------|-------------------------------------------------------------------------------------------------|
| ADA                            | Anti-drug antibody                                                                              |
| ADR                            | Adverse drug reaction                                                                           |
| AE                             | Adverse event                                                                                   |
| AESI                           | Adverse event of special interest                                                               |
| AFP                            | Alpha-fetoprotein                                                                               |
| ALBI                           | Albumin-bilirubin                                                                               |
| ALT                            | Alanine aminotransferase                                                                        |
| AST                            | Aspartate aminotransferase                                                                      |
| AUC                            | Area under the serum concentration-time curve                                                   |
| AUC 0-inf                      | Area under the serum concentration-time curve from 0 to infinity                                |
| BCLC                           | Barcelona Clinic Liver Cancer                                                                   |
| BICR                           | Blinded Independent Central Review                                                              |
| BOR                            | Best objective response                                                                         |
| CD                             | Cluster of differentiation                                                                      |
| CI                             | Confidence interval                                                                             |
| C max                          | Maximum serum concentration                                                                     |
| C min                          | Minimum serum concentration                                                                     |
| C min,1                        | Minimum serum concentration after the first dose                                                |
| CR                             | Complete response                                                                               |
| CRF                            | Case report form                                                                                |
| CSR                            | Clinical Study Report                                                                           |
| CTCAE                          | Common Terminology Criteria for Adverse Events (version 4.03)                                   |
| CTLA-4                         | Cytotoxic T lymphocyte-associated antigen 4                                                     |
| D                              | Durvalumab 1500 mg (20 mg/kg) Q4W                                                               |
| DCO DCR                        | Data cut-off Disease control rate                                                               |
| DCR-16w                        | Disease control rate at 16 weeks                                                                |
| DCR-24w                        | Disease control rate at 24 weeks                                                                |
| DoR                            | Duration of response                                                                            |
| ECOG                           | Eastern Cooperative Oncology Group                                                              |
| EHS                            | Extrahepatic spread                                                                             |
| EMA                            | European Medicines Agency                                                                       |
| EORTC                          | European Organization for Research and Treatment of Cancer                                      |
| ESMO                           | European Society for Medical Oncology                                                           |
| FA                             | Final analysis                                                                                  |
| FAS                            | Full analysis set                                                                               |
| FDA HBV                        | United States Food and Drug Administration Hepatitis B virus                                    |
| HCC                            | Hepatocellular carcinoma                                                                        |
| HCV                            | Hepatitis C virus                                                                               |
| HR                             | Hazard ratio                                                                                    |
| HRQoL                          | Health-related quality of life                                                                  |
| IA                             | Interim analysis                                                                                |
| ICH                            | International Council for Harmonisation of Technical Requirements Pharmaceuticals for Human Use |
| ICI                            | Immune checkpoint inhibitor                                                                     |
| IDMC                           | Independent Data Monitoring Committee                                                           |
| IgG imAE                       | Immunoglobulin G Immune-mediated adverse event                                                  |
| IO                             | Immuno-oncology                                                                                 |
| IV                             | Intravenous                                                                                     |
| mAb                            | Monoclonal antibody                                                                             |
| MTP                            | Multiple testing procedure                                                                      |
| MVI                            | Macrovascular invasion                                                                          |
| nAb                            | Neutralizing antibody                                                                           |
| NCCN                           | National Comprehensive Cancer Network                                                           |
| NI                             | Noninferiority Non-small cell lung                                                              |
| NSCLC                          | cancer                                                                                          |

<div style=\"page-break-after: always\"></div>

| Abbreviation or special term   | Explanation                                                                                   |
|--------------------------------|-----------------------------------------------------------------------------------------------|
| ORR                            | Objective response rate                                                                       |
| OS                             | Overall survival                                                                              |
| PD                             | Progressive disease                                                                           |
| PD-1                           | Programmed cell death-1                                                                       |
| PD-L1                          | Programmed cell death ligand-1                                                                |
| PD-L2                          | Programmed cell death ligand-2                                                                |
| PFS                            | Progression-free survival                                                                     |
| PK                             | Pharmacokinetic(s)                                                                            |
| PopPK                          | Population pharmacokinetics                                                                   |
| PR                             | Partial response                                                                              |
| PRO                            | Patient Reported Outcome                                                                      |
| PS                             | Performance status                                                                            |
| PT                             | Preferred term                                                                                |
| QLQ-HCC18                      | 18-item hepatocellular cancer health-related quality of life questionnaire                    |
| QoL                            | Quality of life                                                                               |
| QxW                            | Every x weeks                                                                                 |
| RECIST 1.1                     | Response Evaluation Criteria in Solid Tumors, version 1.1                                     |
| S                              | Sorafenib 400 mg twice daily                                                                  |
| SAE                            | Serious adverse event                                                                         |
| SAP                            | Statistical Analysis Plan                                                                     |
| SMQ                            | Standardized MedDRA query                                                                     |
| SoC                            | Standard of care                                                                              |
| T                              | Tremelimumab 750 mg (10 mg/kg) Q4W × 7 doses followed by Q12W                                 |
| T300+D                         | Tremelimumab 300 mg (4 mg/kg) for a single priming dose and durvalumab 1500 mg (20 mg/kg) Q4W |
| T75+D                          | Tremelimumab 75 mg (1 mg/kg) Q4W × 4 doses and durvalumab 1500 mg (20 mg/kg) Q4W              |
| TKI                            | Tyrosine kinase inhibitor                                                                     |
| TTR                            | Time to onset of objective response                                                           |
| UC                             | Urothelial carcinoma                                                                          |
| US                             | United States                                                                                 |
| VEGFR                          | Vascular endothelial growth factor receptor                                                   |

<div style=\"page-break-after: always\"></div>

## 1.  Background information on the procedure

## 1.1. Type II variation

Pursuant to Article 16 of Commission Regulation (EC) No 1234/2008, AstraZeneca AB submitted to the European Medicines Agency on 5 April 2022 an application for a variation.

The following variation was requested:

| Variation requested   | Variation requested                                                                                                            | Type    | Annexes affected   |
|-----------------------|--------------------------------------------------------------------------------------------------------------------------------|---------|--------------------|
| C.I.6.a               | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | Type II | I and IIIB         |

Extension of indication to include IMFINZI in combination with tremelimumab for the treatment of adults with unresectable hepatocellular carcinoma (uHCC), based on final results from Study D419CC00002 (HIMALAYA);  This  was  a  randomized,  open-label,  multi-center  phase  III  study  of  durvalumab  and tremelimumab  as  first-line  treatment  in  patients  with  unresectable  hepatocellular  carcinoma.  As  a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. In addition, the MAH took the opportunity to implement minor editorial changes in the SmPC and Package Leaflet. Version 6.1 of the RMP has also been submitted.

The variation requested amendments to the Summary of Product Characteristics and Package Leaflet and to the Risk Management Plan (RMP).

## Information on paediatric requirements

Pursuant to Article 8 of Regulation (EC) No 1901/2006, the application included an EMA Decision(s) P/0106/2021 on the agreement of a paediatric investigation plan (PIP).

At the time of submission of the application, the PIP was not yet completed as some measures were deferred.

## Information relating to orphan market exclusivity

## Similarity

Pursuant to Article 8 of Regulation (EC) No. 141/2000 and Article 3 of Commission Regulation (EC) No 847/2000, the MAH did not submit a critical report addressing the possible similarity with authorised orphan medicinal products because there is no authorised orphan medicinal product for a condition related to the proposed indication.

## Scientific advice

The MAH received Scientific advice from the CHMP on 18 May 2017 (EMEA/H/SA/3558/1/2017/II). The Scientific advice pertained to the clinical aspects of the dossier, such as the principles of the statistical analyses of the Himalaya study and the design of the supportive study 22.

<div style=\"page-break-after: always\"></div>

## 1.2. Steps taken for the assessment of the product

The Rapporteur and Co-Rapporteur appointed by the CHMP were:

Rapporteur:

Aaron Sosa Mejia

Co-Rapporteur:

&lt;N/A&gt;

| Timetable                                            | Actual dates     |
|------------------------------------------------------|------------------|
| Submission date                                      | 5 April 2022     |
| Start of procedure:                                  | 23 April 2022    |
| CHMP Rapporteur Assessment Report                    | 16 June 2022     |
| PRAC Rapporteur Assessment Report                    | 22 June 2022     |
| PRAC members comments                                | 29 June 2022     |
| PRAC Outcome                                         | 7 July 2022      |
| CHMP members comments                                | 11 July 2022     |
| Updated CHMP Rapporteur(s) (Joint) Assessment Report | 13 July 2022     |
| Request for supplementary information (RSI)          | 21 July 2022     |
| CHMP Rapporteur Assessment Report                    | 18 October 2022  |
| PRAC Rapporteur Assessment Report                    | 14 October 2022  |
| PRAC members comments                                | 19 October 2022  |
| PRAC Outcome                                         | 27 October 2022  |
| CHMP members comments                                | 28 October 2022  |
| Updated CHMP Rapporteur Assessment Report            | 3 November 2022  |
| Request for supplementary information (RSI)          | 10 November 2022 |
| CHMP and PRAC Rapporteurs Joint AR (JAR)             | 02 December 2022 |
| Comments from PRAC and CHMP                          | 05 December 2022 |
| Opinion                                              | 15 December 2022 |

<div style=\"page-break-after: always\"></div>

## 2. Scientific discussion

## 2.1. Introduction

## 2.1.1. Problem statement

## Disease or condition

Unresectable hepatocellular carcinoma (uHCC) regardless of tumoral PD-L1 expression.

## State the claimed therapeutic indication

The initially claimed new therapeutic indication in section 4.1 of the SmPC was:

Durvalumab  in  combination  with  tremelimumab  is  indicated  for  the  treatment  of  patients  with unresectable hepatocellular carcinoma.

The indication was updated during the procedure to:

IMFINZI in combination with tremelimumab is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (HCC).

## Epidemiology and risk factors

The incidence of HCC increases progressively with advancing age in all populations, reaching a peak at 70 years (El-Serag 2012, White et al 2017). Rates of both incidence and mortality are 2 to 3 times higher among men than among women in most regions (Sung et al 2021).

The main risk factors for HCC are chronic infection with HBV or HCV, aflatoxin-contaminated foods, heavy alcohol intake, excess body weight, type 2 diabetes, and smoking. The major risk factors vary from region to region, which is reflected in the incidence of HCC across geographic regions (Sung et al 2021). The highest incidence rates are seen in East Asia and Sub-Saharan Africa, while lower rates are seen in Europe and North America (WHO 2019).

Worldwide, HBV causes an estimated 75% to 80% of HCC cases, while HCV causes 10% to 20% of cases (Perz et al 2006). HCV infection (particularly in the US, Japan, and Egypt [Mak et al 2018, McGlynn et al 2015]), excessive alcohol consumption, and non-alcoholic fatty liver disease (linked to the growing prevalence of obesity and type 2 diabetes) represent the main risk factors for HCC (Vogel et al 2019).

## Biologic features

Normal  liver tolerogenic mechanisms  are  likely responsible for chronic liver inflammation or carcinogenesis. Chronic presentation of pathological antigens in the liver can actively suppress immune responses,  thus  inducing  a  state  of  immune  tolerance  to  the  pathogen  or  tumour.  Hepatocellular carcinoma takes advantage of peripheral tolerance to evade cell mediated immune responses, which allows the tumour to grow. Chronic hepatic inflammatory responses are the number one risk factor for liver tumour development (Makarova-Rusher et al 2015).

Moreover, increased expression of immunosuppressive cell populations, such as regulatory T cells and myeloid derived suppressor cells, and inhibitory signalling molecules, such as CTLA 4 and PD 1, have

<div style=\"page-break-after: always\"></div>

been observed in HCC (Gao et al 2009, Hato et al 2014, Pardee and Butterfield 2012) and is additionally associated  with  HBV  and  HCV  infection.  This  upregulation  contributes  to  the  immunosuppressive environment for HCC and highlights the importance of the PD-(L)1 and CTLA-4 pathways in HCC (GoldenMason et al 2007, Pardee and Butterfield 2012, Peng et al 2008).

## Clinical presentation, diagnosis and stage/prognosis

The HCC prognosis and treatment depend on factors such as tumour burden, degree of liver dysfunction, and clinical performance status (PS) (Marrero et al 2018, Vogel et al 2019). Hepatocellular carcinoma classically  develops  and  grows  in  silent  fashion,  making  its  discovery  challenging  prior  to  the development  of  later  stage  disease  (Bialecki  and  Di  Bisceglie  2005),  which  usually  leads  to  a  late diagnosis, with a median survival following diagnosis of approximately 6 to 20 months (McGlynn et al 2015). Hepatocellular carcinoma is a medically complex and difficult to treat disease as the majority of patients have underlying cirrhosis requiring management of both the malignancy and underlying liver disease. Hence, the 5-year survival rate for HCC is less than 20% (Sarveazad et al 2019, Villanueva 2019). Unresectable HCC remains a difficult to treat disease, and the majority of patients will ultimately die of either HCC or complications of liver disease.

## Management

Sorafenib, an oral TKI targeting multiple kinases, including VEGFR-1, -2, and -3 and BRAF, has been the standard of care (SOC) for advanced HCC in the first-line setting since its approval in 2007, which was based on improvement compared to placebo, establishing a median OS of 10.7 months (vs 7.9 months for placebo [Llovet et al 2008]). Subsequent studies have demonstrated a median OS ranging from 10.7 to 13.4 months (Finn et al 2021, Llovet et al 2008, Yamashita et al 2020). In 2018, lenvatinib, another multiple kinase inhibitor against VEGFR-1, -2, and -3 and fibroblast growth factor receptor-1, -2, -3, and -4, was approved as first-line treatment for advanced HCC in patients without main portal vein invasion and ECOG PS 0 to 1. Lenvatinib demonstrated non-inferiority to sorafenib in a Phase III study, with a median OS of 13.6 months vs 12.3 months with sorafenib (Kudo et al 2018). Atezolizumab (a PD-L1 inhibitor)  in  combination  with  bevacizumab  (an  angiogenesis  inhibitor  targeting  vascular  endothelial growth factor A) has also been approved in the first-line setting, after the Phase III IMbrave150 study showed improvements in OS and PFS compared to sorafenib (Finn et al 2020b, Finn et al 2021). The NCCN, ESMO, and Japanese Society of Hepatology guidelines were updated in 2020 to recommend atezolizumab in combination with bevacizumab as the preferred option to treat first-line HCC (NCCN Guidelines 2021, JSH 2021; Vogel and Martinelli 2021 [ie, ESMO Guidelines 2021]).

Regorafenib and cabozantinib (both multitargeted TKIs) have been approved for patients with advanced HCC, who have tolerated and progressed on sorafenib (Abou-Alfa et al 2018, Bruix et al 2017). Another approved second-line therapy is ramucirumab (a monoclonal antibody against VEGFR 2), which has improved survival in patients with serum AFP ≥ 400 ng/mL and previous treatment with sorafenib (Zhu et al 2019). In addition, nivolumab (an anti-PD-1 mAb) in combination with ipilimumab (an anti CTLA-4 mAb) has recently  received  accelerated  approval  from  the  FDA  for  patients  previously  treated  with sorafenib, due to results from the CheckMate 040 study, a Phase II study in which nivolumab (1 mg/kg, Q3W) plus ipilimumab (3 mg/kg Q3W × 4) (N=50; 28/50 [56%] with HBV) achieved a 32% ORR (Yau et al 2020).

## Unmet medical need

Despite recent advances in treatment options, patients with uHCC continue to have a low life expectancy and  the  underlying  liver  disease  and  portal  vein  hypertension  increase  the  risk  of  gastrointestinal

<div style=\"page-break-after: always\"></div>

bleeding  in  patients  with  advanced  HCC,  which  can  be  potentially  life-threatening  (Boregowda  et  al 2019). Currently available therapies provide only a modest improvement in survival with safety profiles that require management due to adverse events such as diarrhoea, hypertension, and palmar-plantar erythrodysaesthesia (PPE)(Cheng et al 2009, Lencioni et al 2014, Llovet et al 2008). Treatment with atezolizumab plus bevacizumab also carries a higher incidence of bleeding,  including  fatal  bleeding, despite attempts to exclude patients at risk for gastrointestinal bleeding from the pivotal study (NCCN Guidelines  2021).  Moreover,  the  underlying  liver  cirrhosis  may  result  in  moderate  liver  dysfunction, which  may  exacerbate  the  toxicity  of  systemic  therapies  such  as  TKIs  (Cheng  et  al  2020).  Hence, additional therapeutic options are needed, including options for patients with uHCC who are at higher risk of bleeding events, so there exist an unmet medical need for better and tolerable treatment options for patients with uHCC.

## 2.1.2. About the product

Durvalumab binds to programmed cell death ligand-1 (PD-L1) (but not programmed cell death ligand2) and thus blocks its interaction with programmed cell death 1 (PD-1) on T-lymphocytes (T-cells) and cluster of differentiation (CD) 80 (B7.1) on immune cells (ICs) and is engineered to reduce antibodydependent  cell-mediated  cytotoxicity  (ADCC).  Blockade  of  PD-L1/PD-1  and  PD-L1/CD80  interactions releases the inhibition of immune responses and may result in tumour regressions including objective responses based on tumour cell reduction as well as in stable disease due to tumour growth control. This mechanism of action may elicit eventually delay of progression and extension of survival.

Durvalumab is approved for the treatment of locally advanced, unresectable, NSCLC in adult patients whose tumours express PD L1 on ≥ 1% of tumour cells and whose disease has not progressed following platinum-based  chemoradiation  therapy  (EMEA/H/C/004771/0000).  Durvalumab  is  also  approved  in combination with standard-of-care platinum-based chemotherapy as 1L treatment of extensive stage small cell lung cancer (ES SCLC; EMEA/H/C/004771/II/0014/G).

<div style=\"page-break-after: always\"></div>

## 2.1.3. The development programme/compliance with CHMP guidance/scientific advice

Table  1.  Summary  of  EMA  Regulatory  Interactions  and  Correspondence  Specific  to  the HIMALAYA Study

| Date                        | Type of interaction             | Summary of outcome                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|-----------------------------|---------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 17 March 2017 - 22 May 2017 | Pre-Phase III Scientific Advice | EMA agreed with the principles of the statistical analysis and commented that the proposed interim analysis may lack power and/or maturity when investigating all subgroups (including patients with low expression of PD-L1 in whom prognosis may be better and treatment efficacy less pronounced). The design of Study 22 is appropriate, but contribution of components is dependent on results and could be driven by PD-L1 expression.                                                                                                                                                                                                                                                                                                                                                          |
| 19 Jan 2022                 | Joint Pre- submission Meeting   | AstraZeneca held a joint pre-submission meeting with the Rapporteur and Co-Rapporteur to review the planned submission of tremelimumab in combination with durvalumab for the treatment of adults with unresectable hepatocellular carcinoma. The Rapporteur acknowledged that HIMALAYA was well- designed to evaluate contribution of components. It was noted, however, that the added benefit of tremelimumab relative to the safety profile of the combination would be a key consideration in the review. Additionally, study integrity will be a key consideration for the Agency during their review. The Rapporteur sought assurance to support that study integrity was maintained, as the non-inferiority margin was adopted without prior agency feedback during the conduct of the study. |

Abbreviations: EMA, European Medicines Agency; HIMALAYA, Study D419CC00002; PD-L1, programmed cell death ligand 1; Study 22, Study D4190C00022.

The Scientific advice given by the EMA was generally followed.

## 2.1.4. General comments on compliance with GCP

N/A

## 2.2. Non-clinical aspects

No new non-clinical data have been submitted in this application, which was considered acceptable by the CHMP.

<div style=\"page-break-after: always\"></div>

## 2.2.1. Ecotoxicity/environmental risk assessment

Durvalumab is an IgG1 monoclonal antibody, a protein being extensively degraded in the patient's body by  regular  proteolytic  mechanisms  before  excretion.  Durvalumab  is  expected  to  biodegrade  in  the environmen t and does not pose a significant risk to the environment. Thus, according to the 'Guideline on the Environmental Risk Assessment of Medicinal Products for Human Use' (EMEA/CHMP/SWP/4447/00 corr2), durvalumab is exempt from the submission of Environmental Risk Assessment studies as the product and excipients do not pose a significant risk to the environment.

## 2.2.2. Discussion and conclusion on non-clinical aspects

No new non-clinical data have been submitted in this application, which is considered acceptable.

Durvalumab is human monoclonal antibody of the IgG1 kappa subclass. Antibodies are considered naturally occurring proteins, which are not expected to remain either stable or biologically active in the environment for any significant period. The justification for not performing any ERA studies is accepted.

## 2.3. Clinical aspects

## 2.3.1. Introduction

## GCP

The Clinical trials were performed in accordance with GCP as claimed by the MAH.

The MAH has provided a statement to the effect that clinical trials conducted outside the community were carried out in accordance with the ethical standards of Directive 2001/20/EC.

## · Tabular overview of clinical studies

## Table 2. Listing of clinical studies

| Study                                                                                                                                                               | Phase              | Objectives of study                                                                                        | Study design and type of control     | Route of administration and dosage regimen             | Route of administration and dosage regimen                               |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------|------------------------------------------------------------------------------------------------------------|--------------------------------------|--------------------------------------------------------|--------------------------------------------------------------------------|
| Pivotal study                                                                                                                                                       | Pivotal study      | Pivotal study                                                                                              | Pivotal study                        | Pivotal study                                          | Pivotal study                                                            |
| HIMALAYA (D419CC00002) Randomized, Open- label, Multi-center Phase III Study of Durvalumab and Tremelimumab as First-line Treatment in Patients with Hepatocellular | III                | Efficacy and safety of durvalumab and tremelimumab in combination versus durvalumab alone and sorafenib as | Randomized, open-label               | Durvalumab 1500 mg Q4W                                 | Durvalumab 1500 mg Q4W                                                   |
|                                                                                                                                                                     |                    |                                                                                                            |                                      | Durvalumab 1500 mg Q4W Tremelimumab 300 mg single dose | Durvalumab 1500 mg Q4W Tremelimumab 300 mg single dose                   |
|                                                                                                                                                                     |                    |                                                                                                            |                                      | Durvalumab 1500 mg Q4W Tremelimumab 75 mg 4 doses      | Durvalumab 1500 mg Q4W Tremelimumab 75 mg 4 doses                        |
| Advanced Carcinoma (HIMALAYA)                                                                                                                                       |                    | SoC                                                                                                        |                                      | Sorafenib (SoC) 400 mg BID                             | Sorafenib (SoC) 400 mg BID                                               |
| Supporting studies                                                                                                                                                  | Supporting studies | Supporting studies                                                                                         | Supporting studies                   | Supporting studies                                     | Supporting studies                                                       |
| Study 22 (D4190C00022) A study of safety, tolerability, and                                                                                                         | I/II               | Safety, tolerability, efficacy, PK, and immunogenicity                                                     | Open-label, multiple-arm, randomized | Part 1                                                 | Tremelimumab 75 mg (1 mg/kg) × 4 doses Durvalumab 1500 mg (20 mg/kg) Q4W |

<div style=\"page-break-after: always\"></div>

| clinical activity of durvalumab and tremelimumab administered as monotherapy, or durvalumab in combination with tremelimumab or bevacizumab in subjects with advanced unresectable HCC          |    |                                                                                            |                             | Part 2A & China Cohort         | Durvalumab monotherapy 1500 mg (20 mg/kg) Q4W Tremelimumab monotherapy 750 mg (10 mg/kg) Q4W × 7 doses followed by Q12W Tremelimumab 75 mg (1 mg/kg) × 4 doses                                                                                                                | Durvalumab monotherapy 1500 mg (20 mg/kg) Q4W Tremelimumab monotherapy 750 mg (10 mg/kg) Q4W × 7 doses followed by Q12W Tremelimumab 75 mg (1 mg/kg) × 4 doses                                                                                                                |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----|--------------------------------------------------------------------------------------------|-----------------------------|--------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| clinical activity of durvalumab and tremelimumab administered as monotherapy, or durvalumab in combination with tremelimumab or bevacizumab in subjects with advanced unresectable HCC          |    |                                                                                            |                             | Part 2B                        | Q4W Tremelimumab IV 300 mg (4 mg/kg) × 1 dose + Durvalumab IV 1500 mg                                                                                                                                                                                                         | Q4W Tremelimumab IV 300 mg (4 mg/kg) × 1 dose + Durvalumab IV 1500 mg                                                                                                                                                                                                         |
| clinical activity of durvalumab and tremelimumab administered as monotherapy, or durvalumab in combination with tremelimumab or bevacizumab in subjects with advanced unresectable HCC          |    |                                                                                            |                             | Part 3                         | Durvalumab monotherapy 1500 mg (20 mg/kg) Q4W Tremelimumab monotherapy 750 mg (10 mg/kg) Q4W × 7 doses followed by Q12W Tremelimumab 75 mg (1 mg/kg) × 4 doses + Durvalumab 1500 mg (20 mg/kg) Q4W Tremelimumab 300 mg (4 mg/kg) × 1 dose + Durvalumab 1500 mg (20 mg/kg) Q4W | Durvalumab monotherapy 1500 mg (20 mg/kg) Q4W Tremelimumab monotherapy 750 mg (10 mg/kg) Q4W × 7 doses followed by Q12W Tremelimumab 75 mg (1 mg/kg) × 4 doses + Durvalumab 1500 mg (20 mg/kg) Q4W Tremelimumab 300 mg (4 mg/kg) × 1 dose + Durvalumab 1500 mg (20 mg/kg) Q4W |
| clinical activity of durvalumab and tremelimumab administered as monotherapy, or durvalumab in combination with tremelimumab or bevacizumab in subjects with advanced unresectable HCC          |    |                                                                                            |                             | Part 4                         | Durvalumab 1120 mg (15 mg/kg) + Bevacizumab 15 mg/kg Q3W                                                                                                                                                                                                                      | Durvalumab 1120 mg (15 mg/kg) + Bevacizumab 15 mg/kg Q3W                                                                                                                                                                                                                      |
| Study 11 (D4190C00011) Phase I multicenter, open-label, doseexploration, and dose-expansion study of Durvalumab in combination with Tremelimumab in subjects with recurrent or metastatic SCCHN | I  | Evaluate safety, tolerability, and efficacy of Durvalumab in combination with Tremelimumab | Non- randomized, open-label | Dose exploration               | Dose exploration                                                                                                                                                                                                                                                              | Dose exploration                                                                                                                                                                                                                                                              |
| Study 11 (D4190C00011) Phase I multicenter, open-label, doseexploration, and dose-expansion study of Durvalumab in combination with Tremelimumab in subjects with recurrent or metastatic SCCHN | I  | Evaluate safety, tolerability, and efficacy of Durvalumab in combination with Tremelimumab | Non- randomized, open-label | Cohort 1                       | Cohort 1                                                                                                                                                                                                                                                                      | Durvalumab 15 mg/kg Q4W Tremelimumab 3 mg/kg Q4W                                                                                                                                                                                                                              |
| Study 11 (D4190C00011) Phase I multicenter, open-label, doseexploration, and dose-expansion study of Durvalumab in combination with Tremelimumab in subjects with recurrent or metastatic SCCHN | I  | Evaluate safety, tolerability, and efficacy of Durvalumab in combination with Tremelimumab | Non- randomized, open-label | Cohort 2                       | Cohort 2                                                                                                                                                                                                                                                                      | Durvalumab 10 mg/kg Q2W Tremelimumab 1 mg/kg Q4W                                                                                                                                                                                                                              |
| Study 11 (D4190C00011) Phase I multicenter, open-label, doseexploration, and dose-expansion study of Durvalumab in combination with Tremelimumab in subjects with recurrent or metastatic SCCHN | I  | Evaluate safety, tolerability, and efficacy of Durvalumab in combination with Tremelimumab | Non- randomized, open-label | Cohort 3                       | Cohort 3                                                                                                                                                                                                                                                                      | Durvalumab 20 mg/kg Q4W Tremelimumab 1 mg/kg Q4W                                                                                                                                                                                                                              |
| Study 11 (D4190C00011) Phase I multicenter, open-label, doseexploration, and dose-expansion study of Durvalumab in combination with Tremelimumab in subjects with recurrent or metastatic SCCHN | I  | Evaluate safety, tolerability, and efficacy of Durvalumab in combination with Tremelimumab | Non- randomized, open-label | Cohort 4                       | Cohort 4                                                                                                                                                                                                                                                                      | Durvalumab 20 mg/kg Q2W Tremelimumab 3 mg/kg Q4W                                                                                                                                                                                                                              |
| Study 11 (D4190C00011) Phase I multicenter, open-label, doseexploration, and dose-expansion study of Durvalumab in combination with Tremelimumab in subjects with recurrent or metastatic SCCHN | I  | Evaluate safety, tolerability, and efficacy of Durvalumab in combination with Tremelimumab | Non- randomized, open-label | Dose exploration               | Dose exploration                                                                                                                                                                                                                                                              | Dose exploration                                                                                                                                                                                                                                                              |
| Study 11 (D4190C00011) Phase I multicenter, open-label, doseexploration, and dose-expansion study of Durvalumab in combination with Tremelimumab in subjects with recurrent or metastatic SCCHN | I  | Evaluate safety, tolerability, and efficacy of Durvalumab in combination with Tremelimumab | Non- randomized, open-label | Cohort A PD-L1 High            | Cohort A PD-L1 High                                                                                                                                                                                                                                                           | Durvalumab 20 mg/kg Q4W Tremelimumab 1 mg/kg Q4W then Durvalumab 10 mg/kg Q2W                                                                                                                                                                                                 |
| Study 11 (D4190C00011) Phase I multicenter, open-label, doseexploration, and dose-expansion study of Durvalumab in combination with Tremelimumab in subjects with recurrent or metastatic SCCHN | I  | Evaluate safety, tolerability, and efficacy of Durvalumab in combination with Tremelimumab | Non- randomized, open-label | Cohort B PD-L1 Low or Negative | Cohort B PD-L1 Low or Negative                                                                                                                                                                                                                                                | Durvalumab 20 mg/kg Q4W Tremelimumab 1 mg/kg Q4W                                                                                                                                                                                                                              |

<div style=\"page-break-after: always\"></div>

|                                                                                                                                                                                                                                                                                                                                     |       |                                                                                                                                                                            |                                                        |                                                                                                                | then Durvalumab 10 mg/kg Q2W                                                                                   |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------|----------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------|
|                                                                                                                                                                                                                                                                                                                                     |       |                                                                                                                                                                            |                                                        | Cohort C prior IMT treatment                                                                                   | Durvalumab 20 mg/kg Q4W Tremelimumab 1 mg/kg Q4W then Durvalumab 10 mg/kg Q2W                                  |
| HAWK (D4193C00001) Phase II, multicenter, single-arm, global study of Durvalumab monotherapy in SCCHN                                                                                                                                                                                                                               | II    | Efficacy of durvalumab monotherapy and health-related quality of life                                                                                                      | Open-label, single-arm                                 | Durvalumab IV 10 mg/kg Q2W for 12 months or until progression of disease                                       | Durvalumab IV 10 mg/kg Q2W for 12 months or until progression of disease                                       |
| Study 21 (D4190C00021) Phase Ib/II study to evaluate the safety, tolerability, and clinical activity of durvalumab in combination with tremelimumab, of durvalumab monotherapy, and of tremelimumab monotherapy in second- and third-line subjects with metastatic or recurrent gastric or gastroesophageal junction adenocarcinoma | Ib/II | Evaluate the safety, antitumor activity, PK, and immunogenicity of Durvalumab in combination with Tremelimumab, of Durvalumab monotherapy, and of Tremelimumab monotherapy | Randomized, multicenter, open-label, comparative study | Phase 1b                                                                                                       | Durvalumab 20 mg/kg + Tremelimumab 1 mg/kg                                                                     |
| Study 21 (D4190C00021) Phase Ib/II study to evaluate the safety, tolerability, and clinical activity of durvalumab in combination with tremelimumab, of durvalumab monotherapy, and of tremelimumab monotherapy in second- and third-line subjects with metastatic or recurrent gastric or gastroesophageal junction adenocarcinoma | Ib/II | Evaluate the safety, antitumor activity, PK, and immunogenicity of Durvalumab in combination with Tremelimumab, of Durvalumab monotherapy, and of Tremelimumab monotherapy | Randomized, multicenter, open-label, comparative study | Phase 2                                                                                                        | Phase 2                                                                                                        |
| Study 21 (D4190C00021) Phase Ib/II study to evaluate the safety, tolerability, and clinical activity of durvalumab in combination with tremelimumab, of durvalumab monotherapy, and of tremelimumab monotherapy in second- and third-line subjects with metastatic or recurrent gastric or gastroesophageal junction adenocarcinoma | Ib/II | Evaluate the safety, antitumor activity, PK, and immunogenicity of Durvalumab in combination with Tremelimumab, of Durvalumab monotherapy, and of Tremelimumab monotherapy | Randomized, multicenter, open-label, comparative study | Arm A                                                                                                          | Durvalumab 20 mg/kg + Tremelimumab 1 mg/kg                                                                     |
| Study 21 (D4190C00021) Phase Ib/II study to evaluate the safety, tolerability, and clinical activity of durvalumab in combination with tremelimumab, of durvalumab monotherapy, and of tremelimumab monotherapy in second- and third-line subjects with metastatic or recurrent gastric or gastroesophageal junction adenocarcinoma | Ib/II | Evaluate the safety, antitumor activity, PK, and immunogenicity of Durvalumab in combination with Tremelimumab, of Durvalumab monotherapy, and of Tremelimumab monotherapy | Randomized, multicenter, open-label, comparative study | Arm B                                                                                                          | Durvalumab 10 mg/kg                                                                                            |
| Study 21 (D4190C00021) Phase Ib/II study to evaluate the safety, tolerability, and clinical activity of durvalumab in combination with tremelimumab, of durvalumab monotherapy, and of tremelimumab monotherapy in second- and third-line subjects with metastatic or recurrent gastric or gastroesophageal junction adenocarcinoma | Ib/II | Evaluate the safety, antitumor activity, PK, and immunogenicity of Durvalumab in combination with Tremelimumab, of Durvalumab monotherapy, and of Tremelimumab monotherapy | Randomized, multicenter, open-label, comparative study | Arm C                                                                                                          | Tremelimumab 10 mg/kg                                                                                          |
| Study 21 (D4190C00021) Phase Ib/II study to evaluate the safety, tolerability, and clinical activity of durvalumab in combination with tremelimumab, of durvalumab monotherapy, and of tremelimumab monotherapy in second- and third-line subjects with metastatic or recurrent gastric or gastroesophageal junction adenocarcinoma | Ib/II | Evaluate the safety, antitumor activity, PK, and immunogenicity of Durvalumab in combination with Tremelimumab, of Durvalumab monotherapy, and of Tremelimumab monotherapy | Randomized, multicenter, open-label, comparative study | Arm D                                                                                                          | Durvalumab 20 mg/kg + Tremelimumab 1 mg/kg                                                                     |
| Study 21 (D4190C00021) Phase Ib/II study to evaluate the safety, tolerability, and clinical activity of durvalumab in combination with tremelimumab, of durvalumab monotherapy, and of tremelimumab monotherapy in second- and third-line subjects with metastatic or recurrent gastric or gastroesophageal junction adenocarcinoma | Ib/II | Evaluate the safety, antitumor activity, PK, and immunogenicity of Durvalumab in combination with Tremelimumab, of Durvalumab monotherapy, and of Tremelimumab monotherapy | Randomized, multicenter, open-label, comparative study | Arm E                                                                                                          | Durvalumab 20 mg/kg + Tremelimumab 1 mg/kg                                                                     |
| Study 1108 (CD-ON-MEDI4736- 1108) Phase I/II study to evaluate the safety, tolerability, and pharmacokinetics of MEDI4736 in subjects with advanced solid tumors                                                                                                                                                                    | I/II  | Safety, tolerability, efficacy, PK, and immunogenicity                                                                                                                     | Open-label, multiple-arm, nonrandomized                | Dose-escalation phase Durvalumab 0.1, 0.3, 1, 3, 10 mg/kg                                                      | Dose-escalation phase Durvalumab 0.1, 0.3, 1, 3, 10 mg/kg                                                      |
| Study 1108 (CD-ON-MEDI4736- 1108) Phase I/II study to evaluate the safety, tolerability, and pharmacokinetics of MEDI4736 in subjects with advanced solid tumors                                                                                                                                                                    | I/II  | Safety, tolerability, efficacy, PK, and immunogenicity                                                                                                                     | Open-label, multiple-arm, nonrandomized                | Q2W + 15 mg/kg Q3W for up to 12 months or until PD Dose-exploration phase Durvalumab 20 mg/kg Q4W for up to 12 | Q2W + 15 mg/kg Q3W for up to 12 months or until PD Dose-exploration phase Durvalumab 20 mg/kg Q4W for up to 12 |
| Study 1108 (CD-ON-MEDI4736- 1108) Phase I/II study to evaluate the safety, tolerability, and pharmacokinetics of MEDI4736 in subjects with advanced solid tumors                                                                                                                                                                    | I/II  | Safety, tolerability, efficacy, PK, and immunogenicity                                                                                                                     | Open-label, multiple-arm, nonrandomized                | Durvalumab 10 mg/kg Q2W up to 12 months                                                                        | Durvalumab 10 mg/kg Q2W up to 12 months                                                                        |
| Study 06 (D4190C00006) Phase Ib open-label study to evaluate the                                                                                                                                                                                                                                                                    | Ib    | Safety, tolerability, and efficacy of durvalumab in                                                                                                                        | Open-label                                             | Dose-escalation phase - combination                                                                            | Dose-escalation phase - combination                                                                            |

<div style=\"page-break-after: always\"></div>

| safety and tolerability of durvalumab (MEDI4736) in combination with tremelimumab in subjects with advanced NSCLC a                                                    |     | combination with tremelimumab                                                                 |                                                       | Durvalumab IV 3-20 mg/kg Q4W or 10 mg/kg Q2W + Tremelimumab IV 1-10 mg/kg Q4W for 6 doses, then Q12W for 3 doses Dose-expansion phase - combination                                                                                                                                                                                                                                                          |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------------------------------------------------------------------------------------------|-------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| safety and tolerability of durvalumab (MEDI4736) in combination with tremelimumab in subjects with advanced NSCLC a                                                    |     | combination with tremelimumab                                                                 |                                                       | Durvalumab 20 mg/kg Q4W for 4 doses then IV 20 mg/kg Q4W for 9 doses + Tremelimumab 1 mg/kg Q4W for 4 doses                                                                                                                                                                                                                                                                                                  |
| Japan Study 02 (D4190C00002) A Phase I, open-label, multicenter study to evaluate the safety, tolerability, and PK of MEDI4736 in patients with advanced solid tumors  | I   | Safety and tolerability of durvalumab monotherapy or in combination with tremelimumab         | Open-label, Non- randomized                           | Durvalumab monotherapy Dose-escalation phase Durvalumab IV 1, 3, 10 mg/kg Q2W; 15 mg/kg Q3W; 20 mg/kg Q4W Dose-expansion phase Durvalumab IV 10 mg/kg Q2W                                                                                                                                                                                                                                                    |
| Japan Study 02 (D4190C00002) A Phase I, open-label, multicenter study to evaluate the safety, tolerability, and PK of MEDI4736 in patients with advanced solid tumors  | I   | Safety and tolerability of durvalumab monotherapy or in combination with tremelimumab         | Open-label, Non- randomized                           | Combination therapy Dose-expansion phase Durvalumab IV 20 mg/kg Q4W for 4 doses then IV 20 mg/kg Q4W + Tremelimumab IV 1 mg/kg Q4W for 4 doses                                                                                                                                                                                                                                                               |
| Study 10 (D4190C00010) Phase I study of MEDI4736 (anti-PD-L1 antibody) in combination with tremelimumab (anti- CTLA-4 antibody) in subjects with advanced solid tumors | I   | Safety, tolerability, and efficacy of the combination of durvalumab and tremelimumab          | Open-label                                            | Combination therapy Dose-exploration phase Durvalumab IV at 20 mg/kg Q4W for 12 months AND Tremelimumab IV 1 mg/kg Q4W (7 doses) then Q12W (2 doses) OR Durvalumab IV 10 mg/kg Q2W for 12 months AND Tremelimumab 3 mg/kg Q4W (7 doses) then Q12W (2 doses) Dose-expansion phase - combination therapy Durvalumab IV 20 mg/kg Q4W for 4 doses then IV 10 mg/kg Q2W + Tremelimumab IV 1 mg/kg Q4W for 4 doses |
| DANUBE (D419BC00001) Phase III study of Durvalumab alone and in combination with Tremelimumab in patients with unresectable stage IV urothelial cancer                 | III | Efficacy and safety of Durvalumab monotherapy and in combination with Tremelimumab versus SoC | Randomized, open-label, controlled (SoC), multicenter | Durvalumab 1500 mg Q4W alone                                                                                                                                                                                                                                                                                                                                                                                 |
| DANUBE (D419BC00001) Phase III study of Durvalumab alone and in combination with Tremelimumab in patients with unresectable stage IV urothelial cancer                 | III | Efficacy and safety of Durvalumab monotherapy and in combination with Tremelimumab versus SoC | Randomized, open-label, controlled (SoC), multicenter | Durvalumab 1500 mg Q4W + Tremelimumab 75 mg Q4W for 4 doses                                                                                                                                                                                                                                                                                                                                                  |
| DANUBE (D419BC00001) Phase III study of Durvalumab alone and in combination with Tremelimumab in patients with unresectable stage IV urothelial cancer                 | III | Efficacy and safety of Durvalumab monotherapy and in combination with Tremelimumab versus SoC | Randomized, open-label, controlled (SoC), multicenter | SoC                                                                                                                                                                                                                                                                                                                                                                                                          |
| KESTREL (D419LC00001) Phase III study of Durvalumab alone and                                                                                                          | III | Efficacy and safety of Durvalumab                                                             | Randomized, open-label, multi-center, global study    | Durvalumab 1500 mg Q4W alone                                                                                                                                                                                                                                                                                                                                                                                 |

<div style=\"page-break-after: always\"></div>

| in combination with Tremelimumab in patients with metastatic SCCHN                                                                                                                                                                                                                                                   |     | monotherapy and in combination with Tremelimumab versus SoC                                        |                                                                     | Durvalumab 1500 mg Q4W + Tremelimumab 75 mg Q4W for 4 doses                                                                           |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|----------------------------------------------------------------------------------------------------|---------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------|
| in combination with Tremelimumab in patients with metastatic SCCHN                                                                                                                                                                                                                                                   |     | monotherapy and in combination with Tremelimumab versus SoC                                        |                                                                     | SoC                                                                                                                                   |
| POSEIDON (D419MC00004) Phase III, randomized, global study to determine the efficacy of durvalumab or durvalumab and tremelimumab in combination with platinum-based chemotherapy for first- line treatment in patients with metastatic NSCLC                                                                        | III | Efficacy, PK, immunogenicity, safety, and tolerability versus SoC                                  | Randomized, multi-center, open-label, comparative active comparator | Durvalumab 1500 mg Q3W for 4 doses + SoC, then Durvalumab 1500 mg Q4W until PD                                                        |
| POSEIDON (D419MC00004) Phase III, randomized, global study to determine the efficacy of durvalumab or durvalumab and tremelimumab in combination with platinum-based chemotherapy for first- line treatment in patients with metastatic NSCLC                                                                        | III | Efficacy, PK, immunogenicity, safety, and tolerability versus SoC                                  | Randomized, multi-center, open-label, comparative active comparator | Durvalumab 1500 mg Q3W for 4 doses + SoC, then Durvalumab 1500 mg Q4W until PD Tremelimumab 75 mg Q3W for 4 doses + 1 dose at week 16 |
| POSEIDON (D419MC00004) Phase III, randomized, global study to determine the efficacy of durvalumab or durvalumab and tremelimumab in combination with platinum-based chemotherapy for first- line treatment in patients with metastatic NSCLC                                                                        | III | Efficacy, PK, immunogenicity, safety, and tolerability versus SoC                                  | Randomized, multi-center, open-label, comparative active comparator | SoC (abraxane + carboplatin, pemetrexed + cisplatin or carboplatin, or gemcitabine + cisplatin or carboplatin)                        |
| ATLANTIC (D4191C00003) Phase II non- comparative, open- label, multicenter, international study of MEDI4736 in patients with locally advanced or metastatic NSCLC (Stage IIIB-IV) who have received at least 2 prior systemic treatment regimens including one platinum- based chemotherapy regimen                  | II  | Efficacy, safety, tolerability, PK, and immunogenicity                                             | Open-label, single-arm, non-randomiz ed                             | Durvalumab 10 mg/kg Q2W for up to 12 months                                                                                           |
| PACIFIC (D4191C00001) Phase III, randomized, double-blind, placebo-controlled, multicenter, international study of durvalumab as sequential therapy in patients with locally advanced, unresectable NSCLC (Stage III) who have not progressed following definitive, platinum-based concurrent chemoradiation therapy | III | Efficacy, safety, tolerability, PK, immunogenicity, and health- related quality of life versus SoC | Randomized, double-blind, placebocontroll ed                        | Durvalumab 10 mg/kg Q2W for up to 12 months                                                                                           |

<div style=\"page-break-after: always\"></div>

| MYSTIC (D419AC00001) Phase III, randomized, open-label, multicenter, global study of durvalumab monotherapy and durvalumab in combination with                                                                                                                                                                                                                                                                                                                               | III   | Efficacy versus SoC                                               | Open-label, randomized, active comparator   | Durvalumab monotherapy Durvalumab IV 20 mg/kg Q4W                                                                                    |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------|-------------------------------------------------------------------|---------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------|
| compared to SoC in patients with advanced or metastatic NSCLC                                                                                                                                                                                                                                                                                                                                                                                                                | III   | Efficacy versus SoC                                               | Open-label, randomized, active comparator   | Combination therapy Durvalumab IV 20 mg/kg Q4W for 4 doses then IV 20 mg/kg Q4W until PD AND Tremelimumab IV 1 mg/kg Q4W for 4 doses |
| NEPTUNE (D419AC00003) Phase III randomized, open-label, multicenter, global study of MEDI4736 in combination with tremelimumab therapy versus standard of care platinum-based chemotherapy in first line treatment of patients with advanced                                                                                                                                                                                                                                 | III   | Efficacy, PK, immunogenicity, safety, and tolerability versus SoC | Open-label, randomized, active comparator   | Combination therapy Durvalumab IV 20 mg/kg Q4W for 4 doses then IV 20 mg/kg Q4W AND Tremelimumab IV 1 mg/kg Q4W for 4 doses          |
| ARCTIC (D4191C00004) Phase III, open-label, randomized, multicenter, international study of durvalumab, given as monotherapy or in combination with tremelimumab, determined by PD-L1 expression, versus SoC in patients with locally advanced or metastatic NSCLC (Stage IIIB-IV) who have received at least 2 prior systemic treatment regimens including one platinum-based chemotherapy regimen and do not have known EGFR TK activating mutations or ALK rearrangements | III   | Efficacy, safety, tolerability, PK, and immunogenicity versus SoC | Open-label, randomized, active comparator   | Durvalumab monotherapy Durvalumab IV 10 mg/kg Q2W for up to 12 months                                                                |
| ARCTIC (D4191C00004) Phase III, open-label, randomized, multicenter, international study of durvalumab, given as monotherapy or in combination with tremelimumab, determined by PD-L1 expression, versus SoC in patients with locally advanced or metastatic NSCLC (Stage IIIB-IV) who have received at least 2 prior systemic treatment regimens including one platinum-based chemotherapy regimen and do not have known EGFR TK activating mutations or ALK rearrangements | III   | Efficacy, safety, tolerability, PK, and immunogenicity versus SoC | Open-label, randomized, active comparator   | Tremelimumab monotherapy Tremelimumab IV 10 mg/kg IV Q4W for 24 weeks followed by 10 mg/kg IV Q12W for 24 weeks                      |

<div style=\"page-break-after: always\"></div>

|                                                                                                                                                                                                                                                                                      |     |                                                                                             |                                           | Combination therapy Durvalumab IV 20 mg/kg Q4W for 12 weeks then IV 10 mg/kg Q2W for 34 weeks + Tremelimumab IV 1 mg/kg Q4W for 12 weeks (maximum of 22 doses of durvalumab + 4 doses of tremelimumab)   |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|---------------------------------------------------------------------------------------------|-------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| CASPIAN (D419QC00001) Phase III, randomized, multicenter, open- label, comparative study to determine the efficacy of durvalumab or durvalumab and tremelimumab in combination with platinum-based chemotherapy for the first-line treatment in patients with extensive disease SCLC | III | Efficacy, PK, immunogenicity, safety, and tolerability versus SoC                           | Open-label, randomized, active comparator | Durvalumab IV 1500 mg Q3W for 4 doses then durvalumab IV 1500 mg Q4W until PD + EP for 4 cycles                                                                                                          |
| CASPIAN (D419QC00001) Phase III, randomized, multicenter, open- label, comparative study to determine the efficacy of durvalumab or durvalumab and tremelimumab in combination with platinum-based chemotherapy for the first-line treatment in patients with extensive disease SCLC | III | Efficacy, PK, immunogenicity, safety, and tolerability versus SoC                           | Open-label, randomized, active comparator | Combination therapy (D + T + EP) Durvalumab IV 1500 mg Q3W for 4 doses then Durvalumab IV 1500 mg Q4W until PD + Tremelimumab IV 75 mg Q3W for 4 doses + EP for 4 cycles                                 |
| CASPIAN (D419QC00001) Phase III, randomized, multicenter, open- label, comparative study to determine the efficacy of durvalumab or durvalumab and tremelimumab in combination with platinum-based chemotherapy for the first-line treatment in patients with extensive disease SCLC | III | Efficacy, PK, immunogenicity, safety, and tolerability versus SoC                           | Open-label, randomized, active comparator | SoC EP for up to 6 cycles b                                                                                                                                                                              |
| CONDOR (D4193C00003) Phase II, randomized, open-label, multi- center, global study of durvalumab monotherapy, tremelimumab monotherapy, and durvalumab in combination with tremelimumab in patients with recurrent                                                                   | II  | Efficacy of durvalumab in combination with tremelimumab and health- related quality of life | Open-label, randomized                    | Durvalumab monotherapy Durvalumab IV 10 mg/kg Q2W for up to 12 months                                                                                                                                    |
| CONDOR (D4193C00003) Phase II, randomized, open-label, multi- center, global study of durvalumab monotherapy, tremelimumab monotherapy, and durvalumab in combination with tremelimumab in patients with recurrent                                                                   | II  | Efficacy of durvalumab in combination with tremelimumab and health- related quality of life | Open-label, randomized                    | Tremelimumab monotherapy Tremelimumab IV 10 mg/kg Q4W for 7 doses then Q12W for 2 doses for up to 12 months                                                                                              |
| CONDOR (D4193C00003) Phase II, randomized, open-label, multi- center, global study of durvalumab monotherapy, tremelimumab monotherapy, and durvalumab in combination with tremelimumab in patients with recurrent                                                                   | II  | Efficacy of durvalumab in combination with tremelimumab and health- related quality of life | Open-label, randomized                    | Combination therapy Durvalumab IV 20 mg/kg Q4W for 4 doses then IV 10 mg/kg Q2W to complete 12 months of treatment + Tremelimumab IV 1 mg/kg Q4W for 4 doses                                             |

<div style=\"page-break-after: always\"></div>

| EAGLE (D4193C00002) Phase III, randomized, open-label, multicenter, global study of durvalumab monotherapy and durvalumab in combination with tremelimumab versus SoC in patients with recurrent or               | III   | Efficacy of durvalumab monotherapy and durvalumab in combination with tremelimumab versus SoC   | Open-label, randomized                       | Durvalumab monotherapy Durvalumab IV 10 mg/kg Q2W Combination therapy Durvalumab IV 20 mg/kg Q4W for 4 doses then IV   |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------|-------------------------------------------------------------------------------------------------|----------------------------------------------|------------------------------------------------------------------------------------------------------------------------|
| metastatic SCCHN D4884C00001 Phase II multicenter, open-label study of                                                                                                                                            | II    | Efficacy and safety                                                                             | Open-label                                   | Durvalumab monotherapy Durvalumab IV 1500 mg Q4W for up to 12 months                                                   |
| monotherapy in patients with advanced solid tumors                                                                                                                                                                | II    | Efficacy and safety                                                                             | Open-label                                   | Tremelimumab monotherapy Tremelimumab IV 750 mg Q4W for 7 doses then Q12W for 2 doses                                  |
| DETERMINE (D4880C00003) Phase IIb, randomized, double-blind study comparing tremelimumab to placebo in second- or third-line treatment of subjects with unresectable pleural or peritoneal malignant mesothelioma | IIb   | Efficacy and safety                                                                             | Randomized, double-blind, placebocontroll ed | Tremelimumab monotherapy Tremelimumab IV 10 mg/kg Q4W for 7 doses (6 months) then Q12W                                 |

[a]   For Study 06, an NCA was done for an interim dataset (DCO 28 February 2017). As the final dataset (DCO 19 November 2019) only had 343 additional samples (all in the dose-expansion phase) compared to the interim, it was determined that an additional NCA for the final dataset was not required. This was supported by the sparse sampling in the dose-expansion phase patients (~2 samples per patient per treatment), which would contribute little to no value to a NCA, which typically relies on intense sampling in order to accurately estimate key PK parameters such as half-life and AUC. Therefore, only the results of the interim NCA are presented.

[b] Patients in the EP alone group were permitted an additional 2 cycles of EP (up to 6 cycles total) per the

Investigator's discretion.

Abbreviations; ALK, anaplastic lymphoma kinase; AUC, area under the serum concentration-time curve; CTLA-4, cytotoxic T-lymphocyte-associated antigen-4; D, durvalumab; DCO, data cutoff; EGFR, epidermal growth factor receptor; EP, etoposide and either carboplatin or cisplatin; IV, intravenous; NCA, noncompartmental analysis; NSCLC, non-small cell lung cancer; PD, progression of disease; PD-L1, programmed cell death ligand-1; PK, pharmacokinetics; Q2W, every 2 weeks; Q3W, every 3 weeks; Q4W, every 4 weeks; Q12W, every 12 weeks; SCCHN, head and neck squamous cell carcinoma; SoC, standard of care; T, tremelimumab; TK, tyrosine kinase.

Durvalumab and tremelimumab are both human monoclonal antibodies (mAb) that act as checkpoint inhibitors with distinct yet complementary mechanisms of action with respect to enhancing the antitumor immune response.

The  clinical  pharmacological  data  are  derived  from  1  pivotal  study  (HIMALAYA)  and  20  supportive durvalumab studies and 17 supportive tremelimumab studies.

<div style=\"page-break-after: always\"></div>

All studies included male and female patients aged 18 years and older with advanced solid tumors. No PK data has been obtained from healthy volunteers.

The clinical pharmacology studies that support this proposed indication are summarized in Table 2.

## 2.3.2. Pharmacokinetics

## Durvalumab population PK analysis

The primary objectives of the PopPK analysis were (1) to characterize the PK of durvalumab, using HIMALAYA and Study 22 data combined with data from previous clinical trials that studies durvalumab in various indications (CD-ON-MEDI4736-1108, ATLANTIC, PACIFIC, CASPIAN and POSEIDON), (2) to assess the impact of pre-defined covariates on individual post-hoc PK parameters and (3) to derive individual  predicted  exposure  metrics  (AUC,  dose1,  Cmax,  dose1,  Cmin,  dose1,  AUC0-inf,  AUCss, Cmax,ss, Cmin,ss) of durvalumab for patients based on individual Empirical Bayes Estimates (EBEs) from the population PK models.

The population PK analysis of durvalumab was derived from a total dataset of 4043 patients, of which 2827  patients  were  from  the  previous  dataset  and  295  were  from  Study  22  and  928  were  from HIMALAYA. 216 BLQ samples (1.45%) were excluded from the analysis of which 83 of those samples were from Study 22 and HIMALAYA. 49 samples (1.5%) from Study 22 and HIMALAYA were also excluded from the analysis due to incorrect PK sample time. Eventually, 14760 serum PK samples from 4043 patients treated with durvalumab were available in the final dataset for analysis.

Previously, durvalumab population PK (Population PK and Exposure-Response Report (MS-2021)) was described by a two-compartment distribution model with time-dependent CL. IIV was included on CL, V1  and  Tmax.  Residuals  were  described  by  a  combined  additive  and  proportional  error  model.  The previous model included several statistically significant covariate effects on CL: WT, ALB, combination therapy, sex, CrCL, LDH, and ECOG; and on V1: WT and sex.

The updated model was re-evaluated based on the current data and previous developed model structure. From  full  covariate  model,  backward  elimination  was  considered  to  find  a  statistically  parsimonious model.  Significance  levels  of  0.001  was  employed.  After  backward  elimination,  the  full  model  was explored by graphical inspection of all covariate effects (plots and correlation coefficients of empirical Bayes estimates of individual random effects from the full model vs. covariates). Results suggested that all previous covariates were important as the objective function value (OFV) increased by ≥ 12 points when excluding either of them. Race, region and tumour type (NSCLC, bladder and HCC) were also tested on CL and V1. These analyses re-confirmed race and region were not significant covariate for durvalumab, while tumour type was considered significant on CL of durvalumab and therefore included in the model.

The following model was chosen as the final model for durvalumab: a two-compartment distribution model with  time-dependent  CL.  IIV  on  CL,  V1  and  Tmax.  Residuals  were  described  by  a  combined proportional and additive error model. The final model included several statistically significant covariate effects on CL: WT, ALB, combination therapy, sex, CrCL, LDH, ECOG and tumour type (NSCLC, bladder and HCC); and on V1: WT and sex.

The  relationships  between  the  covariates  and  the  model  parameters  are  described  in  the  following equations:

<div style=\"page-break-after: always\"></div>

<!-- formula-not-decoded -->

<!-- formula-not-decoded -->

<!-- formula-not-decoded -->

where CLcat.cov, CLcont.cov and CLT,i represent the impact of categorical and continuous covariates and the individual total CL including the time-dependent decrease of CL respectively.

<!-- formula-not-decoded -->

Note: albi=Albumin concentration at baseline, CrCLi=Creatinine clearance at baseline. LDHi=Lactate dehydrogenase at baseline, WTi=Bodyweight at baseline

PK  parameter  estimates  of  the  final  durvalumab  model  along  with  percent  relative  standard  error (%RSE), results of non-parametric bootstrap analysis and shrinkage can be seen in Table 3. GOF plots of DV vs. PRED, DV vs. IPRED, CWRES vs. PRED and CWRES vs. time after dose can be seen in Figure 1. A pcVPC of the final model for HIMALAYA is shown in Figure 2.

The durvalumab population PK model was updated with sparse data from HIMALAYA and Study 22 and pooled with the previous dataset (Studies CASPIAN, PACIFIC, ATLANTIC, POSEIDON and CD-ON-MEDIA4736-1108).

The final model included the following covariate effects on CL: WT, ALB, combination therapy, sex, CrCL, LDH, ECOG and tumour type (solid, NSCLC, bladder and HCC); and on V1: WT and sex. The final model was evaluated by means of non-parametric bootstrap analysis, RSEs, GOF-plots and pcVPCs.

<div style=\"page-break-after: always\"></div>

Table 3. Population PK Model Parameter Estimates durvalumab (Final Model)

<!-- image -->

| Parameter                   | Estimate                    | RSE (%)   | bootstrap 95%CI      | Shrinkage (%)   | Unit   |
|-----------------------------|-----------------------------|-----------|----------------------|-----------------|--------|
| PopulationParameter         |                             |           |                      |                 |        |
| CL                          | 0.277                       | 2.01      | [0.263 ; 0.292]      |                 | L/day  |
| V1                          | 3.45                        | 0.807     | [3.40 ; 3.49]        |                 | L      |
| V2                          | 2.13                        | 2.02      | [1.98 ; 2.29]        | --              | L      |
| Q                           | 0.469                       | 5.15      | [0.411 ; 0.535]      |                 | L/day  |
| Tmax                        | -0.372                      | 4.99      | [-0.419 ; -0.327]    |                 | L/day  |
| TCs0                        | 88.7                        | 9.92      | [58.3 ; 150]         |                 | day    |
| LAM                         | 1.00                        |           |                      |                 |        |
| Covariate                   |                             |           |                      |                 |        |
| Albumin on CL               | -0.659                      | 2.87      | [-0.834 ; -0.506]    |                 |        |
| Creatinine clearance on CL  | 0.121                       | 15.6      | [0.0800 ; 0.162]     |                 |        |
| ECOG status on CL           | -0.0516                     | 20.7      | [-0.0720 ; -0.0278]  |                 |        |
| LDH on CL                   | 0.0442                      | 23.3      | [0.0208 ; 0.0642]    |                 |        |
| Sex on CL                   | -0.149                      | 7.95      | [-0.172 ; -0.126]    |                 |        |
| COMB1 on CL                 | -0.0459                     | 27.0      | [-0.0688 ; -0.0195]  |                 |        |
| COMB2 on CL                 | -0.0417                     | 43.2      | [-0.0886 ; 0.00746]  |                 |        |
| Body weight on CL           | 0.376                       | 8.32      | [0.317 ; 0.443]      | -               |        |
| Tumor type 1 on CL          | -0.0393                     | 46.1      | [-0.0750 ; -0.00306] | --              |        |
| Tumor type 2 on CL          | 0.0622                      | 55.8      | [-0.0131 ; 0.137]    |                 |        |
| Tumor type 3 on CL          | 0.0472                      | 46.1      | [0.00497 ; 0.0932]   | -               |        |
| Sex on V1                   | -0.140                      | 7.60      | [-0.163 ; -0.118]    |                 |        |
| Body weight on V1           | 0.499                       | 5.01      | [0.449 ; 0.549]      |                 |        |
| Interindividual Variability | Interindividual Variability |           |                      |                 |        |
| ETA CL                      | 0.0896                      | 2.85      | [0.0803 ; 0.0982]    | 17.6            |        |
| Cov CL-V1                   | 0.0389                      | 5.34      | [0.0338 ; 0.0441]    |                 |        |
| ETA V1                      | 0.0524                      | 3.32      | [0.0451 ; 0.0598]    | 29.9            |        |
| ETA Tmax                    | 0.0665                      | 9.03      | [0.0436 ; 0.109]     | 59.3            | --     |
| Residual Variability        |                             |           |                      |                 |        |
| Proportional component      | 0.250                       | 0.541     | [0.241 ; 0.258]      | 15.0            |        |
| Additive component          | 4.28                        | 6.70      | [3.39 ; 5.29]        | 15.0            | μg/mL  |

<div style=\"page-break-after: always\"></div>

Figure 1: Final Durvalumab PopPK Model -Basic GOF

<!-- image -->

Note:The blueline is a trend line through thedata points,and thebluearea isthe95% CI around it. Source:Figure 2,Population PK and Exposure-Response Report,Module 5.3.3.5. CI,confidenceinterval;CWRES=conditionalweightedresiduals.

<div style=\"page-break-after: always\"></div>

Figure 2. pcVPC of the final model vs time after dose - HIMALAYA Study

<!-- image -->

Note:Thesolidanddashedlinesrepresent themedian,5t,and95thpercentilesoftheobservations;theshaded redandblueareasrepresent the95%confidenceintervalofthemedian,5th,and95thpercentilespredictedbythe model.

Abbreviations:CI=confidenceinterval,pcVPC=prediction-correctedvisualpredictivecheck Source:/projects/qcp/QCP\\_MODELING/ONC/durvalumab/poppk\\_20210729\\_himalaya/Scripts/s04\\_vpc.R

## Durvalumab and tremelimumab exposure-Response modelling analysis (MS-2021-02)

The ER analysis for both efficacy and safety was based on patients from HIMALAYA study administered 1500 mg Q4W durvalumab and a 300 mg single dose tremelimumab IV. 388 and 397 patients were included in the ER analysis for durvalumab and tremelimumab, respectively. The final durvalumab/tremelimumab PopPK models were used to obtains EBEs of individual PK parameters.

## Exposure-efficacy:

The exposure-efficacy relationships in the HIMALAYA study were explored by Kaplan-Meier plots stratified by durvalumab and tremelimumab exposure quartiles. Several exposure metrics for tremelimumab and durvalumab were derived. For both efficacy outcomes, OS and PFS, Cox Proportional Hazard (CPH) models were developed and a stepwise covariate selection was performed (α = 1% and 0.1%). No significant exposure-efficacy relationships were identified for durvalumab or tremelimumab. The CPH models for OS suggested that AST and NLR were associated with shorter survival in T300+D arm as they were identified  as  statistically  significant  covariates.  Maximum  concentration  following  the  first  dose (Cmax, dose 1) for tremelimumab was also identified as a marginally statistically significant exposure metric (LRT: 11.92 &gt; 10.83) but was removed due to non-significance in the Wald test (p = 0.199), the standard error of coefficient (β) being large and the 95% CI of β containing the null. The removal of this covariate in the CPH model is considered appropriate. Likewise, trough concentration following the first dose (Cmin, dose 1) for tremelimumab was also identified as a marginally significant covariate within PFS based on the LRT but was removed for the same reasons. No other covariates were identified to be significant with PFS.

## Exposure-safety:

Logistic regression modelling did not identify any significant impact of durvalumab or tremelimumab exposure on the incidence of adverse effects.

<div style=\"page-break-after: always\"></div>

## QTcF modelling analysis

Linear mixed-effects exposure-response modelling with an intercept was conducted to characterize the relationship  of  change  from  baseline  of  QTcF  (ΔQTcF)  with  durvalumab  or  tremelimumab  serum concentrations.  The  concentrationΔQTcF analysis  population  consisted  of 293 observations  from  67 patients administered durvalumab and 254 observations from 66 patients administered tremelimumab from  Study  06.  Unscheduled  concentration-QTcF  observations  and  non-central  ECG  records  were excluded from the analysis.

For durvaluma b, the slope for the relationship of ΔQTcF to durvalumab concentration was 0.0048 ms per μg/mL (p = 0.112), with a mean intercept of 0.082 ms (p = 0.950; 90% CI: -2.07, 2.24 ms; Table 4).

The slope for the relationship of ΔQTcF to tremelimumab concentration was -0.012 ms per μg/mL (p = 0.531), and the mean intercept was 0.581 ms (p = 0.629; 90% CI: -1.41, 2.57 ms; Table 5).

The slope or the intercept for tremelimumab and durvalumab were not significantly different from zero.

Table 4: Parameter estimates of durvalumab PKΔQTcF relationship

| Parameter estimates                       | Parameter estimates   | Parameter estimates   | Parameter estimates   | Parameter estimates   | Parameter estimates   | Parameter estimates   |
|-------------------------------------------|-----------------------|-----------------------|-----------------------|-----------------------|-----------------------|-----------------------|
| Parameter                                 | Estimate              | Standard error        | p- value              | 90% confidence limits | 90% confidence limits | Gradient              |
| Intercept (ms)                            | 0.08205               | 1.2916                | 0.9495                | -2.0726               | 2.2367                | 0.000012              |
| Slope (ms/μg/mL)                          | 0.004841              | 0.003007              | 0.1123                | -0.00018              | 0.009858              | 0.003814              |
| Inter individual variability on intercept | 7.8721                | 0.8472                | <.0001                | 6.4588                | 9.2855                | 0.000021              |
| Model error                               | 9.4501                | 0.4275                | <.0001                | 8.7369                | 10.1633               | -8.91E-6              |

PK pharmacokinetic

Table 5: Parameter estimates of Tremelimumab PKΔQTcF relationship

| Parameterestimates                        | Parameterestimates   | Parameterestimates   | Parameterestimates   | Parameterestimates    | Parameterestimates    | Parameterestimates   |
|-------------------------------------------|----------------------|----------------------|----------------------|-----------------------|-----------------------|----------------------|
| Parameter                                 | Estimate             | Standard error       | p- value             | 90% confidence limits | 90% confidence limits | Gradient             |
| Intercept (ms)                            | 0.5806               | 1.1952               | 0.6288               | -1.4137               | 2.5749                | -1.01E-6             |
| Slope (ms/ μg/mL)                         | -0.01225             | 0.01945              | 0.5312               | -0.04470              | 0.02021               | -0.00007             |
| Inter individual variability on intercept | 7.5385               | 0.8414               | <.0001               | 6.1345                | 8.9425                | -2.99E-6             |
| Model error                               | 9.2338               | 0.4544               | <.0001               | 8.4755                | 9.9921                | 4.764E-6             |

PK pharmacokinetic

The upper bound of the 90% 2sided CI for ΔQTcF was less than 10 ms, and the highest observed concentration of durvalumab and tremelimumab had a predicted mean ΔQTcF of less than 5 ms (Figure 3, Figure 4 and Table 6).

<div style=\"page-break-after: always\"></div>

Figure 3. QTcF (change from baseline) versus concentration of durvalumab on intercept full data

<!-- image -->

Cmax,ss maximum plasma concentration at steady state; IQR interquartile range; IV intravenous; Q2W every 2 weeks; Q4W every 4 weeks

Note: Red line is the linear regression line and the shaded area is the 90% CI based on the linear mixed-effects model prediction. Red short dashed horizontal line is 5 msec change from baseline identity line. Red long dashed horizontal line is 10 msec change from baseline identity line. Green dashed vertical lines are observed median +/- IQR predicted Cmax,ss for a 10 mg/kg Q2W IV durvalumab dosing. Green solid line is median predicted Cmax,ss for a 10 mg/kg Q2W IV durvalumab dosing. Blue dashed vertical lines are observed median +/- IQR(interquartile range) predicted Cmax,ss for a 20 mg/kg Q4W IV durvalumab dosing. Blue solid line is median predicted Cmax,ss for a 20 mg/kg Q4W IV durvalumab dosing. Treatment cohorts are 1: 3 mg/kg durvalumab (Q4W) + 1 mg/kg Tremelimumab; 2: 10 mg/kg durvalumab (Q4W) + 1 mg/kg Tremelimumab;3: 15 mg/kg durvalumab (Q4W) + 1 mg/kg Tremelimumab; 4: 10 mg/kg durvalumab (Q4W) + 3 mg/kg Tremelimumab; 5: 20 mg/kg durvalumab (Q4W) + 1 mg/kg Tremelimumab; o1 + (t) qap y 91 :  y/ g + (t) qap y 1 9

<div style=\"page-break-after: always\"></div>

Figure 4. QTcF (change from baseline) versus concentration of tremelimumab on intercept full data

<!-- image -->

Cmax,ss maximum plasma concentration at steady state; IQR interquartile range; IV intravenous; Q2W every 2weeks;Q4Wevery 4weeks

Note: Red line is the linear regression line and the shaded area is the 90% CI based on the linear mixed-effects model prediction. Red short dashed horizontal line is 5 msec change from baseline identity line. Red long dashed horizontal line is 10 msec change from baseline identity line. Treatment cohorts are 1: 3 mg/kg durvalumab (Q4W) + 1 mg/kg Tremelimumab; 2: 10 mg/kg durvalumab (Q4W) + 1 mg/kg Tremelimumab;3: 15 mg/kg durvalumab (Q4W) + 1 mg/kg Tremelimumab; 4: 10 mg/kg durvalumab (Q4W) + 3 mg/kg Tremelimumab; 5: 20 mg/kg durvalumab (Q4W) + 1 mg/kg Tremelimumab; 6: 15 mg/kg durvalumab (Q4W) + 3 mg/kg Tremelimumab; 7: 15 mg/kg durvalumab (Q4W) + 10 mg/kg Tremelimumab; 8: 20 mg/kg durvalumab (Q4W) + 3 mg/kg Tremelimumab; 9: 10 mg/kg durvalumab (Q2W) + 1 mg/kg Tremelimumab; 10: 10 mg/kg durvalumab (Q2W) + 3 mg/kg Tremelimumab; 11: 20 mg/kg durvalumab (Q4W) + 1 mg/kg tremelimumab (Q4W)/ 20 mg/kg durvalumab (Q4W)

Table 6. Summary of maximum observed durvalumab or Tremelimumab serum concentration and predicted mean and CI of ∆QTcF

|              |   Observed Cmax (μg/mL) |    | Cohort Dosing regimen                         | Predicted mean △QTcF (ms)   | 90% CI of predicted mean△QTcF (ms)   |
|--------------|-------------------------|----|-----------------------------------------------|-----------------------------|--------------------------------------|
| Durvalumab   |                   866.6 | 10 | 20mg/kg durvalumab,  4.28 1mg/kg tremelimumab |                             | (0.36, 8.20)                         |
| Tremelimumab |                   233   |  4 | 10mg/kg durvalumab,-2.27 15mg/kg tremelimumab |                             | (-9.49, 4.96)                        |

## Absorption

Durvalumab is administered intravenously and the bioavailability is 100 %.

## Distribution

Distribution studies have not been conducted for durvalumab in the context of this application.

In an analysis that included data from HIMALAYA, the typical CL and central volume of distribution for durvalumab were 0.277 L/day and 3.45 L, respectively. The values differ less than 10% from the values

<div style=\"page-break-after: always\"></div>

derived for the model reported previously. The time-dependent clearance suggests that clearance could decrease by a maximum of 31%, which is also similar to the 39% in the previous model.

## Elimination

No studies regarding durvalumab metabolism have been conducted.

No new data has been provided from HIMALAYA on elimination.

## Dose proportionality and time dependencies

Based on the final Population PK model, time-dependent CL was identified for durvalumab in combination with tremelimumab.

A faster clearance was observed in the low dose cohorts for durvalumab. A dose-proportional increase in Cmax over the dose range of 0.1 to 20 mg/kg was observed following the first IV dose.

Durvalumab clearance has been shown to decrease over time.

For the durvalumab population PK model, estimates of inter-individual variability (CV%) were 29.9% on CL, 22.9% on V1 and 25.8% on Tmax.

## Intra- and inter-individual variability

For the tremelimumab population PK model, estimates of inter-individual variability (CV%) were 32.9% on CL, 24.9% on V1, 46.0% on V2 and 119.2% on Tmax.

For the durvalumab population PK model, estimates of inter-individual variability (CV%) were 29.9% on CL, 22.9% on V1 and 25.8% on Tmax.

## Special populations

The effect  of  intrinsic  factors  (i.e.,  race,  age,  renal  impairment,  hepatic  impairment,  sex,  and  body weight) on the PK of durvalumab has not been studied in specific dedicated studies.

Based on pop PK analyses, albumin levels (ALB), creatinine clearance, ECOG status, LDH, gender, body weight, tumor types, and combination therapy were identified as statistically significant covariates on clearance. Body weight and gender had a statistically significant impact on central volume of distribution. However, none of the covariates were considered as clinically relevant, i.e. impact on durvalumab PK was less than or about 20% in univariate testing. Accordingly, no dose adjustment seems required in these special populations.

## Pharmacokinetic interaction studies

No formal drug-drug interaction studies have been conducted with durvalumab or tremelimumab.

PK drug-drug interaction of durvalumab or tremelimumab with other therapeutics is not anticipated given that durvalumab and tremelimumab are not primarily cleared via hepatic or renal pathways; instead, the primary elimination pathways are protein catabolism via reticuloendothelial system (RES) or target-mediated disposition. Durvalumab and tremelimumab are not expected to induce or inhibit the major drug metabolizing cytochrome P450 pathways.

<div style=\"page-break-after: always\"></div>

## Pharmacokinetics using human biomaterials

No in vitro permeability, in vitro metabolism, or in vitro metabolic drug-drug interaction studies that used human biomaterials have been performed.

## Immunogenicity

In HIMALAYA, immunogenicity data were available from 684 durvalumab ADA-evaluable patients, ie, those patients who had non-missing baseline and at least 1 non-missing post-baseline ADA result for durvalumab.

Table 7: Summary of ADA responses to durvalumab (safety analysis set)

| Parameter                                           | D (N = 388)   | T300+D (N = 388)   | T75+D (N = 152)   |
|-----------------------------------------------------|---------------|--------------------|-------------------|
| Durvalumab ADA evaluable patients                   | 282 (72.7%)   | 294 (75.8%)        | 108 (71.1%)       |
| ADA positive at any visit (ADA prevalence) a        | 20 (7.1%)     | 24 (8.2%)          | 8 (7.4%)          |
| Treatment-emergent ADA positive (ADA incidence) b   | 8 (2.8%)      | 9 (3.1%)           | 5 (4.6%)          |
| Treatment-boosted ADA c                             | 1 (0.4%)      | 0                  | 0                 |
| Treatment-induced ADA (positive post-baseline only) | 7 (2.5%)      | 9 (3.1%)           | 5 (4.6%)          |
| ADA positive at baseline only                       | 12 (4.3%)     | 13 (4.4%)          | 3 (2.8%)          |
| ADA positive post-baseline and positive at baseline | 1 (0.4%)      | 2 (0.7%)           | 0                 |
| Persistently positive d                             | 8 (2.8%)      | 9 (3.1%)           | 4 (3.7%)          |
| Transiently positive é                              | 0             | 2 (0.7%)           | 1 (0.9%)          |
| nAb positive at any time                            | 2 (0.7%)      | 5 (1.7%)           | 0                 |

- b ADA incidence is the proportion of treatment-emergent patients (sum of treatment-induced ADA and treatment-boosted ADA) in the ADA-evaluable population.
- Treatment-boosted ADA is defined as baseline positive ADA titer that was boosted to ≥ 4-fold during the study period.
- P Persistently positive is having at least 2 post-baseline ADA-positive measurements with at least 16 weeks (112 days) between the first and last positive measurements, or an ADA-positive result at the last available assessment. The category may include patients meeting these criteria who were ADA-positive at baseline.
- Transiently positive is ADA-positive as baseline and having at least 1 post-baseline ADA-positive measurement and not fulfilling the conditions for persistently positive.

## 2.3.3. Pharmacodynamics

## Mechanism of action

Durvalumab is a human IgG1k mAb that binds to programmed cell death ligand-1 (PD-L1) and blocks the interaction of PD-L1 with PD-1 and CD80 (B7.1). Expression of PD-L1 can be induced by inflammatory signals  and  can  be  expressed  on  both  tumor  cells  and  tumor-associated  immune  cells  in  the  tumor microenvironment. PD-L1 blocks T-cell function and activation through interactions with PD-1 and CD80 (B7.1). By binding to its receptors PD-L1 reduces cytotoxic T-cell activity, proliferation, and cytokine production.  Blockade  of  PD-L1/PD-1  and  PD-L1/CD80  interactions  releases  the  inhibition  of  immune responses, without inducing antibody-dependent cell-mediated cytotoxicity (ADCC).

Tremelimumab is a human IgG2 mAb directed against cytotoxic  T lymphocyte-associated  antigen-4 (CTLA-4). CTLA-4 is a critical regulatory signal for T-cell expansion and activation following an immune response, and it serves as a natural braking mechanism that maintains T-cell homeostasis. During T-cell

<div style=\"page-break-after: always\"></div>

activation, T cells upregulate CTLA-4, which binds to CD80 and CD86 ligands on antigen-presenting cells, sending an inhibitory signal and preventing CD28-mediated T-cell co-stimulation, thus limiting T-cell activation.  Tremelimumab  blocks  these  events,  leading  to  prolongation  and  enhancement  of  T-cell activation and expansion.

Durvalumab and tremelimumab are checkpoint inhibitors with distinct yet complementary mechanisms of  action  with  respect  to  enhancing  the  antitumor  immune  response  triggered  by  chemotherapy. Tremelimumab mediated blockade  of  CTLA-4  functions  early  in  the  immune  response,  lowering  the threshold for T cell activation, allowing more T cells to be activated and increasing the diversity of the T cell population. This increases the probability that a T cell recognizing a tumor neoantigen can become activated. Durvalumab blockade of PD-L1 is expected to function mainly during the effector phase of T cell function, once T cells enter the tumor, where it acts to block local suppression of T-cell function by PD-L1, enhancing the ability of activated anti-tumor T cells to target and kill tumor cells.

## Primary and secondary pharmacology

## Primary pharmacology

In Study 06, Study 10, and Study 22, circulating lymphocytes (T, B, and NK cells) and proliferating (Ki67+) T cell subsets were quantified.

The data for Study 06 and Study 10 demonstrated that 15 or 20 mg/kg Q4W durvalumab (combined with doses as low as 1 mg/kg Q4W of tremelimumab) result in significant elevations in proliferating CD4 +  Ki67  +  T  cell  quantities,  demonstrating  a  pharmacodynamic  effect  consistent  with  the  proposed mechanisms of action of both durvalumab and tremelimumab. The elevations in CD4 + Ki67 + T cell quantities were dose-proportional to tremelimumab. Additionally, CD8 + Ki67 + T cells were elevated above pre-treatment levels.

In Study 22, substantial and consistent increases in CD4 + Ki67 + T cells were observed in the T300 + D, T, and T75 + D treatment arms that were associated with increasing tremelimumab dose. Increases in CD8 + Ki67 + T cells were observed in all treatment arms and peaked on Day 15. Findings indicated a  potential  saturable  pharmacodynamic  effect  on  this  lymphocyte  population,  because  equivalent elevation magnitudes were observed in the T300 + D and T arms. Among all monitored lymphocyte populations, median CD8 + Ki67 + T cell counts from patients with complete or partial response were elevated at the highest levels above those of stable disease and PD patients. Pairwise analysis using the Wilcoxon method revealed significant differences between median CD8 + Ki67 + T cell counts in patients with complete or partial response vs stable disease or PD patients (p &lt;0.01).

In Study 1108, target engagement was assessed by measuring the reduction of free sPD-L1 in serum before and following durvalumab administration. sPD-L1 data were available from 851 patients in the dose-escalation, dose-exploration, and dose-expansion cohorts following administration of durvalumab 0.1 to 10 mg/kg Q2W, 15 mg/kg Q3W, and 20 mg/kg Q4W, respectively.

Mean baseline sPD-L1 was approximately 137 pg/mL (range: 67 to 681 pg/mL). Following administration of 0.1 to 20 mg/kg durvalumab, sPD-L1 concentrations were maximally suppressed at Day 14 (or after the first dose) for all doses except 0.1 mg/kg. The extent and duration of the suppression was dosedependent. Complete sPD-L1 suppression was observed around the dose levels at  0.3 mg/kg. Following 10 mg/kg Q2W, approximately 97% of patients demonstrated complete sPD-L1 suppression throughout the dosing interval.

Suppression of free sPD-L1 was similar among 10 mg/kg Q2W, 15 mg/kg Q3W, and 20 mg/kg Q4W cohorts.

<div style=\"page-break-after: always\"></div>

Similar results were observed in Japan Study 02, where sPD-L1 was completely suppressed in all patients following administration of durvalumab 1, 3, 10 mg/kg Q2W; 15 mg/kg Q3W; and 20 mg/kg Q4W.

Likewise,  suppression  of  free  sPD-L1  was  observed  following  treatment  with  the  durvalumab  and tremelimumab combination in all study groups in Study 10 and in all but 3 patients in Study 06.

## Secondary pharmacology

Overall, concentration-QTc-analysis did not identify a significant linear relationship between tremelimumab or durvalumab serum concentrations and Δ QTcF. The predicted mean ΔQTcF and upper 90% CI at the maximum observed concentration for tremelimumab or durvalumab in the dataset were below the threshold of clinical concern. See section QTcF modelling analysis under section 2.3.2

## Exposure-response-relationships

Assessment  of  an  exposure-efficacy  relationship  was  conducted  using  overall  survival  (OS)  and progression-free  survival  (PFS)  as  efficacy  parameters  in  patients  from  HIMALAYA,  for  whom  the different exposure metrics could be calculated.

For the exposure-response analysis for efficacy (OS and PFS), only the T300 + D cohort was used, but with the SoC cohort as a comparator in some of the analyses. The exposure-response Cox proportionalhazards (CPH model) for OS and PFS was developed based on durvalumab and tremelimumab-treated patients in the HIMALAYA study. Simulated durvalumab and tremelimumab serum concentration-time PK profiles, based on individual post-hoc PK parameters, were used as a measure of exposure after T300 + D.

## Exposure-efficacy relationship

## Overall survival (OS)

The  data  for  OS  were  stratified  by  model-predicted  exposures  metrics  and  overlaid  with  data  from patients  in  the  SoC  arm.  There  were  6  exposure  metrics  used  for  durvalumab  (AUCdose 1,  Cmin,dose 1, Cmax,dose 1, AUCss, Cmin,ss, and Cmax,ss).

Figure 5 and Figure 6 shows the OS Kaplan-Meier (KM) plots for exposure metrics of durvalumab. The number of patients at risk is indicated below each plot. The KM plots indicated that there was no clear relationship between efficacy and exposure to durvalumab with all quartiles overlapping each other.

<div style=\"page-break-after: always\"></div>

Figure 5: OS Kaplan-Meier plots for durvalumab exposure metrics by quartiles at dose 1

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

Figure 6: OS Kaplan-Meier plots for durvalumab exposure metrics by quartiles at Steady State

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

The  covariates,  aspartate  aminotransferase  (AST)  and  neutrophil-to-lymphocyte  ratio  (NLR)  were identified as significant in the final model. Higher AST and NLR were associated with shorter survival in T300 + D arm, suggesting they are prognostic factors for OS. The OS Kaplan Meier plot stratified by these 2 significant covariates can be found in Figure 7. A Forest plot of the final CPH model for OS is showed in Figure 8.

<div style=\"page-break-after: always\"></div>

Figure 7: OS Kaplan Meier plots stratified by significant covariates

<!-- image -->

Time in days

Figure 8. Forest plot of the final Cox proportional-hazards model for OS

<!-- image -->

Note: Numbers at the right of the graph are the predicted HR and associated 95% CI.

## Progression-free survival (PFS)

Figure  9  shows  PFS  Kaplan-Meier  curves  for  patients  receiving  durvalumab  in  combination  with tremelimumab  AUCss,  Cmin,ss,  Cmax,ss  for  durvalumab),  data  stratified  by  model-predicted  exposures metrics and overlaid with data from patients in the SoC arm. The number of patients at risk is indicated below the plot.

The plot indicated no clear efficacy relationship to durvalumab exposure with all quartiles overlapping each other.

Timein days

<div style=\"page-break-after: always\"></div>

Figure  9:  PFS  Kaplan-Meier  plots  for  durvalumab  exposure  metrics by quartiles at Steady State

<!-- image -->

<div style=\"page-break-after: always\"></div>

Note: Shaded areas are the 95% CI around theKaplan-Meier curves.Vertical ticksrepresent the right censoring. AUCss,area under the serum concentration-time curve at steady state; CI,confidence interval;Cmax,maximum concentration,Cmin,minimum concentration;SoC,standard of care.

<!-- image -->

## Exposure-safety relationship

For assessment of an exposure-safety relationship, the evaluated safety endpoints were Grade 3 and above treatment-related AEs from HIMALAYA, Grade 3 and above AESIs, and AEs leading to durvalumab treatment discontinuation.

## Grade 3 and above treatment-related AEs

The probability  of  AEs  calculated  in  quartiles  of  the  AUCdose 1  exposure  metrics  for  durvalumab  and tremelimumab is shown in Figure 10. This figure summarizes the logistic regression results assessing the impact of exposure on the probability of AEs. The p-values associated with exposure effects were relatively large, indicating that the relationship was not statistically significant.

<div style=\"page-break-after: always\"></div>

Figure 10. Relationship between the probability of having Grade 3 and above treatment-related AEs and AUCdose 1 for durvalumab and tremelimumab

<!-- image -->

Note: The black solid circles are the observed AE, and the open squares with error bars are the observed probability of response at each exposure quartile. The black lines are the logistic regression between two variables, and the gray area represents the associated confidence interval. AE, adverse event; AUC, area under the serum concentration-time curve.

## Grade 3 and Above Treatment-related AESIs

The probability of AESIs calculated in quartiles of the AUCdose 1 exposure metrics for durvalumab and tremelimumab is shown in Figure 11.

The p-values associated with exposure effects were relatively large, indicating that the relationship was not statistically significant.

<div style=\"page-break-after: always\"></div>

Figure 11. Relationship between the probability of having Grade 3 and above treatment-related AESIs and AUC, dose 1 for durvalumab and tremelimumab

<!-- image -->

Note: The black solid circles are the observed AEs, and the open squares with error bars are the observed probability of response at each exposure quartile. The black lines are the logistic regression between two variables, and the gray area represents the associated confidence interval.

Abbreviations: AE, adverse event; AUC, area under the serum concentration-time curve.

## 2.3.4. Discussion on clinical pharmacology

Durvalumab and tremelimumab are checkpoint inhibitors with distinct yet complementary mechanisms of action with respect to enhancing the antitumor immune response. Tremelimumab mediated blockade of CTLA-4 functions early in the immune response, lowering the threshold for T cell activation, allowing more T cells to be activated and increasing the diversity of the T cell population. This increases the probability that a T cell recognizing a tumor neoantigen can become activated. Durvalumab blockade of PD-L1 is expected to function mainly during the effector phase of T cell function, once T cells enter the tumor, where it acts to block local suppression of T-cell function by PD-L1, enhancing the ability of activated anti-tumor T cells to target and kill tumor cells.

Durvalumab (Imfinzi) was approved in 2018 in the EU for treatment of adults with locally advanced, unresectable  NSCLC,  whose  disease  has  not  progressed  following  platinum-based  chemoradiation therapy.

The clinical pharmacology of durvalumab as monotherapy has previously been described adequately.

The  Applicant  is  currently  seeking  marketing  approval  for  the  use  of  a  durvalumab  (IMFINZI)  in combination with a single, priming dose of tremelimumab for the treatment of patients with unresectable hepatocellular carcinoma (uHCC).

The purpose of the present application is to update the product information for durvalumab administered in combination with tremelimumab for this indication.

The  clinical  pharmacological  data  are  derived  from  1  pivotal  study  (HIMALAYA)  and  20  supportive durvalumab studies and 17 supportive tremelimumab studies.

<div style=\"page-break-after: always\"></div>

All studies included male and female patients aged 18 years and older with advanced solid tumors. No PK data has been obtained from healthy volunteers.

The clinical pharmacology programme in special populations is considered adequate and typical for a protein drug product being administered intravenously.

The effect of hepatic and renal impairment was not formally tested in dedicated clinical trials; this is acceptable since durvalumab is a human IgG antibody, which is expected to be degraded into small peptides and amino acids via catabolic pathways in the same way as endogenous IgG.

Assessment of an exposure-efficacy relationship was conducted using OS and PFS as efficacy parameters in patients from HIMALAYA, for whom the different exposure metrics could be calculated.

OS and PFS were explored by Kaplan-Meier (KM) estimates and analyzed by Cox proportional-hazards models.

For OS the KM plots indicated that there was no clear relationship between efficacy and exposure to durvalumab with all quartiles overlapping each other.

The  covariates,  aspartate  aminotransferase  (AST)  and  neutrophil-to-lymphocyte  ratio  (NLR)  were identified as significant in the final model. Higher AST and NLR were associated with shorter survival in T300 + D arm, suggesting they are prognostic factors for OS.

For PFS the KM plots indicated no clear efficacy relationship to durvalumab exposure with all quartiles overlapping each other. Overall, no covariate was identified to be related with PFS in this analysis.

Additional explorative analyses of the covariates, body weight, and ADA status for durvalumab exposure (data not shown) did not indicate any clear trend between OS or PFS and body weight or ADA status. However, the small number of ADA-positive patients after durvalumab treatment mean that the KaplanMeier plots for ADA status should be interpreted with caution.

For assessment of exposure-safety relationship, the evaluated safety endpoints were Grade 3 and above treatment-related adverse events (AEs) from HIMALAYA, Grade 3 and above Adverse event of special interest (AESIs) and AEs leading to durvalumab treatment discontinuation.

None  of  the  tremelimumab  or  durvalumab  exposure  metrics  in  a  logistic  regression  analysis  were identified to have an influence on safety events.

A body weight-AE analysis did not identify any clear trend between the probability of AEs and increasing or decreasing body weight.

Both the ADA incidence and prevalence were similar across treatment arms (D, T300+D and T75+D), it is agreed that the presence of tremelimumab did not have an apparent effect on the immunogenicity of durvalumab.

## 2.3.5. Conclusions on clinical pharmacology

The clinical pharmacology of durvalumab in combination with tremelimumab has overall been adequately described.

## 2.4. Clinical efficacy

This extension of indication for durvalumab is based on efficacy data from HIMALAYA, a randomised, open-label, multicentre Phase III study in patients with unresectable hepatocellular carcinoma (HCC) not

<div style=\"page-break-after: always\"></div>

eligible  for  locoregional  therapy  and  with  no  prior  systemic  therapy  for  HCC.  Additional  supportive evidence of clinical efficacy is provided from study 22, a randomised, phase I/II, open-label study.

Table  8.  Overview  of  Studies  in  the  Clinical  Development  Program  for  Durvalumab  in Combination With Tremelimumab and Durvalumab Monotherapy in Patients With uHCC

| Study number and acronym   | Studytitle                                                                                                                                                                                                                  | Study design                                                               | Objective                                                                                    | DCO date(s)        | Location in Module5   |
|----------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------|----------------------------------------------------------------------------------------------|--------------------|-----------------------|
| Pivotal Study              | Pivotal Study                                                                                                                                                                                                               | Pivotal Study                                                              | Pivotal Study                                                                                | Pivotal Study      | Pivotal Study         |
| D419CC00002 HIMALAYA       | A Randomized,Open-label, MulticenterPhaseIIIStudyof Durvalumab and Tremelimumab as First-line TreatmentinPatients WithAdvancedHepatocellular Carcinoma (HIMALAYA)                                                           | Phase III, randomized, open-label, sponsor-blind, multicenter.global study | To assess the efficacy and safety ofT300+D vs S and D vs S                                   | FA:27 August 2021  | 5.3.5.1               |
| SupportiveStudy            | SupportiveStudy                                                                                                                                                                                                             | SupportiveStudy                                                            | SupportiveStudy                                                                              | SupportiveStudy    | SupportiveStudy       |
| D4190C00022 Study 22       | A Study of Safety,Tolerability, and Clinical Activity of DurvalumabandTremelimumab Administered as Monotherapy,or Durvalumabin CombinationWith TremelimumaborBevacizumab in Subjects with Advanced Hepatocellular Carcinoma | PhaseI/II,randomized, open-label, multicenter. international study         | Parts 2 and 3:To assess the safety, tolerability, and clinical activity of T300+D, D, and T. | FA:06November 2020 | 5.3.5.2               |

(20mg/kg)Q4W;uHCC=unresectablehepatocellularcarcinoma.

## 2.4.1. Main study

A Randomized, Open-label, Multicenter Phase III Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma (HIMALAYA)

Study design for the pivotal trial is illustrated in Figure 12.

Figure 12. HIMALAYA: Study Design

<!-- image -->

Patient numbers shown correspond to the actual enrollment.

<div style=\"page-break-after: always\"></div>

Enrollment into the T75+D arm was closed following protocol edition 4.0 (29 November 2018). Patients randomized to T75+D prior to protocol amendment 3 could continue on their assigned study treatment, provided the Investigator and patient agreed this was i n the patient's best interest. Patients randomized to T75+D arm who had not completed or started all 4 doses of tremelimumab could either complete the full schedule or continue with durvalumab monotherapy only

## Methods

## Study participants

Patients were enrolled at 181 sites and randomized at 170 study centers in 16 countries: Brazil (13 centers), Canada (9), France (14), Germany (10), Hong Kong (5), India (10), Italy (8), Japan (27), South Korea (8), Russian Federation (10), Spain (6), Taiwan (9), Thailand (9), Ukraine (8), United States of America (21), and Vietnam (3).

## Inclusion Criteria

For inclusion in the study, patients had to fulfill all of the following criteria:

1. Age ≥ 18 years at the time of screening.
2. Body weight &gt; 30 kg.
3.  Written  informed  consent  and  any  locally  required  authorization  obtained  from  the  patient/legal representative prior to performing any protocol-related procedures, including screening evaluations.
4. Confirmed HCC based on histopathological findings from tumor tissues.
5. Must not have received prior systemic therapy for HCC.

6.  Ineligible  for  locoregional  therapy  for  unresectable  HCC.  For  patients  who  progressed  after locoregional therapy for HCC, locoregional therapy must have been completed ≥ 28 days prior to the baseline scan for the current study.

7. BCLC stage B (ie, not eligible for locoregional therapy) or stage C.
8. Child-Pugh score class A.
9. ECOG performance status of 0 or 1 at enrollment.

10. Patients with HBV infection, characterized by positive HBsAg and/or anti-HBcAb with detectable HBV DNA ( ≥ 10 IU/mL or above the limit of detection per local or central laboratory standard), must be treated with antiviral therapy, per institutional practice, to ensure adequate viral suppression (HBV DNA ≤ 2000 IU/mL) prior to enrollment. Patients were to remain on antiviral therapy for the study duration and for 6 months after the last dose of study treatment. Patients who tested positive for HBc with undetectable HBV DNA (&lt; 10 IU/mL or under the limit of detection per local or central laboratory standard) did not require antiviral therapy prior to enrollment. These patients were tested at every cycle to monitor HBV DNA levels and antiviral therapy initiated if HBV DNA was detected ( ≥ 10 IU/mL or above the limit of detection per local or central laboratory standard). HBV DNA detectable patients were to initiate and remain on antiviral therapy for the study duration and for 6 months after the last dose of study treatment.

11. Patients with HCV infection: Confirmed diagnosis of HCV characterized by the presence of detectable HCV RNA or anti-HCV antibody upon enrollment.

12. At least 1 measurable lesion, not previously irradiated, that could be accurately measured at baseline as ≥ 10 mm in the longest diameter (except lymph nodes, which must have a short axis ≥ 15 mm) with CT or MRI, and that is suitable for accurate repeated measurements as per RECIST 1.1 guidelines. A

<div style=\"page-break-after: always\"></div>

lesion which progressed after previous ablation or transarterial chemoablation could be measurable if it met these criteria.

13. Adequate organ and marrow function, as defined below. Criteria ' a', ' b, ' ' c, ' and ' f ' could not be met with transfusions, infusions, or growth factor support administered within 14 days of starting the first dose.

- a. Hemoglobin ≥ 9 g/dL
- b. Absolute neutrophil count ≥ 1000/ μ L
- c. Platelet count ≥ 75000/ μ L
- d. TBL ≤ 2.0 × ULN
- e. AST and ALT ≤ 5 × ULN
- f. Albumin ≥ 2.8 g/dL

g.  INR ≤ 1.6.  Note:  INR  prolongation  due  to  anticoagulants  for  prophylaxis  (eg,  atrial  fibrillation)  in patients without liver cirrhosis could be an exception h. Calculated creatinine clearance ≥ 50 mL/min as determined by Cockcroft-Gault (using actual body weight) or 24 h urine creatinine clearance

14.  Evidence  of  postmenopausal  status  or  negative  urinary  or  serum  pregnancy  test  for  female premenopausal patients.

15. Life expectancy of at least 12 weeks.

## Exclusion Criteria

Any of the following was regarded as a criterion for exclusion from the study:

1. Involvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site).
2. Previous study treatment (s) assignment in the present study.
3.  Concurrent  enrollment  in  another  clinical  study,  unless  it  is  an  observational  (non-interventional) clinical study or during the follow-up period of an interventional study.
4. Received an IP within 28 days prior to the first dose of study treatment.

5. Any unresolved toxicity NCI CTCAE Grade ≥ 2 from previous anticancer therapy with the exception of alopecia, vitiligo, and the laboratory values defined in the inclusion criteria:

- Patients with Grade ≥ 2 neuropathy were evaluated on a case-by-case basis after consultation with the Study Physician
- Patients  with  irreversible  toxicity  not  reasonably  expected  to  be  exacerbated  by  treatment  with durvalumab or tremelimumab could be included only after consultation with the Study Physician.

6. Any concurrent chemotherapy, study treatment, or biologic or hormonal therapy for cancer treatment. Concurrent  use  of  hormonal  therapy  for  non-cancer-related  conditions  (eg,  hormone  replacement therapy) was acceptable.

7.  Known  allergy  or  hypersensitivity  to  any  of  the  study  treatments  or  any  of  the  study  treatment excipients.

<div style=\"page-break-after: always\"></div>

8. Radiotherapy treatment to more than 30% of the bone marrow or with a wide field of radiation within 28 days of the first dose of study treatment.

9. Major surgical procedure (as defined by the Investigator) within 28 days prior to the first dose of study treatments. Note: Local surgery of isolated lesions for palliative intent was acceptable.

10. History of allogeneic organ transplantation (eg, liver transplant).

11. History of hepatic encephalopathy within the past 12 months or requirement for medications to prevent  or  control  encephalopathy  (eg,  no  lactulose,  rifaximin,  etc  if  used  for  purposes  of  hepatic encephalopathy).

12. Clinically meaningful ascites, defined as any ascites requiring non-pharmacologic intervention (eg, paracentesis) to maintain symptomatic control, within 6 months prior to the first scheduled dose. Patients on stable doses of diuretics for ascites for ≥ 2 months were eligible.

13. Patients with main portal vein thrombosis (ie, thrombosis in the main trunk of the portal vein, with or without blood flow) on baseline imaging.

14. Active or prior documented GI bleeding (eg, esophageal varices or ulcer bleeding) within 12 months. Note: For patients with a history of GI bleeding for more than 12 months or assessed as high risk for esophageal varices by the Investigator, adequate endoscopic therapy according to institutional standards was required).

15. Current symptomatic or uncontrolled hypertension defined as DBP &gt; 90 mmHg or SBP &gt; 140 mmHg.

16. Any condition interfering with swallowing pills, uncontrolled diarrhea, or other contraindication to oral therapy.

17. Active or prior documented autoimmune or inflammatory disorders (including inflammatory bowel disease [eg, colitis or Crohn's disease], diverticulitis [with the exception of diverticulosis], systemic lupus erythematosus, Sarcoidosis syndrome, or Wegener syndrome [granulomatosis with polyangiitis, Graves' disease, rheumatoid arthritis, hypophysitis, uveitis, etc]). Patients without active disease in the last 5 years were excluded unless discussed with the Study Physician and considered appropriate for study participation.

The following were exceptions to this criterion:

- Vitiligo or alopecia
- Hypothyroidism (eg, following Hashimoto syndrome) stable on hormone replacement
- Any chronic skin condition not requiring systemic therapy
- Patients with celiac disease controlled by diet alone

18. Co-infection with HBV and HCV or HBV and HDV. HBV positive (presence of HBsAg and/or anti-HBcAb with detectable HBV DNA); HCV positive (presence of anti-HCV antibodies); or HDV positive (presence of anti-HDV antibodies).

19.  Uncontrolled  intercurrent  illness,  including  but  not  limited  to,  ongoing  or  active  infection, symptomatic  congestive  heart  failure,  uncontrolled  hypertension,  unstable  angina  pectoris,  cardiac arrhythmia, ILD, serious chronic GI conditions associated with diarrhea, inferior vena cava thrombosis, or psychiatric illness/social situations that would limit compliance with study requirements, substantially increase the risk of incurring AEs, or compromise the ability of the patient to give written informed consent.

20. History of another primary malignancy except for:

<div style=\"page-break-after: always\"></div>

- Malignancy treated with curative intent and with no known active disease ≥ 5 years before the first dose of study treatment and of low potential risk for recurrence
- Patients with a history of prostate cancer of stage ≤ T2cN0M0 without biochemical recurrence or progression  and  who,  in  the  opinion  of  the  Investigator,  are  not  deemed  to  require  active intervention
- Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease
- Adequately treated carcinoma in situ without evidence of disease

## 21. History of leptomeningeal carcinomatosis.

22. History of, or current, brain metastases or spinal cord compression. Patients with suspected brain metastases at screening should have an MRI (preferred) or CT, each preferably with IV contrast of the brain prior to study entry.

23. Known fibrolamellar HCC, sarcomatoid HCC, or mixed cholangiocarcinoma and HCC.

24. History of active primary immunodeficiency.

25. Active infection including TB (clinical evaluation that included clinical history, physical examination and radiographic findings, and TB testing in line with local practice), or HIV (positive HIV1/2 antibodies)

26. Current or prior use of immunosuppressive medication within 14 days before the first dose of study treatment, with the exception of the following:

- Intranasal, inhaled, topical steroids, or local steroid injections (eg, intra-articular injection)
- Systemic  corticosteroids  at  physiologic  doses  not  to  exceed  10  mg/day  of  prednisone  or equivalent
- Steroids as premedication for hypersensitivity reactions (eg, CT scan premedication)

27. Receipt of live attenuated vaccine within 30 days prior to the first dose of study treatment. Note: Patients, if enrolled, should not receive live vaccine while receiving study treatment and up to 30 days after the last dose of study treatment.

28. Female patients who were pregnant or breastfeeding, or male or female patients of reproductive potential who were not willing to employ effective birth control from screening to 90 days after the last dose of durvalumab monotherapy or 180 days after the last dose of durvalumab plus tremelimumab combination therapy. Not engaging in sexual activity, as per the patient ' s preferred and usual lifestyle, for the total duration of the treatment and washout periods was an acceptable practice.

29.  Prior  randomization  or  treatment  in  a  previous  durvalumab  and/or  tremelimumab  clinical  study regardless of treatment arm assignment.

30. Patients who had received anti-PD-1, anti-PD-L1, or anti-CTLA-4 prior to the first dose of study treatment.

<div style=\"page-break-after: always\"></div>

## Treatments

Table 9. Study Treatments

| Treatment arm   | Description                                                                                                                                                                                                                                                                           |
|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| D               | Durvalumab monotherapy 1500 mg Q4W until confirmed PD, unacceptable toxicity, or any discontinuation criteria were met                                                                                                                                                                |
| T75+D           | Tremelimumab (75 mg) × 4 doses + durvalumab (1500 mg) Q4W followed by durvalumab monotherapy (1500 mg) Q4W until confirmed PD, unacceptable toxicity, or any discontinuation criteria were met. a                                                                                     |
| T300+D          | Tremelimumab (300 mg) × 1 dose + durvalumab (1500 mg) Q4W, followed by durvalumab 1500 mg monotherapy Q4W until confirmed PD, unacceptable toxicity, 0r any discontinuation criteria were met                                                                                         |
| S               | Sorafenib 400 mg (2 × 200 mg tablets) orally BID, until confirmed PD at the Investigator's discretion, unacceptable toxicity, or any discontinuation criteria were met. (Suspected sorafenib-related toxicities were managed based on the approved product label for each country). b |

- Following protocol amendment 3, enrollment into the T75+D arm was closed. Patients randomized to T75+D prior to protocol amendment 3 could continue on assigned study treatment (provided the Investigator and patient agreed it was in the best interest of the patient) until confirmed PD or any other discontinuation criteria were met. If a patient assigned to T75+D had not completed or started all 4 doses of tremelimumab,the patient was able to continue to complete the full schedule or continue with durvalumab monotherapy only.
- In countries where sorafenib was not approved, the following modification was followed: sorafenib dose may be reduced to 400 mg (2 × 200 mg tablets) orally once daily. If additional dose reduction was required, the sorafenib dose could be reduced to a single 400 mg dose (2 × 200-mg tablets) orally every other day.

BID, twice daily; CSP, Clinical Study Protocol; Q4W, every 4 weeks; PD, disease progression.

The proposed dosing regimen for the relevant arm for this procedure (T300+D, arm C) is new and encompasses one single initial dose of tremelimumab 300 mg in combination with durvalumab 1500 mg and thereafter, durvalumab monotherapy iv Q4W until PD or unacceptable toxicity.

The relevant comparator arm for the current procedure was the standard of care arm (SOC, arm D), which contains sorafenib 400 mg orally twice daily as standardly dosed, and treatment should have also been given until PD or unacceptable toxicity. No cross-over was allowed.

The two other treatment arms with D (durvalumab 1500 mg Q4W, arm A) and T75+D (tremelimumab 75 mg Q4W × 4 doses + durvalumab 1500 mg Q4W, followed by durvalumab 1500 mg Q4W, arm B) are not of relevance for this procedure.

It  is  noted  that  although  the  combination  of  a  CTLA-4  inhibitor,  such  as  tremelimumab,  and  an immunecheckpoint inhibitor such as durvalumab is not new, it is the first time that the anti-CTLA-4 is given only as an induction dose and then monotherapy with durvalumab is continued until PD. Moreover, the already approved combination therapy with ipilimumab + nivolumab differs as nivolumab is PD-1 inhibitor, while durvalumab is a PD-L1 inhibitor.

The Applicant claims that pharmacodynamic results reported for tremelimumab and durvalumab in Study 006 suggest that the pharmacodynamic effects of anti-CTLA-4 are mainly associated with the first dosing cycle and subside in subsequent cycles regardless of dose. Moreover, these results led to the hypothesis that a single dose of tremelimumab might accomplish similar pharmacodynamic effects as seen in Study 006  and  also  seen  for  ipilimumab,  while  also  limiting  the  toxicity  associated  with  the  second  (and subsequent) anti-CTLA-4 dosing cycles.

<div style=\"page-break-after: always\"></div>

## Objectives

Table 10. Study Objectives and Endpoints

| Objective                                                                                                                | Outcome measure                                                                                                                                                                                                                                                                       |
|--------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Primary objective:                                                                                                       | Primaryendpoint/variables:                                                                                                                                                                                                                                                            |
| To assess the efficacy of T300+D vs S (for superiority)                                                                  | OS                                                                                                                                                                                                                                                                                    |
| Key secondary objectives:                                                                                                | Key secondary endpoint/variables:                                                                                                                                                                                                                                                     |
| To assess the efficacy of D vs S (for non- inferiority)                                                                  | OS                                                                                                                                                                                                                                                                                    |
| To assess the efficacy of D vs S (for superiority)                                                                       | OS                                                                                                                                                                                                                                                                                    |
| Secondary objectives:                                                                                                    | Secondaryendpoint/variables:                                                                                                                                                                                                                                                          |
| To assess the efficacy of D vs S and T300+D vs S                                                                         | OS18,OS24,and OS36 PFS, TTP, ORR, DCR, DCR-16w, DCR-24w, and DoR, accordingtoRECIST 1.1usingInvestigator assessments                                                                                                                                                                  |
| To assess the efficacy of D and T300+D in patients with an opportunity for 32 weeks of follow-up                         | ORR, BOR, and DoR according to RECIST1.1 and mRECIST by BICR                                                                                                                                                                                                                          |
| To assess the efficacy of D vs S and T300+D vs S by PD-L1 expression                                                     | OS PFS,TTP,ORR,DCR,DCR-16w,DCR-24W,andDoR according toRECIST 1.1 usingInvestigator assessments                                                                                                                                                                                        |
| To assess disease-related symptoms, impacts, and HRQoL in D vs S and T300+D vs S                                         | EORTC QLQ-C30:Time to deterioration in globalhealth status/QoL, functioning (physical), multi-term symptom (fatigue), single-item symptoms (appetite loss, nausea) EORTC QLQ-HCC18: Time to deterioration in single-item symptoms (shoulder pain, abdominal pain, abdominal swelling) |
| To investigate the immunogenicity of D and T300+D                                                                        | Presenceof ADA for durvalumaband tremelimumab                                                                                                                                                                                                                                         |
| To evaluate the population PK and pharmacodynamics in D and T300+D                                                       | Durvalumabandtremelimumabconcentrations andPK parameters in individual arms                                                                                                                                                                                                           |
| Safety objectives:                                                                                                       | Safety endpoint/variables:                                                                                                                                                                                                                                                            |
| To assess the safety and tolerability profile across all treatment arms                                                  | AEs and laboratory findings a                                                                                                                                                                                                                                                         |
| Exploratory objectives:                                                                                                  | Exploratoryendpoint/variables:                                                                                                                                                                                                                                                        |
| To assess PFSfromrechallenge in the T300+Darmandto assessPFSfromfirst post-discontinuation therapy in D, T300+D, and S b | PFSFR and PFSNT usingInvestigator assessments                                                                                                                                                                                                                                         |

<div style=\"page-break-after: always\"></div>

| Objective                                                                                                                                                            | Outcomemeasure                                                                                                                                                                                                                              |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| To assess the efficacy of Dvs S and T300+D vs S using irRECIST and mRECIST for HCC b                                                                                 | PFS,TTP,ORR,DCR, DCR-16w,DCR-24w,andDoR according to irRECIST and mRECIST and by BICR,if performed                                                                                                                                          |
| To investigate the relationship between the progressive changes in AFP level and efficacy parameters b                                                               | Association of AFP expression level with: OS PFS, TTP, ORR, DoR, DCR, DCR-16w, and DCR-24w according to RECIST 1.1 usingInvestigator assessments                                                                                            |
| To investigate the efficacy of D vs S and T300+D vs S by baseline gene expression b                                                                                  | Association of interferon-gamma and immune-related gene expression, as measured by mRNA levels from baseline tumor biopsies and blood, with OS PFS,TTP,ORR,DoR,DCR,DCR-16w,andDCR-24w according to RECIST 1.1 usingInvestigator assessments |
| Toinvestigate the efficacy of Dvs S and T300+Dvs S by candidatebiomarkers that may correlatewith drug activity or identify patients likely to respond to treatment b | Associationofintratumoralimmunecellnumbers (specifically CD8+ T cells), ctDNA, and/or tumor mutations with: OS PFS,TTP,ORR,DoR,DCR,DCR-16w and DCR-24w according toRECIST 1.1 usingInvestigator assessments                                 |
| Toinvestigate the efficacy of Dvs S in patients who are at low risk of early mortality based on baseline characteristics b                                           | OS                                                                                                                                                                                                                                          |
| To assess the efficacy of D vs T300+D in the overall population and in the population defined by PD-L1 expression b                                                  | OS PFS, TTP, ORR, DCR, DCR-16w, DCR-24w and DoR, by according to RECIST 1.1 using Investigator assessments                                                                                                                                  |
| Toassesspatient-reported treatment tolerability directly using specific items of the PRO-CTCAE questionnaire in D vs S and T300+D vs S                               | PRO-CTCAE symptoms (11 items)                                                                                                                                                                                                               |
| Healthcareresource utilization                                                                                                                                       | EQ-5D-5L Hospital admission form                                                                                                                                                                                                            |
| To assess physician-reported patient outcome in D vs S and T300+D vs S                                                                                               | ECOG performance status                                                                                                                                                                                                                     |
| To assess the efficacy of the discontinued immunotherapy arm (T75+D) for descriptive purposes                                                                        | OS PFS, TTP, ORR, DCR, DCR-16w, DCR-24w, and DoR according to RECIST 1.1 using Investigator assessments                                                                                                                                     |

## Outcomes/endpoints

Please refer to Table 10 above regarding the objectives and endpoints for the pivotal study Himalaya.

## Sample size

This  study  was  planned  to  screen  approximately  1650  patients,  with  no  prior  systemic  therapy  for hepatocellular  carcinoma  (HCC)  and  not  eligible  for  locoregional  therapy,  in  order  to  randomize approximately  1310  patients.  (This  included  1155  patients  randomized  to  Arms  A  (Durvalumab monotherapy), C (T300+D), D (S) with 385 per arm; and approximately 155 patients in Arm B (T75+D), randomized prior to the closure of this arm). The study was sized to characterize the OS benefit of Arm C vs. Arm D (T300+D vs S).

<div style=\"page-break-after: always\"></div>

The sample size estimation assumed an exponentially distributed OS and a 2-month delay in separation of the OS curves for Arm C vs. Arm D. A non-uniform accrual of patients with a duration of 22 months was assumed when estimating the analysis times.

For the efficacy comparisons, the median OS for sorafenib (Arm D) was assumed to be 11.5 months, with an 18-month OS rate of 33.8%.

## Durvalumab 1500 mg plus tremelimumab 300 mg × 1 dose (Arm C) versus sorafenib 400 mg BID (Arm D) (OS in FAS [ITT])

The assumed OS treatment effect was an average HR of 0.70 for Arm C versus Arm D. This translates to an increase in median OS from 11.5 months to 16.5 months, and in the 18-month OS rate from 33.8% to 46.8% in Arm C versus Arm D. Final analysis of OS was planned to be performed when approximately 515 events in Arm C and Arm D combined (~67% maturity) have occurred. This number of OS events was foreseen to provide 97% power to demonstrate a statistically significant difference in OS at a 2sided 4.25% significance level. The smallest treatment difference that could be observed as statistically significant at the final analysis was foreseen to be an average HR of 0.84 (an increase in median OS from 11.5 months to 13.7 months in Arm C versus Arm D).

No formal sample size calculations were associated with the analyses planned for IA1. However, global enrollment was required to be completed prior to the DCO for IA1.

There were 2 IAs and a FA planned for HIMALAYA. Any major changes to the planned analyses were addressed in protocol amendments finalized prior to the date of the first DCO for Interim analysis 1 for ORR (02 September 2019). These changes were informed by the open-label Study 22 and study readouts from external studies in the same disease area, including KEYNOTE-240 and CheckMate-459. No HIMALAYA data were available for use to modify the protocol design or statistical analysis plan.

The sample size calculations were updated several times while the study was ongoing. Major changes were implemented in the Protocol version 4 (29 Nov 2018) and in Protocol version 6 (20 Aug 2019). In protocol version 4, the arm durvalumab + tremelimumab 75 mg was closed due to unfavourable results obtained in the supportive Study 22. At this point, the sample size for the remaining arms was increased to 385 and the number of required events at the second interim analysis and at the final analysis was changed. In protocol version 6, the median OS and 18-month OS rate for sorafenib was increased from 10 months and 28.7 % to 11.5 months and 33.8 %, respectively. The required number of events at the second interim analysis and at the final analysis were also changed.

The Applicant claimed that the changes made in the protocol and SAP were solely informed by external data including Study 22 and KEYNOTE-240 and CheckMate-459. Nevertheless, changes in the sample size while the study is ongoing can jeopardize the interpretation of the results since they may alter the behavior of study participants and personnel. The changes were implemented between 1 and 2 years from study start, and one month before the first interim analysis (2 Sep 2019). Therefore, the sample size calculations are not considered relevant and the study results were assessed based on the size of the confidence intervals.

## Randomisation

Subjects were planned to be randomized in a 1:1:1:1 ratio to one of the following 4 arms:

- 1) Arm A: Durvalumab 1500 mg monotherapy
- 2) Arm B: Tremelimumab 75 mg × 4 doses plus Durvalumab 1500 mg combination therapy
- 3) Arm C: Tremelimumab 300 mg × 1 dose plus Durvalumab 1500 mg combination therapy

<div style=\"page-break-after: always\"></div>

## 4) Arm D: Sorafenib 400 mg BID.

Protocol amendment 4 closed enrolment to Arm B. As a result of protocol amendment 4, subjects were randomized  in  a  1:1:1  ratio  to  Arm  A,  Arm  C  and  Arm  D.  Subjects  randomized  to  Arm  B  prior  to amendment 4 could have remained on study as planned until discontinuation criteria were met at the discretion of the investigator.

Randomization  was  foreseen  to  be  stratified  according  to  macrovascular  invasion  (yes  versus  no), etiology of liver disease (hepatitis B virus [confirmed HBV] versus hepatitis C virus [confirmed HCV] versus others), and ECOG PS (0 versus 1).

A randomization list was produced for each of the randomization stratum. A blocked randomization was generated, and all centers used the same list in order to minimize any imbalance in the number of patients assigned to each treatment arm.

## Blinding (masking)

The study was open-label. The Study Team, responsible for the conduct of the study, was blinded to randomized treatment assignment until formal study unblinding occured at Interim Analysis 2 (IA2) or the Final Analysis (FA). The Study Team members were not planned to have access to any information regarding the interim analysis results. If a Study Team member was needed to join the Submission Team, this member was not allowed to re-join the Study Team until the Study Team and Study Database are formally unblinded at IA2 or FA. This study used an external IDMC that comprised independent therapeutic area experts and biostatisticians to assess ongoing safety as well as the interim efficacy analyses. The IDMC remit was to report to the Sponsor and if applicable recommend changes to study conduct.

Measures were in place to ensure that the Study team was blinded to treatment assignment and results from the interim analyses. An IDMC assessed safety data ongoing and performed the interim analyses.

## Statistical methods

## Full analysis set

The full analysis set (FAS) was planned to include all randomized patients, including patients who were randomized  in  error.  The  FAS  was  planned  to  be  used  for  all  efficacy  analyses  (including  PROs). Treatment arms were to be compared on the basis of randomized study drug(s), regardless of the study drug(s) actually received. Patients who were randomized but did not subsequently go on to receive study drug(s) were included in the analysis in the treatment arm to which they were randomized.

For IA1 an additional analysis set was planned to be defined: FAS subjects with an opportunity for 32 weeks of follow up at the time of IA1 (FAS32w, i.e., randomized ≥ 32 weeks prior to IA1 DCO).

The primary analysis was performed using the FAS, which includes all randomized patients. For the first IA, only subjects who had the opportunity to attend at least 32 weeks of follow-up were included. The results of the first IA are not related to the primary objectives of the study.

<div style=\"page-break-after: always\"></div>

## Statistical analyses

Table 11. Formal Statistical Analyses to be Conducted and Pre-planned Sensitivity

Endpoint

Overall survival (OS)

ProgressionFree Survival (PFS)

Time to progression (TTP)

Analysis

Primary analysis:Stratifiedlog-ranktest(forp-value),

HRfromCoxmodel(with95%CI)

Sensitivityanalyses:

Attritionbias.Kaplan-Meierplotof time-to-censoringwhere thecensoringindicator

of the primary analysisisreversed.

Exploratoryanalysisusingmax-combotest.

ImpactofCOVID19.OSanalysiswill be repeatedbutsubjectswhodiedfromCOVID-19

InfectionwillbecensoredattheirCOVID

infectiondeathdate.

Primary analysis: Stratified log-rank test using

Investigator assessments perRECIST 1.1 (for p-value),

HRfromCoxmodel(with95%CI)

Primary analysis:Stratified log-rank test using

Investigator assessmentsperRECIST 1.1(for p-value),

HR from Cox model (with 95% CI)

| Endpoint                                                                  | Analysis                                                                                                                                       |
|---------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------|
| Objective response rate (ORR)                                             | IA1: Exact confidence intervals; IA2 and FA: Logistic regression using Investigator assessmentsper RECIST 1.1 (oddsratiowith95%CI and p-value) |
| Best Objective Response (BoR)                                             | Descriptive statistics                                                                                                                         |
| Duration ofresponse (DoR)                                                 | Descriptive statistics including KM plot                                                                                                       |
| Disease control rate (DCR, DCR-16w, DCR-24w)                              | Descriptive statistics                                                                                                                         |
| Proportion of subjects alive at 18m (Os18)                                | KMestimatesofOSat18months                                                                                                                      |
| Proportion of subjects alive at 24m (OS24)                                | KMestimatesofOSat24months                                                                                                                      |
| Proportion of subjects alive at 36m (OS36)                                | KMestimatesofOSat36months Stratified chi-square test of difference in KM estimators at a fixed time point (36 months) (for p-value)            |
| PFS from rechallenge                                                      | Summarized by treatment armusingInvestigator assessments per RECIST 1.1.                                                                       |
| PFSonnexttreatment                                                        | Summarized by treatment arm                                                                                                                    |
| Time todeterioration(EORTCQLQ-C30 and EORTC QLQ-HCC18)                    | Stratified 1og-rank test (for p-value), HR from Cox model (with 95% CI), KM plot                                                               |
| EORTC QLQ-C30, EORTC QLQ-HCC18                                            | Average changefrombaseline using anMMRM analysis,Summarystatistics                                                                             |
| Improvement based best overall response (EORTC QLQ-C30, EORTC QLQ- HCC18) | Logistic regression with odds ratio, 95% CI and p-value                                                                                        |
| EQ-5D-5L,PGIC, PRO-CTCAE                                                  | Summarystatistics                                                                                                                              |

EORTC European Organisation for Research and Treatment of Cancer; EQ-5D-5L EuroQoL 5-Dimension, 5-Level health state utility index; MMRM Mixed effect model repeat measurement; OS overall survival; QLQ-C3030-item core quality of life questionnaire; QLQ-HCC1818-item hepatocellular cancer healthrelated quality of life questionnaire.

## Overall survival

The primary OS endpoint was to be analysed using a stratified log-rank tests adjusting for etiology of liver  disease  (confirmed  HBV  versus  confirmed  HCV  versus  others),  ECOG  (0  versus  1),  and macrovascular invasion (yes versus no) for generation of the p-value and using rank tests for association

<div style=\"page-break-after: always\"></div>

as the testing approach, which corresponds to Cox regression with the Breslow approach for handling ties (Breslow, 1974).

The effect of Arm C vs. Arm D treatment was to be estimated by the HR from stratified Cox proportional hazards  model  (with  ties=Efron  and  stratification  variables  as  listed  above)  together  with  its corresponding  95%  confidence  interval  (CI)  calculated  using  a  profile  likelihood  approach.  The stratification variable used the values recorded in the randomization system (IWRS).

If there is &gt;10% discordance in stratification factors as recorded in IWRS versus the Case Report Form (CRF), then a sensitivity analysis of the primary endpoint OS was to be performed using CRF based stratification factors.

Secondary OS analyses were to be performed using the same methodology as for primary analysis described above.

## Censoring rules for OS

Any subject not known to have died at the time of analysis was planned to be censored based on the last recorded date on which the subject was known to be alive.

## Assumptions of Proportionality

The  assumption  of  proportionality  of  hazard  was  to  be  assessed  first  by  examining  plots  of complementary log-log (event times) versus log (time) and, if these raise concerns, by fitting a timedependent  covariate  to  assess  the  extent  to  which  this  represents  random  variation.  If  a  lack  of proportionality of hazard is evident, the variation in treatment effect was to be described by presenting piecewise  HR  calculated  over  distinct  time  periods.  The  Grambsch-Therneau  test  and  Schoenfeld residuals may have also been used to check violation of the proportional hazards assumption. As a lack of  proportionality  was  expected  (due  to  delayed  effect  in  IO  agents),  a  three-component  stratified MaxCombo test was planned to be used as a sensitivity analysis with the same stratification factors as the primary analysis. The Restricted Mean Survival Time (RMST) was also to be analysed up to the minimum of the largest observed event time in each of the two arms and /or suitable clinically relevant timepoint. In addition, an area-under-the-curve approach (Kaplan-Meier method) and Royston-Parmar model (Royston and Parmar 2011, 2013) may also have been used.

## Sensitivity analysis

- Censoring patterns: A sensitivity analysis for OS was planned to examine the censoring patterns to  rule  out  attrition  bias,  achieved  by  a  Kaplan-Meier  plot  of  time-to-censoring  where  the censoring indicator of OS was reversed.
- Impact  of  switching  (crossover  outside  of  this  study)  to  other  immunotherapies  (or  other potentially active investigational agents) on OS analyses: Exploratory analyses of OS adjusting for the impact of subsequent switching of immunotherapy or the investigational treatment may have been performed, if a sufficient proportion of subjects switched.
- Effect of COVID-19: A sensitivity analysis was planned to be conducted to assess for the potential impact of COVID deaths on OS. This was to be assessed by repeating the OS analysis except that any subject who had a death with primary/secondary cause as COVID-19 Infection was to be censored at their COVID infection death date.
- Effect of covariates on the HR estimate: Cox proportional hazards modelling was to be employed to assess the effect of pre-specified covariates on the HR estimate for the primary OS treatment comparisons. As an exploratory analysis, the covariates from the model in the primary analysis and the model containing additional covariates may have been presented.

<div style=\"page-break-after: always\"></div>

## OS12, OS18, OS24, and OS36

OS12, OS18, OS24, and OS36 were to be defined as the Kaplan-Meier estimate of OS at 12 months, 18 months, 24 months, and 36 months. OS12, OS18, OS24, and OS36, along with their 95% CI, were to be summarized (using the Kaplan- Meier curve) and presented by treatment arm. An analysis of OS36 was to be performed to compare Arm C vs. Arm D using a stratified chisquare test for the difference in KM estimators (cloglog transformed) for Arms C and D at a fixed time point (36 months). The test was to be conducted using the methods described in (Klein et al., 2007), including cloglog transformation on KM  estimators,  with  randomization  stratification  factors  (macrovascular  invasion,  etiology  of  liver disease, and ECOG). Note that the adjustment for the stratification factors was planned to be applied only if there were sufficient number of events and subjects at risk available in each strata at 36 months. Otherwise, an unstratified chisquare test was to be used to compare the difference in KM estimators at 36 months.

OS was analysed using a stratified log-rank tests adjusting for the factors used at randomization: etiology of  liver  disease  (confirmed  HBV  versus  confirmed  HCV  versus  others),  ECOG  (0  versus  1),  and macrovascular invasion (yes versus no). The HR was to be estimated using a stratified Cox model. The fulfilment  of  the  proportional  hazard  assumption  was  investigated  using  a  graphical  approach  and  a maxcombo test. Sensitivity analyses were planned to explore the impact of treatment switch, covid 19 and effect of covariates. Censoring patterns were examined using the reverse Kaplan-Meier method. Patients not known to have died were censored at the last observation date.

The statistical method implemented to analysis OS is overall endorsed. The Applicant has clarified that the  concordance  rate  between  stratification  factors  entered  in  the  IWRS  vs  eCRF  at  screening  and baseline is high and due to &lt;10% discordance rate, the threshold for triggering the sensitivity analysis was  not  met.  Hence,  no  sensitivity  analysis  for  primary  efficacy  analysis  of  OS  adjusted  for  eCRF stratification factors at baseline has been conducted, which is acceptable.

## Objective response rate based on Investigator assessment (ORR)

Data obtained up until progression, or the last evaluable assessment in the absence of progression, was planned to be included in the assessment of ORR. Subjects who went off treatment without progression, received a subsequent therapy, and then responded were planned not be included as responders in the ORR. ORR based on at least one confirmed response will also be derived and reported in CSR.

Logistic  regression  models  adjusting  for  the  same  factors  as  the  primary  endpoint  (etiology  of  liver disease, ECOG, and macrovascular invasion) was planned to be fitted. The results of the analysis were planned to be presented in terms of an odds ratio together with its associated profile likelihood 95% CI (e.g. using the option 'LRCI' in SAS procedure GENMOD) and p -value (based on twice the change in loglikelihood resulting from the addition of a treatment factor to the model).

Additionally, at IA2 and FA a stratified Cochran Mantel -Haenszel (CMH) test was planned to be performed using randomization stratification factors (macrovascular invasion, etiology of liver disease, and ECOG). CMH test results were foreseen to include odds ratios and p-values.

## Progression Free Survival by Investigator (PFS)

Analysis of PFS (time to first progression) was planned to be performed to compare Arm C vs. Arm D and Arm A vs. Arm D using the same methodology as for OS. Exploratory analyses compared Arm A vs. Arm C.

<div style=\"page-break-after: always\"></div>

Table 12. Censoring rules for PFS

| Assessment                                                                                  | Outcome    | DateofProgressionor Censoring                               |
|---------------------------------------------------------------------------------------------|------------|-------------------------------------------------------------|
| Nobaselineassessmentsornoevaluableresponse visits（excludingdeathswithin2visitsofbaseline)   | Censored   | Randomizationdate                                           |
| Nobaselineorevaluabletumor assessmentsanddeathProgressedDateofdeath within2visitsofbaseline |            |                                                             |
| Progressiondocumentedbetweenscheduledvisits                                                 |            | ProgressedDate of assessment ofprogression                  |
| Noprogression(ordeath)attimeofanalysis                                                      | Censored   | Dateoflastevaluabletumor assessment                         |
| Deathbetweenassessmentvisits                                                                | Progressed | Dateofdeath                                                 |
| Death orprogression after 2 ormore missed visits                                            | Censored   | Dateoflastevaluabletumor assessmentpriortothe2missed visits |

PFS Progression-free survival.

## Interim analyses

Two interim analyses and a final analysis were planned as described below:

Interim Analysis 1 (IA1): The first interim analysis was planned to be performed after approximately 100 subjects per treatment arm have had the opportunity for 32 weeks of follow-up and not prior to the last subject enrolled. The objective was to evaluate the efficacy of Arm A and Arm C in terms of ORR and DoR. The analysis set for ORR and DoR were the FAS-32wA. BICR of radiological scans were to be performed on all subjects included in IA1 who have been randomized and have had the opportunity for at least 32 weeks follow-up. Both Investigator (using RECIST 1.1) and BICR (using RECIST 1.1 and mRECIST)  assessments  were  planned  for  IA1.  Therefore,  ORR  and  DoR  (for  both  confirmed  and unconfirmed responses) according to both Investigator using RECIST 1.1 and BICR using RECIST 1.1 and mRECIST were reported for IA1.

Interim Analysis 2 (IA2): The second interim analysis was planned to be performed when approximately 404 OS events in Arm C and Arm D combined (~52% maturity), approximately 30 months after the first subject was randomized. The goal was to evaluate the efficacy of Arm C vs. Arm D (for superiority) and then  Arm  A  vs.  Arm  D  (for  non-inferiority,  then  superiority)  in  terms  of  OS.  It  is  anticipated  that approximately 453 OS events would have occurred across Arms A and D combined (~59% maturity) at the time of the DCO for IA2.

Final Analysis (FA): The final analysis was expected to be performed when approximately 515 OS events in Arm C and Arm D combined (~67% maturity), approximately 37.5 months after the first subject was randomized. The primary objective was to assess the efficacy of Arm C vs. Arm D in terms of OS for superiority. The key secondary objectives were to assess the efficacy of Arm A vs. Arm D in terms of OS (for non-inferiority, then superiority). It was anticipated that approximately 560 OS events would have occurred across Arms A and D combined (~73% maturity) at the time of the DCO for the final analysis. Efficacy  data  for  Arm  B  (which  was  closed  for  enrollment  with  Amendment  4)  were  planned  to  be summarized descriptively, however were not be formally analysed.

## Multiplicity

To strongly control the familywise error rate (FWER) at the 5% level (2-sided), an alpha level of 0.1% was planned to be spent on the interim ORR analysis (IA1) while the remaining 4.9% alpha level were

<div style=\"page-break-after: always\"></div>

planned to be spent on all OS analyses. The primary objective of OS was to be tested (H1: Arm C vs. Arm D) with 4.9% for this comparison.

Since two analyses of OS were planned (Interim Analysis, Final Analysis), the Lan DeMets approach (Lan and DeMets 1983) that approximates the O'Brien and Fleming spending function was planned to be used to maintain an overall 2-sided 4.9% type I error across the two planned analyses of OS (Interim and Final) for the primary comparison (H1: Arm C vs. Arm D).

If all the OS analyses (H1, H2, and H3) were considered successful (superiority tests were statistically significant  and  non-inferiority  was  achieved),  the  4.9%  alpha  level  were  to  be  passed  to  test  the difference in the three-year survival rates (OS36) between Arm C and Arm D; otherwise, the test would not have been conducted. The study was to be considered positive (a success) if the primary OS analysis result was statistically significant at either IA2 or FA. If significance was achieved at IA2, it did not need to be tested again at FA.

Figure 13. Multiple testing strategy

<!-- image -->

The MAH planned to perform 2 interim and 1 final analyses. The first interim analysis was planned to be performed after 100 subjects per treatment arm have had the opportunity for 32 weeks of follow-up. The objective is to evaluate the efficacy of Arm A and Arm C in terms of ORR and DoR. This analysis was not related to the primary objective of the study. The second interim analysis was related to OS and planned to be performed after 404 OS events were observed (~52% maturity). The final OS analysis was planned  to  be  performed  after  515  OS  events  (~67%  maturity)  had  been  observed.  The  MAH implemented a hierarchical approach to protect the type I error due to multiple hypotheses being tested (OS superiority for T300+D vs S, OS non-inferiority for D vs S, OS superiority D vs S). An inflation of the type I error due to multiple looks was avoided using an alpha spending function.

The implemented strategy to control the type I error is endorsed. Of note, the results presented in the CSR corresponds to the final analysis for OS.

## Changes to Planned Analyses

Changes to the statistical analyses planned are shown in Table 13. The AstraZeneca study team was responsible for all changes to the planned statistical analyses. All major changes were made prior to the DBL for the final analysis (DCO: 27 August 2021) (data not shown). Minor changes to the algorithms for counting the number of dose delays for S and for determination of analysis windows for T and D were made after the SAP was finalized.

<div style=\"page-break-after: always\"></div>

Table 13. Changes to Planned Analyses

| KeyDetailsofChange(Section of Report Affected)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | Reason for Change                                                                 |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------|
| Two additional efficacy endpoints that were not detailed in the CSP were calculated: time to response and time from randomization to first subsequent therapy or death. Neither endpoint is reported in theCSR                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | To support the payer analysis                                                     |
| Section 6.5 of the CSP (see Appendix 16.1.1) does not define or provide instructions for determining AEPIs. The latest list of PTs was used to determine both AESIs and AEPIs (Section 9.8.6.2)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | For completeness                                                                  |
| The following details of the non-inferiority approach were added to the SAP(see Sections 1.3 and 4.2.2.1 of Appendix 16.1.9) to supplement the information provided on the non-inferiority margin in Sections 8.2 and 8.5 of the CSP (see Appendix 16.1.1): results of the 3 studies used to determine the non-inferiority margin clarification that the assumedHRfor the comparison of Dvs S is based on the results in Checkmate 459 for nivolumab vs sorafenib in the same population (Yau et al 2019) resultsfrom 4 other studies that were designedwith non-inferiority toasorafenib control infirst-line HCC Section 4.2.2.1 also specifies that for the interim and final analyses of the primary OS and key secondary analyses (including non-inferiority),adjusted alphalevels are derived based on the exact number of OSevents using theLan andDeMets approach that approximates the O'BrienFleming spendingfunction. Section 4.2.2.1 clarifies that the primary analysis method (log-rank test)will be used to assess non-inferiority and superiority for the | Provisionofadditionaldetailsandsources for the chosenstatistical analysis methods |
| The CSPindicated that details of the China cohort and the corresponding analysisplan would be outlinedin a China-specific amendment and SAP. As no patients were enrolled in the China cohort, a China-specificSAP was not prepared                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | No longer required                                                                |
| A testofthe3-yearoverallsurvivalrate(OS36)betweenT300+D andSwasadded totheMTPinSAPSection4.2.1.Thetestis describedinSAPSection 4.2.3.7.Section 4.2.1clarifiesthat onlyin the case thatall OSanalyseswerestatisticallysignificant andnon- inferioritywasachievedforDvsS,wouldthe4.9%alphalevelbe passed to test the difference in the 3-year survival rates(OS36) betweenT300+DandS.Section4.2.3.7providesthedetailsofthe testforOS36;thetestwouldbeperformedusingthestratified method describedin(Kleinet al2007),using stratificationfactors collectedatrandomization(macrovascularinvasion,etiology of liverdisease,andECOG).Theadjustmentforstratificationfactors wouldbeappliedonlyif therearesufficientnumberofeventsand numberofsubjectsatriskavailableineachstratumat36months, otherwiseunstratifiedmethodsfrom(Kleinetal2007)wouldbe used.                                                                                                                                                                                                                        | Tofurtherassessefficacybetween T300+D and S                                       |

AEPI,adverse event of possible interest;AESI,adverse event of special interest;CSP,clinical study protocol; CSR,clinical studyreport；D,durvalumabmonotherapy1500mgQ4W;ECOG.Eastem Cooperative Oncology Group:HCC,hepatocellularcarcinoma:HR,hazardratio;OS,overallsuvival;OS36,OSat36months;PT preferred term;S,sorafenib400mg twice daily;SAP,statistical analysisplan;T75+D,tremelimumab75mg ×4 doses+durvalumab1500mgQ4W;T300+D.tremelimumab300mg×1dose+durvalumab1500mgQ4W.

<div style=\"page-break-after: always\"></div>

<!-- image -->

| Key details of ainendment (section of this report affected)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | Reasonforamendment                                                                                                                                                                                                                                                                              |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Nomajorupdates                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | Released to correct administrative errorsnoted inCSPversion 4.0                                                                                                                                                                                                                                 |
| Protocol amendment 5,Protocol version 6.0 (20 August 2019)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |                                                                                                                                                                                                                                                                                                 |
| Statistical analysis methods revised to change dual primary objectives to hierarchical approach with a single primary objective (T300+D vs S for superiority) and 2 key secondary objectives(DvsSfor non-inferiority,thenDvsSfor superiority)of OS (Section9.8): The multiple testing strategy was updated to reflect the procedure for controlling the type 1 error given the update from dual primary objectives to a hierarchical approach with a single primary objective and 2key secondary objectives of OS ORRandPROendpointswereremovedfrom theMTP The number of events, maturity, power and 2-sided significance levels for these analyseswere updated | An IA of the ongoing Study 22 suggested that the best clinical benefit (intermsofORRandOS)wasobservedinpatientswhoreceived the T300+D combination when compared to durvalumab monotherapy, tremelimumab monotherapy, or T75+D. As a result, the primary analysisfor the current studywasrevised |
| Efficacy assessments in IA1, ie, RECIST 1.1 and mRECIST analyses (ORR, BOR, DoR) by BICR for the IA1 set of patients with an opportunity for 32 weeks of follow-up were added as a secondary objective. It was also clarified that enrollment had to be completed beforeIA1 could beperformed (Section8)                                                                                                                                                                                                                                                                                                                                                        | To clarify analyses in IA1                                                                                                                                                                                                                                                                      |
| The order of hypotheses for superiority was changed: H1: T300+D vs S and H3: D vs S.A new hypothesis was added -H2: for non-inferiority D vs S (Section 9.8)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | To align with revised objectives                                                                                                                                                                                                                                                                |

There are 4 versions of the SAP: SAP edition 1 (25 Oct 2017), SAP edition 2 (23 Aug 2019), SAP edition 3 (15 May 2020), and SAP edition 4 (30 July 2021). Several amendments were done to the study protocol throughout the study and the SAP was therefore updated. Major changes to the study design were made in Protocol version 5 (20 Aug 2019) where the objectives of the study, primary endpoints and the testing hierarchy were modified.

<div style=\"page-break-after: always\"></div>

## Results

## Participant flow

## Figure 14. Patient Disposition

<!-- image -->

- Informed consent received. The reported value of 2011 includes 61 rescreened subjects who each received a new subject ID code during the rescreening phaseper protocol.The actual number of subjectsenrolled was1950.
- b Patients confirmed alive in follow-up or on active study treatment at the time of final analysis reported 'study completion' on the disposition eCRF.
- Patientsongoinginstudy are thesameaspatientswho completed thefinal analysis.
- P Percentages are calculated from the number of patients who received treatment in the Global Study.For combination therapy patients durvalumab reason is reported.

Compl., completed; D, durvalumab monotherapy 1500 mg Q4W; DCO, data cutoff; Discont., discontinued or discontinuation; PD, disease progression; Q4W,every4weeks;S,sorafenib400 mgtwice daily;T75+D,tremelimumab75mg×4 doses+durvalumab1500mgQ4W;T300+D,tremelimumab 300mg×1dose+durvalumab1500mgQ4W

Source: Table 14.1.1

<div style=\"page-break-after: always\"></div>

Table 14. Subject Disposition (All subjects, DCO 27 Aug 2021)

|                                                     | Number(%)of subjects   | Number(%)of subjects                 | Number(%)of subjects               | Number(%)of subjects   | Number(%)of subjects   |
|-----------------------------------------------------|------------------------|--------------------------------------|------------------------------------|------------------------|------------------------|
|                                                     | Durva 1500 mg          | Treme 300 mg x1 dose + Durva 1500 mg | Treme 75 mg x4 doses + Durva1500mg | Sora 400 mg BID        | Total                  |
| Subjects enrolleda                                  |                        |                                      |                                    |                        | 2011                   |
| Subjects randomized                                 | 389                    | 393                                  | 153                                | 389                    | 1324                   |
| Subjectswhowerenotrandomizedb                       |                        |                                      |                                    |                        | 687                    |
| Eligibility criteria not fulfilled                  |                        |                                      |                                    |                        | 654 (95.2)             |
| Other                                               |                        |                                      |                                    |                        | 33 (4.8)               |
| Subjectswhoreceivedtreatment                        | 386 (99.2)             | 389 (99.0)                           | 153 (100)                          | 374 (96.1)             | 1302 (98.3)            |
| Subjectswho did notreceive treatment                | 3 (0.8)                | 4 (1.0)                              | 0                                  | 15 (3.9)               | 22 (1.7)               |
| Subjects ongoing study treatment at data cut-offe   | 44 (11.4)              | 44 (11.3)                            | 5 (3.3)                            | 21 (5.6)               | 114 (8.8)              |
| Subjects who discontinued initial study treatmented | 342 (88.6)             | 345 (88.7)                           | 148 (96.7)                         | 353 (94.4)             | 1188 (91.2)            |
| Subject decision                                    | 23 (6.0)               | 19 (4.9)                             | 6 (3.9)                            | 34 (9.1)               | 82 (6.3)               |
| Adverse event                                       | 30 (7.8)               | 52 (13.4)                            | 24 (15.7)                          | 63 (16.8)              | 169 (13.0)             |
| Severenon-compliancetoprotocol                      | 1 (0.3)                | 0                                    | 0                                  | 1 (0.3)                | 2 (0.2)                |
| Objective disease progression                       | 222 (57.5)             | 183 (47.0)                           | 88 (57.5)                          | 170 (45.5)             | 663 (50.9)             |
| Development ofstudyspecificdiscontinuationcriteria  | 3 (0.8)                | 5 (1.3)                              | 0                                  | 2 (0.5)                | 10 (0.8)               |
| Subject lost to follow-up                           | 0                      | 1 (0.3)                              | 0                                  | 0                      | 1 (0.1)                |
| Subjective disease progression                      | 44 (11.4)              | 61 (15.7)                            | 21 (13.7)                          | 66 (17.6)              | 192 (14.7)             |
| Other                                               | 19 (4.9)               | 24 (6.2)                             | 9 (5.9)                            | 17 (4.5)               | 69 (5.3)               |
| Subjects ongoing studyef                            | 0                      | 0                                    | 0                                  | 0                      | 0                      |
| Subjects who terminated studye                      | 389 (100)              | 393 (100)                            | 153 (100)                          | 389 (100)              | 1324 (100)             |
| Death                                               | 275 (70.7)             | 260 (66.2)                           | 122 (79.7)                         | 280 (72.0)             | 937 (70.8)             |
| Lost to follow-up                                   | 1 (0.3)                | 1 (0.3)                              | 0                                  | 7 (1.8)                | 9 (0.7)                |
| Screen failure                                      | 0                      | 0                                    | 0                                  | 0                      | 0                      |
| Withdrawal by subject                               | 9 (2.3)                | 7 (1.8)                              | 1 (0.7)                            | 20 (5.1)               | 37 (2.8)               |
| Other                                               | 104 (26.7)             | 125 (31.8)                           | 30 (19.6)                          | 82 (21.1)              | 341 (25.8)             |
| Completed final analysisf                           | 104 (26.7)             | 125 (31.8)                           | 30 (19.6)                          | 80 (20.6)              | 339 (25.6)             |

root/cdar/d419/d419cc00002/ar/csr/restricted\\_tlf/prod/program/dm001.sasdm001afa.rtf01DEC2021:11:26kwxd463

No  study  sites  were  terminated  or  paused  due  to  the  COVID-19  pandemic.  Patient  enrollment  was completed prior to the start of the pandemic. A total of 107 patients were impacted by visit, procedure, or treatment delays due to the pandemic, resulting in 281 protocol deviations (Table 15).

<div style=\"page-break-after: always\"></div>

Table 15. Important Protocol Deviations (FAS)

|                                                                                                                                                                      | N (%) of patients   | N (%) of patients   | N (%) of patients   | N (%) of patients   | N (%) of patients   |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------|---------------------|---------------------|---------------------|---------------------|
| Important protocol deviations *                                                                                                                                      | D (N= 389)          | T300+D (N=393)      | T75+D (N=153)       | S (N= 389)          | Total (N=1324)      |
| Number of subjects with at least 1 important deviation                                                                                                               | B (0.8)             | 9 (2.3)             | 3 (2.0)             | 21 (5.4)            | 36 (2.7)            |
| Active or prior documented autoinmme orinflammatory disorders b                                                                                                      | 0                   | 0                   | 0                   | 1 (0.3)             | 1 (0.1)             |
| Additional investigational systemic anticancer therapy concurent with those umder investigation in this study (as specified in CSP Section 7.7)                      | 0                   | 1 (0.3)             | 0                   | 0                   | 1 (0.1)             |
| Baseline tumor assessments (RECIST1.1) performed more than 28 days before the first dose of study treatment                                                          | 0                   | 0                   | 0                   | 2 (0.5)             | 2 (0.2)             |
| Child-Pugh score was not class A                                                                                                                                     | 0                   | 1 (0.3)             | 1 (0.7)             | 3 (0.8)             | 5 (0.4)             |
| Concurent chemotherapy. radiotherapy, immumotherapy, biologic or hormonal therapy for cancer treatment other than those umder investigation in this study            | 0                   | 1 (0.3)             | 1 (0.7)             | 0                   | 2 (0.2)             |
| Patient randomized but did not receive study treatment                                                                                                               | 3 (0.8)             | 4 (1.0)             | 0                   | 15 (3.9)            | 22 (1.7)            |
| Patientreceived/used incorrect medication (ie, expired medication, incorrect kit ID, incoirect dose, altermative study treatment to what which they were randomized) | 0                   | 2 (0.5)             | 0                   | 0                   | 2 (0.2)             |
| Patients co-infected with HBV and HCV, or co-infected with HBV and hepatitis D vinus (HDV). c                                                                        | 0                   | 1 (0.3)             | 0                   | 0                   | 1 (0.1)             |
| Patients with main portal vein tumor thrombosis (Vp4)                                                                                                                | 0                   | 1 (0.3)             | 1 (0.7)             | 0                   | 2 (0.2)             |

The same patient may have had more than 1 important protocol deviation

- Includes inflanmatory bowel disease (eg, colitis or Crohn's disease), diverticulitis (with the exception of diverticulosis), systemic hupus erythematosus, Sarcoidosis syndrome, or Wegener syndrome (gramulomatosis with polyangitis, Graves' disease, theumatoid arthritis, hypophysitis, uveitis, etc.). Active disease (outside of the allowed exceptions) in the last 5 years that has not been discussed with the Study Physician and considered appropriate for study participation
- HBV positive (presence of HbsAg and/or anti-HbcAb with detectable HBV DNA); HCV positive (presence of anti-HCV antibodies); HDV positive (presence of anti-HDV antibodies)

<div style=\"page-break-after: always\"></div>

Table 16. Not randomized patients with 'other' reason for screening failure

| Reason for screening failure                                                                                         |   Number of patients |
|----------------------------------------------------------------------------------------------------------------------|----------------------|
| Because it was possible that selection criterion 12 would not be satisfied.                                          |                    1 |
| Eligibility was not able to be verified within 28 days so patient was reconsented with a new screening id: e7824009. |                    1 |
| Exceeded screening time (new screening number 0704006)                                                               |                    1 |
| Incorrect activation of the patient                                                                                  |                    1 |
| Issue due to sorafenib shipment                                                                                      |                    1 |
| Not recorded                                                                                                         |                    7 |
| Patient died due to progression disease, before randomization.                                                       |                    1 |
| Patient doesn't meet inclusion criteria 3, as patient withdrew informed consent                                      |                    1 |
| Patient was withdrawal                                                                                               |                    1 |
| Screen fail due to insurance reasons                                                                                 |                    1 |
| Screen failure                                                                                                       |                    2 |
| Screening assessment could not be completed during screening date                                                    |                    1 |
| Screening assessments were not completed during screening.                                                           |                    2 |
| Screening period was greater than 28 days because some examinations was missing                                      |                    1 |
| Sf due to death                                                                                                      |                    1 |
| Subject does not come to site                                                                                        |                    1 |
| Subject fell out of screening window.                                                                                |                    1 |
| Subject was unable to provide tumor sample                                                                           |                    1 |
| Subject withdrawn in the middle of screening                                                                         |                    1 |
| Time for screening was exceeded.                                                                                     |                    1 |
| Screening assessments were not completed during screening.                                                           |                    1 |
| Unable to be randomized within 28 days of icf                                                                        |                    1 |
| Unable to submit tumor sample                                                                                        |                    1 |
| Withdrawal during screening                                                                                          |                    2 |

Of 1950 patients enrolled in the pivotal study, 61 were rescreened and 1324 were randomized to 1 of the 4 original treatment arms. The Applicant has clarified that of the 687 non-randomized patients, 654 did not fulfil eligibility criteria and 33 were not randomized due to other reasons. The screen failure reasons of these 33 patients as collected as free text field in CRF are summarized in Table 16: 10/33 patients  were  not  randomized  due  to  inability  to  complete  screening  procedures  within  the  28-day window, 6/33 withdrew informed consent or failed to return to clinic, 2/33 were unable to provide the required tumor tissue sample, and 2/33 died prior to randomization. In addition, 9/33 did not report more  specific  screen  failure  reasons.  Other  reasons  were  reported  in  1  patient  each  and  included insurance coverage issues, incorrect screening, inability to verify eligibility, or local issues with sorafenib supply.  The  clarification  is  accepted,  and  the  screen  failure  reasons  are  in  line  with  what  could  be expected for a clinical trial with the targeted patient population.

## Recruitment

The first patient was enrolled on 11 October 2017 and the last patient on 19 June 2019. The median follow-up for OS at DCO (27 August 2021) was ~33 months in the T300+D arm and ~32 months in the S arm.

<div style=\"page-break-after: always\"></div>

## Conduct of the study

Table 17. Protocol Amendments and Other Significant Changes to Study Conduct

| Key detailsof amendment(sectionof thisreport affected)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | Reasonforamendment                                                                                                                                                                                                         |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Protocolamendment 1,Protocol version 2.0 (20Deceimber 2017)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |                                                                                                                                                                                                                            |
| Updated descriptionsof risksfor durvalumab,tremelimumab,and the combination of durvalumab with tremelimumab (Section 12.2.4). Toxicity Management Guidelines replaced with new version from 01 November 2017.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | To align with updates across the clinical program and Investigator's Brochure                                                                                                                                              |
| Inclusion of the exploratory objective: to assessPFSfrom rechallenge in the durvalumab plus tremelimumab combination arms only, and to assess PFS from first post-IP discontinuation therapy in all arms                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | Additional exploratory objectiveofinterest                                                                                                                                                                                 |
| Section 9.3 IC10 amended toclarify treatment ofpatientswithHBVinfectionwith antiviral clarify that patients who test positive for HBc with undetectable HBV DNA (< 10 IU/ml) do not require antiviral therapy prior to enrollment. These patients were to be tested at every cycle to monitor HBV DNA levels and initiate antiviral therapy ifHBV DNA was detected(>10IU/ml).HBV DNA detectable patientswere to initiate and remain on antiviral therapy for the study duration and for 6 months after thelastdoseofIP New IC15 requiring patients to have a life expectancy of at least 12 weeks non-pharmacologic intervention eg, paracentesis or escalation in pharmacologic intervention tomaintain symptomatic control),within 6 months prior to the first scheduled dose\", rather than “ascites that require ongoing paracentesis, within 6 weeks prior to the first scheduled dose to control symptoms.\" The amended EC12 alsoindicates patients onstable doses of diuretics for ascites for>2 months are eligible EC22 qualified to indicate that a history of, or current, brain metastases was an exclusion | IC10: to ensure patients receive antiviral medication as clinicallyindicated IC15: for compliance with new CSP template EC12:to clarify protocol definition of clinicallymeaningful ascites EC22: to ensure patient safety |
| Updated AESI terminology (Section 12.2.4)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | To alignwithupdates across the clinical program                                                                                                                                                                            |
| Protocol amendment 2,Protocolversion3.0(23January 2018)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                                                                                                                                                                                            |
| No majorupdates                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Released tocorrecterrorsnotedinCSPversion 2.0                                                                                                                                                                              |
| Protocol amendment3,Protocolversion4.0(29November 2018)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                                                                                                                                                                                            |

| Key details of amendment (section of thisreport affected)                                                                                                                                                                                                                                                                                                                                                                                                                             | Reasonfor amendment                                                                                                                                                                                                                                                                                                                    |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Enrollment into the T75+D arm was closed, based on results from a pre-planned IA evaluating tolerability and clinicalactivityin StudyD419CC00022.Allother arms were unchanged (Section 9.1)                                                                                                                                                                                                                                                                                           | In the ongoingStudy 22,safety data showed that theT75+Dregimen was tolerable with no new safety signals.However,efficacy data for theT75+Dregimendidnotdifferentiateitfromthedurvalumab monotherapy arm. Thus, there was insufficient clinical activity observed towarrant continuing enrollment in the T75+D arm in the current study |
| Following closure of enrollment in the T75+D arm,the primary and secondary objectives were re-aligned: The original primary objective of OS for T75+D vs S was replaced with D vs S and T300+D vs S for OS. Other supportive endpoints were clarified for consistency across the CSP, and a new endpoint (DCR-16w)was added (Section 8)                                                                                                                                               | To alignwith study design changes                                                                                                                                                                                                                                                                                                      |
| Themultiple testing strategy was updated toreflect the procedure for controlling the type 1 error as a result of the changes to the primary and secondary objectives. PRO endpointswere added to theMTP(Section 9.8.3)                                                                                                                                                                                                                                                                | To alignwithstudy designchanges                                                                                                                                                                                                                                                                                                        |
| Update such that IA1 was performed after approximately 100 patients per treatment arm had the opportunity for 32 rather than 24 weeks of follow-up (Section 9.8.9)                                                                                                                                                                                                                                                                                                                    | To ensure 24 weeks of imaging follow-up,the baseline scan needs to be8weeks prior to thefirst follow-up scan,ie, a total of 32weeks                                                                                                                                                                                                    |
| Thesamplesizewas updated to align with closure ofenrollment in the T75+D arm.The number of events, maturity, power and 2-sided significance levels for these analyses were updated accordingly and theMTPwas updated toreflect therevised procedurefor controlling the type 1 error. No changes were made to the assumed HRs, timelines, or medianOS.ThestatisticalmethodswererevisedtoindicatetheT75+Darmwouldbe summarized descriptively, but not formally analyzed (Section 9.8.1) | To alignwith study design changes                                                                                                                                                                                                                                                                                                      |
| Patients in the T75+D arm could continue toreceive their assigned treatment according to the CSP (Section 9.4)                                                                                                                                                                                                                                                                                                                                                                        | To align with study design changes                                                                                                                                                                                                                                                                                                     |
| Patients in theT75+D arm whowere eligibleforrechallenge could berechallengedwith either75mgtremelimumab×4dosesor300mgtremelimumabx1doseincombination withdurvalumab1500mg(withprior approvalfrom theAstraZenecaclinical team) (Section 9.4.1.5)                                                                                                                                                                                                                                       | To alignwith study design changes                                                                                                                                                                                                                                                                                                      |
| EC19 amended to include “inferior vena cava thrombosis\" (Section9.3.2)                                                                                                                                                                                                                                                                                                                                                                                                                | Patientswithinferiorvenacavathrombosiswereexcludedduetothe riskofpulmonaryembolism andsuddendeath                                                                                                                                                                                                                                      |
| Protocol amendment4,Protocolversion5.0(17Deceimber 2018)                                                                                                                                                                                                                                                                                                                                                                                                                              | Protocol amendment4,Protocolversion5.0(17Deceimber 2018)                                                                                                                                                                                                                                                                               |

<div style=\"page-break-after: always\"></div>

| No major updates                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | Released to correct administrative errors noted in CSPversion 4.0                                                                                                                                                                                                                                                                                                        |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Protocol amendment 5,Protocolversion 6.0(20August 2019)                                                                                                                                                                                                                                                                                                                                                                                                                                        | Protocol amendment 5,Protocolversion 6.0(20August 2019)                                                                                                                                                                                                                                                                                                                  |
| Statistical analysis methods revised to change dual primary objectives to hierarchical approach with a single primary objective (T300+D vs S for superiority) and 2 key (Section 9.8): type 1 error given the update from dual primary objectives to a hierarchical approach with a singleprimary objective and 2key secondary objectives ofOs ORR andPRO endpointswereremoved from theMTP The number of events, maturity, power and 2-sided significance levels for these analyseswereupdated | An IA of the ongoing Study 22 suggested that the best clinical benefit (in terms of ORR and Os)was observed in patients who received the T300+D combination when compared to durvalumab monotherapy, tremelimumab monotherapy, or T75+D. As a result, the primary analysis for the current study was revised                                                             |
| Efficacy assessmentsinIA1,ie,RECIST 1.1 and mRECIST analyses(ORR,BOR,DoR) by BICRfor the IA1set of patientswith an opportunity for 32weeks of follow-upwere added as a secondary objective. It was also clarified that enrollment had to be completed before IA1 could be performed (Section 8)                                                                                                                                                                                                | To clarify analyses in IA1                                                                                                                                                                                                                                                                                                                                               |
| The order of hypotheses for superiority was changed: H1: T300+D vs S and H3: D vs S. A                                                                                                                                                                                                                                                                                                                                                                                                         | To alignwith revised objectives                                                                                                                                                                                                                                                                                                                                          |
| The assessment of efficacy for the comparison of D vs T300+D in the overall population and in the population defined byPD-L1 expressionwas changed from a secondary to an exploratoryobjective(Section8)                                                                                                                                                                                                                                                                                       | Archival tissueup to3years of agewas allowedfor theHIMALAYA study. Data suggest that sample age may affect PD-L1 expression status (eg,PD-L1 expression measured in an older sample might be lower than PD-L1 expression at the current time for a patient). Therefore,it was decided to change the assessment of efficacy by PD-L1expression toan exploratory objective |
| An exploratory objective relating to patients with early mortality risk was added (Section 8)                                                                                                                                                                                                                                                                                                                                                                                                  | This was an exploratory objective of interest                                                                                                                                                                                                                                                                                                                            |
| Protocol amendment 6,Protocol version 7.0 (22 September 2021)                                                                                                                                                                                                                                                                                                                                                                                                                                  | Protocol amendment 6,Protocol version 7.0 (22 September 2021)                                                                                                                                                                                                                                                                                                            |

| Key detailsof amendment (section of thisreport affected)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | Reasonfor amendment        |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------|
| The OS at 36months (OS36)was added to the secondary objectives (proportion of patients alive at 36 months after randomization [OS36]). The OS36 was defined as the KM estimate of OS at 36 months after randomization (Section 9.8.4.1). Clarifiedthatpatientsin all treatment arms,notjustdurvalumab,maycontinuetoreceive treatment following thefinal primary analysisDCO. Added that long-term follow-up data may be collected in eCRFs post final primary analysisfor approximately3years and defined end of study,iflong-termfollow-up is collected post final primary analysis, as the last visit of the last patient in the study. | To further assess efficacy |

AESI, adverse event of special interest;BICR,blinded independent central review;BOR,best overallresponse;CSP,Clinical StudyProtocol;D,durvalumab monotherapy1500 mg Q4W;DCO,data cut-off;DCR-16w,disease control rate at 16 weeks;DNA,deoxyribonucleic acid;DoR,duration ofresponse; EC,exclusion criterion;HBc,hepatitis B core;HBV,hepatitis Bvirus;HR,hazard ratio;IA1,interim analysis 1;IC,inclusion criterion;IP,investigational product;KM,Kaplan-Meier; mRECIST, modified Response Evaluation Criteria inSolid Tumors; MTP,multiple testing procedure; ORR, objective response rate; OS, overall survival;PD-L1, programmed cell death ligand-1; PFS, progression-free survival; PRO, patient-reported outcome; Q4W, every 4 weeks; RECIST 1.1,Response Evaluation Criteria in Solid Tumors version 1.1; S, sorafenib 400 mg twice daily;T75+D, tremelimumab75 mg × 4 doses + durvalumab 1500mgQ4W;T300+D,tremelimumab300mg×1dose+durvalumab1500mgQ4W.

Table 18. Summary of Overall Survival: T300+D Versus Sorafenib and D Versus Sorafenib (PDL1 Analysis Set)

| Subgroup                   | Treatment   |   Number of Patients | Events (%)   | Median (months) (95% CI)   | Hazard Ratio (95% CI)   |
|----------------------------|-------------|----------------------|--------------|----------------------------|-------------------------|
| PD-L1 Evaluable patients a | T300+D      |                  337 | 229 (68.0)   | 16.00 (13.11, 19.58)       | 0.84 (0.70, 1.00)       |
|                            | D           |                  344 | 248 (72.1)   | 16.46 (13.83, 19.12)       | 0.90 (0.76, 1.08)       |
|                            | Sorafenib   |                  329 | 248 (75.4)   | 14.55 (12.75, 16.85)       |                         |
| TIP <1% b                  | T300+D      |                  189 | 128 (67.7)   | 14.26 (11.43, 21.29)       | 0.83 (0.65, 1.05)       |
|                            | D           |                  190 | 141 (74.2)   | 15.06 (12.68, 18.53)       | 0.93 (0.73, 1.17)       |
|                            | Sorafenib   |                  181 | 138 (76.2)   | 13.93 (12.39, 16.69)       |                         |
| TIP ≥1% b                  | T300+D      |                  148 | 101 (68.2)   | 17.35 (13.50, 23.03)       | 0.85 (0.65, 1.11)       |
|                            | D           |                  154 | 107 (69.5)   | 17.22 (12.29, 24.38)       | 0.87 (0.66, 1.13)       |
|                            | Sorafenib   |                  148 | 110 (74.3)   | 15.93 (10.68, 21.72)       | -                       |

The analysis was performed using stratified log-rank test adjusting for treatment, aetiology of liver disease (HBV versus HCV versus others), ECOG PS (0 versus 1), and macro-vascular invasion (yes versus no). The values of the stratification factors were obtained from the interactive web response system. Unstratified analyses.

<div style=\"page-break-after: always\"></div>

CI = confidence interval; D = durvalumab 1500 mg Q4W; ECOG = Eastern Cooperative Oncology Group; HBV = hepatitis B virus; HCV = hepatitis C virus; PDL1 = programmed cell death ligand 1; PS = performance status; QxW = every X weeks; T300+D = tremelimumab 300 mg for a single dose and durvalumab 1500 mg Q4W; TIP = Tumour and Immune Cell Positivity. Source:CSR table 14.2.1.3

## Baseline data

Table 19. Demographic and Baseline Patient Characteristics in HIMALAYA (Pivotal Study) and Study 22 (Supportive Study)

| Study Analysis set (DCO)                  | HIMALAYA FAS (Final Analysis)   | HIMALAYA FAS (Final Analysis)   | HIMALAYA FAS (Final Analysis)   | Study 22 (Parts 2 and 3) FAS (Final Analysis)   | Study 22 (Parts 2 and 3) FAS (Final Analysis)   |
|-------------------------------------------|---------------------------------|---------------------------------|---------------------------------|-------------------------------------------------|-------------------------------------------------|
|                                           | D (N = 389)                     | T300+D (N = 393)                | S (N = 389)                     | D (N = 104)                                     | T300+D (N = 75)                                 |
| Age (years)                               |                                 |                                 |                                 |                                                 |                                                 |
| Mean                                      | 62.6                            | 63.0                            | 63.5                            | 64.0                                            | 64.4                                            |
| SD                                        | 11.47                           | 11.65                           | 11.12                           | 10.81                                           | 11.24                                           |
| Median                                    | 64.0                            | 65.0                            | 64.0                            | 64.5                                            | 66.0                                            |
| Min                                       | 20                              | 22                              | 18                              | 32                                              | 26                                              |
| Max                                       | 86                              | 86                              | 88                              | 89                                              | 86                                              |
| Age group (years), n (%)                  |                                 |                                 |                                 |                                                 |                                                 |
| < 65                                      | 203 (52.2)                      | 195 (49.6)                      | 195 (50.1)                      | 52 (50.0)                                       | 34 (45.3)                                       |
| ≥ 65 - < 75                               | 130 (33.4)                      | 145 (36.9)                      | 137 (35.2)                      | 33 (31.7)                                       | 31 (41.3)                                       |
| ≥ 75                                      | 56 (14.4)                       | 53 (13.5)                       | 57 (14.7)                       | 19 (18.3)                                       | 10 (13.3)                                       |
| Sex, n (%)                                |                                 |                                 |                                 |                                                 |                                                 |
| Male                                      | 323 (83.0)                      | 327 (83.2)                      | 337 (86.6)                      | 92 (88.5)                                       | 65 (86.7)                                       |
| Female                                    | 66 (17.0)                       | 66 (16.8)                       | 52 (13.4)                       | 12 (11.5)                                       | 10 (13.3)                                       |
| Region group, n (%)                       |                                 |                                 |                                 |                                                 |                                                 |
| Asia (excl. Japan)                        | 167 (42.9)                      | 156 (39.7)                      | 156 (40.1)                      | 47 (45.2)                                       | 31 (41.3)                                       |
| Rest of World (incl. Japan)               | 222 (57.1)                      | 237 (60.3)                      | 233 (59.9)                      | 57 (54.8)                                       | 44 (58.7)                                       |
| Race, n (%)                               |                                 |                                 |                                 |                                                 |                                                 |
| White                                     | 160 (41.1)                      | 182 (46.3)                      | 179 (46.0)                      | 35 (33.7)                                       | 27 (36.0)                                       |
| Black or African American                 | 2 (0.5)                         | 7 (1.8)                         | 10 (2.6)                        | 10 (9.6)                                        | 4 (5.3)                                         |
| Asian                                     | 212 (54.5)                      | 195 (49.6)                      | 189 (48.6)                      | 55 (52.9)                                       | 44 (58.7)                                       |
| Native Hawaiian or other Pacific Islander | 0                               | 1 (0.3)                         | 0                               | 2 (1.9)                                         | 0                                               |
| American Indian or Alaska Native          | 0                               | 0                               | 0                               | 1 (1.0)                                         | 0                                               |
| Other                                     | 15 (3.9)                        | 7 (1.8)                         | 5 (1.3)                         | 1 (1.0)                                         | 0                                               |
| Ethnic group, n (%)                       |                                 |                                 |                                 |                                                 |                                                 |
| Hispanic or Latino                        | 13 (3.3)                        | 21 (5.3)                        | 21 (5.4)                        | 5 (4.8)                                         | 4 (5.3)                                         |
| Not Hispanic or Latino                    | 376 (96.7)                      | 372 (94.7)                      | 362 (93.1)                      | 99 (95.2)                                       | 71 (94.7)                                       |
| Weight group (kg), n (%)                  |                                 |                                 |                                 |                                                 |                                                 |
| < 70                                      | 218 (56.0)                      | 190 (48.3)                      | 202 (51.9)                      | 47 (45.2)                                       | 49 (65.3)                                       |
| ≥ 70 - < 90                               | 130 (33.4)                      | 158 (40.2)                      | 137 (35.2)                      | 41 (39.4)                                       | 20 (26.7)                                       |
| ≥ 90                                      | 41 (10.5)                       | 45 (11.5)                       | 50 (12.9)                       | 15 (14.4)                                       | 5 (6.7)                                         |

<div style=\"page-break-after: always\"></div>

Table 19. Demographic and Baseline Patient Characteristics in HIMALAYA (Pivotal Study) and Study 22 (Supportive Study)

| Study Analysis set (DCO)     | HIMALAYA FAS (Final Analysis)   | HIMALAYA FAS (Final Analysis)   | HIMALAYA FAS (Final Analysis)   | Study 22 (Parts 2 and 3) FAS (Final Analysis)   | Study 22 (Parts 2 and 3) FAS (Final Analysis)   |
|------------------------------|---------------------------------|---------------------------------|---------------------------------|-------------------------------------------------|-------------------------------------------------|
|                              | D (N = 389)                     | T300+D (N = 393)                | S (N = 389)                     | D (N = 104)                                     | T300+D (N = 75)                                 |
| BMI group (kg/m 2 ), n (%)   | BMI group (kg/m 2 ), n (%)      | BMI group (kg/m 2 ), n (%)      | BMI group (kg/m 2 ), n (%)      | BMI group (kg/m 2 ), n (%)                      | BMI group (kg/m 2 ), n (%)                      |
| Underweight (< 18.5)         | 15 (3.9)                        | 19 (4.8)                        | 17 (4.4)                        | 7 (6.7)                                         | 4 (5.3)                                         |
| Normal (≥ 18.5 - < 25.0)     | 210 (54.0)                      | 188 (47.8)                      | 195 (50.1)                      | 47 (45.2)                                       | 47 (62.7)                                       |
| Overweight (≥ 25.0 - < 30.0) | 114 (29.3)                      | 128 (32.6)                      | 125 (32.1)                      | 32 (30.8)                                       | 17 (22.7)                                       |
| Obese (≥ 30.0)               | 47 (12.1)                       | 56 (14.2)                       | 48 (12.3)                       | 17 (16.3)                                       | 6 (8.0)                                         |
| Alcohol use, n (%) a         | Alcohol use, n (%) a            | Alcohol use, n (%) a            | Alcohol use, n (%) a            | Alcohol use, n (%) a                            | Alcohol use, n (%) a                            |
| Never                        | 150 (38.6)                      | 162 (41.2)                      | 147 (37.8)                      | NA                                              | NA                                              |
| Current                      | 62 (15.9)                       | 54 (13.7)                       | 60 (15.4)                       | NA                                              | NA                                              |
| Former                       | 176 (45.2)                      | 176 (44.8)                      | 182 (46.8)                      | NA                                              | NA                                              |
| Missing                      | 1 (0.3)                         | 1 (0.3)                         | 0                               | NA                                              | NA                                              |

a Alcohol use was not captured in the Study 22 eCRF.

Baseline is the last assessment prior to the intake of the first dose of any study drug; for patients not treated, the last assessment on or prior to treatment allocation (Study 22 Part 2B) or randomization (HIMALAYA and Study 22 Parts 2A and 3) was used.

Abbreviations: BMI = body mass index; DCO = data cut-off; eCRF = electronic case report form; Excl. = excluding; FAS = full analysis set; Max = maximum; Min = minimum; N = total number of patients; n = number of patients in a treatment arm; NA = not applicable; SD = standard deviation.

Table  20.  Disease  Characteristics  at  Screening  in  HIMALAYA  (Pivotal  Study)  and  Study  22 (Supportive Study)

| Study Analysis set (DCO)         | HIMALAYA FAS (Final Analysis)   | HIMALAYA FAS (Final Analysis)   | HIMALAYA FAS (Final Analysis)   | Study 22 (Parts 2 and 3) FAS (Final Analysis)   | Study 22 (Parts 2 and 3) FAS (Final Analysis)   |
|----------------------------------|---------------------------------|---------------------------------|---------------------------------|-------------------------------------------------|-------------------------------------------------|
|                                  | D (N = 389)                     | T300+D (N = 393)                | S (N = 389)                     | D (N = 104)                                     | T300+D (N = 75)                                 |
| ECOG performance status, n (%)   |                                 |                                 |                                 |                                                 |                                                 |
| 0                                | 244 (62.7)                      | 246 (62.6)                      | 239 (61.4)                      | 52 (50.0)                                       | 46 (61.3)                                       |
| 1                                | 145 (37.3)                      | 147 (37.4)                      | 148 (38.0)                      | 52 (50.0)                                       | 29 (38.7)                                       |
| BCLC stage, n (%) a              |                                 |                                 |                                 |                                                 |                                                 |
| Early (A)                        | NA                              | NA                              | NA                              | 1 (1.0)                                         | 1 (1.3)                                         |
| Intermediate (B)                 | 80 (20.6)                       | 77 (19.6)                       | 66 (17.0)                       | 9 (8.7)                                         | 13 (17.3)                                       |
| Advanced (C)                     | 309 (79.4)                      | 316 (80.4)                      | 323 (83.0)                      | 80 (76.9)                                       | 58 (77.3)                                       |
| Etiology of liver disease, n (%) |                                 |                                 |                                 |                                                 |                                                 |
| HBV-positive                     | 119 (30.6)                      | 122 (31.0)                      | 119 (30.6)                      | 40 (38.5)                                       | 27 (36.0)                                       |
| HCV-positive                     | 107 (27.5)                      | 110 (28.0)                      | 104 (26.7)                      | 29 (27.9)                                       | 21 (28.0)                                       |
| Others                           | 163 (41.9)                      | 161 (41.0)                      | 166 (42.7)                      | 35 (33.7)                                       | 27 (36.0)                                       |
| MVI and/or EHS, n (%)            |                                 |                                 |                                 |                                                 |                                                 |
| MVI = Yes and/or EHS = Yes b     | 255 (65.6)                      | 263 (66.9)                      | 251 (64.5)                      | 72 (69.2)                                       | 58 (77.3)                                       |

<div style=\"page-break-after: always\"></div>

Table  20.  Disease  Characteristics  at  Screening  in  HIMALAYA  (Pivotal  Study)  and  Study  22 (Supportive Study)

| Study Analysis set (DCO)                          | HIMALAYA FAS (Final Analysis)   | HIMALAYA FAS (Final Analysis)   | HIMALAYA FAS (Final Analysis)   | Study 22 (Parts 2 and 3) FAS (Final Analysis)   | Study 22 (Parts 2 and 3) FAS (Final Analysis)   |
|---------------------------------------------------|---------------------------------|---------------------------------|---------------------------------|-------------------------------------------------|-------------------------------------------------|
|                                                   | D (N = 389)                     | T300+D (N = 393)                | S (N = 389)                     | D (N = 104)                                     | T300+D (N = 75)                                 |
| MVI = No and EHS=No                               | 133 (34.2)                      | 128 (32.6)                      | 137 (35.2)                      | 12 (11.5)                                       | 13 (17.3)                                       |
| Child-Pugh score, n (%)                           |                                 |                                 |                                 |                                                 |                                                 |
| A/5                                               | 284 (73.0)                      | 295 (75.1)                      | 277 (71.2)                      | 79 (76.0)                                       | 51 (68.0)                                       |
| A/6                                               | 96 (24.7)                       | 92 (23.4)                       | 102 (26.2)                      | 23 (22.1)                                       | 23 (30.7)                                       |
| B/7                                               | 1 (0.3)                         | 2 (0.5)                         | 10 (2.6)                        | 2 (1.9)                                         | 1 (1.3)                                         |
| Alpha-fetoprotein, n (%)                          |                                 |                                 |                                 |                                                 |                                                 |
| < 400 ng/ml                                       | 247 (63.5)                      | 243 (61.8)                      | 256 (65.8)                      | 62 (59.6)                                       | 39 (52.0)                                       |
| ≥ 400 ng/ml                                       | 137 (35.2)                      | 145 (36.9)                      | 124 (31.9)                      | 39 (37.5)                                       | 35 (46.7)                                       |
| Missing                                           | 5 (1.3)                         | 5 (1.3)                         | 9 (2.3)                         | 3 (2.9)                                         | 1 (1.3)                                         |
| ALBI score                                        |                                 |                                 |                                 |                                                 |                                                 |
| 1                                                 | 198 (50.9)                      | 217 (55.2)                      | 203 (52.2)                      | NA                                              | NA                                              |
| 2                                                 | 189 (48.6)                      | 174 (44.3)                      | 185 (47.6)                      | NA                                              | NA                                              |
| 3                                                 | 2 (0.5)                         | 1 (0.3)                         | 1 (0.3)                         | NA                                              | NA                                              |
| Missing                                           | 0                               | 1 (0.3)                         | 0                               | NA                                              | NA                                              |
| PD-L1 expression level, n (%) c                   |                                 |                                 |                                 |                                                 |                                                 |
| Positive (TIP ≥ 1%)                               | 154 (39.6)                      | 148 (37.7)                      | 148 (38.0)                      | 55 (52.9)                                       | 27 (36.0)                                       |
| Negative (TIP < 1%)                               | 190 (48.8)                      | 189 (48.1)                      | 181 (46.5)                      | 35 (33.7)                                       | 38 (50.7)                                       |
| Missing                                           | 42 (10.8)                       | 52 (13.2)                       | 45 (11.6)                       | 14 (13.5)                                       | 10 (13.3)                                       |
| Prior treatment with sorafenib/VEGFR TKI, n (%) d |                                 |                                 |                                 |                                                 |                                                 |
| Yes                                               | NA                              | NA                              | NA                              | 66 (63.5)                                       | 55 (73.3)                                       |
| No                                                | NA                              | NA                              | NA                              | 38 (36.5)                                       | 20 (26.7)                                       |

a In HIMALAYA, patients were enrolled only if they had BCLC Stage B (not eligible for locoregional therapy) or Stage C. In Study 22, BCLC Stage was not specified in the inclusion criteria and collection of BCLC scores was not mandated at screening until protocol amendment 3 (20 July 2017); as a result, baseline BCLC scores were missing for some patients in Part 2A (see Section 9.2.2, Study 22 CSR, Module 5.3.5.2).

b Includes all patients with 'MVI = Yes and EHS = No/Missing,' 'MVI = No/Missing and EHS = Yes,' and 'MVI = Yes and EHS = Yes.'

c PD-L1 expression level was defined as 'Positive' if PD-L1 staining of any intensity in tumor cell membranes and/or tumorassociated immune cells covered ≥ 1% of tumor area (TIP ≥ 1%), and 'Negative' if PD-L1 staining of any intensity in tumor cell membranes and/or tumor-associated immune cells covered &lt; 1% of tumor area (TIP &lt; 1%).

d Per inclusion criteria, no patients in HIMALAYA received prior systemic therapy for HCC (first-line setting only). In Study 22, patients were required to be immunotherapy-naïve and had either progressed on, were intolerant to, or have refused treatment with sorafenib or another approved VEGFR TKI (first-line and second-line settings).

Abbreviations: BCLC = Barcelona Clinic Liver Cancer; eCRF = electronic case report form; DCO = data cut-off; ECOG = Eastern Cooperative Oncology Group; EHS = extrahepatic spread; FAS = full analysis set; HBV = hepatitis B virus; HCV = hepatitis C virus; MVI = macrovascular invasion; N = total number of patients; n = number of patients in a treatment arm; NA, not applicable; PD-L1 = programmed cell death ligand-1; TIP = tumor immune percentage; TKI = tyrosine kinase inhibitor; VEGFR = vascular endothelial growth factor receptor.

## Prior cancer therapy

<div style=\"page-break-after: always\"></div>

Per inclusion criteria, no patients in HIMALAYA received prior systemic therapy for HCC (first-line setting only).  Overall,  the  most  common  disease-related  medical  procedures  prior  to  study  entry,  including ablative  therapy,  therapeutic  embolization,  regional  chemotherapy,  and  HCC-related  surgery,  were similar across treatment arms and consistent with that typically seen in the target patient population.

In study 22, the prior anticancer treatment modalities reported were prior treatment with sorafenib/VEGFR TKI (55/75 patients, 73.3%). Most patients had undergone prior  TACE or RFA Per protocol, all patients were immunotherapy-naïve.

## Post-IP Discontinuation Anticancer Systemic Therapy

Table 21. Post- Discontinuation Anticancer Systemic Therapy

|                               | Nunber (%) of patients   | Nunber (%) of patients   | Nunber (%) of patients   | Nunber (%) of patients   | Nunber (%) of patients   |
|-------------------------------|--------------------------|--------------------------|--------------------------|--------------------------|--------------------------|
| Anticancer therapy            | D (N =389)               | T300+D (N=393)           | T75+D (N =153)           | S (N = 389)              | Total (N =1324)          |
| Total number of subjects      | 168 (43.2)               | 160 (40.7)               | 67 (43.8)                | 175 (45.0)               | 570 (43.1)               |
| Immunotherapy                 | 20 (5.1)                 | 15 (3.8)                 | 5 (3.3)                  | 89 (22.9)                | 129 (9.7)                |
| Atezolizumab                  | 11 (2.8)                 | 6 (1.5)                  | 1 (0.7)                  | 14 (3.6)                 | 32 (2.4)                 |
| Avelumab                      | 0                        | 0                        | 0                        | 1 (0.3)                  | 1 (0.1)                  |
| Cancer Vaccines               | 0                        | 0                        | 0                        | 1 (0.3)                  | 1 (0.1)                  |
| Durvalumab                    | 0                        | 0                        | 0                        | 2 (0.5)                  | 2 (0.2)                  |
| Immunotherapy                 | 0                        | 0                        | 0                        | 4 (1.0)                  | 4 (0.3)                  |
| Investigational Immunotherapy | 1 (0.3)                  | 0                        | 0                        | 0                        | 1 (0.1)                  |
| Ipilimumab                    | 2 (0.5)                  | 0                        | 0                        | 2 (0.5)                  | 4 (0.3)                  |
| Mgd 013                       | 0                        | 2 (0.5)                  | 0                        | 2 (0.5)                  | 4 (0.3)                  |
| Monoclonal Antibodies         | 3 (0.8)                  | 2 (0.5)                  | 1 (0.7)                  | 7 (1.8)                  | 13 (1.0)                 |
| Nivolumab                     | 5 (1.3)                  | 5 (1.3)                  | 3 (2.0)                  | 47 (12.1)                | 60 (4.5)                 |
| Pembrolizumab                 | 1 (0.3)                  | 0                        | 0                        | 17 (4.4)                 | 18 (1.4)                 |
| Spartalizumab                 | 0                        | 0                        | 0                        | 1 (0.3)                  | 1 (0.1)                  |
| Tremelimumab                  | 0                        | 0                        | 0                        | 2 (0.5)                  | 2 (0.2)                  |
| Cytotoxic chemotherapy        | 18 (4.6)                 | 20 (5.1)                 | 7 (4.6)                  | 25 (6.4)                 | 70 (5.3)                 |
| Capecitabine                  | 5 (1.3)                  | 3 (0.8)                  | 1 (0.7)                  | 4 (1.0)                  | 13 (1.0)                 |
| Capecitabine;oxaliplatin      | 1(03)                    | 0                        | 0                        | 0                        | 1 (0.1)                  |
| Carboplatin                   | 0                        | 0                        | 0                        | 1 (0.3)                  | 1 (0.1)                  |
| Carboplatin;etoposide         | 0                        | 1 (0.3)                  | 0                        | 0                        | 1 (0.1)                  |
| Cisplatinb                    | 9 (2.3)                  | 6 (1.5)                  | 5 (3.3)                  | 5 (1.3)                  | 25 (1.9)                 |
| Cisplatin;doxorubicin         | 0                        | 2 (0.5)                  | 0                        | 0                        | 2 (0.2)                  |
| Cisplatin;fluorouracil        | 0                        | 1 (0.3)                  | 0                        | 2 (0.5)                  | 3 (0.2)                  |
| Cyclophosphamide              | 1 (0.3)                  | 0                        | 0                        | 1 (0.3)                  | 2 (0.2)                  |
| Doxorubicin                   | 0                        | 4 (1.0)                  | 1 (0.7)                  | 7 (1.8)                  | 12 (0.9)                 |
| Fluorouracil                  | 5 (1.3)                  | 5 (1.3)                  | 3 (2.0)                  | 7 (1.8)                  | 20 (1.5)                 |
| Folfox                        | 0                        | 4 (1.0)                  | 0                        | 2 (0.5)                  | 6 (0.5)                  |
| Gemcitabine                   | 3 (0.8)                  | 1 (0.3)                  | 0                        | 2 (0.5)                  | 6 (0.5)                  |
| Gemcitabine;oxaliplatin       | 0                        | 0                        | 0                        | 1 (0.3)                  | 1 (0.1)                  |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|                                      | Nunber (%) of patients   | Nunber (%) of patients   | Nunber (%) of patients   | Nunber (%) of patients   | Nunber (%) of patients   |
|--------------------------------------|--------------------------|--------------------------|--------------------------|--------------------------|--------------------------|
| Anticancer therapy                   | D (N=389)                | T300+D (N =393)          | T75+D (N =153)           | S (N = 389)              | Total (N =1324)          |
| Irinotecan                           | 1 (0.3)                  | 0                        | 0                        | 1 (0.3)                  | 2 (0.2)                  |
| Oxaliplatinb                         | 7 (1.8)                  | 2 (0.5)                  | 1 (0.7)                  | 8 (2.1)                  | 18 (1.4)                 |
| Tegafur                              | 0                        | 0                        | 0                        | 1 (0.3)                  | 1 (0.1)                  |
| Uracil                               | 0                        | 0                        | 0                        | 1 (0.3)                  | 1 (0.1)                  |
| Vinorelbine                          | 0                        | 1 (0.3)                  | 0                        | 0                        | 1 (0.1)                  |
| Targeted therapy                     | 155 (39.8)               | 147 (37.4)               | 64 (41.8)                | 108 (27.8)               | 474 (35.8)               |
| Cabozantinib                         | 20 (5.1)                 | 24 (6.1)                 | 6 (3.9)                  | 26 (6.7)                 | 76 (5.7)                 |
| Capmatinib                           | 0                        | 0                        | 0                        | 1 (0.3)                  | 1 (0.1)                  |
| H3b 6527                             | 0                        | 1 (0.3)                  | 0                        | 0                        | 1 (0.1)                  |
| Lenvatinib                           | 68 (17.5)                | 55 (14.0)                | 23 (15.0)                | 32 (8.2)                 | 178 (13.4)               |
| Olaparib                             | 1 (0.3)                  | 0                        | 0                        | 0                        | 1 (0.1)                  |
| Pegargiminase                        | 1 (0.3)                  | 1 (0.3)                  | 0                        | 1 (0.3)                  | 3 (0.2)                  |
| Regorafenib                          | 26 (6.7)                 | 29 (7.4)                 | 17 (11.1)                | 62 (15.9)                | 134 (10.1)               |
| Sorafenib                            | 98 (25.2)                | 105 (26.7)               | 51 (33.3)                | 12 (3.1)                 | 266 (20.1)               |
| Tyrosine Kinase Inhibitors           | 0                        | 2 (0.5)                  | 0                        | 0                        | 2 (0.2)                  |
| Antiangiogenic therapy               | 20 (5.1)                 | 11 (2.8)                 | 9 (5.9)                  | 19 (4.9)                 | 59 (4.5)                 |
| Bevacizumab                          | 12 (3.1)                 | 6 (1.5)                  | 1 (0.7)                  | 16 (4.1)                 | 35 (2.6)                 |
| Ramucirumab                          | 8 (2.1)                  | 7 (1.8)                  | 7 (4.6)                  | 3 (0.8)                  | 25 (1.9)                 |
| Thalidomide                          | 2 (0.5)                  | 0                        | 1 (0.7)                  | 0                        | 3 (0.2)                  |
| Homeopathic therapy                  | 1 (0.3)                  | 0                        | 0                        | 2 (0.5)                  | 3 (0.2)                  |
| Herbal anticancer remedies           | 1 (0.3)                  | 0                        | 0                        | 2 (0.5)                  | 3 (0.2)                  |
| Other                                | 1 (0.3)                  | 3 (0.8)                  | 0                        | 9 (2.3)                  | 13 (1.0)                 |
| Fenbendazole                         | 0                        | 0                        | 0                        | 1 (0.3)                  | 1 (0.1)                  |
| Folinic Acid                         | 1 (0.3)                  | 1 (0.3)                  | 0                        | 3 (0.8)                  | 5 (0.4)                  |
| Investigational Antineoplastic Drugs | 0                        | 2 (0.5)                  | 0                        | 3 (0.8)                  | 5 (0.4)                  |
| Investigational Drug                 | 0                        | 0                        | 0                        | 2 (0.5)                  | 2 (0.2)                  |

Patients may have received more than 1 post-IP discontinuation therapy.

D, durvalumab monotherapy 1500 mg Q4W; FAS, Full Analysis Set; N, number of patients in treatment group; Q4W,every4weeks;S,sorafenib400mg twicedaily;T75+D,tremelimumab75mg×4doses+durvalumab 1500mgQ4W;T300+D,tremelimumab300mg×1dose+durvalumab1500mgQ4W. Source:Iable 14.1.17

<div style=\"page-break-after: always\"></div>

## Numbers analysed

## Table 22. Analysis sets

|                                                     | Durva1500 mg   |   Treme300 mg x1 dose + Durva1500mg |   Treme 75 mg x4 doses + Durva1500 mg | Sora400mg BID   |   Total |
|-----------------------------------------------------|----------------|-------------------------------------|---------------------------------------|-----------------|---------|
| Subjectsrandomized                                  | 389            |                                 393 |                                   153 | 389             |    1324 |
| Subjects included in full analysis set              | 389            |                                 393 |                                   153 | 389             |    1324 |
| Subjects includedin safety analysis set             | 388            |                                 388 |                                   152 | 374             |    1302 |
| Subjects excluded from safety analysis set          | 3              |                                   4 |                                     0 | 15              |      22 |
| Didnotreceivetreatment                              | 3              |                                   4 |                                     0 | 15              |      22 |
| SubjectsincludedinDurvalumabPKanalysisset           | 357            |                                 348 |                                   142 |                 |     847 |
| Subjects excluded from Durvalumab PK analysis seta  | 34             |                                  44 |                                    10 |                 |      88 |
| Did notreceive treatment                            | 3              |                                   4 |                                     0 |                 |       7 |
| No post-dose data available                         | 31             |                                  40 |                                    10 |                 |      81 |
| SubjectsincludedinTremelimumabPKanalysisset         |                |                                 386 |                                   142 |                 |     528 |
| Subjects excluded from TremelimumabPK analysis setb |                |                                   6 |                                    12 |                 |      18 |
| Did notreceive treatment                            |                |                                   4 |                                     2 |                 |       6 |
| No post-dose data available                         |                |                                   2 |                                    10 |                 |      12 |

Full analysis set - all randomized subjects analysed on an ITT basis.

PK analysis sets - all subjects who received at least 1 dose of study drugs and for whom any postdose data are available.

Safety analysis set - all subjects who received at least one dose of study treatment.

ADA evaluable sets - all subjects who have non-missing baseline ADA and at least one non-missing post-baseline ADA result.

Results in categoriesSubjects included in safety analysis set',Subjects included in PK analysis set' and'Subjects included in ADA evaluable set' are calculated on basis of actual arm , in other categories on basis of planned anm.

aSubjects excluded from theDurvalumab PK analysis are either not part of the safety analysis set or belong to the safety analysis set but are missing a Durvalumab postdose PK assessment.

b Subjects excluded from the Tremelimumab PK analysis are either not part of the safety analysis set or belong to the safety analysis set but are missing a Tremelimumab postdose PK assessment.

root/cdar/d419/d419cc00002/ar/csr/restricted\\_tlf/prod/program/dm003.sasdm003fa.rtf08NOV2021:16:23kwxd463

<div style=\"page-break-after: always\"></div>

## Outcomes and estimation

## Primary endpoint: Overall survival

## Table 23. Overall Survival in HIMALAYA (Pivotal Study)

| Study Analysis set (DCO)                                             | HIMALAYA FAS (Final Analysis)   | HIMALAYA FAS (Final Analysis)   | HIMALAYA FAS (Final Analysis)   |
|----------------------------------------------------------------------|---------------------------------|---------------------------------|---------------------------------|
|                                                                      | D (N = 389)                     | T300+D (N = 393)                | S (N = 389)                     |
| HR (compared to sorafenib) a                                         | 0.86                            | 0.78                            | -                               |
| 95% CI a                                                             | 0.73 - 1.02                     | 0.66 - 0.92                     | -                               |
| 96.02% CI for HR (T300+D vs S) a, b                                  | -                               | 0.65 - 0.93                     | -                               |
| 2-sided p - value (T300+D vs S)                                      | -                               | 0.0035                          | -                               |
| 95.67% CI for HR (D vs S) a, c                                       | 0.73 - 1.03                     | -                               | -                               |
| 2-sided p-value (D vs S) d                                           | 0.0674                          | -                               | -                               |
| Median OS (months) e                                                 | 16.56                           | 16.43                           | 13.77                           |
| 95% CI for median OS e                                               | 14.06 - 19.12                   | 14.16 - 19.58                   | 12.25 - 16.13                   |
| OS rate at 12 months,% e                                             | 59.3                            | 60.2                            | 56.2                            |
| OS rate at 18 months,% e                                             | 47.4                            | 48.7                            | 41.5                            |
| OS rate at 24 months,% e                                             | 39.6                            | 40.5                            | 32.6                            |
| OS rate at 36 months,% e                                             | 24.7                            | 30.7                            | 20.2                            |
| Deaths, n (%)                                                        | 280 (72.0)                      | 262 (66.7)                      | 293 (75.3)                      |
| Censored patients, n (%)                                             | 109 (28.0)                      | 131 (33.3)                      | 96 (24.7)                       |
| Still in survival follow-up at DCO f                                 | 104 (26.7)                      | 125 (31.8)                      | 79 (20.3)                       |
| Terminated prior to death g                                          | 109 (28.0)                      | 131 (33.3)                      | 96 (24.7)                       |
| Lost to follow-up                                                    | 1 (0.3)                         | 1 (0.3)                         | 7 (1.8)                         |
| Withdrawn consent                                                    | 4 (1.0)                         | 5 (1.3)                         | 10 (2.6)                        |
| Median (range) duration of follow-up in censored patients (months) h | 31.61 (1.91 - 45.70)            | 32.36 (6.18 - 42.84)            | 30.36 (0.03 - 43.60)            |
| Median (95% CI) duration of follow-up in all patients (months) i     | 32.56 (31.57 - 33.71)           | 33.18 (31.74 - 34.53)           | 32.23 (30.42 - 33.71)           |

a The HR was calculated using a Cox proportional hazards model adjusting for treatment arm, etiology of liver disease (HBV vs HCV vs all others), ECOG (0 vs 1), and MVI (yes vs no). An HR &lt; 1 favors either the T300+D arm or the D arm compared with the S arm in terms of being associated with a longer OS.

b T300+D vs S (primary objective in HIMALAYA). Statistical significance for T300+D vs S was based on a 2-sided interim p &lt; 0.0419 (overall alpha 4.9%), as defined in the MTP.

c D vs S (key secondary objective in HIMALAYA). The non-inferiority margin for D vs S was 1.08, as defined in the MTP.

d The analysis was performed using a stratified log-rank test adjusting for treatment arm, etiology of liver disease (HBV vs HCV vs all others), ECOG (0 vs 1), and MVI (yes vs no).

e Calculated using the Kaplan-Meier method.

- f Patients confirmed alive in follow-up or on active study treatment at the time of final ana lysis reported 'study completion' on the disposition CRF.
- g Includes patients with unknown survival status or patients who were lost to follow-up.
- h Median for duration of follow-up is the arithmetic median.

i Calculated using the reverse Kaplan-Meier technique (with censor indicator reversed).

Abbreviations: CI = confidence interval; CRF = case report form; DCO = data cut-off; FAS = full analysis set; HR = hazard ratio; IA = interim analysis; OS = overall survival.

<div style=\"page-break-after: always\"></div>

Figure 15. Kaplan-Meier Plot of Overall Survival in the T300+D and S Arms in HIMALAYA, FAS (Final Analysis)

<!-- image -->

Abbreviations: FAS = Full Analysis Set; Q4W = every 4 weeks; S = sorafenib 400 mg twice daily; T300+D = tremelimumab 300 mg × 1 dose + durvalumab 1500 mg Q4W.

Figure 16. Kaplan-Meier Plot of Overall Survival in the D and S Arms in HIMALAYA, FAS (Final Analysis)

<!-- image -->

Abbreviations: D = durvalumab monotherapy 1500 mg Q4W; FAS = Full Analysis Set; Q4W = every 4 weeks; S = sorafenib 400 mg twice daily

<div style=\"page-break-after: always\"></div>

## Secondary endpoints:

## Progression-free survival (PFS)

## Table 24. Progression-free Survival by Investigator Assessment According to RECIST 1.1 (FAS)

|                                                                    | Number (%) of patients   | Number (%) of patients   | Number (%) of patients   |
|--------------------------------------------------------------------|--------------------------|--------------------------|--------------------------|
|                                                                    | D (N = 389)              | T300+D (N = 393)         | S (N = 389)              |
| Hazard ratio (D vs S and T300+D vs S)                              | 1.02                     | 0.90                     | -                        |
| 95% CI for hazard ratio                                            | 0.88 - 1.19              | 0.77 - 1.05              | -                        |
| 2-sided p-value                                                    | 0.7736                   | 0.1625                   | -                        |
| Median PFS (months) a                                              | 3.65                     | 3.78                     | 4.07                     |
| 95% CI for median PFS a                                            | 3.19 - 3.75              | 3.68 - 5.32              | 3.75 - 5.49              |
| Total PFS events, n (%) b                                          | 345 (88.7)               | 335 (85.2)               | 327 (84.1)               |
| Median (range) duration of follow-up in all patients (months)      | 3.61 (0.03 - 44.02)      | 3.75 (0.03 - 41.46)      | 3.75 (0.03 - 33.41)      |
| Median (range) duration of follow-up in censored patients (months) | 27.63 (0.03 - 44.02)     | 27.55 (0.03 - 41.46)     | 1.95 (0.03 - 33.18)      |

· Calculated using the Kaplan-Meier technique.

- Patients who had not progressed or died, or who progressed or died after 2 or more missed visits, were censored at the latest evaluable RECIST 1.1 assessment, or Day 1 if there were no evaluable visits. Patients who have no evaluable visits or baseline data were censored at Day 1 unless they died within 2 visits of baseline. Patients who die without tumor progression will be censored at the time of death.

Progression determined by Investigator assessment. Lost to follow-up is defined as patients who have no RECIST 1.1 progression or death at the time of the DCO and have a termination status of 'Lost to follow-up' from the Disposition module. Withdrawn consent is defined as patients who have no RECIST 1.1 progression or death at the time of DCO and whose termination status is 'Withdrawn consent' on the Disposition module. The analysis methods used to obtain the hazard ratio, confidence interval, and 2-sided p-value are the same as for the primary OS analysis.

A hazard ratio of &lt; 1 favours IO treatment arms to be associated with a longer progression-free survival than sorafenib.

Abbreviations: CI = confidence interval; D = durvalumab monotherapy 1500 mg; Q4W; DCO = data cut-off; ECOG PS, Eastern Cooperative Oncology Group performance status; FAS = Full Analysis Set; IO = immuno-oncology; HBV, hepatitis B virus; HCV, hepatitis C virus; N = total number of patients; n = number of PFS events;  PFS = progression-free survival; Q4W = every 4 weeks; RECIST 1.1 = Response Evaluation Criteria in Solid Tumors Version 1.1; S = sorafenib 400 mg twice daily; T75+D = tremelimumab 75 mg × 4 doses + durvalumab 1500 mg Q4W; T300+D = tremelimumab 300 mg × 1 dose + durvalumab 1500 mg Q4W.

<div style=\"page-break-after: always\"></div>

Figure  17.  Kaplan-Meier  Plot  for  Progression-free  Survival  by  Investigator  Assessment According to RECIST 1.1 (FAS)

<!-- image -->

Abbreviations: D = durvalumab monotherapy 1500 mg; Q4W; FAS = Full Analysis Set; Q4W = every 4 weeks; N = total number of patients; PFS = progression-free survival; RECIST 1.1 = Response Evaluation Criteria in Solid Tumors Version 1.1; S = sorafenib 400 mg twice daily; T75+D = tremelimumab 75 mg × 4 doses + durvalumab 1500 mg Q4W; T300+D = tremelimumab 300 mg × 1 dose + durvalumab 1500 mg Q4W.

<div style=\"page-break-after: always\"></div>

Table 25: Progression-free survival (FAS 32w FUP) based on BICR assessments per RECIST 1.1 (DCO 27-AUG-2021)

|                                                               | Number(%)of subjects   | Number(%)of subjects                         | Number(%)of subjects                      | Number(%)of subjects    |
|---------------------------------------------------------------|------------------------|----------------------------------------------|-------------------------------------------|-------------------------|
|                                                               | Durva 1500 mg (N=236)  | Treme 300 mg x1 dose + Durva 1500 mg (N=234) | Treme75mg x4doses + Durva 1500 mg (N=153) | Sora 400 mg BID (N=236) |
| Total eventsa, n (%)                                          | 194 (82.2)             | 172 (73.5)                                   |                                           | 163 (69.1)              |
| RECIST progression                                            | 175 (74.2)             | 148 (63.2)                                   |                                           | 137 (58.1)              |
| Target Lesionsb                                               | 106 (44.9)             | 81 (34.6)                                    |                                           | 76 (32.2)               |
| Non Target Lesionsb                                           | 101 (42.8)             | 74 (31.6)                                    |                                           | 68 (28.8)               |
| New Lesionsb                                                  | 50 (21.2)              | 53 (22.6)                                    |                                           | 45 (19.1)               |
| Death in the absence of progression                           | 19 (8.1)               | 24 (10.3)                                    |                                           | 26 (11.0)               |
| Censored subjects, n (%)                                      | 42 (17.8)              | 62 (26.5)                                    |                                           | 73 (30.9)               |
| Censored RECIST progressionc                                  | 0                      | 0                                            |                                           | 1 (0.4)                 |
| Censored deathd                                               | 11 (4.7)               | 17 (7.3)                                     |                                           | 44 (18.6)               |
| Progression-free at time of analysis                          | 0                      | 0                                            |                                           | 0                       |
| Lost to follow-up                                             | 0                      | 0                                            |                                           | 2 (0.8)                 |
| Withdrawn consent                                             | 0                      | 0                                            |                                           | 2 (0.8)                 |
| Study completione                                             | 31 (13.1)              | 45 (19.2)                                    |                                           | 24 (10.2)               |
| Median progression-free survival (months)f                    | 3.48                   | 3.65                                         |                                           | 3.78                    |
| 95% CI for median progression-free survivalf                  | 2.17-3.68              | 3.52 - 3.94                                  |                                           | 3.68 - 5.32             |
| Hazard ratio                                                  | 1.19                   | 0.96                                         |                                           |                         |
| 95%CI for hazard ratio                                        | 0.97 -1.47             | 0.77 - 1.19                                  |                                           |                         |
| 2-sided p-value                                               | 0.0971                 | 0.6668                                       |                                           |                         |
| Median (range) duration of follow-up in all subjects (months) | 3.07 (0.03 -19.42)     | 3.61 (0.03 -16.59)                           |                                           | 3.61 (0.03 -16.43)      |
| Median(range)durationoffollow-upincensoredsubjects(months)    | 8.99 (0.03 - 19.42)    | 9.33 (0.03 -16.59)                           |                                           | 5.49 (0.03 -13.96)      |

Progressionis determined byBICR,RECIST 1.1. CI=Confidence interval. NR=Not reached.FAS 32wFUP=Full analysis set with opportunity for 32weeks of follow-up at IA1 DCO.

Lost to follow up is defined as subjects whom have no RECIST 1.1 progression or death at the time of the data cutoff and have a termination status of Lost to follow-up' from the Disposition module.

Withdrawn consent is defined as all subjects whom have no RECIST 1.1 progression or death at the time of data cut off and whose termination Status is 'Withdrawn consent' on the Disposition module.

Subjectswhohavenotprogressed ordied,orwhoprogressor die aftertwo ormore missedvisits,are censored at the latest evaluableRECISTassessment,orday1if there are no

evaluablevisits.Subjectswhohave noevaluablevisits or donot have baseline data will be censored at study day1 unless they diewithin 2visits of baseline.

dDeath occurred after 2 or more missed visits after last evaluable RECIST assessment (or randomization).

b Target Lesions, Non Target Lesions and New Lesions are not necessarily mutually exclusive categories. RECIST progression event occurred after 2 or more missed visits afer last evaluable RECIST assessment (or randomization)

Other recorded on disposition eCRF with specified status of'Study terminated by sponsor.fCalculated using theKaplan-Meier technique.

root/cdar/d419/d419cc00002/ar/csr/restricted\\_tlf/prod/program/eff004.saseff004hfa.rtf08NOV2021:16:24kwxd463

The analysis methods used to obtain the hazard ratio, confidence interval and 2-sided p-value are the same as for the primary OS analysis. A hazard ratio &lt; 1 favours IO treatment arms to be associated with a longer progression-free survival than sorafenib.

PFS by BICR by mRECIST was also performed in the FAS 32w FUP (not shown), and this did not show a statistically significant difference of PFS between the three arms (D vs T300+D vs S) either.

<div style=\"page-break-after: always\"></div>

## Overall response rate (ORR) and best objective response

Table  26.  Objective  Response  Rate  Based  on  Investigator  Assessment  (Confirmed Responses) According to RECIST 1.1 (FAS)

|               |     | Number of                |                   | Comparison between arms   | Comparison between arms   | Comparison between arms   |
|---------------|-----|--------------------------|-------------------|---------------------------|---------------------------|---------------------------|
| Treatment arm | N   | patients with response a | Response rate (%) | Odds ratio b              | 95% CI                    | 2-sided p-value           |
| D             | 389 | 66                       | 17.0              | 3.80                      | 2.29, 6.57                | <0.0001                   |
| T300+D        | 393 | 79                       | 20.1              | 4.69                      | 2.85, 8.04                | <0.0001                   |
| S             | 389 | 20                       | 5.1               | -                         | -                         | -                         |

The analysis was performed using a logistic regression model adjusted for treatment with factors for etiology of liver disease, ECOG PS, and MVI. An odds ratio of &gt; 1 favors IO treatment arms.

Abbreviations: CI = confidence interval; ECOG PS = Eastern Cooperative Oncology Group performance status; FAS = Full Analysis Set; IO = immuno-oncology; MVI = macrovascular invasion; Q4W = every 4 weeks; S = sorafenib 400 mg twice daily; T300+D = tremelimumab 300 mg × 1 dose + durvalumab 1500 mg Q4W.

Table 27. Best Objective Response Based on Investigator Assessment (Confirmed Response) According to RECIST 1.1 (FAS)

|                 |                    | Number (%) of patients   | Number (%) of patients   | Number (%) of patients   |
|-----------------|--------------------|--------------------------|--------------------------|--------------------------|
| Response status | BOR                | D (N = 389)              | T300+D (N = 393)         | S (N = 389)              |
| Response        | Total              | 66 (17.0)                | 79 (20.1)                | 20 (5.1)                 |
| Response        | Complete response  | 6 (1.5)                  | 12 (3.1)                 | 0                        |
| Response        | Partial response   | 60 (15.4)                | 67 (17.0)                | 20 (5.1)                 |
| Non-response    | Total              | 323 (83.0)               | 314 (79.9)               | 369 (94.9)               |
| Non-response    | Stable disease     | 147 (37.8)               | 157 (39.9)               | 216 (55.5)               |
| Non-response    | Progression        | 160 (41.1)               | 141 (35.9)               | 118 (30.3)               |
| Non-response    | RECIST progression | 143 (36.8)               | 117 (29.8)               | 91 (23.4)                |
| Non-response    | Death              | 17 (4.4)                 | 24 (6.1)                 | 27 (6.9)                 |
| Non-response    | Not evaluable      | 16 (4.1)                 | 16 (4.1)                 | 35 (9.0)                 |

Abbreviations: BOR = best objective response; D = durvalumab monotherapy 1500 mg; Q4W; FAS = Full Analysis Set; N = total number of patients; Q4W = every 4 weeks; RECIST 1.1 = Response Evaluation Criteria In Solid Tumors Version 1.1; S = sorafenib 400 mg twice daily; T300+D = tremelimumab 300 mg × 1 dose + durvalumab 1500 mg Q4W.

Table 28. Objective response rate based on BICR assessment (confirmed response) according to RECIST 1.1 (FAS 32w FUP) -DCO 27 AUG 2021

|                                    | Durva1500mg (N=236)   | Treme300mgx1dose+ Durva1500mg (N=234)   | Treme75mgx4doses+ Durva1500mg (N=153)   | Sora400mg BID (N=236)   |
|------------------------------------|-----------------------|-----------------------------------------|-----------------------------------------|-------------------------|
| Subjectswithobjectiveresponse,n(%) | 36 (15.3)             | 44 (18.8)                               |                                         | 12 (5.1)                |
| Objectiveresponserate(%)           | 15.3                  | 18.8                                    |                                         | 5.1                     |
| 95%exactCI                         | 10.92,20.49           | 14.01,24.41                             |                                         | 2.65, 8.71              |

CI=Confidenceinterval

RECISTversion1.1.

Lost tofollowup andwithdrawnconsent aredefined assubjectswhohave noRECIST1.1progressionor death at the timeof theDCOand have aterminationstatus ofLost tofollow-up

or'Withdrawn consent'respectively in theDispositionmodule.FAS32wFUP=Full analysis set withopportunityfor32weeks of follow-upat IA1DCO.

<div style=\"page-break-after: always\"></div>

Table 29. Disagreements between investigator and BICR of RECIST progression per RECIST 1.1 (FAS 32w FUP) -DCO 27 AUG 2021

|                                                                    | Number (%) of subjects   | Number (%) of subjects                     | Number (%) of subjects                    | Number (%) of subjects   | Difference                     | Difference                                         |
|--------------------------------------------------------------------|--------------------------|--------------------------------------------|-------------------------------------------|--------------------------|--------------------------------|----------------------------------------------------|
|                                                                    | Durva 1500 mg (N=236)    | Treme300mg x1 dose + Durva 1500 mg (N=234) | Treme75mgx4 doses + Durva 1500 mg (N=153) | Sora 400 mg BID (N=236)  | Durva 1500 mg- Sora 400 mg BID | Treme300 mg x1 dose+Durva1500 mg - Sora 400 mg BID |
| RECIST progressiona declared by:                                   |                          |                                            |                                           |                          |                                |                                                    |
| Investigator andcentralreview                                      | 160 (67.8)               | 138 (59.0)                                 |                                           | 123 (52.1)               |                                |                                                    |
| Progression date agreement(within 2weeks)                          | 90 (38.1)                | 61 (26.1)                                  |                                           | 63 (26.7)                |                                |                                                    |
| Progression date >=2weeks earlier by central review than by        | 47 (19.9)                | 61 (26.1)                                  |                                           | 46 (19.5)                |                                |                                                    |
| Investigator                                                       |                          |                                            |                                           |                          |                                |                                                    |
| Progression date >=2 weeks earlier by Investigator than by central | 23 (9.7)                 | 16 (6.8)                                   |                                           | 14 (5.9)                 |                                |                                                    |
| review                                                             |                          |                                            |                                           |                          |                                |                                                    |
| Investigatorbut not centralreview                                  | 26 (11.0)                | 36 (15.4)                                  |                                           | 45 (19.1)                |                                |                                                    |
| CentralreviewbutnotInvestigator                                    | 15 (6.4)                 | 10 (4.3)                                   |                                           | 14 (5.9)                 |                                |                                                    |
| No Progression by both                                             | 35 (14.8)                | 50 (21.4)                                  |                                           | 54 (22.9)                |                                |                                                    |
| Early Discrepancy Rate (EDR)b                                      | 0.26                     | 0.30                                       |                                           | 0.35                     | -0.09                          | -0.05                                              |
| Late Discrepancy Rate (LDR)c                                       | 0.56                     | 0.58                                       |                                           | 0.50                     | 0.05                           | 0.07                                               |

## Duration of response and time to response

Table 30. Duration of Response and Time to Onset of Objective Response in HIMALAYA (Final Analysis) According to Investigator Assessment per RECIST 1.1 (FAS)

| Study Analysis set (DCO)                 | HIMALAYA FAS (Final Analysis)   | HIMALAYA FAS (Final Analysis)   | HIMALAYA FAS (Final Analysis)   |
|------------------------------------------|---------------------------------|---------------------------------|---------------------------------|
| Response assessment                      | Investigator per RECIST 1.1 a   | Investigator per RECIST 1.1 a   | Investigator per RECIST 1.1 a   |
|                                          | D (N = 66)                      | T300+D (N = 79)                 | S (N = 20)                      |
| Patients with objective response, n (%)  | 38                              | 44                              | 13                              |
| DoR from onset of response (months) b, c |                                 |                                 |                                 |
| 25th percentile                          | 7.43                            | 8.54                            | 6.51                            |
| Median                                   | 16.82                           | 22.34                           | 18.43                           |
| 75th percentile                          | NR                              | NR                              | 25.99                           |
| Percentage remaining in response c       |                                 |                                 |                                 |
| At 6 months                              | 81.8                            | 82.3                            | 78.9                            |
| At 12 months                             | 57.8                            | 65.8                            | 63.2                            |
| TTR from randomization (months)          |                                 |                                 |                                 |
| 25th percentile                          | 1.87                            | 1.84                            | 1.89                            |
| Median                                   | 2.09                            | 2.17                            | 3.78                            |
| 75th percentile                          | 3.98                            | 3.98                            | 8.44                            |

Abbreviations: CR = complete response; DCO = data cut-off; DoR = duration of response; FAS = full analysis set; N = total number of patients; n = number of patients in a treatment arm; NR = not reached; PR = partial response; RECIST = Response Evaluation Criteria in Solid Tumors; TTR = time to onset of objective response.

## Patient-reported outcomes (PROs)

Patient-reported symptoms, function, and health-related quality of life (HRQoL) were collected in the HIMALAYA study using the EORTC QLQ C30 and its HCC module (EORTC QLQ HCC18). At baseline,

<div style=\"page-break-after: always\"></div>

patient-reported symptoms, functioning, and HRQoL scores were comparable between the HIMALAYA study arms.

Table 31. Summary of Change from Baseline Using MMRM in EORTC QLQ-30 (FAS)

<!-- image -->

|                      |                              | Number (%o) of patients   | Number (%o) of patients   | Number (%o) of patients   | Number (%o) of patients   |
|----------------------|------------------------------|---------------------------|---------------------------|---------------------------|---------------------------|
| Symptom Seale Item   | Statistic                    | (N=389)                   | T300+D (N=393)            | T75+D (N=153)             | S (N=389)                 |
| GHS/QoL              |                              |                           |                           |                           |                           |
| GHS/QoL              | n                            | 282                       | 249                       | 116                       | 254                       |
| GHS/QoL              | Adjusted mean (SE)           | -1.8 (1.26)               | -5.8 (1.29)               | -6.2 (2.04)               | NE                        |
| GHS/QoL              | 95% CI                       | 4.30, 0.65                | -8.37, -3.32              | -10.22,-2.21              | NE                        |
| GHS/QoL              | Estimated difference         | NE                        | NE                        |                           |                           |
| GHS/QoL              | 95% CI for difference        | NE                        | NE                        |                           |                           |
| GHS/QoL              | p-value                      | NE                        | NE                        |                           |                           |
| Fumction             |                              |                           |                           |                           |                           |
| Physical fimctioning | n                            | 282                       | 249                       | 116                       | 254                       |
| Physical fimctioning | Adjusted mean (SE)           | -0.9 (1.16)               | -2.7 (1.19)               | -4.4 (1.87)               | NE                        |
| Physical fimctioning | 10 %56                       | -3.18, 1.37               | -5.05, -0.39              | -8.05, -0.71              | NE                        |
| Physical fimctioning | Estimated difference         | NE                        | NE                        |                           |                           |
| Physical fimctioning | 95% CI for difference        | NE                        | NE                        |                           |                           |
| Physical fimctioning | p-value                      | NE                        | NE                        |                           |                           |
| Symptoms             |                              |                           |                           |                           |                           |
| Fatigue              | n                            | 282                       | 249                       | 116                       | 254                       |
| Fatigue              | Adjusted mean (SE)           | 1.7 (1.40)                | 1.9 (1.43)                | 4.3 (2.27)                | NE                        |
| Fatigue              | 95% CI                       | -1.09,4.43                | -0.91,4.72                | -0.14, 8.75               | NE                        |
| Fatigue              | Estimated difference         | NE                        | NE                        |                           |                           |
| Fatigue              | 95% CI for difference        | NE                        | NE                        |                           |                           |
| Fatigue              | p-value                      | NE                        | NE                        |                           |                           |
| Appetite loss        | n                            | 282                       | 249                       | 116                       | 254                       |
| Appetite loss        | Adjusted mean (SE)           | 3.8 (1.62)                | 1.7 (1.65)                | 2.8 (2.63)                | NE                        |
| Appetite loss        | 95% CI                       | 0.64, 7.00                | -1.58,4.91                | -2.36, 7.97               | NE                        |
| Appetite loss        | Estimated difference         | NE                        | NE                        |                           |                           |
| Appetite loss        | 95%。 CI for difference       | NE                        | NE                        |                           |                           |
| Appetite loss        | p-value                      | NE                        | NE                        |                           |                           |
| Nausea               | n                            | 282                       | 249                       | 116                       | 254                       |
| Nausea               | Adjusted mean (SE)           | 1.2 (1.18)                | 0.7 (1.20)                | 3.1 (1.91)                | NE                        |
| Nausea               | 95% CI                       | -1.16, 3.47               | -1.64, 3.08               | -0.61, 6.87               | NE                        |
|                      | Estimated difference         | NE                        | NE                        |                           |                           |
|                      | 95%CIfordifference           | NE                        | NE                        |                           |                           |
|                      | p-value                      | NE                        | NE                        |                           |                           |
| Diarhea              | n                            | 282                       | 249                       | 116                       | 254                       |
|                      | Adjusted mean (SE)           | 1.2 (1.43)                | -1.0 (1.45)               | 5.7 (2.31)                | NE                        |
|                      | 10 %56                       | -1.62,3.97                | -3.83, 1.86               | 1.20, 10.28               | NE                        |
|                      | Estimateddifference          | NE                        | NE                        |                           |                           |
|                      | 95%CI for difference p-value | NE NE                     | NE NE                     |                           |                           |

TheanalysissetincludesasubsetoftheFASwithanevaluablebaseline assessment and atleast1evaluable post-baseline assessment. Change from baseline is derived using a MMRM analysis of all the post-baseline scores for each visit. The model includes treatment, visit, and treatment by visit interaction as explanatory vaniablesand thebaseline score as a covariate.

ofsymptomatology/problems.

All scales and single-item measures range in score from 0 to 100. A high scale score represents a higher response level. A high score for fumctional scales (physical, role, emotional, cognitive, social) and global health status/QoL represents a highfiuctioning/QoL, but a highscore for a symptom scale/item represents a high level

Adjusted mean: adjusted meanchangefrombaseline.

Estimated difference:overall estimate of thetreatment differencebetweenD(monotherapy orcombination therapy) and S.

95%CI:95%CIfor adjustedmeanchange.

CIconfidence interval;D,duvalumabmonotherapy 1500mg:EORTC QLQ-C30,Euopean Organization for Research and Treatment of Cancer 30-item core quality oflife questiomnaire; FAS, Full Analysis Set: MvRMmixed-effectmodelforrepeatedmeasurement;N,mumberofpatientsintreatmentarmNE,not evaluable;QoL,QualityofLife;Q4W,every4weeks;S,sorafenib400mgtwicedaily;SE,standarderror; T75+D, tremelimumab 75 mg ×4 doses + duuvalmab 1500mg Q4W; T300+D, tremelimumab 300 mg

x 1 dose+ duvalumab1500mgQ4W.

<div style=\"page-break-after: always\"></div>

Table 32. Summary of Change from Baseline in EORTC QLQ-HCC18 Symptoms (FAS)

<!-- image -->

|                    |                       | Number (%) of patients   | Number (%) of patients   | Number (%) of patients   | Number (%) of patients   |
|--------------------|-----------------------|--------------------------|--------------------------|--------------------------|--------------------------|
| Symptom Scale Item | Statistic             | D (N= 389)               | T300+D (N= 393)          | T75+D (N = 153)          | S (N= 389)               |
| Abdominal swelling | n                     | 280                      | 238                      | 112                      | 253                      |
| Abdominal swelling | Adjusted mean (SE)    | 1.0 (1.32)               | -0.1 (1.37)              | -0.7 (2.15)              | NE                       |
| Abdominal swelling | 95%CI                 | -1.64, 3.56              | -2.84, 2.55              | -4.93, 3.52              | NE                       |
| Abdominal swelling | Estimated difference  | NE                       | NE                       |                          |                          |
|                    | 95% CI for difference | NE                       | NE                       |                          |                          |
|                    | p-value               | NE                       | NE                       |                          |                          |
| Abdominal pain     | n                     | 280                      | 238                      | 112                      | 253                      |
| Abdominal pain     | Adjusted mean (SE)    | 0.6 (1.49)               | -1.4 (1.54)              | -0.5 (2.42)              | NE                       |
| Abdominal pain     | ID %56                | -2.30, 3.53              | -4.41, 1.62              | -5.29,4.20               | NE                       |
| Abdominal pain     | Estimated difference  | NE                       | NE                       |                          |                          |
| Abdominal pain     | 95%CI for difference  | NE                       | NE                       |                          |                          |
| Abdominal pain     | p-value               | NE                       | NE                       |                          |                          |
| Shoulder pain      | n                     | 280                      | 238                      | 112                      | 253                      |
|                    | Adjusted mean (SE)    | -2.4 (1.51)              | -1.7 (1.56)              | -4.8 (2.46)              | NE                       |
|                    | 10%56                 | -5.35, 0.59              | -4.75, 1.35              | -9.66, 0.01              | NE                       |
|                    | Estimated difference  | NE                       | NE                       |                          |                          |
|                    | 95% CI for difference | NE                       | NE                       |                          |                          |
|                    | p-value               | NE                       | NE                       |                          |                          |

EORTC Score Interpretation: All scales and single-item measuues range in score from 0 to 100. A high scale score represents a higher response level. A high score for fiuctional scales (physical, role, emotional, cognitive, social) and global health status/QoL represents a high fimctioning/QoL,but a high score for a symptom seale/item represents a high level of symptomatology/problems.

CI, confidence interval; D, duvalmab monotherapy 1500 mg; EORIC QLQ-HCC18, Euuopean Organization for Research and Treatment of Cancer 18-item hepatocellular cancer health-related quality of life questiomaire; FAS, Full Analysis Set; N, mumber of patients in treatment anm; NE, not evaluable; QoL, Quality ofLife; Q4W every 4 weeks; S, sorafenib 400 mg twice daily; SE, standard error; T75+D, tremelimumab 75 mg

x 4 doses + duvalumab 1500 mg Q4W; T300+D, tremelimmmab 300 mg x 1 dose + dhuvalumab 1500 mg Q4W. Source: able 14.2.9.]

## Ancillary analyses

Subgroup analyses

<div style=\"page-break-after: always\"></div>

Figure 18. Forest plots of Overall survival, subgroup analysis, FAS, DCO 27 AUG 2021

Treatment Arms:T300+D Vs.S

<!-- image -->

## Hazard ratio and 95% CI.

A hazard ratio &lt;1 implies a lower risk of death for the Treme 300 mg x 1 dose + Durva 1500 mg treatment arm.

For analysismethods,refertoTable14.2.1.3.

Subgroup analyses for stratification factors, etiology of liver disease (HBV versus HCV versus others) and macro-vascular invasion (yes versus no) are performed using values collected from the pathology at screening eCRF. Others (for etiology of liver disease) is defined as no active viral hepatitis identified.

ValuesofECOG are obtainedfromperformancestatuseCRF.

Size of circle is proportional to the number of events.

Grey band represents the 95% confidence interval for the overall (all subjects) hazard ratio.

D = Durva 1500 mg,T300+D = Treme 300 mg x1 dose + Durva 1500 mg, S = Sora 400 mg BID

root/cdar/d419/d419cc00002/ar/csr/restricted\\_tlf/prod/program/ef003.saseff003fa.rtf 08NOV2021:16:24kwxd463

Abbreviations: AFP = alpha-fetoprotein; BCLC = Barcelona Clinic Liver Cancer; ECOG = Eastern Cooperative Oncology Group; EHS = extrahepatic spread; FAS = full analysis set; HBV = hepatitis B virus; HCV = hepatitis C virus; HR = hazard ratio; MVI = macrovascular invasion; OS = overall survival; PD-L1 = programmed cell death ligand-1; TIP = tumor immune percentage.

<div style=\"page-break-after: always\"></div>

Table 33. Subgroup Analysis of Overall Survival by PD-L1 Expression Level, HIMALAYA (FAS)

| PD-L1 expression      | Treatment   |     | Number (%) of events   | Comparison to S   | Comparison to S   |
|-----------------------|-------------|-----|------------------------|-------------------|-------------------|
| subgroup              | arm         | N   |                        | HR a              | 95% CI            |
| Positive: TIP ≥ 1% b  | D           | 154 | 107 (69.5)             | 0.87              | 0.66, 1.13        |
| Positive: TIP ≥ 1% b  | T300+D      | 148 | 101 (68.2)             | 0.85              | 0.65, 1.11        |
| Positive: TIP ≥ 1% b  | S           | 148 | 110 (74.3)             | -                 | -                 |
| Negative: TIP < 1% b  | D           | 190 | 141 (74.2)             | 0.93              | 0.73, 1.17        |
| Negative: TIP < 1% b  | T300+D      | 189 | 128 (67.7)             | 0.83              | 0.65, 1.05        |
| Negative: TIP < 1% b  | S           | 181 | 138 (76.2)             | -                 | -                 |
| Positive: TIP ≥ 5% c  | D           | 70  | 47 (67.1)              | 0.90              | 0.59, 1.38        |
| Positive: TIP ≥ 5% c  | T300+D      | 67  | 44 (65.7)              | 0.94              | 0.60, 1.47        |
| Positive: TIP ≥ 5% c  | S           | 66  | 46 (69.7)              | -                 | -                 |
| Negative: TIP < 5% c  | D           | 274 | 201 (73.4)             | 0.92              | 0.75, 1.12        |
| Negative: TIP < 5% c  | T300+D      | 270 | 185 (68.5)             | 0.84              | 0.69, 1.03        |
| Negative: TIP < 5% c  | S           | 263 | 202 (76.8)             | -                 | -                 |
| Positive: TIP ≥ 10% c | D           | 37  | 26 (70.3)              | 0.88              | 0.47, 1.66        |
| Positive: TIP ≥ 10% c | T300+D      | 34  | 21 (61.8)              | 0.88              | 0.44, 1.79        |
| Positive: TIP ≥ 10% c | S           | 33  | 21 (63.6)              | -                 | -                 |
| Negative: TIP < 10% c | D           | 307 | 222 (72.3)             | 0.89              | 0.74, 1.08        |
| Negative: TIP < 10% c | T300+D      | 303 | 208 (68.6)             | 0.83              | 0.69, 1.01        |
| Negative: TIP < 10% c | S           | 296 | 227 (76.7)             | -                 | -                 |

a HR &lt; 1 favors the IO treatment arm.

b HR and 95% CI were estimated from an unstratified Cox proportional hazards model with treatment as the only covariate and using the Efron method to control for ties.

c HR and 95% CI were estimated from a Cox proportional hazards model adjusting for treatment, etiology of liver disease (HBV vs HCV vs others), ECOG performance status (0 vs 1), and MVI (yes vs no).

PD-L1 expression level is based on the TIP score method as: PDL1 Positive (TIP ≥ 1%) or PD -L1 Negative (TIP &lt; 1%). The TIP 1% cut-off is the only validated cut-off at which HIMALAYA patient samples were read. Additional PD-L1 TIP cut-offs of 5% and 10% should be interpreted in an exploratory manner.

Abbreviations: CI = confidence interval; D = durvalumab monotherapy 1500 mg Q4W; ECOG = Eastern Cooperative Oncology Group; FAS = Full Analysis Set; HR = hazard ratio; IO, immuno-oncology; MVI = macrovascular invasion; PD-L1 = programmed cell death ligand 1; Q4W = every 4 weeks; S = sorafenib 400 mg twice daily; T300+D = tremelimumab 300 mg × 1 dose + durvalumab 1500 mg Q4W; TIP = tumor and immune cell positivity.

## Sensitivity analyses

## Non-proportional hazards

Some evidence of delayed treatment effect was observed as illustrated by the lack of parallel lines in the log-log(survival) against log(time from randomization to death) for the individual treatment arms (Figure 19). This was also noted in the survival curves with D vs S (separation at 9 months) and T300+D vs S (separation at 4 months). This finding is expected, as IO agents have illustrated delayed treatment effects in clinical settings. The assumption of non-proportionality was rigorously assessed with a post hoc analysis performed to test the linear interaction between treatment and time, and no significant interaction was found (T300+D vs S: nominal p = 0.094, D vs S: nominal p = 0.34).

<div style=\"page-break-after: always\"></div>

Figure 19. Complementary Log-log(event) vs Log(time) to Assess Assumptions of Proportionality of Hazards for OS (FAS)

<!-- image -->

D, durvalumab monotherapy 1500 mg Q4W; FAS, Full Analysis Set; Q4W, every 4 weeks; OS, Overall Survival; S, sorafenib 400 mg twice daily; T300+D, tremelimumab 300 mg × 1 dose + durvalumab 1500 mg Q4W.

Source: Figure 14.2.1.9

## Inversed Censoring

The reverse KM survival curve shown in Figure 20 is constructed by reversing the 'censor' and 'event' of the standard KM curve (data not shown). Figure 20 shows that the curves for arms D, T300+D and S remain close to 1 for the first 26 months post randomization, indicating nearly complete follow-up for this period of time. No meaningful difference in the length of follow-up among arms D, T300+D and S can be seen in the figure, which is also evidenced by similar median follow-up times in censored patients (D: 31.61 months, T300+D: 32.36 months, and S: 30.36 months).

Figure 20. Overall Survival, Sensitivity Analysis, KM Plot with Inversed Censoring Indicators (FAS)

<!-- image -->

D, durvalumab monotherapy 1500 mg Q4W; FAS, Full Analysis Set; KM, Kaplan Meier; Q4W, every 4 weeks; S, sorafenib 400 mg twice daily; T300+D, tremelimumab 300 mg × 1 dose + durvalumab 1500 mg Q4W. Source: Figure 14.2.1.1.3

<div style=\"page-break-after: always\"></div>

## Contribution of components

Table 34.  Data From HIMALAYA (Pivotal Study) and Study 22 (Supportive Study) Relevant to the Recommended T300+D Regimen in Patients with uHCC

| Study Analysis set            | HIMALAYA FAS (Final Analysis)          | HIMALAYA FAS (Final Analysis)          | Study 22 (Parts 2 and 3) FAS (Final Analysis)   | Study 22 (Parts 2 and 3) FAS (Final Analysis)   | Study 22 (Parts 2 and 3) FAS (Final Analysis)   |
|-------------------------------|----------------------------------------|----------------------------------------|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|
|                               | D (N = 389)                            | T300+D (N = 393)                       | D (N = 104)                                     | T300+D (N = 75)                                 | T (N = 69)                                      |
| Median OS (months) a          | 16.56                                  | 16.43                                  | 12.91                                           | 17.05                                           | 17.05                                           |
| 95% CI for median OS          | 14.06, 19.12                           | 14.16, 19.58                           | 8.74, 16.79                                     | 10.55, 22.83                                    | 11.33, 20.24                                    |
| HR (95% CI) for T300+D vs D   | 0.90 (0.76, 1.07)                      | 0.90 (0.76, 1.07)                      | -                                               | -                                               | -                                               |
| OS rate at 12 months,% a      | 59.3                                   | 60.2                                   | 50.4                                            | 57.6                                            | 59.8                                            |
| OS rate at 18 months,% a      | 47.4                                   | 48.7                                   | 34.0                                            | 47.8                                            | 43.3                                            |
| OS rate at 24 months,% a      | 39.6                                   | 40.5                                   | 26.2                                            | 38.3                                            | 30.9                                            |
| OS rate at 36 months,% a      | 24.7                                   | 30.7                                   | -                                               | -                                               | -                                               |
| Tumor response assessment     | Investigator assessment per RECIST 1.1 | Investigator assessment per RECIST 1.1 | BICR per RECIST 1.1                             | BICR per RECIST 1.1                             | BICR per RECIST 1.1                             |
|                               | D (N = 389)                            | T300+D (N = 393)                       | D (N = 104)                                     | T300+D (N = 75)                                 | T (N = 69)                                      |
| Median PFS a                  | 3.65                                   | 3.78                                   | 2.07                                            | 2.17                                            | 2.69                                            |
| 95% CI for median PFS         | 3.19, 3.75                             | 3.68, 5.32                             | 1.84, 2.86                                      | 1.91, 5.42                                      | 1.87, 5.29                                      |
| Progression-free at DCO n (%) | 32 (8.2)                               | 49 (12.5)                              | 8 (7.7)                                         | 11 (14.7)                                       | 4 (5.8)                                         |
| ORR (%) b                     | 17.0                                   | 20.1                                   | 11.5                                            | 24.0                                            | 7.2                                             |
| Complete Response b           | 6 (1.5)                                | 12 (3.1)                               | 0                                               | 1 (1.3)                                         | 0                                               |
| Partial Response b            | 60 (15.4)                              | 67 (17.0)                              | 12 (11.5)                                       | 17 (22.7)                                       | 5 (7.2)                                         |
| DCR (%) c                     | 54.8 d                                 | 60.1 d                                 | 37.5 b                                          | 45.3 b                                          | 49.3 b                                          |
| Median DoR (months) d, e      | 16.82                                  | 22.34                                  | 14.95                                           | 18.43                                           | 23.95                                           |
| Median TTR (months) d, f      | 2.09                                   | 2.17                                   | 3.65                                            | 2.28                                            | 1.81                                            |

- f TTR is the time to onset of confirmed response from from randomization (HIMALAYA; Study 22 Parts 2A and 3) or from treatment allocation (Study 22 Part 2B).

Abbreviations: BICR = blinded independent central review; CI = confidence interval; CR = complete response; DCO = data cutoff; DCR = disease control rate; DoR = duration of response; FAS = Full Analysis Set; HR = hazard ratio; ORR = objective response rate; OS = overall survival; PR = partial response; RECIST = Response Evaluation Criteria in Solid Tumors; TTR = time to onset of objective response; uHCC = unresectable hepatocellular carcinoma.

## Additional sensitivity analyses following inaccurate survival information at site 6208

GCP findings from the PMDA concerning the HIMALAYA trial, indicated that survival information was inaccurate for 4 subjects at site 6208. Following question regarding this issue, the supplementary analysis of OS with the corrected data was provided.

<div style=\"page-break-after: always\"></div>

In total the site 6208 enrolled 14 patients in HIMALAYA study. Overall survival data for 4/14 enrolled patients was affected, and no discrepancies in survival information were identified for the remaining 10/14 patients after onsite review.

Table 35 . Overall survival data for affected 4/14 enrolled patients at site 6208

| Subject   |                                |               | SurvivalStatus/DateofDeath(mm/dd/yyyy)   | SurvivalStatus/DateofDeath(mm/dd/yyyy)   | SurvivalStatus/DateofDeath(mm/dd/yyyy)   | SurvivalStatus/DateofDeath(mm/dd/yyyy)   | Variance (days): CRFvS death certificat   |
|-----------|--------------------------------|---------------|------------------------------------------|------------------------------------------|------------------------------------------|------------------------------------------|-------------------------------------------|
| Number    | Randomizatio nDate (mm/dd/yyyy | Treatment Arm | CRF                                      | Source document /medical record          | Local oncology registry                  | Death certificate                        | e                                         |
|           | 01/26/2018                     | S             | 03/05/20 18                              | N/A                                      | 03/04/20 18                              | 03/04/20 18                              | 1                                         |
|           | 04/05/2018                     | S             | Alive on 09/03/20 21                     | Alive on 09/03/20 21                     | 08/12/20 21                              | 08/12/20 21                              | 22                                        |
|           | 07/15/2019                     | T300+D        | 08/05/20 19                              | 08/05/20 19                              | 07/25/20 19                              | 07/25/20 19                              | 11                                        |
|           | 07/16/2019                     | D             | 04/23/20 20                              | 04/23/20 20                              | 07/23/20 19                              | 07/23/20 19                              | 275                                       |

D = durvalumab 1500 mg Q4W; N/A = not applicable; Q4w = every 4 weeks; S = sorafenib 400 mg twice daily; T300+D = tremelimumab 300 mg for a single dose and durvalumab 400 mg Q4w; T75+D = tremelimumab 75 mg Q4W × 4 doses and durvalumab1500 mg Q4W.

Table 36. Sensitivity Analysis of OS by Removing Site 6208 (Full Analysis Set)

|                                   | Number (%) of subjects   | Number (%) of subjects   | Number (%) of subjects   | Number (%) of subjects   |
|-----------------------------------|--------------------------|--------------------------|--------------------------|--------------------------|
|                                   | D (N=385)                | T300+D (N=391)           | T75 +D (N=151)           | S (N=383)                |
| Deaths,n (%)                      | 277 (71.9)               | 260 (66.5)               | 121 (80.1)               | 288 (75.2)               |
| Censoredsubjects,n (%)            | 108 (28.1)               | 131 (33.5)               | 30 (19.9)                | 95 (24.8)                |
| Median overall survival (months)a | 16.56                    | 16.66                    | 16.56                    | 13.77                    |
| 95%CIformedianoverall survivala   | 14.06 -19.12             | 14.19 -20.37             | 12.71 - 19.78            | 12.25 - 16.13            |
| Hazard ratiob                     | 0.87                     | 0.77                     |                          |                          |
| 95% CIforhazard ratiob            | 0.73 - 1.02              | 0.65 -0.91               |                          |                          |

Calculated using the Kaplan-Meier technique.

CI = confidence interval; D = durvalumab 1500 mg Q4w; IO = immuno-oncology; NR = not reached; Q4W = every 4 weeks; S = sorafenib 400 mg twice daily: T300+D = tremelimumab 300 mg for a single dose and durvalumab 400 mg Q4W; T75+D = tremelimumab 75 mg Q4W × 4 doses and durvalumab 1500 mg Q4W.

The analysis was performed using a Cox proportional hazards model adjusting for treatment, etiology of liver disease (hepatitis B virus vs. hepatitis C virus vs. others), Eastern Cooperative Oncology Group performance status (0 vs. 1), and macro-vascular invasion (yes vs. no). Values of the variables used for adjustment were obtained from the Interactive Voice Response System. Note: Table does not include subjects from Russian site 6208. A hazard ratio &lt; 1 favors IO treatment arms to be associated with a longer overall survival than sorafenib, A hazard ratio &lt; 1 favors IO treatment arms to be associated with a longer overall survival than sorafenib.

<div style=\"page-break-after: always\"></div>

Figure 21. KM Plot of OS by Removing Site 6208 (Full Analysis Set)

<!-- image -->

Figure does not include subjects from Russian site 6208

D = Duma 1500 mg, T300+D = Treme 300 mg x1 dese + Durva 1500 mg, T75=D = Treme 75 mg x4 -doses + Durva 1500 mg, S = Sora 400 mg BD

The Applicant has provided the requested sensitivity analysis, using the most conservative approach by removing all 14 patients enrolled at this site and this showed that the OS HR was of 0.77 (95%CI: 0.65, 0.91) for T300+D vs. S comparison, which is the main scope of the current procedure. There is overall consistency between the sensitivity analysis and the primary analysis, which is considered reassuring.

## Summary of main study

The following table summarises the efficacy results from the main study supporting the present application. This summary should be read in conjunction with the discussion on clinical efficacy as well as the benefit risk assessment (see later sections).

Table 37: Summary of Efficacy for trial HIMALAYA

| Title: A Randomized, Open-label, Multi-center Phase III Study of Durvalumab and Tremelimumab as First-line Treatment in Patients with Advanced Hepatocellular Carcinoma (HIMALAYA)   | Title: A Randomized, Open-label, Multi-center Phase III Study of Durvalumab and Tremelimumab as First-line Treatment in Patients with Advanced Hepatocellular Carcinoma (HIMALAYA)   | Title: A Randomized, Open-label, Multi-center Phase III Study of Durvalumab and Tremelimumab as First-line Treatment in Patients with Advanced Hepatocellular Carcinoma (HIMALAYA)   |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study identifier                                                                                                                                                                     | EudraCT number: 2016-005126-11, NCT number: NCT03298451                                                                                                                              | EudraCT number: 2016-005126-11, NCT number: NCT03298451                                                                                                                              |
| Design                                                                                                                                                                               | Randomized, open-label, multicentre Phase III study                                                                                                                                  | Randomized, open-label, multicentre Phase III study                                                                                                                                  |
|                                                                                                                                                                                      | Duration of main phase: Duration of Run-in phase: Duration of Extension phase:                                                                                                       | Not applicable Not applicable Not applicable                                                                                                                                         |
| Hypothesis                                                                                                                                                                           | Superiority for T300+D vs S                                                                                                                                                          | Superiority for T300+D vs S                                                                                                                                                          |
|                                                                                                                                                                                      | D                                                                                                                                                                                    | Durvalumab 1500 mg Q4W until PD or unacceptable toxicity, N=389                                                                                                                      |
|                                                                                                                                                                                      | T300+D                                                                                                                                                                               | Tremelimumab 300 mg as single dose plus durvalumab 1500 mg Q4W followed by durvalumab monotherapy 1500 mg Q4W until PD or unacceptable toxicity, N=393                               |
|                                                                                                                                                                                      | S                                                                                                                                                                                    | Sorafenib monotherapy 400 mg twice daily until PD or unacceptable toxicity, N=389                                                                                                    |

<div style=\"page-break-after: always\"></div>

Title: A Randomized, Open-label, Multi-center Phase III Study of Durvalumab and Tremelimumab as First-line Treatment in Patients with Advanced Hepatocellular Carcinoma (HIMALAYA)

Study identifier

Endpoints and definitions

Database lock

## Results and Analysis

| Analysis description                            | Primary Analysis                                                 | Primary Analysis                                                 | Primary Analysis                                                 | Primary Analysis                                                 |
|-------------------------------------------------|------------------------------------------------------------------|------------------------------------------------------------------|------------------------------------------------------------------|------------------------------------------------------------------|
| Analysis population and time point description  | Intent to treat, final analysis                                  | Intent to treat, final analysis                                  | Intent to treat, final analysis                                  | Intent to treat, final analysis                                  |
| Descriptive statistics and estimate variability | Treatment group                                                  | D                                                                | T300+D                                                           | S                                                                |
| Descriptive statistics and estimate variability | Number of subjects                                               | 389                                                              | 393                                                              | 389                                                              |
| Descriptive statistics and estimate variability | OS (Months)                                                      | 16.56                                                            | 16.43                                                            | 13.77                                                            |
| Descriptive statistics and estimate variability | 95%CI                                                            | 14.06; 19.12                                                     | 14.16; 19.58                                                     | 12.25; 16.13                                                     |
| Descriptive statistics and estimate variability | PFS by INV (months)                                              | 3.65                                                             | 3.78                                                             | 4.07                                                             |
| Descriptive statistics and estimate variability | 95%CI                                                            | 3.19; 3.75                                                       | 3.68; 5.32                                                       | 3.75; 5.49                                                       |
| Descriptive statistics and estimate variability | ORR (%)                                                          | 17                                                               | 20.1                                                             | 5.1                                                              |
| Descriptive statistics and estimate variability | DoR (%)                                                          | 16.82                                                            | 22.34                                                            | 18.43                                                            |
| Effect estimate per comparison                  | Primary endpoint OS                                              | Comparison groups T300+D vs S                                    | Comparison groups T300+D vs S                                    | Comparison groups T300+D vs S                                    |
| Effect estimate per comparison                  | Primary endpoint OS                                              | Stratified HR                                                    | 0.78                                                             | 0.78                                                             |
| Effect estimate per comparison                  | Primary endpoint OS                                              | 95% CI                                                           | 0.66, 0.92                                                       | 0.66, 0.92                                                       |
| Effect estimate per comparison                  | Primary endpoint OS                                              | P-value                                                          | 0.0035                                                           | 0.0035                                                           |
| Effect estimate per comparison                  | Secondary endpoint OS                                            | Comparison groups                                                | D vs S (non-inferior)                                            | D vs S (non-inferior)                                            |
| Effect estimate per comparison                  | Secondary endpoint OS                                            | Stratified HR                                                    | 0.86                                                             | 0.86                                                             |
| Effect estimate per comparison                  | Secondary endpoint OS                                            | 95.67% CI                                                        | 0.73; 1.03*                                                      | 0.73; 1.03*                                                      |
| Effect estimate per comparison                  | Secondary endpoint OS                                            | P-value                                                          | NA                                                               | NA                                                               |
| Effect estimate per comparison                  | Secondary endpoint OS                                            | Comparison groups                                                | D vs S (superior)                                                | D vs S (superior)                                                |
| Effect estimate per comparison                  | Secondary endpoint OS                                            | Stratified HR                                                    | 0.86                                                             | 0.86                                                             |
| Effect estimate per comparison                  | Secondary endpoint OS                                            | 95.67% CI                                                        | 0.73; 1.03                                                       | 0.73; 1.03                                                       |
| Effect estimate per comparison                  | Secondary endpoint OS                                            | P-value                                                          | 0.0674 (NS)                                                      | 0.0674 (NS)                                                      |
| Notes                                           | *below prespecified clinical NI (non-inferiority) margin of 1.08 | *below prespecified clinical NI (non-inferiority) margin of 1.08 | *below prespecified clinical NI (non-inferiority) margin of 1.08 | *below prespecified clinical NI (non-inferiority) margin of 1.08 |

EudraCT number: 2016-005126-11, NCT number: NCT03298451

T75+D

Primary endpoint  OS

Key Secondary

OS

endpoints

Other secondary

endpoints

27 August 2021

Tremelimumab 75 mg Q4W × 4

doses + durvalumab 1500 mg Q4W, followed by durvalumab

monotherapy 1500 mg Q4W. Arm closed prematurely, results not

shown.

OS of T300+D vs S

Non-Inferiority of D vs S and superiority of D

vs S.

Progression-free survival, overall response rate and duration of response

PFS, ORR,

DoR

<div style=\"page-break-after: always\"></div>

## Clinical studies in special populations

Table 38. Patient Counts by Age Category -Controlled Trial Versus Non-controlled Trial (Full Analysis Set)

| Age   | Controlled trials (N=1324)   | Non-controlled trials (N=332)   |
|-------|------------------------------|---------------------------------|
| < 65  | 667 (50.4)                   | 175 (52.7)                      |
| 65-74 | 467 (35.3)                   | 108 (32.5)                      |
| 75-84 | 181 (13.7)                   | 46 (13.9)                       |
| 85+   | 9 (0.7)                      | 3 (0.9)                         |

Note: Controlled trial includes only HIMALAYA and non-controlled trail includes only Study 22.

## In vitro biomarker test for patient selection for efficacy PD-L1 testing

The relationship between PD-L1 expression level and clinical outcomes (eg, OS, PFS, and ORR) was investigated, and the results are presented by treatment arm.

PD-L1 expression was determined by the analytically validated VENTANA PD-L1 (SP263) assay using the TIP score method. The TIP score was defined as the total percentage of the tumor area covered by tumor cells with PD-L1 membrane staining at any intensity and/or tumor-associated immune cells with any pattern of PD-L1 staining at any intensity. Two PD-L1 expression subgroups were defined:

- PD-L1 TIP ≥ 1% (Positive): PD-L1 staining of any intensity in tumour cell membranes and/or tumour-associated immune cells covering ≥ 1% of the tumor area
- PD-L1 TIP &lt; 1% (Negative): PD-L1 staining of any intensity in tumour cell membranes and/or tumour-associated immune cells covering &lt; 1% of the tumor area.

Collection of patient samples for analysis of PD-L1 expression

Patients were strongly encouraged to provide a fresh tissue biopsy for the purpose of PD-L1 expression analyses at screening. The tumour specimen submitted to the central laboratory for PD-L1 expression analysis should be of sufficient quantity and quality (with pathology quality control) to allow for PD-L1 immunohistochemical (IHC) analyses. Newly acquired or archived specimens with limited tumour content and fine needle aspirates were not acceptable for defining tumour PD-L1 expression.

- MANDATORY: Provision of a tumour biopsy, formalin fixed and embedded in paraffin, for the purpose of PD-L1 expression analyses (and for enabling exploratory analyses as described in the proceeding  section).  A  newly  acquired  tumor  biopsy  (&lt;3  months)  was  strongly  preferred; however, if not feasible with an acceptable clinical risk, an archival sample taken ≤ 3 years prior to screening could have been submitted. Note: the tumor biopsy was optional for the China cohort.
- Samples should have been collected via an image-guided core needle (at least 18 gauge) or an excisional archival tumour biopsy sample. Where institutional practice, in this setting, uses a smaller gauge needle, samples should have been submitted with tissue adequate to ensure that a valid result can be achieved (ie, total tissue quantity submitted should have been similar to core needle or excisional biopsy requirements).
- When fresh tissue was obtained, 2 cores should have been placed in formalin and processed to a single paraffin-embedded block. It was anticipated that 4 passes of an 18 gauge core needle would provide sufficient tissue for both PD-L1 analyses and exploratory analyses as described below. Tumour lesions used for fresh biopsies should not have been the same lesions used as

<div style=\"page-break-after: always\"></div>

RECIST 1.1 TLs, unless there were no other lesions suitable for biopsy, and in this instance, only core  needle  (not  excisional/incisional)  biopsy  was  allowed.  For  patients  with  a  single  TL,  if screening  biopsy  was  collected  prior  to  screening  imaging  for  baseline  tumour  assessment, allowed approximately 2 weeks before imaging scans were acquired.

- OPTIONAL: Additional  archived  tumour  tissue  block  (formalin  fixed  and  paraffin  embedded), where such samples exist in a quantity sufficient to allow for analysis. Tumour tissue block was preferred. If a tissue block was unavailable, unstained sections from the tissue block may be submitted.
- OPTIONAL: Tumour biopsy at the time of progression was requested
- OPTIONAL: Additional tumour biopsies collected as part of clinical care (eg, for mixed responses or upon PD) could have been submitted for further analysis.
- Additional archived tissue not intended for PD-L1 testing, and optional biopsies obtained at the time of progression or part of clinical care were not to be collected in China. Additionally, China study sites were not to submit tumour tissue blocks and only unstained sections from the tissue block were to be submitted for analysis.
- The Ventana SP263 IHC assay was to be used to determine PD-L1 expression in all available specimens. To meet the requirement of the United States Food and Drug Administration for approval of a companion diagnostic, sections of the tumour were to be retained at Ventana and/or at the Investigation Use only testing laboratory for potential additional studies to support potential test approval.

The Ventana SP163 PD-L1 assay was validated as an appropriate method for the selection of patients who would obtain benefit from durvalumab monotherapy in the PACIFIC trial, whose outcome led to the PD-L1 restricted indication of this anti-PD-L1 product in the locally advanced unresectable NSCLC setting after chemoradiotherapy. Thus, the choice of PD-L1 assay is acceptable.

## Supportive study

Figure 22. Study 22: Study Design

<!-- image -->

Following protocol amendment 5, enrollment into the T75+D arm in Part 3 was closed. Patients already randomized to T75+D could continue on assigned study treatment (provided the Investigator and patient thought it in the best interests of the patient) until confirmed progressive disease or any other discontinuation criteria were met. Weight-based dosing regimen was used in Parts 2A; fixed-dosing regimens were used in Part 2B and Part 3 (durvalumab only).

Abbreviations: D = durvalumab 1500 mg (20 mg/kg) Q4W; DoR, duration of response; HCC = hepatocellular carcinoma; n = number of subjects in a treatment arm; PD-L1 = programmed cell death ligand-1; OS, overall survival; ORR, objective response rate; Q8W, every 8 weeks; Q4W = every 4 weeks; Q8 = every 8 weeks; Q12W = every 12 weeks; T = tremelimumab 750 mg (10 mg/kg) Q4W × 7 doses followed by Q12W; T300+D = tremelimumab 300 mg (4 mg/kg) × 1 dose + durvalumab 1500 mg (20 mg/kg) Q4W; T75+D = tremelimumab 75 mg (1 mg/kg) Q4W × 4 doses + durvalumab 1500 mg (20 mg/kg) Q4W, followed by durvalumab 1500 mg (20 mg/kg) Q4W.

<div style=\"page-break-after: always\"></div>

Study 22 was a randomized, multicenter, international, open-label, multipart study designed to evaluate the  safety,  tolerability,  and  clinical  activity  of  durvalumab  and  tremelimumab  administered  as monotherapy, and durvalumab in combination with tremelimumab or bevacizumab, in patients with advanced HCC. The study was comprised of multiple parts but only Parts 2 and 3 of Study 22 are relevant for this procedure.

The primary objectives of Parts 2 and 3 were to:

- Assess the safety and tolerability of durvalumab  and tremelimumab  administered as monotherapy and durvalumab administered in combination with tremelimumab to subjects with advanced HCC.

The secondary objectives were to:

- Evaluate  the  efficacy  of  durvalumab  and  tremelimumab  administered  as  monotherapy  and durvalumab in combination with tremelimumab in subjects with advanced HCC.
- Evaluate the relationship between baseline and pharmacodynamic biomarkers and measures of clinical  outcomes  of  durvalumab  and  tremelimumab  administered  as  monotherapy,  and durvalumab in combination with tremelimumab in subjects with advanced HCC.

The final analysis of data in all study parts was performed 12 months after the first dose of investigational product was given to the last patient enrolled in the study (DCO: 06 November 2020).

## Patient population

In Study 22, eligible patients were aged ≥ 18 years (≥ 20 years for Japanese patients) with advanced HCC confirmed pathologically or with non-invasive methods. This study enrolled immunotherapy-naïve patients who progressed on, were intolerant to, or refused treatment with sorafenib or another approved VEGFR TKI. Patients with co-infection of viral hepatitis B and hepatitis C, active or prior documented GI bleeding within 12 months, ascites requiring non-pharmacologic intervention within 6 months, hepatic encephalopathy  within  12 months  before  the  start  of  treatment,  and  active  or  prior  documented autoimmune or inflammatory disorders were excluded.

In  Part 2A  of  Study  22,  eligible  patients  were  randomized  in  a  1:1:1  ratio  to  each  of  the  following 3 treatment arms: D: Durvalumab 20 mg/kg Q4W; T: Tremelimumab 10 mg/kg Q4W × 7 doses followed by Q12W; T75+D: Tremelimumab 1 mg/kg Q4W × 4 doses + durvalumab 20 mg/kg Q4W, followed by durvalumab 20 mg/kg Q4W

Part  2B  was  a  safety  run-in  for  the  combination  regimen  consisting  of  a  single,  priming  dose  of tremelimumab (300 mg) added to durvalumab Q4W. Part 3 was a dose expansion cohort of patients enrolled in Parts 2A and B. Eligible patients were randomized in a 2:2:1:2 ratio to each of the following 4 treatment arms: D: Durvalumab 1500 mg (20 mg/kg) Q4W; T300+D: Tremelimumab 300 mg (4 mg/kg) × 1 dose + durvalumab 1500 mg (20 mg/kg) Q4W; T: Tremelimumab 750 mg (10 mg/kg) Q4W × 7 doses followed by Q12W; T75+D: Tremelimumab 75 mg (1 mg/kg) Q4W× 4 doses + durvalumab 1500 mg (20 mg/kg) Q4W, followed by durvalumab 1500 mg (20 mg/kg) Q4W.

In Part 2A, patients were stratified based on viral status (uninfected, HCV infected, or HBV infected) and PD-L1 expression (positive, negative, or non-evaluable). In Part 3, patients were stratified based on viral status (uninfected, HCV infected, or HBV infected) and sorafenib-based therapy (refusers or all others).

<div style=\"page-break-after: always\"></div>

Table 39. Previous Disease-related Treatment Modalities in Parts 2 and 3 (FAS)

|                        | Nunber (%) of patients   | Nunber (%) of patients   | Nunber (%) of patients   | Nunber (%) of patients   | Nunber (%) of patients   |
|------------------------|--------------------------|--------------------------|--------------------------|--------------------------|--------------------------|
|                        | D (N =104)               | T300+D (N = 75)          | T (N = 69)               | T75+D (N =84)            | Total (N = 332)          |
| Systemic therapy a     | 66 (63.5)                | 55 (73.3)                | 44 (63.8)                | 55 (65.5)                | 220 (66.3)               |
| Carotuximab            | 1 (1.0)                  | 0                        | 0                        | 0                        | 1 (0.3)                  |
| Regorafenib            | 1 (1.0)                  | 0                        | 0                        | 0                        | 1 (0.3)                  |
| Sorafenib              | 66 (63.5)                | 55 (73.3)                | 44 (63.8)                | 55 (65.5)                | 220 (66.3)               |
| Radiotherapy           | 16 (15.4)                | 22 (29.3)                | 15 (21.7)                | 22 (26.2)                | 75 (22.6)                |
| Cancer-related surgery | 37 (35.6)                | 34 (45.3)                | 23 (33.3)                | 37 (44.0)                | 131 (39.5)               |
| Other                  | 49 (47.1)                | 25 (33.3)                | 31 (44.9)                | 39 (46.4)                | 144 (43.4)               |

D, durvalumab monotherapy 1500 mg (20 mg/kg) Q4W; FAS, Full Analysis Set; Q4W, every 4 weeks; T, tremelimumab monotherapy 750 mg (10 mg/kg) Q4W × 7 doses followed by every 12 weeks; T75+D, tremelimumab 75 mg (1 mg/kg) × 4 doses + durvalumab 1500 mg (20 mg/kg) Q4W; T300+D, tremelimumab 300 mg (4 mg/kg) × 1 dose + durvalumab 1500 mg (20 mg/kg) Q4W.

## Results

A total of 326 (98.2%) patients in the FAS of Parts 2 and 3 received study treatment. At the final DCO, 93.3% of patients across all treatment arms discontinued study treatment. The most frequently reported reason for discontinuing study treatment was HCC disease progression in 66.6% of patients; 11% of patients discontinued due to AEs. The rate of study treatment discontinuation due to PD or AEs was similar across the T300+D and D treatment arms.

The number of patients in Parts 2 and 3 with important protocol deviations with the potential to affect the analyses was low (13 patients overall [3.9%]).

For patient demographics and disease characteristics, please refer to Table 19 and Table 20 in the Results section above Error! Reference source not found. .

<div style=\"page-break-after: always\"></div>

Table 40. Overall Survival in Parts 2 and 3 (FAS)

<!-- image -->

|                                                                       | D (N =104)         | T300+D (N = 75)    | T (N = 69)         | T75+D (N =84)      |
|-----------------------------------------------------------------------|--------------------|--------------------|--------------------|--------------------|
| Median OS (months) a                                                  | 12.91              | 17.05              | 17.05              | 11.30              |
| 95% CI for median OSa                                                 | 8.74-16.79         | 10.55-22.83        | 11.33-20.24        | 8.38-14.95         |
| Deaths, n (%)                                                         | 78 (75.0)          | 49 (65.3)          | 55 (79.7)          | 64 (76.2)          |
| Censored patients, n (%)                                              | 26 (25.0)          | 26 (34.7)          | 14 (20.3)          | 20 (23.8)          |
| Still in survival follow-up                                           | 20 (19.2)          | 23 (30.7)          | 12 (17.4)          | 15 (17.9)          |
| Terminated prior todeath                                              | 6 (5.8)            | 3 (4.0)            | 2 (2.9)            | 5 (6.0)            |
| Lost to follow-up                                                     | 0                  | 1 (1.3)            | 0                  | 2 (2.4)            |
| Withdrawn consent                                                     | 3 (2.9)            | 2 (2.7)            | 2 (2.9)            | 2 (2.4)            |
| Other                                                                 | 3 (2.9) d          | 0                  | 0                  | 1 (1.2) e          |
| OS rate at 12 months, % a                                             | 50.4               | 57.6               | 59.8               | 49.4               |
| 95%CIfor OS rate at 12 months a                                       | 40.3-59.7          | 45.5-68.0          | 47.1-70.4          | 38.1-59.7          |
| OS rate at 18 months, % a                                             | 34.0               | 47.8               | 43.3               | 35.5               |
| 95% CI for OS rate at 18 months a                                     | 24.9-43.3          | 35.9-58.7          | 31.3-54.7          | 25.2-45.9          |
| OS rate at 24 months, % a                                             | 26.2               | 38.3               | 30.9               | 30.3               |
| 95% CI for OS rate at 24 months a                                     | 17.9-35.3          | 26.9-49.6          | 20.3-42.2          | 20.7-40.6          |
| Duration of follow-up in censored patients (months), median (range) f | 23.18 (1.84-44.29) | 24.61 (0.95-35.58) | 31.03 (1.81-44.02) | 29.82 (0.03-43.14) |

- a Calculated using the Kaplan-Meier technique.
- b Includes patients known to be alive at the data cut-off.
- C Includes patients with unknown survival status who terminated study participation and patients who were lost to follow-up.
- P *Other? reasons (1 patient each): psychiatric issues and study compliance, adverse event, and patient did not receivetreatment.
- 'Other'reason: patient did not receive treatment.
- f Medianforduration offollow-upis the arithmeticmedian.Duration offollow-upwascalculatedfromdate ofrandomization(Part 2A,Part 3) or date of first study treatment dose (Part 2B)

CI, confidence interval; D, durvalumab monotherapy 1500 mg (20 mg/kg) Q4W; FAS, Full Analysis Set; OS, overall survival; Q4W, every 4 weeks; T, tremelimumab monotherapy 750 mg (10 mg/kg) Q4W × 7 doses followed by every 12 weeks; T75+D, tremelimumab 75 mg (1 mg/kg) × 4 doses + durvalumab 1500 mg (20 mg/kg) Q4W; T300+D, tremelimumab 300 mg (4 mg/kg) × 1 dose + durvalumab 1500 mg (20 mg/kg) Q4W.

<div style=\"page-break-after: always\"></div>

| D      |   104 |   82 |   68 |   58 |   50 |   42 |   33 |   24 |   17 |   14 | 12   |   7 |   7 |   6 | 3 0   |
|--------|-------|------|------|------|------|------|------|------|------|------|------|-----|-----|-----|-------|
| T300+D |    75 |   68 |   56 |   49 |   42 |   38 |   34 |   27 |   19 |   17 | 11   |   5 |   0 |   0 | 0 0   |
| T      |    69 |   62 |   52 |   47 |   40 |   35 |   29 |   21 |   18 |   16 | 13   |   9 |   8 |   6 | 2 0   |
| T75+D  |    84 |   69 |   56 |   48 |   39 |   31 |   28 |   24 |   23 |   61 | 1I   |   6 |   5 |   4 | 2 0   |

Figure 23. Kaplan-Meier Plot of Overall Survival in Parts 2 and 3 (FAS)

<!-- image -->

CI,confidenceinterval;D,durvalumabmonotherapy1500mg(20mg/kg)Q4W;FAS,full analysisset;Os, overallsurvival;Q4W.every4weeks;T,tremelimumabmonotherapy750mg（10mg/kg)Q4W×7doses followedbyevery12weeks;T75+D,tremelimumab75mg（1mg/kg)×4doses+durvalumab1500mg (20mg/kg)Q4W;T300+D,tremelimumab300mg（4mg/kg)x1dose+durvalumab1500mg(20mg/kg)Q4W. Source:Figure 14.2.1.

Table 41. Confirmed Objective Response Rate in Parts 2 and 3 Based on BICR According to RECIST 1.1 (FAS)

|                                           | D (N =104)   | T300+D (N = 75)   | T (N = 69)   | T75+D (N = 84)   |
|-------------------------------------------|--------------|-------------------|--------------|------------------|
| Patients with objective response, n (%) a | 12 (11.5)    | 18 (24.0)         | 5 (7.2)      | 8 (9.5)          |
| ORR (%)                                   | 11.5         | 24.0              | 7.2          | 9.5              |
| 95%exact CI                               | 6.1, 19.3    | 14.9.35.3         | 2.4, 16.1    | 4.2,17.9         |

<div style=\"page-break-after: always\"></div>

Table 42. Duration and Onset of Objective Response in Patients with Confirmed Objective Response in Parts 2 and 3 Based on BICR According to RECIST 1.1 (FAS)

|                                                                                                      | D (N =104)                                                                                           | T300+D (N = 75)                                                                                      | T (N = 69)                                                                                           | T75+D (N =84)                                                                                        |
|------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------|
| Number of patients with objective response, n (%)                                                    | 12 (11.5)                                                                                            | 18 (24.0)                                                                                            | 5 (7.2)                                                                                              | 8 (9.5)                                                                                              |
| Number of responders who subsequently progressed or died, n                                          | 6                                                                                                    | 9                                                                                                    | 3                                                                                                    | 4                                                                                                    |
| Duration of response from onset of response (months) a b                                             | Duration of response from onset of response (months) a b                                             | Duration of response from onset of response (months) a b                                             | Duration of response from onset of response (months) a b                                             | Duration of response from onset of response (months) a b                                             |
| Median                                                                                               | 14.95                                                                                                | 18.43                                                                                                | 23.95                                                                                                | 13.21                                                                                                |
| 25th, 75t percentile                                                                                 | 8.54, NR                                                                                             | 5.59, 23.95                                                                                          | 4.07, NR                                                                                             | 10.15, NR                                                                                            |
| Percentage remaining in response b                                                                   | Percentage remaining in response b                                                                   | Percentage remaining in response b                                                                   | Percentage remaining in response b                                                                   | Percentage remaining in response b                                                                   |
| 6 months                                                                                             | 83.3                                                                                                 | 71.8                                                                                                 | 60.0                                                                                                 | 87.5                                                                                                 |
| 12 months                                                                                            | 56.3                                                                                                 | 64.6                                                                                                 | 60.0                                                                                                 | 58.3                                                                                                 |
| Time to onset ofresponse from randomization (Parts 2A and 3)/treatment allocation (Part 2B) (months) | Time to onset ofresponse from randomization (Parts 2A and 3)/treatment allocation (Part 2B) (months) | Time to onset ofresponse from randomization (Parts 2A and 3)/treatment allocation (Part 2B) (months) | Time to onset ofresponse from randomization (Parts 2A and 3)/treatment allocation (Part 2B) (months) | Time to onset ofresponse from randomization (Parts 2A and 3)/treatment allocation (Part 2B) (months) |
| Median                                                                                               | 3.65                                                                                                 | 2.28                                                                                                 | 1.81                                                                                                 | 2.86                                                                                                 |
| 25th, 75th percentile                                                                                | 2.71, 5.59                                                                                           | 1.81, 3.68                                                                                           | 1.81, 1.84                                                                                           | 1.84,3.83                                                                                            |

BICR, blinded independent central review; D, durvalumab monotherapy 1500 mg (20 mg/kg) Q4W; FAS, Full Analysis Set; NR, not reached; Q4W, every 4 weeks; RECIST 1.1, Response Evaluation Criteria In Solid Tumours Version 1.1; T, tremelimumab monotherapy 750 mg (10 mg/kg) Q4W x 7 doses followed by every 12 weeks; T75+D, tremelimumab 75 mg (1 mg/kg) × 4 doses + durvalumab 1500 mg (20 mg/kg) Q4W; T300+D, tremelimumab 300 mg (4 mg/kg) × 1 dose + durvalumab 1500 mg (20 mg/kg) Q4W.

## Overall Survival (Part 2 Only)

A total of 125 patients were randomized/allocated to treatment in Part 2: 40 in the D arm, 10 in the T300+D arm, 36 in the T arm, and 39 in the T75+D arm. At the final DCO, 81.6% of patients in part 2 had died (FAS): 80.0% in the D arm, 70.0% in the T300+D arm, 80.6% in the T arm, and 87.2% in the T75+D arm. The percentage of patients alive at the final DCO and in survival follow-up (including those still receiving study treatment) was highest in the T300+D arm (30.0%) compared to the other 3 arms (10.3% to 17.5%).

The Kaplan-Meier estimate of median OS was highest for patients receiving T300+D (28.06 months) compared to patients receiving D (11.78 months), T (17.05 months), or T75+D (13.34 months).

## Overall Survival (Part 3 Only)

Part 3 included the following number of patients per treatment arm: 64 in D arm; 65 in T300+D arm; 33 in T arm; 45 in T75+D arm. Median OS was higher for patients in the T300+D (16.16 months) and T arms (17.54 arms) compared to D (13.57 months) and T75+D (11.30 months).

## 2.4.2. Discussion on clinical efficacy

## Design and conduct of clinical studies

The efficacy of the new active substance, tremelimumab (T), in combination with the already approved PD-L1 inhibitor durvalumab (D) for the treatment of unresectable hepatocellular carcinoma (uHCC) is primarily based on the pivotal Himalaya study. This was a randomised, open-label, multicentre Phase III study in patients with uHCC not eligible for locoregional therapy. Patients were recruited from 181 sites across 16 countries, mostly from countries with an EU-like population. No prior systemic therapy was allowed and only patients with mild or no symptoms pertaining to the HCC and/or liver cirrhosis were

<div style=\"page-break-after: always\"></div>

eligible, which is not considered reflective of the general patient population with uHCC. However, the inclusion and exclusion criteria are reflected in the SmPC section 5.1, so this is acceptable. 1324 patients were randomised to 4 arms, durvalumab monotherapy (D, n=389); tremelimumab single dose 300 mg +  durvalumab  (T300+D,  n=393);  Tremelimumab  75  mg  x  4  +  durvalumab  (T75+D,  n=153);  and sorafenib (S, n=389). Randomization was stratified according to macrovascular invasion (yes versus no), etiology of liver disease (hepatitis B virus [confirmed HBV] versus hepatitis C virus [confirmed HCV] versus others), and ECOG PS (0 versus 1). The stratification factors are considered clinically relevant as they are important prognostic factors for the outcome of uHCC. Other important prognostic factors could have been added, such as AFP levels; however, considering the size of the pivotal trial, it is considered appropriate to limit the number of stratification factors to three. Additional supportive evidence of clinical efficacy was provided from study 22, a randomised, phase I/II, open-label study.

The overall design of the pivotal Himalaya study is endorsed as it allows to assess the efficacy of the proposed dosing of tremelimumab single dose 300 mg + durvalumab 1500 mg iv followed by durvalumab monotherapy 1500 mg iv Q4W (T300+D) versus standard of care (Sorafenib - S) in the proposed firstline setting. Moreover, the Applicant included a durvalumab monotherapy arm and an arm with another combination regimen of T75+D, which was abolished after some time.

Baseline characteristics for patients included in the Himalaya study showed that the median age in the relevant arms (T300+D vs the S arm vs the T300+D arm of study 22) were 65 vs 64 vs 66 years of age; however, approximately half of the patients were &lt;65 years of age and the vast majority of the patients were male (83.2% vs 86.6% vs 86.7%) and of white (46.3% vs 46% vs 36%) or Asian (49.6% vs 48.6% vs 58.7%) race.  Alcohol use was only registered in the pivotal Himalaya study and it is noted that a large proportion was never users (~40%) or former users (~45%). The baseline characteristics are well balanced between the arms, but only approximately 46% of the study population are considered EU like according  to  region  and  race  characteristics.  Moreover,  the  alcohol  use  in  the  study  population  is considered lower than for the EU population.

Disease characteristics showed that most patients were ECOG PS 0 (~60%) and of advanced Barcelona Clinic Liver Cancer (BCLC) stage C (~80%). Additionally, macrovascular invasion and/or extrahepatic spread was observed for many (~65%). However, the poor prognostic factor of AFP &gt;400 ng/ml was observed in approximately a third of the patients, which is also reflected by the distribution of the ChildPugh score categories, showing that many of the included patients have a favourable prognosis.

It is noted that only a third of the included patients had tumours that were PD-L1 positive (TIP ≥ 1%) and that there were ~13% of the patients in the D+T containing arms, who had missing data on PD-L1 status. Overall, the important disease characteristics are well distributed between the treatment arms. Regarding the level of poor prognostic factors, it is considered that these are lower than expected for the  targeted  patient  population,  which  should  be  kept  in  mind  when  interpreting  the  results  of  the studies.

The primary objective of the pivotal Himalaya study was to assess superiority of efficacy of T300+D vs standard of care (sorafenib) regarding OS for the ITT population. The two key secondary objectives of the trial were to assess non-inferiority of the efficacy of durvalumab monotherapy versus SoC (sorafenib) regarding  OS  and  superiority  of  the  efficacy  of  durvalumab  monotherapy  versus  SoC  (sorafenib) regarding OS. Other important secondary endpoints are PFS and overall response rate plus duration of response. The current MAA for tremelimumab is based on efficacy results from the primary objective of the pivotal study. The primary objective and key secondary objectives pertain to overall survival, and this is endorsed, considering the targeted patient population and the robustness of OS as an endpoint.

Although it does not preclude a benefit/risk assessment, the overall conduct of the study is considered suboptimal due to the changes in primary endpoints and sample size especially considering the open

<div style=\"page-break-after: always\"></div>

label design.  Additionally, interpretation of radiological assessments of tumour response is hindered because of the lack of blinded central review of the assessments in the final analysis.

## Efficacy data and additional analyses

## The pivotal Himalaya study:

The primary objective was met as treatment with T300+D showed a statistically significant and clinically relevant improvement in OS compared to standard of care, sorafenib. Median OS was improved from 13.77 months to 16.43 months, HR 0.78 (96.02% CI: 0.65, 0.92). The analysis was performed after ~33 months of follow up and 66.7% of events in the T300+D arm and 75.3% events in the S arm, respectively, so the OS data are considered mature. The KM curves begin to separate after 4 months of therapy and stay separated.

It is acknowledged that Himalaya was primarily designed to demonstrate superiority of T300+D vs S in terms of OS and was amended to demonstrate non-inferiority of D vs S for OS as the next analysis in the  hierarchical  testing.  Moreover,  the  study  design  allowed  for  assessment  of  the  contribution  of tremelimumab to the combination regimen, through prespecified exploratory analyses of T300+D vs D, which showed an HR of 0.90 (95%CI: 0.76, 1.07) for OS, which was 16.43 months vs 16.56 months, respectively. The Applicant has further argued that due to the complementary mechanisms of action of tremelimumab and durvalumab, the reduction in risk of death, more patients achieving a BOR of CR plus more durable responses in the T300+D arm that the addition of tremelimumab is justified. Additionally, a post-hoc analysis calculating piecewise constant treatment effects favoured T300+D independent of selected time interval when compared to either S or D, further illustrating the OS benefit offered by T300+D compared with D. However, there are remaining uncertainties regarding the optimal dosing regimen e.g. would more than one single dose of tremelimumab have had a significant contribution to added efficacy compared to T300+D and is 300 mg the optimal dose or could the same efficacy and maybe a better safety profile have been obtained with several but lower doses of tremelimumab.

The secondary endpoint of ORR by investigator was 20.1% for the T300+D arm compared to 5.1% in the sorafenib arm, while 3.1% of the patients in the T300+D arm had a complete response (CR) vs no patients in the S arm. Confirmed ORR by BIRC was slightly lower in the T300+D arm (18.8%), but this is not directly comparable with ORR by Investigator, since the evaluation was only done in a subset of patients.  The  improvement  of  the  response  rate  both  by  INV  and  by  BIRC  is  considered  borderline clinically meaningful in its magnitude; however, the responders in the T300+D arm (n=79) had durable responses with a median DoR of 22.34 months.

The PFS analyses were not in the testing hierarchy, so they are not controlled for multiplicity. PFS by investigator  was  not  clinically  significantly  improved,  since  the  median  PFS  was  3.78  months  in  the T300+D arm versus 4.07 months in the S arm; HR 0.90 (95%CI: 0.77, 1.05). The PFS analyses are mature with 85.2% and 84.1% events in the T300+D and S arms, respectively and the KM curves do not  clearly  separate  at  any  time.  This  finding  is  considered  consistent  with  the  pattern  of  efficacy generally observed for immunotherapy, where PFS benefit is often lacking or of a small magnitude, while OS is often clinically significantly improved. Hence, this could be considered an acceptable result as the primary endpoint was OS, and that an OS benefit has been shown for the proposed treatment regimen T300+D vs S.

However, there are uncertainties when interpreting PFS and ORR considering that the final analysis in an open label setting was done by investigators. Additionally, assessments were performed using RECIST 1.1.  although  in  the  immunotherapy  setting,  irRECIST  may  have  been  more  appropriate/more informative. Nevertheless, rate of possible pseudoprogression of HCC with CTLA-4/PD-L1 inhibition is currently unknown, which creates uncertainty around PFS and ORR data, since patients with confirmed

<div style=\"page-break-after: always\"></div>

PD (according to RECIST 1.1) were discontinued from IP. Confirmation of PD required a follow-up scan evaluated by Confirmation of Radiological Progression criteria preferably at the next scheduled visit and no earlier than 4 weeks after the initial assessment of PD. In the HIMALAYA study, confirmation of PD was not mandatory as RECIST 1.1 used for final analysis does not require confirmation of progression and therefore was not done in the study. The lack of data on potential pseudoprogression is of concern as patients could be denied potentially beneficial treatment. This issue remains to be answered in clinical practice.

Additionally, assessments by BICR were performed only on a subset of patients evaluable for 32 weeks of follow up (for interim analysis 1), and included RECIST 1.1, irRECIST, and mRECIST. Following interim analysis  1,  no  further  BICR  assessments  were  performed.  In  view  of  the  robustness  of  the  primary endpoint (OS) the Applicant's approach regarding PFS can be accept ed.

The  study  design  of  Himalaya  allowed  for  assessment  of  the  contribution  of  tremelimumab  to  the combination regimen, through prespecified exploratory analyses of T300+D vs D, which showed an HR of  0.90  (95%CI:  0.76,  1.07)  for  OS,  which  was  16.43  months  vs  16.56  months,  respectively.  The Applicant has also provided a rationale for the addition of tremelimumab to durvalumab for the HCC indication, which is primarily based on the following: the combined blockade of CTLA-4 and PD-(L)1 to increase effector T-cell response through two distinct yet complementary mechanisms of action and an approximately  10%  reduction  in  the  average  risk  of  death  was  observed  with  T300+D  versus  D. Moreover, while the objective response rates with T300+D and D were similar in HIMALAYA (20.1% vs. 17.0%), twice as many BORs of CR were observed in HIMALAYA with T300+D (12 [3.1%]) compared to D (6 [1.5%]).

The provided arguments are acknowledged and it is accepted that the Applicant seeks an approval for the T300+D regimen. However, there remains to be unanswered questions to what would have been the optimal dosing regimen e.g. would more than one single dose of tremelimumab have had a significant contribution to added efficacy compared to T300+D and is 300 mg the optimal dose or could the same efficacy  and  maybe  a  better  safety  profile  have  been  obtained  with  several  but  lower  doses  of tremelimumab.

PRO  data  was  collected  as  a  secondary  endpoint.  Since  the  pivotal  study  was  open-label  and  PRO endpoints were not multiplicity-protected, clinical meaningfulness of PRO data is not considered relevant and the Applicant has agreed to delete them from the SmPC.

No additional information on changes in AFP were provided as these data were not collected in the HIMALAYA study.

Relevant subgroup analyses of the primary endpoint of OS show that the benefit of T300+D vs S is maintained across important subgroups of age of less than or ≥ 65 years, HBV or other reasons for liver disease, ECOG performance status, macrovascular invasion (MVI), AFP at baseline and BCLB score C.

## The supportive Study 22:

The supportive study 22 was a randomized, multicentre, open-label, multipart study designed to evaluate the safety and efficacy of durvalumab and/or tremelimumab in patients with advanced HCC in the 2L+ setting. The study was comprised of multiple parts, but the results from the T300+D arm is considered of  most  relevance  for  the  proposed  indication  (n=75),  although  the  study  randomised  patients  to  4 treatment arms. Patients were immunotherapy-naïve patients with advanced HCC, who had progressed on, were intolerant to, or refused treatment with sorafenib or another approved Vascular endothelial growth factor receptor (VEGFR) TKI. Due to different stratification factors in Parts 2A and 3 and lack of randomisation altogether in Part 2B, pooling of efficacy data is inappropriate. Fortunately, OS data from

<div style=\"page-break-after: always\"></div>

Part 2 and 3 is available separately as well. Although there were no interim analyses planned in the Original Protocol (09 April 2015), in the end 6 interim analyses were performed (and added through Protocol Amendments).

Baseline data for the T300+D arm showed that the median age was 66 years and the vast majority of the patients were male (86.7%) and of white (36%) or Asian (58.7%) race. Disease characteristics show that the vast majority of patients were ECOC PS 0 (61.3%) and disease of advanced BCLC stage C (77.3%) plus macrovascular invasion and/or extrahepatic spread (77.3%).

In  conclusion,  Study  22  is  an  early  phase,  exploratory  study  that  was  amended  several  times.  The primary objective of the study was to assess the safety and tolerability, whereas efficacy was a secondary objective and there was no hierarchical testing procedure or correction for multiplicity. The efficacy data quality should be viewed in this light. Moreover, out of the 75 patients in Study 22, who were treated with T300+D, only 55 patients had received prior treatment with sorafenib and were thus truly 'second line'. Due to the lack of a SoC comparator arm in Study 22, there is no benchmark for the results of the T300+D study arm, as there is insufficient understanding of the relevance of the efficacy as observed in the other study arms. In addition, the exploratory design of Study 22 and in particular the lack of a SAP that would provide for formal comparisons between the study arms, hampers both the contextualisation and interpretation of the efficacy results obtained in these 55 patients. As a consequence, the time-toevent endpoints cannot be interpreted adequately. It is noted that the ORR in these 55 patients was only 20%, which cannot be considered dramatic (EMA/CHMP/205/95 Rev.5).

The final analysis showed a median OS of 17 months (65.3% events) for patients who received the proposed dosing regimen of T300+D, while the ORR was 24% and the duration of response (DoR) was 18  months.  The  Applicant  compares  this  result  to  durvalumab  monotherapy;  however,  this  is  not approved for or is standard of care (SOC) in the 2L+ setting, so this comparison is not considered relevant for the current application. Since none of the arms of Study 22 contained any SOC, the results for the T300+D arm are considered supportive of efficacy for the proposed dosing regimen in the firstline setting.

## 2.4.3. Conclusions on the clinical efficacy

The results from the pivotal Himalaya study show a statistically significant and clinically relevant OS benefit over standard of care in the first-line setting of unresectable HCC.

## 2.5. Clinical safety

## Introduction

Table 43. Summary of Clinical Studies Included in the Submission Package

| Study Name (Study Number) Status DCO       | Phase Study Design                                         | Patient Population                                  | No. of patients Assigned and Treated (Treatment group)        |
|--------------------------------------------|------------------------------------------------------------|-----------------------------------------------------|---------------------------------------------------------------|
| Studies in HCC                             | Studies in HCC                                             | Studies in HCC                                      | Studies in HCC                                                |
| HIMALAYA (D419CC00002) Ongoing 27 Aug 2021 | Phase III Randomized, open-label, comparative, multicenter | Advanced HCC with no prior systemic therapy for HCC | 1324 (total) 393 (T300+D) 389 (D) 389 (Sorafenib) 153 (T75+D) |

<div style=\"page-break-after: always\"></div>

Table 43. Summary of Clinical Studies Included in the Submission Package

| Study Name (Study Number) Status DCO        | Phase Study Design                                        | Patient Population        | No. of patients Assigned and Treated (Treatment group)   |
|---------------------------------------------|-----------------------------------------------------------|---------------------------|----------------------------------------------------------|
| Study 22 (D4190C00022) Complete 06 Nov 2020 | Phase II Randomized, open-label, comparative, multicenter | Advanced unresectable HCC | 326 (total) 74 (T300+D) 101 (D) 82 (T75+D) 69 (T)        |

## HCC-tumor Pools

The pivotal safety dataset used to characterize the safety profile of durvalumab in combination with tremelimumab in the proposed indication was derived from pooled data from HIMALAYA and Study 22. The populations in the HCC-tumor pools are described below:

- HCC T300+D pool: This population consists of all patients who have received at least 1 dose of durvalumab given at a dose of 1500mg IV Q4W (or equivalent) in combination with tremelimumab 300 mg IV x 1 dose (or equivalent) for HCC.
- HCC D pool: This population consists of all patients who have received at least 1 dose of durvalumab monotherapy given at a dose of 20 mg/kg Q4W IV (or equivalent) for HCC.

## Patient exposure

Table 44. Summary of Study Treatment Exposure (Safety Analysis Set)

|                                         | HCC-tumor pool                          | HCC-tumor pool                          | Pan-tumor pool                          | Pan-tumor pool                          | Pan-tumor pool                          |
|-----------------------------------------|-----------------------------------------|-----------------------------------------|-----------------------------------------|-----------------------------------------|-----------------------------------------|
|                                         | T300+D                                  | D                                       | D                                       | T75+D                                   | T750                                    |
|                                         | (N = 462)                               | (N = 492)                               | (N = 4045)                              | (N = 3319)                              | (N = 643)                               |
| Total treatment duration (weeks) a      | Total treatment duration (weeks) a      | Total treatment duration (weeks) a      | Total treatment duration (weeks) a      | Total treatment duration (weeks) a      | Total treatment duration (weeks) a      |
| n                                       | 462                                     | 492                                     | 4045                                    | 3319                                    | 643                                     |
| Mean (SD)                               | 41.9 (44.34)                            | 38.0 (41.49)                            | 28.9 (32.18)                            | 30.1 (37.06)                            | 17.1 (18.46)                            |
| Median (min, max)                       | 20.0 (2, 185)                           | 19.9 (1, 193)                           | 16.1 (0, 220)                           | 16.0 (1, 222)                           | 12.0 (1, 176)                           |
| Total treatment years                   | 370.6                                   | 358.6                                   | 2240.4                                  | 1912.2                                  | 210.5                                   |
| Total treatment duration (weeks); n (%) | Total treatment duration (weeks); n (%) | Total treatment duration (weeks); n (%) | Total treatment duration (weeks); n (%) | Total treatment duration (weeks); n (%) | Total treatment duration (weeks); n (%) |
| ≥ 24                                    | 222 (48.1)                              | 225 (45.7)                              | 1671 (41.3)                             | 1219 (36.7)                             | 129 (20.1)                              |
| ≥ 52                                    | 131 (28.4)                              | 120 (24.4)                              | 793 (19.6)                              | 590 (17.8)                              | 36 (5.6)                                |
| ≥ 76                                    | 92 (19.9)                               | 82 (16.7)                               | 246 (6.1)                               | 292 (8.8)                               | 14 (2.2)                                |
| ≥ 104                                   | 66 (14.3)                               | 53 (10.8)                               | 179 (4.4)                               | 219 (6.6)                               | 6 (0.9)                                 |

<div style=\"page-break-after: always\"></div>

Table 45. Duration of Exposure (Safety Analysis Set)

|                                              |                       | D               | T300+D (N =388)     | T300+D (N =388)   | T300+D (N =388)   | T75+D (N =152)      | T75+D (N =152)   | T75+D (N =152)   | S               |
|----------------------------------------------|-----------------------|-----------------|---------------------|-------------------|-------------------|---------------------|------------------|------------------|-----------------|
|                                              |                       | (N =388)        | Tremelimumab        | Tremelimumab      | Durvalumab        | Tremelimumab        | Tremelimumab     | Durvalumab       | (N =374)        |
|                                              |                       | Total study a   | Initial treatment b | Rechallenge       | Total study a     | Initial treatment b | Rechallenge      | Total study a    |                 |
| Total treatment duration c (months)          | N                     | 388             | 388                 | 30                | 388               | 152                 | 12               | 152              | 374             |
| Total treatment duration c (months)          | Mean (SD)             | 9.7 (10.16)     | 0.9 (0.04)          | 0.9 (0.00)        | 10.6 (10.82)      | 3.0 (1.14)          | 2.2 (1.27)       | 9.3 (10.38)      | 7.5 (8.48)      |
| Total treatment duration c (months)          | Median (min, max)     | 5.5 (0.2, 44.4) | 0.9 (0.4, 0.9)      | 0.9 (0.9, 0.9)    | 5.5 (0.4, 42.7)   | 3.6 (0.7, 5.6)      | 1.9 (0.9, 3.7)   | 4.6 (0.7, 44.2)  | 4.1 (0.1, 38.6) |
| Total treatment duration c (months)          | Totaltreatmentyears   | 312.7           | 29.6                | 2.3               | 341.7             | 38.6                | 2.2              | 118.0            | 234.9           |
| Actual treatment duration d (months)         | N                     | 388             | 388                 | 30                | 388               | 152                 | 12               | 152              | 374             |
|                                              | Mean (SD)             | 9.3 (9.84)      | 0.9 (0.04)          | 0.9 (0.00)        | 10.1 (10.47)      | 2.9 (1.02)          | 2.1 (1.26)       | 8.9 (9.98)       | 7.2 (8.35)      |
|                                              | Median (min, max)     | 4.6 (0.2, 44.4) | 0.9 (0.4, 0.9)      | 0.9 (0.9, 0.9)    | 5.5 (0.4, 42.6)   | 3.6 (0.7, 3.7)      | 1.8 (0.9, 3.7)   | 4.6 (0.7, 41.9)  | 3.7 (0.1, 38.6) |
|                                              | Total treatment years | 301.4           | 29.6                | 2.3               | 326.2             | 36.6                | 2.1              | 112.7            | 224.5           |
| Total duration of cycle delays - total study | N                     | 180             | 0                   | 0                 | 194               | 60                  | 60               | 88               | 182             |
| (months)                                     | Mean (SD)             | 0.7 (1.22)      | NA                  | NA                | 1.0 (1.28)        | 0.4 (0.54)          | 0.4 (0.54)       | 0.7 (0.95)       | 0.7 (0.69)      |
| (months)                                     | Median (min, max)     | 0.3 (0.0, 10.3) | NA                  | NA                | 0.5 (0.0, 94)     | 0.1 (0.0, 1.9)      | 0.1 (0.0, 1.9)   | 0.3 (0.0, 5.4)   | 0.5 (0.0, 3.7)  |

Total study exposure includes initial treatment and rechallenge phase, where rechallenge occurred.

b Initial treatment phase includes the start of study treatment to last treatment or last treatment prior to rechallenge, where rechallenge occurred.

Total treatment duration for immunotherapies=(last dose date + 27 days or date of death or DCO, whichever occuured earlier -first dose date + 1)/(365.25/12). Total treatment duration for S = (last dose date or date of death or DCO, whichever occurred earlier - first dose date + 1)/(365.25/12).

P Actual treatment duration = (intended exposure - total duration of dose delays)/(365.25/12).

Patientswhotookinfusionearlier than plannedwereset toOfor calculation.

D, durvalumab monotherapy 1500 mg Q4W; DCO, data cut-off max, maximum; min, minimum; NA, not applicable; Q4W, every 4 weeks; S, sorafenib 400 mg twice daily;SD,standard deviation;T75+D,tremelimumab75mg×4 doses +durvalumab1500 mgQ4W;T300+D,tremelimumab 300mg×1 dose+durvalumab1500mgQ4W.

Source:Table 14.3.1.1l.

<div style=\"page-break-after: always\"></div>

## Adverse events

## Table 46. Overview of AEs in the HIMALAYA T300+D and S Arms and the HCC T300+D Pool (Safety Analysis Set)

|                                                                                                                   | Number (%) of patients a   | Number (%) of patients a   | Number (%) of patients a   |
|-------------------------------------------------------------------------------------------------------------------|----------------------------|----------------------------|----------------------------|
|                                                                                                                   | HCC T300+D pool            | HIMALAYA T300+D arm        | HIMALAYA S arm             |
| AE category                                                                                                       | (N = 462)                  | (N = 388)                  | (N = 374)                  |
| Any AE                                                                                                            | 451 (97.6)                 | 378 (97.4)                 | 357 (95.5)                 |
| Any AE possibly related to any study treatment b                                                                  | 355 (76.8)                 | 294 (75.8)                 | 317 (84.8)                 |
| Any AE possibly related to durvalumab b                                                                           | 349 (75.5)                 | 288 (74.2)                 | NA                         |
| Any AE possibly related to tremelimumab b                                                                         | 224 (48.5)                 | 175 (45.1)                 | NA                         |
| Any AE possibly related to sorafenib b                                                                            | NA                         | NA                         | 317 (84.8)                 |
| Any AE of CTCAE Grade 3 or 4 c                                                                                    | 240 (51.9)                 | 196 (50.5)                 | 196 (52.4)                 |
| Any AE of CTCAE Grade 3 or 4 c possibly related to any study treatment b                                          | 127 (27.5)                 | 100 (25.8)                 | 138 (36.9)                 |
| Any AE with outcome of death                                                                                      | 34 (7.4)                   | 30 (7.7)                   | 27 (7.2)                   |
| Any SAE (including events with outcome of death) d                                                                | 189 (40.9)                 | 157 (40.5)                 | 111 (29.7)                 |
| Any AE leading to discontinuation of any study treatment                                                          | 63 (13.6)                  | 53 (13.7)                  | 63 (16.8)                  |
| Any AE leading to discontinuation of any study treatment, possibly related to any study treatment b               | 41 (8.9)                   | 32 (8.2)                   | 41 (11.0)                  |
| Any AE leading to dose delay or interruption of any study treatment e                                             | 149 (32.3)                 | 134 (34.5)                 | 178 (47.6)                 |
| Any AE leading to dose delay or interruption of any study treatment e , possibly related to any study treatment b | NE                         | 83 (21.4)                  | 144 (38.5)                 |

a Patients with multiple events in the same category are counted only once in that category; patients with events in more than 1 category are counted once in each of those categories.

b As assessed by the investigator. Missing responses are counted as related.

c All CTCAE grades per patient, not just the maximum, are considered when identifying whether there is a Grade 3 or 4.

d Seriousness, as assessed by the investigator. An AE with missing seriousness is considered serious.

e Includes AEs on the AE CRF form with action taken indicating dose delay or dose interruption, and AEs meeting study level dose delay definitions, where applicable.

Note: Includes AEs with an onset date on or after the date of first dose or pre-treatment AEs that increase in severity on or after the date of first dose up to and including 90 days following the date of last dose of study treatment or up to and including the date of initiation of the first subsequent therapy (whichever occurs first).

AE, adverse event; CRF, case report form; CSR, Clinical Study Report; CTCAE, Common Terminology Criteria for Adverse Events (version 4.03); HCC, hepatocellular carcinoma; HCC T300+D pool, all patients from HIMALAYA and Study 22 who have received at least 1 dose of durvalumab given at a dose of 1500 mg IV Q4W (or equivalent) in combination with tremelimumab 300 mg IV × 1 dose (or equivalent) for HCC for any line of therapy; IV, intravenous; NA, not applicable; NE, not evaluated; Q4W, every 4 weeks; S, sorafenib 400 mg twice daily; SAE, serious adverse event; T300+D, tremelimumab 300 mg (4 mg/kg) for a single priming dose and durvalumab 1500 mg (20 mg/kg) Q4W.

<div style=\"page-break-after: always\"></div>

## Common adverse events

Table 47 . Adverse Events by Preferred Term Occurring in ≥10% of Patients in Any Treatment Arm (Safety Analysis Set)

|                                                      | Number (%) of patients a   | Number (%) of patients a   | Number (%) of patients a   | Number (%) of patients a   |
|------------------------------------------------------|----------------------------|----------------------------|----------------------------|----------------------------|
| System organ class MedDRA preferred term             | D (N=388)                  | T300+D (N=388)             | T75+D (N=152)              | S (N= 374)                 |
| Patients with any AE                                 | 345 (88.9)                 | 378 (97.4)                 | 145 (95.4)                 | 357 (95.5)                 |
| Gastrointestinal disorders                           | 195 (50.3)                 | 236 (60.8)                 | 79 (52.0)                  | 265 (70.9)                 |
| Dianhoea                                             | 58 (14.9)                  | 103 (26.5)                 | 32 (21.1)                  | 167 (44.7)                 |
| Constipation                                         | 42 (10.8)                  | 36 (9.3)                   | 12 (7.9)                   | 35 (9.4)                   |
| Abdominal pain                                       | 37 (9.5)                   | 46 (11.9)                  | 26 (17.1)                  | 63 (16.8)                  |
| Nausea                                               | 37 (9.5)                   | 47 (12.1)                  | 14 (9.2)                   | 53 (14.2)                  |
| Skin and subcutaneous tissue disorders               | 135 (34.8)                 | 198 (51.0)                 | 70 (46.1)                  | 243 (65.0)                 |
| Pnuitus                                              | 56 (14.4)                  | 89 (22.9)                  | 27 (17.8)                  | 24 (6.4)                   |
| Rash                                                 | 40 (10.3)                  | 87 (22.4)                  | 27 (17.8)                  | 51 (13.6)                  |
| Alopecia                                             | 5 (1.3)                    | 2 (0.5)                    | 1 (0.7)                    | 53 (14.2)                  |
| Palmar-plantar erythrodysaesthesia syndrome          | 1 (0.3)                    | 3 (0.8)                    | 3 (2.0)                    | 174 (46.5)                 |
| Investigations                                       | 123 (31.7)                 | 155 (39.9)                 | 50 (32.9)                  | 122 (32.6)                 |
| Aspartate aminotransferase increased                 | 56 (14.4)                  | 48 (12.4)                  | 16 (10.5)                  | 24 (6.4)                   |
| Alanine aminotransferase increased                   | 44 (11.3)                  | 36 (9.3)                   | 10 (6.6)                   | 20 (5.3)                   |
| Metabolism and nutition disorders                    | 101 (26.0)                 | 145 (37.4)                 | 42 (27.6)                  | 123 (32.9)                 |
| Decreased appetite                                   | 53 (13.7)                  | 66 (17.0)                  | 25 (16.4)                  | 67 (17.9)                  |
| General disorders and administration site conditions | 149 (38.4)                 | 180 (46.4)                 | 73 (48.0)                  | 174 (46.5)                 |
| Asthenia                                             | 49 (12.6)                  | 39 (10.1)                  | 20 (13.2)                  | 44 (11.8)                  |
| Fatigue                                              | 38 (9.8)                   | 66 (17.0)                  | 25 (16.4)                  | 71 (19.0)                  |
| Pyrexia                                              | 36 (9.3)                   | 50 (12.9)                  | 16 (10.5)                  | 33 (8.8)                   |
| Oedema peripheral                                    | 24 (6.2)                   | 33 (8.5)                   | 16 (10.5)                  | 19 (5.1)                   |
| Respiratory, thoracic and mediastinal disorders      | 73 (18.8)                  | 90 (23.2)                  | 34 (22.4)                  | 95 (25.4)                  |
| Cough                                                | 31 (8.0)                   | 30 (7.7)                   | 17 (11.2)                  | 22 (5.9)                   |
| Psychiatic disorders                                 | 41 (10.6)                  | 57 (14.7)                  | 14 (9.2)                   | 26 (7.0)                   |
| Insommia                                             | 21 (5.4)                   | 40 (10.3)                  | 10 (6.6)                   | 16 (4.3)                   |
| Endocrine disorders                                  | 41 (10.6)                  | 92 (23.7)                  | 32 (21.1)                  | 20 (5.3)                   |
| Hypothyroidism                                       | 19 (4.9)                   | 47 (12.1)                  | 20 (13.2)                  | 16 (4.3)                   |
| Vascular disorders                                   | 31 (8.0)                   | 48 (12.4)                  | 12 (7.9)                   | 73 (19.5)                  |
| Hypertension                                         | 17 (4.4)                   | 23 (5.9)                   | 6 (3.9)                    | 68 (18.2)                  |

- Each patient has only been represented with the maximum reported CTCAE grade foreach system organ class/preferred term

Includes AEs with an onset date on or after the date of first dose or pre-treatment AEs that increase in severity on or afterthedate of firstdoseuptoand including90daysfollowing thedateof last dose of study medication or up to and including the date of initiation of the first subsequent therapy (whichever occured first).

Preferred terms are ordered by decreasing frequency in the D anm.

PatientswithanAEofmaximmCTCAE Grade5aftertheDCOhavebeenresetto'uknownattheDCO.This affected0patients inthe D am0patients intheT300+Dam0patients in theT75+D am, and 0patients in the S anm.

MedDRA version 23.1.CTCAEversion4.03.

AE, adverse event; CTCAE, Common Terminology Criteria for Adverse Events; D, duvalumab monotherapy 1500 mg Q4W; DCO, data cut-off; IP, investigational product; MedDRA, Medical Dictionary for Regulatory Activities; Q4W, every4 weeks; S, sorafenib 400 mg twice daily; T75+D, tremelimumab 75 mg × 4 doses + duvalumab 1500 mg Q4W; T300+D, tremelimumab 300 mg × 1 dose + duuvalumab 1500 mg Q4W.

<div style=\"page-break-after: always\"></div>

Table 48. Adverse Events and Event Rate Occurring in ≥ 10% of Patients in Any Treatment Group by Preferred Term (Safety Analysis Set)

|                                       | HCC-tumor pool             | HCC-tumor pool                  | HCC-tumor pool             | HCC-tumor pool               | Pan-tumor pool             | Pan-tumor pool                  | Pan-tumor pool            | Pan-tumor pool                  | Pan-tumor pool             | Pan-tumor pool                  |
|---------------------------------------|----------------------------|---------------------------------|----------------------------|------------------------------|----------------------------|---------------------------------|---------------------------|---------------------------------|----------------------------|---------------------------------|
|                                       | T300+D                     | T300+D                          | D                          | D                            | D                          | D                               | T75+D                     | T75+D                           | T750                       | T750                            |
|                                       | (N = 462)                  | (N = 462)                       | (N = 492)                  | (N = 492)                    | (N = 4045)                 | (N = 4045)                      | (N = 3319)                | (N = 3319)                      | (N = 643)                  | (N = 643)                       |
| MedDRA preferred                      | Numbe r (%) of patient s a | Event rate (per 100 pt years) b | Numbe r (%) of patient s a | Event rate (per 100 pt years | Numbe r (%) of patient s a | Event rate (per 100 pt years) b | Number (%) of patient s a | Event rate (per 100 pt years) b | Numbe r (%) of patient s a | Event rate (per 100 pt years) b |
| term Patients with any AE             | 451 (97.6)                 | 121.7                           | 443 (90.0)                 | ) 123.5                      | 3825 (94.6)                | 170.7                           | 3151 (94.9)               | 164.8                           | 609 (94.7)                 | 289.3                           |
| Pruritus                              | 118 (25.5)                 | 31.8                            | 76 (15.4)                  | 21.2                         | 463 (11.4)                 | 20.7                            | 623 (18.8)                | 32.6                            | 173 (26.9)                 | 82.2                            |
| Diarrhoea                             | 117 (25.3)                 | 31.6                            | 78 (15.9)                  | 21.7                         | 650 (16.1)                 | 29.0                            | 780 (23.5)                | 40.8                            | 257 (40.0)                 | 122.1                           |
| Rash                                  | 115 (24.9)                 | 31.0                            | 53 (10.8)                  | 14.8                         | 395 (9.8)                  | 17.6                            | 442 (13.3)                | 23.1                            | 128 (19.9)                 | 60.8                            |
| Fatigue                               | 83 (18.0)                  | 22.4                            | 62 (12.6)                  | 17.3                         | 997 (24.6)                 | 44.5                            | 775 (23.4)                | 40.5                            | 150 (23.3)                 | 71.3                            |
| Decreased appetite                    | 76 (16.5)                  | 20.5                            | 68 (13.8)                  | 19.0                         | 769 (19.0)                 | 34.3                            | 687 (20.7)                | 35.9                            | 166 (25.8)                 | 78.9                            |
| Aspartate aminotransfer ase increased | 71 (15.4)                  | 19.2                            | 85 (17.3)                  | 23.7                         | 277 (6.8)                  | 12.4                            | 268 (8.1)                 | 14.0                            | 35 (5.4)                   | 16.6                            |
| Pyrexia                               | 64 (13.9)                  | 17.3                            | 44 (8.9)                   | 12.3                         | 525 (13.0)                 | 23.4                            | 494 (14.9)                | 25.8                            | 100 (15.6)                 | 47.5                            |
| Abdominal pain                        | 58 (12.6)                  | 15.7                            | 54 (11.0)                  | 15.1                         | 318 (7.9)                  | 14.2                            | 307 (9.2)                 | 16.1                            | 84 (13.1)                  | 39.9                            |
| Nausea                                | 57 (12.3)                  | 15.4                            | 49 (10.0)                  | 13.7                         | 678 (16.8)                 | 30.3                            | 625 (18.8)                | 32.7                            | 166 (25.8)                 | 78.9                            |
| Hypothyroidis m                       | 55 (11.9)                  | 14.8                            | 33 (6.7)                   | 9.2                          | 380 (9.4)                  | 17.0                            | 378 (11.4)                | 19.8                            | 29 (4.5)                   | 13.8                            |
| Alanine aminotransfer ase increased   | 53 (11.5)                  | 14.3                            | 70 (14.2)                  | 19.5                         | 256 (6.3)                  | 11.4                            | 242 (7.3)                 | 12.7                            | 31 (4.8)                   | 14.7                            |
| Lipase increased                      | 46 (10.0)                  | 12.4                            | 28 (5.7)                   | 7.8                          | 87 (2.2)                   | 3.9                             | 212 (6.4)                 | 11.1                            | 37 (5.8)                   | 17.6                            |
| Constipation                          | 45 (9.7)                   | 12.1                            | 54 (11.0)                  | 15.1                         | 652 (16.1)                 | 29.1                            | 571 (17.2)                | 29.9                            | 103 (16.0)                 | 48.9                            |
| Cough                                 | 45 (9.7)                   | 12.1                            | 43 (8.7)                   | 12.0                         | 643 (15.9)                 | 28.7                            | 435 (13.1)                | 22.7                            | 102 (15.9)                 | 48.5                            |
| Anaemia                               | 43 (9.3)                   | 11.6                            | 36 (7.3)                   | 10.0                         | 509 (12.6)                 | 22.7                            | 532 (16.0)                | 27.8                            | 96 (14.9)                  | 45.6                            |
| Arthralgia                            | 43 (9.3)                   | 11.6                            | 45 (9.1)                   | 12.5                         | 559 (13.8)                 | 25.0                            | 376 (11.3)                | 19.7                            | 54 (8.4)                   | 25.7                            |
| Asthenia                              | 42 (9.1)                   | 11.3                            | 52 (10.6)                  | 14.5                         | 463 (11.4)                 | 20.7                            | 437 (13.2)                | 22.9                            | 77 (12.0)                  | 36.6                            |
| Vomiting                              | 34 (7.4)                   | 9.2                             | 23 (4.7)                   | 6.4                          | 423 (10.5)                 | 18.9                            | 405 (12.2)                | 21.2                            | 107 (16.6)                 | 50.8                            |
| Weight decreased                      | 32 (6.9)                   | 8.6                             | 15 (3.0)                   | 4.2                          | 285 (7.0)                  | 12.7                            | 349 (10.5)                | 18.3                            | 71 (11.0)                  | 33.7                            |
| Back pain                             | 30 (6.5)                   | 8.1                             | 50 (10.2)                  | 13.9                         | 448 (11.1)                 | 20.0                            | 329 (9.9)                 | 17.2                            | 41 (6.4)                   | 19.5                            |
| Dyspnoea                              | 28 (6.1)                   | 7.6                             | 26 (5.3)                   | 7.2                          | 598 (14.8)                 | 26.7                            | 456 (13.7)                | 23.8                            | 151 (23.5)                 | 71.7                            |

a Number (%) of patients with AEs, sorted in decreasing frequency of preferred term (HCC-tumor pool T300+D column).

b Number of patients with AEs divided by the total duration of treatment across all patients in given group, multiplied by 100.

Patients with multiple AEs are counted once for each preferred term.

Includes AEs with an onset date on or after the date of first dose or pre-treatment AEs that increase in severity on or after the date of first dose up to and including 90 days following the date of last dose of study medication or up to and including the date of initiation of the first subsequent therapy (whichever occurs first).

Disease progression AEs reported in Study 1108, Study 6, Study 10, and Study 11 are not included in this summary.MedDRA version 23.1.

<div style=\"page-break-after: always\"></div>

AE, adverse event; D, durvalumab 1500 mg (or equivalent); HCC, hepatocellular carcinoma; IV, intravenous; MedDRA, Medical Dictionary for Regulatory Activities; pt, patient; Q4W, every 4 weeks; T300+D, tremelimumab 300 mg for a single dose in combination with durvalumab 1500 mg Q4W; T75+D, durvalumab given at a dose of 20 mg/kg Q4W (or equivalent) IV in combination with tremelimumab 1 mg/kg Q4W (or equivalent), for any line of therapy (across tumor types); T750, tremelimumab monotherapy 10 mg/kg Q4W (or equivalent) for any line of therapy (across tumor types). Source: Table 2.7.4.2.5, Pooled Safety Outputs, Module 5.3.5.3.

Table  49.  Adverse  Events  of  Maximum  CTCAE  Grade  3  or  4  by  System  Organ  Class  and Preferred Term (Frequency ≥5% in Any Treatment Arm) (Safety Analysis Set)

|                                             | Number (%) of patients a   | Number (%) of patients a   | Number (%) of patients a   | Number (%) of patients a   |
|---------------------------------------------|----------------------------|----------------------------|----------------------------|----------------------------|
| System organ class MedDRA preferred term    | D (N = 388)                | T300+D (N = 388)           | T75+D (N =152)             | S (N =374)                 |
| PatientswithAEofmaximumCTCAEGrade3or4       | 144 (37.1)                 | 196 (50.5)                 | 60 (39.5)                  | 196 (52.4)                 |
| Investigations                              | 56 (14.4)                  | 69 (17.8)                  | 27 (17.8)                  | 53 (14.2)                  |
| Aspartate aminotransferase increased        | 26 (6.7)                   | 20 (5.2)                   | 10 (6.6)                   | 12 (3.2)                   |
| Lipase increased                            | 16 (4.1)                   | 24 (6.2)                   | 5 (3.3)                    | 11 (2.9)                   |
| Vascular disorders                          | 5 (1.3)                    | 11 (2.8)                   | 5 (3.3)                    | 23 (6.1)                   |
| Hypertension                                | 4 (1.0)                    | 7 (1.8)                    | 3 (2.0)                    | 23 (6.1)                   |
| Skin andsubcutaneoustissuedisorders         | 1 (0.3)                    | 15 (3.9)                   | 4 (2.6)                    | 49 (13.1)                  |
| Palmar-plantar erthyrodysaesthesia syndrome | 0                          | 0                          | 1 (0.7)                    | 34 (9.1)                   |

Preferred terms are ordered by decreasing frequency in the D arm.

IncludesAEs with an onset date on or after the date of first dose or pre-treatment AEs that increase inseverity on or after the date of first dose up toandincluding9odays following the date of last dose of study medication or up to and including the date of initiation of the first subsequent therapy (whichever occurred first).

MedDRA version 23.1. CTCAE version 4.03.

AE, adverse event; CTCAE, Common Terminology Criteria for Adverse Events; D, durvalumab monotherapy 1500 mg Q4W; DCO, data cut-off; IP, investigational product; MedDRA, Medical Dictionary for Regulatory Activities; Q4W, every 4 weeks; S, sorafenib 400 mg twice daily; T75+D, tremelimumab 75 mg × 4 doses + durvalumab 1500 mg Q4W; T300+D, tremelimumab 300 mg × 1 dose + durvalumab 1500 mg Q4W.

Table  50.  Adverse  Events  of  Maximum  CTCAE  Grade  3  or  4  by  Preferred  Term (≥ 5% of Patients in Any Treatment Group) (Safety Analysis Set)

|                                                    | Number (%) of patients a   | Number (%) of patients a   | Number (%) of patients a   | Number (%) of patients a   | Number (%) of patients a   |
|----------------------------------------------------|----------------------------|----------------------------|----------------------------|----------------------------|----------------------------|
|                                                    | HCC-tumor pool             | HCC-tumor pool             | Pan-tumor pool             | Pan-tumor pool             | Pan-tumor pool             |
|                                                    | T300+D                     | D                          | D                          | T75+D                      | T750                       |
| MedDRA preferred term                              | (N = 462)                  | (N = 492)                  | (N = 4045 )                | (N = 3319 )                | (N = 643)                  |
| Patients with any AE of maximum CTCAE Grade 3 or 4 | 222 (48.1)                 | 188 (38.2)                 | 1600 (39.6)                | 1642 (49.5)                | 344 (53.5)                 |
| Aspartate aminotransferase increased               | 34 (7.4)                   | 36 (7.3)                   | 83 (2.1)                   | 73 (2.2)                   | 15 (2.3)                   |
| Lipase increased                                   | 33 (7.1)                   | 17 (3.5)                   | 51 (1.3)                   | 143 (4.3)                  | 20 (3.1)                   |
| Diarrhoea                                          | 18 (3.9)                   | 8 (1.6)                    | 34 (0.8)                   | 92 (2.8)                   | 81 (12.6)                  |
| Anaemia                                            | 13 (2.8)                   | 11 (2.2)                   | 177 (4.4)                  | 169 (5.1)                  | 20 (3.1)                   |
| Colitis                                            | 10 (2.2)                   | 0                          | 10 (0.2)                   | 44 (1.3)                   | 32 (5.0)                   |
| Dyspnoea                                           | 3 (0.6)                    | 4 (0.8)                    | 126 (3.1)                  | 93 (2.8)                   | 40 (6.2)                   |

Patients with multiple AEs are counted once for each preferred term.

Includes AEs with an onset date on or after the date of first dose or pre-treatment AEs that increase in severity on or after the date of first dose up to and including 90 days following the date of last dose of study medication, or up to and including the date of initiation of the first subsequent therapy (whichever occurs first).

Disease progression AEs reported in Study 1108, Study 6, Study 10, and Study 11 are not included in this summary.

<div style=\"page-break-after: always\"></div>

MedDRA version 23.1.

AE, adverse event; CTCAE, Common Terminology Criteria for Adverse Events (version 4.03); D, durvalumab 1500 mg (or equivalent); HCC, hepatocellular carcinoma; IV, intravenous; MedDRA, Medical Dictionary for Regulatory Activities; Q4W, every 4 weeks; T300+D, tremelimumab 300 mg for a single dose in combination with durvalumab 1500 mg Q4W; T75+D, durvalumab given at a dose of 20 mg/kg Q4W (or equivalent) IV in combination with tremelimumab 1 mg/kg Q4W (or equivalent), for any line of therapy (across tumor types); T750, tremelimumab monotherapy 10 mg/kg Q4W (or equivalent) for any line of therapy (across tumor types).

Table 51. Adverse Events with CTCAE Grade 3 or 4, Possibly Related to Investigational Product (Frequency of ≥ 2%) by System Organ Class, Preferred Term and Maximum Reported CTCAE Grade (HCC Pool; Safety Analysis Set)

|                                            |                              | Number (%) of patients a HCC-tumor pool   | Number (%) of patients a HCC-tumor pool   |
|--------------------------------------------|------------------------------|-------------------------------------------|-------------------------------------------|
| System organ class / MedDRA Preferred term | Maximum reported CTCAE grade | T300 + D (N = 462)                        | D (N = 492)                               |
| Patients with any treatment-related AE     | Total                        | 57 (12.3)                                 | 27 (5.5)                                  |
| Patients with any treatment-related AE     | Grade 3                      | 50 (10.8)                                 | 24 (4.9)                                  |
| Patients with any treatment-related AE     | Grade 4                      | 7 (1.5)                                   | 3 (0.6)                                   |
| Gastrointestinal disorders                 | Total                        | 14 (3.0)                                  | 6 (1.2)                                   |
| Gastrointestinal disorders                 | Grade 3                      | 14 (3.0)                                  | 6 (1.2)                                   |
| Diarrhoea                                  | Total                        | 14 (3.0)                                  | 6 (1.2)                                   |
| Diarrhoea                                  | Grade 3                      | 14 (3.0)                                  | 6 (1.2)                                   |
| Investigations                             | Total                        | 44 (9.5)                                  | 22 (4.5)                                  |
| Investigations                             | Grade 3                      | 37 (8.0)                                  | 19 (3.9)                                  |
| Investigations                             | Grade 4                      | 7 (1.5)                                   | 3 (0.6)                                   |
| Amylase increased                          | Total                        | 15 (3.2)                                  | 3 (0.6)                                   |
| Amylase increased                          | Grade 3                      | 14 (3.0)                                  | 2 (0.4)                                   |
| Amylase increased                          | Grade 4                      | 1 (0.2)                                   | 1 (0.2)                                   |
| Aspartate aminotransferase increased       | Total                        | 18 (3.9)                                  | 12 (2.4)                                  |
| Aspartate aminotransferase increased       | Grade 3                      | 18 (3.9)                                  | 11 (2.2)                                  |
| Aspartate aminotransferase increased       | Grade 4                      | 0                                         | 1 (0.2)                                   |
| Lipase increased                           | Total                        | 22 (4.8)                                  | 8 (1.6)                                   |
|                                            | Grade 3                      | 16 (3.5)                                  | 7 (1.4)                                   |
|                                            | Grade 4                      | 6 (1.3)                                   | 1 (0.2)                                   |

Each patient has only been represented with the maximum reported CTCAE grade for each system organ class / preferred term. Number (%) of patients with AEs, sorted by international SOC order and alphabetical PT and then maximum grade.

Table includes events occurring in greater than or equal to 2% of patients in either group.

Includes AEs with an onset date on or after the date of first dose or pre-treatment AEs that increase in severity on or after the date of first dose up to and including 90 days following the date of last dose of study medication or up to and including the date of initiation of the first subsequent therapy (whichever occurs first).

Possibly related to treatment, as assessed by the investigator. Missing responses are counted as related.

MedDRA version 23.1.

CTCAE (version 4.03).

AE = adverse event; CTCAE = Common Terminology Criteria for Adverse Events; D = durvalumab 1500 mg Q4W;

HCC = hepatocellular carcinoma; PT = preferred term; MedDRA = Medical Dictionary for Regulatory Activities; QxW = every X weeks; SOC = System Organ Class; T300+D = tremelimumab 300 mg for single dose and durvalumab 1500 mg Q4W.

## Adverse drug reactions (ADRs)

Table 52: Adverse reactions in patients with HCC treated with durvalumab in combination with tremelimumab 300 mg

|                                          | Durvalumab in combination with tremelimumab 300 mg (n=462)   | Durvalumab in combination with tremelimumab 300 mg (n=462)   | Durvalumab in combination with tremelimumab 300 mg (n=462)   | Durvalumab in combination with tremelimumab 300 mg (n=462)   |
|------------------------------------------|--------------------------------------------------------------|--------------------------------------------------------------|--------------------------------------------------------------|--------------------------------------------------------------|
| Adverse Reaction                         | Frequency of any Grade                                       | Frequency of any Grade                                       | Frequency of Grade 3-4                                       | Frequency of Grade 3-4                                       |
| Infections and infestations              |                                                              |                                                              |                                                              |                                                              |
| Upper respiratory tract infections a     | Common                                                       | 39 (8.4%)                                                    |                                                              |                                                              |
| Pneumonia b                              | Common                                                       | 20 (4.3%)                                                    | Common                                                       | 6 (1.3%)                                                     |
| Influenza                                | Common                                                       | 10 (2.2%)                                                    |                                                              |                                                              |
| Dental and oral soft tissue infections c | Common                                                       | 6 (1.3%)                                                     |                                                              |                                                              |
| Oral candidiasis                         | Uncommon                                                     | 3 (0.6%)                                                     |                                                              |                                                              |
| Blood and lymphatic system disorders     | Blood and lymphatic system disorders                         | Blood and lymphatic system disorders                         | Blood and lymphatic system disorders                         | Blood and lymphatic system disorders                         |
| Immune thrombocytopenia d                | Not known                                                    |                                                              |                                                              |                                                              |
| Endocrine disorders                      | Endocrine disorders                                          | Endocrine disorders                                          | Endocrine disorders                                          | Endocrine disorders                                          |

<div style=\"page-break-after: always\"></div>

|                                                                           | Durvalumab in combination with tremelimumab 300 mg (n=462)   | Durvalumab in combination with tremelimumab 300 mg (n=462)   | Durvalumab in combination with tremelimumab 300 mg (n=462)   | Durvalumab in combination with tremelimumab 300 mg (n=462)   |
|---------------------------------------------------------------------------|--------------------------------------------------------------|--------------------------------------------------------------|--------------------------------------------------------------|--------------------------------------------------------------|
| Adverse Reaction                                                          | Frequency of any Grade                                       | Frequency of any Grade                                       | Frequency of Grade 3-4                                       | Frequency of Grade 3-4                                       |
| Hypothyroidism e                                                          | Very common                                                  | 60 (13.0%)                                                   |                                                              |                                                              |
| Hyperthyroidism f                                                         | Common                                                       | 44 (9.5%)                                                    | Uncommon                                                     | 1 (0.2%)                                                     |
| Thyroiditis g                                                             | Common                                                       | 8 (1.7%)                                                     |                                                              |                                                              |
| Adrenal insufficiency                                                     | Common                                                       | 6 (1.3%)                                                     | Uncommon                                                     | 1 (0.2%)                                                     |
| Hypopituitarism/Hypophysitis                                              | Uncommon                                                     | 4 (0.9%)                                                     |                                                              |                                                              |
| Diabetes insipidus d                                                      | Not known                                                    |                                                              |                                                              |                                                              |
| Type 1 diabetes mellitus d                                                | Not known                                                    |                                                              |                                                              |                                                              |
| Nervous system disorders                                                  |                                                              |                                                              |                                                              |                                                              |
| Myasthenia gravis                                                         | Uncommon                                                     | 2 (0.4%)                                                     |                                                              |                                                              |
| Meningitis                                                                | Uncommon                                                     | 1 (0.2%)                                                     | Uncommon                                                     | 1 (0.2%)                                                     |
| Guillain-Barré syndrome d                                                 | Not known                                                    |                                                              |                                                              |                                                              |
| Encephalitis d                                                            | Not known                                                    |                                                              |                                                              |                                                              |
| Cardiac disorders                                                         |                                                              |                                                              |                                                              |                                                              |
| Myocarditis                                                               | Uncommon                                                     | 2 (0.4%)                                                     |                                                              |                                                              |
| Respiratory, thoracic and mediastinal disorders                           | Respiratory, thoracic and mediastinal disorders              | Respiratory, thoracic and mediastinal disorders              | Respiratory, thoracic and mediastinal disorders              | Respiratory, thoracic and mediastinal disorders              |
| Cough/Productive cough                                                    | Very common                                                  | 50 (10.8%)                                                   | Uncommon                                                     | 1 (0.2%)                                                     |
| Pneumonitis h                                                             | Common                                                       | 11 (2.4%)                                                    | Uncommon                                                     | 1 (0.2%)                                                     |
| Dysphonia                                                                 | Uncommon                                                     | 4 (0.9%)                                                     |                                                              |                                                              |
| Interstitial lung disease                                                 | Uncommon                                                     | 1 (0.2%)                                                     |                                                              |                                                              |
| Gastrointestinal disorders                                                |                                                              |                                                              |                                                              |                                                              |
| Diarrhoea                                                                 | Very common                                                  | 117 (25.3%)                                                  | Common                                                       | 18 (3.9%)                                                    |
| Abdominal pain i                                                          | Very common                                                  | 91 (19.7%)                                                   | Common                                                       | 10 (2.2%)                                                    |
| Lipase increased                                                          | Common                                                       | 46 (10.0%)                                                   | Common                                                       | 33 (7.1%)                                                    |
| Amylase increased                                                         | Common                                                       | 41 (8.9%)                                                    | Common                                                       | 20 (4.3%)                                                    |
| Colitis j                                                                 | Common                                                       | 16 (3.5%)                                                    | Common                                                       | 12 (2.6%)                                                    |
| Pancreatitis k                                                            | Common                                                       | 6 (1.3%)                                                     | Uncommon                                                     | 3 (0.6%)                                                     |
| Intestinal perforation d                                                  | Not known                                                    |                                                              |                                                              |                                                              |
| Large intestine perforation d                                             | Not known                                                    |                                                              |                                                              |                                                              |
| Hepatobiliary disorders                                                   |                                                              |                                                              |                                                              |                                                              |
| Aspartate aminotransferase increased/Alanine aminotransferase increased l | Very common                                                  | 83 (18.0%)                                                   | Common                                                       | 41 (8.9%)                                                    |
| Hepatitis m                                                               | Common                                                       | 23 (5.0%)                                                    | Common                                                       | 8 (1.7%)                                                     |
| Skin and subcutaneous tissue disorders                                    | Skin and subcutaneous tissue disorders                       | Skin and subcutaneous tissue disorders                       | Skin and subcutaneous tissue disorders                       | Skin and subcutaneous tissue disorders                       |
| Rash n                                                                    | Very common                                                  | 150 (32.5%)                                                  | Common                                                       | 14 (3.0%)                                                    |
| Pruritus                                                                  | Very common                                                  | 118 (25.5%)                                                  |                                                              |                                                              |
| Dermatitis o                                                              | Common                                                       | 6 (1.3%)                                                     |                                                              |                                                              |
| Night sweats                                                              | Common                                                       | 6 (1.3%)                                                     |                                                              |                                                              |
| Pemphigoid                                                                | Uncommon                                                     | 1 (0.2%)                                                     |                                                              |                                                              |
| Musculoskeletal and connective tissue disorders                           | Musculoskeletal and connective tissue disorders              | Musculoskeletal and connective tissue disorders              | Musculoskeletal and connective tissue disorders              | Musculoskeletal and connective tissue disorders              |
| Myalgia                                                                   | Common                                                       | 16 (3.5%)                                                    | Uncommon                                                     | 1 (0.2%)                                                     |
| Myositis                                                                  | Uncommon                                                     | 3 (0.6%)                                                     | Uncommon                                                     | 1 (0.2%)                                                     |
| Polymyositis                                                              | Uncommon                                                     | 1 (0.2%)                                                     | Uncommon                                                     | 1 (0.2%)                                                     |
| Renal and urinary disorders                                               | Renal and urinary disorders                                  | Renal and urinary disorders                                  | Renal and urinary disorders                                  | Renal and urinary disorders                                  |
| Blood creatinine increased                                                | Common                                                       | 21 (4.5%)                                                    | Uncommon                                                     | 2 (0.4%)                                                     |
| Dysuria                                                                   | Common                                                       | 7 (1.5%)                                                     |                                                              |                                                              |
| Nephritis p                                                               | Uncommon                                                     | 3 (0.6%)                                                     | Uncommon                                                     | 2 (0.4%)                                                     |
| Cystitis noninfective d                                                   | Not known                                                    |                                                              |                                                              |                                                              |
| General disorders and administration site conditions                      | General disorders and administration site conditions         | General disorders and administration site conditions         | General disorders and administration site conditions         | General disorders and administration site conditions         |
| Pyrexia                                                                   | Very common                                                  | 64 (13.9%)                                                   | Uncommon                                                     | 1 (0.2%)                                                     |
| Oedema peripheral q                                                       | Very common                                                  | 48 (10.4%)                                                   | Uncommon                                                     | 2 (0.4%)                                                     |
| Injury, poisoning and procedural complications                            | Injury, poisoning and procedural complications               | Injury, poisoning and procedural complications               | Injury, poisoning and procedural complications               | Injury, poisoning and procedural complications               |

<div style=\"page-break-after: always\"></div>

|                             | Durvalumab in combination with tremelimumab 300 mg (n=462)   | Durvalumab in combination with tremelimumab 300 mg (n=462)   | Durvalumab in combination with tremelimumab 300 mg (n=462)   |
|-----------------------------|--------------------------------------------------------------|--------------------------------------------------------------|--------------------------------------------------------------|
| Adverse Reaction            | Frequency of any Grade                                       | Frequency of any Grade                                       | Frequency of Grade 3-4                                       |
| Infusion-related reaction r | Common                                                       | 6 (1.3%)                                                     |                                                              |

- c  Includes periodontitis, pulpitis dental, tooth abscess and tooth infection.
- d  Adverse reaction was not observed in the HCC pool, but was reported in patients treated with durvalumab or durvalumab + tremelimumab in AstraZeneca-sponsored clinical studies.
- e  Includes blood thyroid stimulating hormone increased, hypothyroidism and immune-mediated hypothyroidism.
- f  Includes blood thyroid stimulating hormone decreased and hyperthyroidism.
- g  Includes autoimmune thyroiditis, immune-mediated thyroiditis, thyroiditis and thyroiditis subacute.
- h  Includes immune-mediated pneumonitis and pneumonitis.
- i  Includes abdominal pain, abdominal pain lower, abdominal pain upper and flank pain.
- j  Includes colitis, enteritis and enterocolitis.

k  Includes pancreatitis and pancreatitis acute.

- l  Includes alanine aminotransferase increased, aspartate aminotransferase increased, hepatic enzyme increased and transaminases increased.
- m  Includes autoimmune hepatitis, hepatitis, hepatocellular injury, hepatotoxicity and immune-mediated hepatitis.
- n  Includes eczema, erythema, rash, rash macular, rash maculo-papular, rash papular and rash pruritic.
- o  Includes dermatitis and immune-mediated dermatitis.
- p  Includes autoimmune nephritis and immune-mediated nephritis.
- q  Includes oedema peripheral and peripheral swelling.
- r  Includes infusion-related reaction and urticaria.

## Adverse events of special interest

Table 53. Overview of imAEs in the HIMALAYA T300+D and S Arms and the HCC T300+D Pool (Safety Analysis Set)

|                                                      | Number (%) of patients a   | Number (%) of patients a   | Number (%) of patients a   |
|------------------------------------------------------|----------------------------|----------------------------|----------------------------|
| AE category                                          | HCC T300+D pool            | HIMALAYA T300+D arm        | HIMALAYA S arm             |
| AE category                                          | (N = 462)                  | (N = 388)                  | (N = 374)                  |
| Any AE                                               | 167 (36.1)                 | 142 (36.6)                 | 28 (7.5)                   |
| Any AE of CTCAE Grade 3 or 4                         | 62 (13.4)                  | 51 (13.1)                  | 9 (2.4)                    |
| Any SAE (including AEs with outcome of death) b      | 47 (10.2)                  | 40 (10.3)                  | 4 (1.1)                    |
| Any AE with outcome of death                         | 6 (1.3)                    | 6 (1.5)                    | 0                          |
| Received systemic corticosteroids                    | 119 (25.8)                 | 97 (25.0)                  | 15 (4.0)                   |
| Received high dose corticosteroids                   | 94 (20.3)                  | 78 (20.1)                  | 7 (1.9)                    |
| Received endocrine therapy                           | 69 (14.9)                  | 65 (16.8)                  | 13 (3.5)                   |
| Received other immunosuppressants                    | 15 (3.2)                   | 15 (3.9)                   | 0                          |
| Any AE leading to discontinuation of study treatment | 26 (5.6)                   | 22 (5.7)                   | 6 (1.6)                    |

f Patients with multiple events in the same category are counted only once in that category; patients with events in more than 1 category are counted once in each of those categories.

g Seriousness, as assessed by the investigator. An AE with missing seriousness is considered serious.

Note: Includes AEs with an onset date on or after the date of first dose or pre-treatment AEs that increase in severity on or after the date of first dose up to and including 90 days following the date of last dose of study treatment or up to and including the date of initiation of the first subsequent therapy (whichever occurs first).

AE, adverse event; CSR, Clinical Study Report; CTCAE, Common Terminology Criteria for Adverse Events (version 4.03); HCC, hepatocellular carcinoma; HCC T300+D pool, all patients from HIMALAYA and Study 22 who have received at least 1 dose of durvalumab given at a dose of 1500 mg IV Q4W (or equivalent) in combination with tremelimumab 300 mg IV × 1 dose (or equivalent) for HCC for any line of therapy; IV, intravenous; Q4W, every 4 weeks; S, sorafenib 400 mg twice daily; SAE, serious adverse event; T300+D, tremelimumab 300 mg (4 mg/kg) for a single priming dose and durvalumab 1500 mg (20 mg/kg) Q4W.

<div style=\"page-break-after: always\"></div>

Table 54. Immune-Mediated Adverse Events Categories Reported for &gt; 2% of Patients in the HCC Pool (Safety Analysis Set)

|                           | Number (%) of patients a   | Number (%) of patients a   | Number (%) of patients a   | Number (%) of patients a   |
|---------------------------|----------------------------|----------------------------|----------------------------|----------------------------|
|                           | HCC T300+D Pool (N = 462)  | HCC T300+D Pool (N = 462)  | HCC D Pool (N = 492)       | HCC D Pool (N = 492)       |
| imAE category             | Any Grade                  | CTCAE Grade 3 or 4         | Any Grade                  | CTCAE Grade 3 or 4         |
| Any imAE                  | 167 (36.1)                 | 62 (13.4)                  | 81 (16.5)                  | 31 (6.3)                   |
| Hypothyroid events        | 45 (9.7)                   | 0                          | 25 (5.1)                   | 0                          |
| Hepatic events            | 34 (7.4)                   | 23 (5.0)                   | 31 (6.3)                   | 21 (4.3)                   |
| Diarrhoea/colitis         | 30 (6.5)                   | 17 (3.7)                   | 7 (1.4)                    | 3 (0.6)                    |
| Dermatitis/rash           | 26 (5.6)                   | 9 (1.9)                    | 4 (0.8)                    | 1 (0.2)                    |
| Hyperthyroid              | 21 (4.5)                   | 1 (0.2)                    | 6 (1.2)                    | 0                          |
| Other rare/ miscellaneous | 10 (2.2)                   | 2 (0.4)                    | 2 (0.4)                    | 0                          |

Includes AEs with an onset date on or after the date of first date or pre-treatment AEs that increase in severity on or after the date of first dose up to and including 90 days following the date of last dose of study treatment or up to and including the date of initiation of the first subsequent therapy (whichever occurs first).

AE, adverse event; CTCAE, Common Terminology Criteria for Adverse Events (version 4.03); D, durvalumab 1500 mg (20 mg/kg) Q4W; HCC, hepatocellular carcinoma; imAE, immune-mediated adverse event; Q4W, every 4 weeks; T300+D, tremelimumab 300 mg (4 mg/kg) for a single priming dose and durvalumab 1500 mg (20 mg/kg) Q4W.

In the HCC pool (n=462), the following immune mediated adverse drug reactions have been reported:

- immune-mediated pneumonitis occurred in 6 (1.3%) patients, including Grade 3 in 1 (0.2%) patient and Grade 5 (fatal) in 1 (0.2%) patient. The median time to onset was 29 days (range: 5-774 days). Six patients received systemic corticosteroids, and 5 of the 6 patients received high-dose corticosteroid treatment (at least 40 mg prednisone or equivalent per day). One patient also received other immunosuppressants. Treatment was discontinued in 2 patients. Resolution occurred in 3 patients.
- immune-mediated hepatitis occurred in 34 (7.4%) patients, including Grade 3 in 20 (4.3%) patients, Grade 4 in 1 (0.2%) patient and Grade 5 (fatal) in 3 (0.6%) patients. The median time to onset was 29 days (range: 13-313 days). All patients received systemic corticosteroids, and 32 of the 34 patients received high-dose corticosteroid treatment (at least 40 mg prednisone or equivalent per day). Nine patients also received other immunosuppressants. Treatment was discontinued in 10 patients. Resolution occurred in 13 patients.
- immune-mediated colitis or diarrhoea occurred in 31 (6.7%) patients, including Grade 3 in 17 (3.7%) patients. The median time to onset was 23 days (range: 2-479 days). All patients received systemic corticosteroids, and 28 of the 31 patients received high-dose corticosteroid treatment (at least 40 mg prednisone or equivalent per day). Four patients also received other immunosuppressants. Treatment was discontinued in 5 patients. Resolution occurred in 29 patients.

Intestinal perforation was observed in patients receiving Imfinzi in combination with tremelimumab (rare) in studies outside of the HCC pool.

- immune-mediated hypothyroidism occurred in 46 (10.0%) patients. The median time to onset was 85 days (range: 26-763 days). One patient received high-dose corticosteroid treatment (at least 40 mg prednisone or equivalent per day). All patients required other therapy including hormone

<div style=\"page-break-after: always\"></div>

replacement therapy. Resolution occurred in 6 patients. Immune-mediated hypothyroidism was preceded by immune-mediated hyperthyroidism in 4 patients.

-  immune-mediated hyperthyroidism occurred in 21 (4.5%) patients, including Grade 3 in 1 (0.2%) patient. The median time to onset was 30 days (range: 13-60 days). Four patients received systemic corticosteriods, and all of the four patients received high-dose corticosteroid treatment (at least 40 mg prednisone or equivalent per day). Twenty patients required other therapy (thiamazole, carbimazole, propylthiouracil, perchlorate, calcium channel blocker, or beta-blocker). One patient discontinued treatment due to hyperthyroidism. Resolution occurred in 17 patients.

- immune-mediated thyroiditis occurred in 6 (1.3%) patients. The median time to onset was 56 days (range: 7-84 days). Two patients received systemic corticosteroids, and 1 of the 2 patients received high-dose corticosteroid treatment (at least 40 mg prednisone or equivalent per day). All patients required other therapy including hormone replacement therapy. Resolution occurred in 2 patients.

-  immune-mediated adrenal insufficiency occurred in 6 (1.3%) patients, including Grade 3 in 1 (0.2%) patient. The median time to onset was 64 days (range: 43-504 days). All patients received systemic corticosteroids, and 1 of the 6 patients received high-dose corticosteroid treatment (at least 40 mg prednisone or equivalent per day). Resolution occurred in 2 patients.

- immune-mediated hypophysitis/hypopituitarism occurred in 5 (1.1%) patients. The median time to onset for the events was 149 days (range: 27-242 days). Four patients received systemic corticosteroids, and 1 of the 4 patients received high-dose corticosteroid treatment (at least 40 mg prednisone or equivalent per day). Three patients also required endocrine therapy. Resolution occurred in 2 patients.

- immune-mediated nephritis occurred in 4 (0.9%) patients, including Grade 3 in 2 (0.4%) patients. The median time to onset was 53 days (range: 26-242 days). All patients received systemic corticosteroids, and 3 of the 4 patients received high-dose corticosteroid treatment (at least 40 mg prednisone or equivalent per day). Treatment was discontinued in 2 patients. Resolution occurred in 3 patients.

- immune-mediated rash or dermatitis (including pemphigoid) occurred in 26 (5.6%) patients, including Grade 3 in 9 (1.9%) patients and Grade 4 in 1 (0.2%) patient. The median time to onset was 25 days (range: 2-933 days). All patients received systemic corticosteroids and 14 of the 26 patients received high-dose corticosteroid treatment (at least 40 mg prednisone or equivalent per day). One patient received other immunosuppressants. Treatment was discontinued in 3 patients. Resolution occurred in 19 patients.

Immune-mediated type 1 diabetes mellitus was observed in patients receiving Imfinzi in combination with tremelimumab (uncommon) in studies outside of the HCC pool.

<div style=\"page-break-after: always\"></div>

## Serious adverse event/deaths/other significant events

Table 55 . Serious Adverse Events by System Organ Class and Preferred Term (≥ 2% Patients in Any Treatment Arm; Safety Analysis Set)

|                                                    | Number (%) of patients a   | Number (%) of patients a   | Number (%) of patients a   | Number (%) of patients a   |
|----------------------------------------------------|----------------------------|----------------------------|----------------------------|----------------------------|
| System Organ Class MedDRAPreferredTerm             | D (N = 388)                | T300+D (N =388)            | T75+D (N = 152)            | S (N = 374)                |
| Patients with any SAE                              | 115 (29.6)                 | 157 (40.5)                 | 52 (34.2)                  | 111 (29.7)                 |
| Gastrointestinal disorders                         | 22 (5.7)                   | 48 (12.4)                  | 14 (9.2)                   | 35 (9.4)                   |
| Oesophageal varices haemorrhage                    | 4 (1.0)                    | 1 (0.3)                    | 3 (2.0)                    | 2 (0.5)                    |
| Diarrhoea                                          | 2 (0.5)                    | 9 (2.3)                    | 4 (2.6)                    | 6 (1.6)                    |
| Infections and infestations                        | 21 (5.4)                   | 43 (11.1)                  | 10 (6.6)                   | 23 (6.1)                   |
| Sepsis                                             | 4 (1.0)                    | 8 (2.1)                    | 2 (1.3)                    | 0                          |
| Pneumonia                                          | 3 (0.8)                    | 7 (1.8)                    | 6 (3.9)                    | 8 (2.1)                    |
| General disordersandadministration site conditions | 18 (4.6)                   | 11 (2.8)                   | 7 (4.6)                    | 9 (2.4)                    |
| Death                                              | 8 (2.1)                    | 4 (1.0)                    | 5 (3.3)                    | 5 (1.3)                    |
| Hepatobiliary disorders                            | 16 (4.1)                   | 14 (3.6)                   | 8 (5.3)                    | 15 (4.0)                   |
| Hepatitis                                          | 1 (0.3)                    | 3 (0.8)                    | 4 (2.6)                    | 0                          |
| Respiratory, thoracic, and mediastinal disorders   | 11 (2.8)                   | 9 (2.3)                    | 6 (3.9)                    | 9 (2.4)                    |
| Pneumonitis                                        | 2 (0.5)                    | 4 (1.0)                    | 3 (2.0)                    | 1 (0.3)                    |
| Blood and lymphatic system disorders               | 2 (0.5)                    | 6 (1.5)                    | 4 (2.6)                    | 3 (0.8)                    |
| Anaemia                                            | 1 (0.3)                    | 5 (1.3)                    | 3 (2.0)                    | 2 (0.5)                    |

Preferred terms are ordered by decreasing frequency in the D arm.

Includes AEs with an onset date on or after the date of first dose or pre-treatment AEs that increase in severity on or after the date of first dose up to and including 90 days following the date of last dose of study medication or up to and including the date of initiation of the first subsequent therapy (whichever occurred first).

Patientswith anAEofmaximumCTCAEGrade5 aftertheDCOhavebeenresetto'unknown'at theDCO.This affected 0 patients in the D arm, 0 patients in the T300+D arm, 0 patients in the T75+D arm, and 0 patients in the

Sarm.

MedDRA version 23.1. CTCAE version 4.03.

AE, adverse event; CTCAE, Common Terminology Criteria for Adverse Events; D, durvalumab monotherapy 1500 mg Q4W; DCO, data cut-off; IP, investigational product; MedDRA, Medical Dictionary for Regulatory Activities; Q4W,every4 weeks; S,sorafenib 400 mg twice daily; T75+D, tremelimumab 75 mg× 4 doses + durvalumab 1500 mg Q4W; T300+D, tremelimumab 300 mg × 1 dose + durvalumab 1500 mg Q4W.

## Treatment-related Serious Adverse Events

In the Safety Analysis Set, treatment-related SAEs  were  reported  for more  patients in the tremelimumab-containing arms than in the D and S arms (D, 8.2%; T300+D, 17.5%; T75+D, 18.4%; S, 9.4% patients). There were no treatment-related SAEs by PT reported by ≥ 5% patients. As with all SAEs, the majority of treatment-related SAEs occurred in the CTCAE Grade 3 or 4 category within every SOC. The frequency of treatment-related CTCAE Grade 3 or 4 SAEs was 24 patients (6.2%) in arm D, 44 patients (11.3%) in arm T300+D, 19 patients (12.5%) in arm T75+D, and 22 patients (5.9%) in arm S. Few treatment-related SAEs resulted in death.

- 17.5% of the SAEs (40.5%) in the T300+D arm were treatment-related. The below table describes treatment-related SAEs for the T300+D and S arms of the Himalaya study and the HCC pool (frequency more than 1%).

<div style=\"page-break-after: always\"></div>

Table  56.  Time  to  Onset,  Discontinuation,  Resolution  and  Duration  of  Treatment  related Serious Adverse Events (Frequency of ≥ 1%) by Preferred Term

|                           |                    |                        | HIMALAYA           | HIMALAYA    |             | HCC-tumour pool    | HCC-tumour pool   |
|---------------------------|--------------------|------------------------|--------------------|-------------|-------------|--------------------|-------------------|
| Preferred term            | Parameters (days)  | Descriptive statistics | T300 + D (N = 388) | D (N = 388) | S (N = 374) | T300 + D (N = 462) | D (N = 492)       |
| Colitis                   | Time to onset      | n                      | 6                  | 2           | 0           | 9                  | 2                 |
|                           |                    | Mean                   | 219.5              | 104.0       |             | 228.2              | 104.0             |
|                           |                    | Minimum                | 8                  | 11          |             | 8                  | 11                |
|                           |                    | Median                 | 21.5               | 104.0       |             | 25.0               | 104.0             |
|                           |                    | Maximum                | 815                | 197         |             | 815                | 197               |
|                           | Duration of        | n                      | 6                  | 2           | 0           | 9                  | 2                 |
|                           | events             | Mean                   | 54.2               | 39.5        |             | 50.3               | 39.5              |
|                           |                    | Minimum                | 7                  | 36          |             | 7                  | 36                |
|                           |                    | Median                 | 51.0               | 39.5        |             | 43.0               | 39.5              |
|                           |                    | Maximum                | 99                 | 43          |             | 99                 | 43                |
|                           | Time to            | n                      | 2                  | 1           | 0           | 2                  | 1                 |
|                           | discontinuation    | Mean                   | 1.0                | 1.0         |             | 1.0                | 1.0               |
|                           |                    | Minimum                | 1                  | 1           |             | 1                  | 1                 |
|                           |                    | Median                 | 1.0                | 1.0         |             | 1.0                | 1.0               |
|                           |                    | Maximum                | 1                  | 1           |             | 1                  | 1                 |
|                           | Time to resolution | n                      | 6                  | 1           | 0           | 9                  | 1                 |
|                           |                    |                        |                    | 43.0        |             | 50.3               | 43.0              |
|                           |                    | Mean                   | 54.2 7             |             |             | 7                  | 43                |
|                           |                    | Minimum                | 51.0               | 43          |             |                    |                   |
|                           |                    | Median                 | 99                 | 43.0 43     |             | 43.0 99            | 43.0 43           |
| Diarrhoea                 | Time to onset      | Maximum n              | 7                  | 1           | 6           | 9                  | 2                 |
| Diarrhoea                 |                    | Mean                   | 24.1               | 63.0        | 78.7        | 37.8               | 39.5              |
| Diarrhoea                 |                    | Minimum                | 2                  | 63          | 25          | 2                  | 16                |
| Diarrhoea                 |                    | Median                 | 14.0               | 63.0        | 67.5        | 24.0               | 39.5              |
| Diarrhoea                 |                    | Maximum                | 66                 | 63          | 162         | 115                | 63                |
| Diarrhoea                 | Duration of        | n                      | 7                  | 1           | 6           | 9                  | 2                 |
| Diarrhoea                 | events             | Mean                   | 37.3               |             | 22.3        | 34.6               | 43.5              |
| Diarrhoea                 |                    | Minimum                | 7                  | 82.0 82     | 1           | 7                  | 5                 |
| Diarrhoea                 |                    | Median                 | 52.0               | 82.0        | 4.5         | 25.0               | 43.5              |
| Diarrhoea                 |                    | Maximum                | 72                 | 82          | 112         | 72                 | 82                |
| Diarrhoea                 | Time to            | n                      | 0                  | 0           | 1           | 0                  | 1                 |
| Diarrhoea                 | discontinuation    | Mean                   |                    |             | 102.0       |                    | 1.0               |
| Diarrhoea                 |                    | Minimum                |                    |             | 102         |                    | 1                 |
| Diarrhoea                 |                    | Median                 |                    |             | 102.0       |                    | 1.0               |
| Diarrhoea                 | Time to resolution | Maximum n              | 7                  | 0           | 102 5       | 9                  | 1 1               |
| Diarrhoea                 |                    | Mean                   | 37.3               |             | 4.4         | 34.6               | 5.0               |
| Diarrhoea                 |                    | Minimum                | 7                  |             | 1           | 7                  | 5                 |
| Diarrhoea                 |                    | Median                 | 52.0               |             | 4.0         | 25.0               | 5.0               |
| Diarrhoea                 |                    | Maximum                | 72                 |             | 8           | 72                 | 5                 |
| Hepatic function abnormal | Time to onset      | n                      | 1                  | 5           | 1           | 2                  | 9                 |
|                           |                    | Mean                   | 36.0               | 119.2       | 7.0         | 257.0              | 115.1             |
|                           |                    | Minimum                | 36                 | 15          | 7           | 36                 | 15                |
|                           |                    | Median                 | 36.0               | 29.0        | 7.0         | 257.0              | 43.0              |
|                           |                    | Maximum                | 36                 | 467         | 7           | 478                | 467               |
|                           | Duration of        | n                      | 1                  | 5           | 1           | 2                  | 9                 |
|                           | events             |                        | 141.0              | 133.8       | 37.0        | 169.5              | 124.2             |
|                           |                    | Mean Minimum           | 141                | 13          | 37          | 141                | 9                 |
|                           |                    | Median                 | 141.0              | 92.0        | 37.0        | 169.5              | 57.0              |
|                           |                    | Maximum                | 141                | 413         | 37          | 198                | 413               |
|                           | Time to            | n                      | 1                  | 0           | 0           | 2                  | 3                 |
|                           | discontinuation    | Mean                   | 29.0               |             |             | 200.5              | 112.0             |
|                           |                    | Minimum                | 29 29.0            |             |             | 29 200.5           | 1                 |
|                           |                    | Median Maximum         | 29                 |             |             | 372                | 57.0 278          |
|                           | Time to resolution | n                      | 1                  | 3           | 1           | 1                  | 4                 |
|                           |                    | Mean                   | 141.0              | 66.3        | 37.0        | 141.0              | 52.0              |
|                           |                    | Minimum Median         | 141                | 13          | 37          | 141                | 9                 |
|                           |                    | Maximum                | 141.0 141          | 92.0 94     | 37.0 37     | 141.0 141          | 52.5 94           |

Note: Table includes events occurring in ≥ 1% of patients in either group.

<div style=\"page-break-after: always\"></div>

D = durvalumab 1500 mg Q4W; HCC = hepatocellular carcinoma; QxW = every X weeks; S = sorafenib 400 mg twice daily; T300+D = tremelimumab 300 mg for single dose and durvalumab 1500 mg Q4W.

## Deaths

Table 57. All Deaths (Full Analysis Set) -DCO: 27 AUG 2021

|                                                                               | Number(%) of subjects   | Number(%) of subjects   | Number(%) of subjects                                  | Number(%) of subjects   |
|-------------------------------------------------------------------------------|-------------------------|-------------------------|--------------------------------------------------------|-------------------------|
| Category                                                                      | Durva 1500 mg (N=389)   | Durva1500mg (N=393)     | Treme300mgxldose+Treme75mg14doses+ Durva1500mg (N=153) | Sora400mg BID (N=389)   |
| Totalnumberofdeaths                                                           | 280 (72.0)              | 262 (66.7)              | 123 (80.4)                                             | 293 (75.3)              |
| Deathrelatedtodiseaseunderinvestigationonly                                   | 245 (63.0)              | 221 (56.2)              | 103 (67.3)                                             | 256 (65.8)              |
| AEwithoutcomeofdeathonly                                                      | 19 (4.9)                | 24 (6.1)                | 9 (5.9)                                                | 20 (5.1)                |
| AEwithoutcomeofdeathonly(AEstart datefallingafter90daysfollowupperiod)        | 2 (0.5)                 | 3 (0.8)                 | 1 (0.7)                                                | 0                       |
| NumberofsubjectswithdeathrelatedtodiseaseprogressionandanAEwithoutcomeofdeath | 6 (1.5)                 | 8 (2.0)                 | 4 (2.0)                                                | 7 (1.8)                 |
| Otherdeaths                                                                   | 8 (2.1)                 | 6 (1.5)                 | 6 (3.9)                                                | 10 (2.0)                |

Table 58. Adverse Events with Outcome of Death by Preferred Term (Safety Analysis Set)

|                                    | Number (%) of patients a   | Number (%) of patients a   | Number (%) of patients a   | Number (%) of patients a   |
|------------------------------------|----------------------------|----------------------------|----------------------------|----------------------------|
| MedDRAPreferredTerm                | D (N =388)                 | T300+D (N =388)            | T75+D (N = 152)            | S (N =374)                 |
| Immune-mediated hepatitis          | 0                          | 2 (0.5)                    | 0                          | 0                          |
| Intemal haemorrhage                | 0                          | 1 (0.3)                    | 0                          | 0                          |
| Myocarditis                        | 0                          | 1 (0.3)                    | 0                          | 0                          |
| Liver abscess                      | 0                          | 0                          | 0                          | 1 (0.3)                    |
| Peritonitis                        | 0                          | 0                          | 0                          | 1 (0.3)                    |
| Pneumonia                          | 0                          | 0                          | 2 (1.3)                    | 2 (0.5)                    |
| Sepsis                             | 0                          | 1 (0.3)                    | 1 (0.7)                    | 0                          |
| Cerebral haematoma                 | 0                          | 0                          | 0                          | 1 (0.3)                    |
| Cerebral haemorrhage               | 0                          | 1 (0.3)                    | 0                          | 0                          |
| Haemorrhage intracranial           | 0                          | 2 (0.5)                    | 0                          | 0                          |
| Hepatic encephalopathy             | 0                          | 0                          | 0                          | 1 (0.3)                    |
| Myasthenia gravis                  | 0                          | 1 (0.3)                    | 0                          | 0                          |
| Nervous system disorder            | 0                          | 1 (0.3)                    | 0                          | 0                          |
| Thrombocytopenia                   | 0                          | 1 (0.3)                    | 0                          | 0                          |
| Haematuria                         | 0                          | 0                          | 0                          | 1 (0.3)                    |
| Acuterespiratory distress syndrome | 0                          | 1 (0.3)                    | 0                          | 0                          |
| Dyspnoea                           | 0                          | 0                          | 0                          | 1 (0.3)                    |
| Epistaxis                          | 0                          | 0                          | 0                          | 1 (0.3)                    |
| Pneumonitis                        | 0                          | 2 (0.5)                    | 0                          | 0                          |
| Pulmonary embolism                 | 0                          | 1 (0.3)                    | 0                          | 1 (0.3)                    |
| Respiratory failure                | 0                          | 0                          | 0                          | 1 (0.3)                    |

Includes AEs with an onset date on or after the date of first dose or pre-treatment AEs that increase in severity on or after the date of first dose up to and including 90 days following the date of last dose of study medication or up to and including the date of initiation of the first subsequent therapy (whichever occurred first).

PatientswithanAEofmaximumCTCAEGrade5aftertheDCOhavebeenresetto'unknownattheDCO.This affected0patients in the D arm,Opatients in theT300+D arm,0patients in theT75+D arm,and 0patients in the S arm.

MedDRAversion23.1.CTCAE version 4.03.

Below is the table of the treatment-related (as assessed by the investigator) AEs leading to death.

<div style=\"page-break-after: always\"></div>

Table 59. Adverse Events with outcome of death, possibility related to investigational product by system organ class, preferred term and maximum reported CTCAE grade (Safety Analysis Set)

|                                                 |                              | Number (%) of subjectsa   | Number (%) of subjectsa   | Number (%) of subjectsa                                     | Number (%) of subjectsa   |
|-------------------------------------------------|------------------------------|---------------------------|---------------------------|-------------------------------------------------------------|---------------------------|
| System organ class / MedDRA Preferred term      | Maximum reported CTCAE grade | Duva 1500 mg (N=388)      | Duva 1500 mg (N=388)      | Treme300mg xl dose+Treme75mg x4doses + Duva 1500 mg (N=152) | Sora 400 mg BID (N=374)   |
| Subjects with any AE                            | Grade 5                      | 0                         | 9 (2.3)                   | 2 (1.3)                                                     | 3 (0.8)                   |
| Infectionsandinfestations                       | Grade 5                      | 0                         | 0                         | 1 (0.7)                                                     | 0                         |
| Septic shock                                    | Grade 5                      | 0                         | 0                         | 1 (0.7)                                                     |                           |
| Nervous system disorders                        | Grade 5                      | 0                         | 2 (0.5)                   | 0                                                           | 1 (0.3)                   |
| Cerebral haematoma                              | Grade 5                      | 0                         |                           | 0                                                           | 1 (0.3)                   |
| Myasthenia gravis                               | Grade 5                      | 0                         | 1 (0.3)                   | 0                                                           | 0                         |
| Nervous system disorder                         | Grade 5                      | 0                         | 1 (0.3)                   | 0                                                           |                           |
| Cardiac disorders                               | Grade 5                      |                           | 1 (0.3)                   | 0                                                           |                           |
| Myocarditis                                     | Grade 5                      | 0                         | 1 (0.3)                   | 0                                                           | 0                         |
| Respiratory,thoracic and mediastinal disorders  | Grade 5                      | 0                         | 2 (0.5)                   |                                                             |                           |
| Acuterespiratory distresssyndrome               | Grade 5                      |                           | 1 (0.3)                   |                                                             | 0                         |
| Pneumonitis                                     | Grade 5                      | 0                         | 1 (0.3)                   | 0                                                           | 0                         |
| Hepatobiliary disorders                         | Grade 5                      | 0                         | 4 (1.0)                   | 1 (0.7)                                                     | 1 (0.3)                   |
| Hepatic failure                                 | Grade 5                      | 0                         | 1 (0.3)                   | 1 (0.7)                                                     | 1 (0.3)                   |
| Hepatitis                                       | Grade 5                      | 0                         | 1 (0.3)                   | 0                                                           |                           |
| Immune-mediated hepatitis                       | Grade 5                      | 0                         | 2 (0.5)                   | 0                                                           | 0                         |
| Renal and urinary disorders                     | Grade 5                      | 0                         | 0                         | 0                                                           | 1 (0.3)                   |
| Haematuria                                      | Grade 5                      |                           | 0                         | 0                                                           | 1 (0.3)                   |
| Generaldisordersandadministrationsiteconditions | Grade 5                      |                           | 0                         | 1 (0.7)                                                     |                           |
| Multiple organ dysfunction syndrome             | Grade 5                      |                           | 0                         | 1 (0.7)                                                     | 0                         |

Number (%) of subjects with AEs, sorted by intemational SOC order and alphabetical PT and then maximum grade.

and including 90 days following the date of last dose of study medication or up to and including the date of initiation of the fist subsequent therapy (whichever occurs first). Subjects who have a maximum CTCAE grade 5 post the DCO, havebeen reset to umknown at the DCO. This afects 0 subjects in group Durva 1500 mg and 0 subjects in groupTreme 300 mg x1 dose +Duva 1500 mg and 0 subjects in group Treme 75 mg x4 doses + Duva 1500 mg and 0 subjects in group 'Sora 400 mg BID'.

Includes adverse events with an onset date on or after the date of first dose or pre-treatment AEs that increase in severity on or after the date of first dose up to

Possibly related to treatment, as assessed by the investigator. Missing responses are counted as related.

MedDRA version 23.1.

CTCAE = Common Temminology Criteria for Adverse Events (version 4.03).

root/cdar/d419/d419cc00002/ar/csr/restricted\\_tlf/prod/program/ae003c.sasae003cefa.rtf08NOV2021:16:41kwxd463

Laboratory findings

Haematology

<div style=\"page-break-after: always\"></div>

Table  60.  Clinically  important  changes  in  haematology  and  clinical  chemistry  parameters (Safety Analysis set) -DCO: 27 AUG 2021

|               | n/N#(%o)ofsubjects      | n/N#(%o)ofsubjects      | n/N#(%o)ofsubjects          | n/N#(%o)ofsubjects                    | n/N#(%o)ofsubjects                    | n/N#(%o)ofsubjects                    | n/N#(%o)ofsubjects                    | n/N#(%o)ofsubjects                    | n/N#(%o)ofsubjects                    | n/N#(%o)ofsubjects      | n/N#(%o)ofsubjects      | n/N#(%o)ofsubjects          |
|---------------|-------------------------|-------------------------|-----------------------------|---------------------------------------|---------------------------------------|---------------------------------------|---------------------------------------|---------------------------------------|---------------------------------------|-------------------------|-------------------------|-----------------------------|
|               | Durva1500mg             | Durva1500mg             | Durva1500mg                 | Treme300mgx1dose+Durva 1500mg (N=388) | Treme300mgx1dose+Durva 1500mg (N=388) | Treme300mgx1dose+Durva 1500mg (N=388) | Treme75mgx4doses+Durva 1500mg (N=152) | Treme75mgx4doses+Durva 1500mg (N=152) | Treme75mgx4doses+Durva 1500mg (N=152) | Sora400mgBID (N=374)    | Sora400mgBID (N=374)    | Sora400mgBID (N=374)        |
| Parameter     | >=1 CTCAE grade changes | >=2 CTCAE grade changes | CTCAE grade changes to3or 4 | >=1 CTCAE grade changes               | >=2 CTCAE grade changes               | CTCAE grade changes to 3or 4          | >=1 CTCAE grade changes               | >=2 CTCAE grade changes               | CTCAE grade changes to 3or 4          | >=1 CTCAE grade changes | >=2 CTCAE grade changes | CTCAE grade changes to3or 4 |
| B-Hemoglobin  | 158/373 (42.4)          | 24/373 (6.4)            | 18/373 (4.8)                | 195/378 (51.6)                        | 26/378 (6.9)                          | 18/378 (4.8)                          | 61/148 (41.2)                         | 14/148 (9.5)                          | 8/148 (5.4)                           | 142/352 (40.3)          | 25/352 (7.1)            | 21/352 (6.0)                |
| B-Leukocytes  | 112/370 (30.3)          | 11/370 (3.0)            | 5/370 (1.4)                 | 76/376 (20.2)                         | 8/376 (2.1)                           | 3/376 (0.8)                           | 35/147 (23.8)                         | 2/147 (1.4)                           | 2/ 147 (1.4)                          | 106/352 (30.1)          | 11/352 (3.1)            | 4/352 (1.1)                 |
| B-Lymphocytes | 160/ 371 (43.1)         | 64/ 371 (17.3)          | 32/371 (8.6)                | 156/ 377 (41.4)                       | 78/377 (20.7)                         | 42/ 377 (11.1)                        | 62/147 (42.2)                         | 25/147 (17.0)                         | 19/ 147 (12.9)                        | 138/351 (39.3)          | 68/351 (19.4)           | 35/351 (10.0)               |
| B-Neutrophils | 58/372 (15.6)           | 20/372 (5.4)            | 5/372 (1.3)                 | 48/378 (12.7)                         | 15/378 (4.0)                          | 3/378 (0.8)                           | 22/148 (14.9)                         | 7/148 (4.7)                           | 2/148 (1.4)                           | 48/351 (13.7)           | 21/351 (6.0)            | 7/351 (2.0)                 |
| B-Platelets   | 108/372 (29.0)          | 12/372 (3.2)            | 8/372 (2.2)                 | 109/378 (28.8)                        | 14/378 (3.7)                          | 6/378 (1.6)                           | 41/148 (27.7)                         | 7/148 (4.7)                           | 5/148 (3.4)                           | 122/352 (34.7)          | 16/352 (4.5)            | 11/352 (3.1)                |

Table 61. Clinically Important Changes in Haematology Parameters (Safety Analysis Set)

|                  | n/N(%)ofpatients       | n/N(%)ofpatients            | n/N(%)ofpatients       | n/N(%)ofpatients            | n/N(%)ofpatients       | n/N(%)ofpatients            | n/N(%)ofpatients       | n/N(%)ofpatients            | n/N(%)ofpatients       | n/N(%)ofpatients             |
|------------------|------------------------|-----------------------------|------------------------|-----------------------------|------------------------|-----------------------------|------------------------|-----------------------------|------------------------|------------------------------|
|                  | HCC-tumorpool          | HCC-tumorpool               | HCC-tumorpool          | HCC-tumorpool               | Pan-tumorpool          | Pan-tumorpool               | Pan-tumorpool          | Pan-tumorpool               | Pan-tumorpool          | Pan-tumorpool                |
|                  | T300+D (N = 462)       | T300+D (N = 462)            | D (N = 492)            | D (N = 492)                 | D (N = 4045)           | D (N = 4045)                | T75+D (N =3319)        | T75+D (N =3319)             | T750 (N = 643)         | T750 (N = 643)               |
| Parameter        | ≥2 CTCAE grade changes | CTCAE grade changes to 3or4 | ≥2 CTCAE grade changes | CTCAE grade changes to 3or4 | ≥2 CTCAE grade changes | CTCAE grade changes to 3or4 | ≥2 CTCAE grade changes | CTCAE grade changes to 3or4 | ≥2 CTCAE grade changes | CTCAE grade changes to 3 or4 |
| Hemoglobin       | 31/452 (6.9)           | 22/452 (4.9)                | 31/476 (6.5)           | 23/476 (4.8)                | 209/3868 (5.4)         | 193/3868 (5.0)              | 195/3162 (6.2)         | 178/3162 (5.6)              | 28/538 (5.2)           | 25/538 (4.6)                 |
| Leukocytes       | 14/450 (3.1)           | 5/450 (1.1)                 | 15/473 (3.2)           | 6/473 (1.3)                 | 75/3868 (1.9)          | 22/3868 (0.6)               | 59/3158 (1.9)          | 16/3158 (0.5)               | 11/585 (1.9)           | 4/585 (0.7)                  |
| Lymphocytes- Low | 86/431 (20.0)          | 51/431 (11.8)               | 81/450 (18.0)          | 38/450 (8.7)                | 738/3828 (19.3)        | 506/3828 (13.2)             | 617/3126 (19.7)        | 418/3126 (13.4)             | 48/513 (9.4)           | 37/513 (7.2)                 |
| Neutrophils      | 19/431 (4.4)           | 4/431 (0.9)                 | 24/451 (5.3)           | 6/451 (1.3)                 | 119/3833 (3.1)         | 37/3833 (1.0)               | 87/3104 (2.8)          | 18/3104 (0.6)               | 15/544 (2.8)           | 5/544 (0.9)                  |
| Platelets        | 14/452 (3.1)           | 6/452 (1.3)                 | 16/475 (3.4)           | 14/475 (2.9)                | 64/3865 (1.7)          | 44/3865 (1.1)               | 59/3154 (1.9)          | 36/3154 (1.1)               | 14/585 (2.4)           | 9/585 (1.5)                  |

Derivedfromlaboratory assessments between the startoftreatment andupto andincluding90daysfollowing thedateoflast doseofstudymedicationoruntil the initiation of the first subsequent therapy (whichever occurred first).

Patient'sworst(highest CTCAEgrade)changesfrom baseline are used.

Percentageshadbeencalculated using thenumberof patientswith abaselinevalueanda postbaselinevalue.

CTCAE,Common Terminology Criteria for Adverse Events (version 4.03); D, durvalumab 1500 mg (or equivalent);HCC,hepatocellular carcinoma; IV, T750, tremelimumab monotherapy 10 mg/kg Q4W (or equivalent) for any line of therapy (across tumor types).

Source:Table 2.7.4.10.2,Pooled Safety Outputs,Module 5.3.5.3.

<div style=\"page-break-after: always\"></div>

## Clinical chemistry

Table 62. Clinically Important Changes in Clinical Chemistry Parameters (Safety Analysis Set)

|                              | n/N a (%) of patients   | n/N a (%) of patients   | n/N a (%) of patients      | n/N a (%) of patients   | n/N a (%) of patients   | n/N a (%) of patients      | n/N a (%) of patients   | n/N a (%) of patients   | n/N a (%) of patients      | n/N a (%) of patients   | n/N a (%) of patients   | n/N a (%) of patients         |
|------------------------------|-------------------------|-------------------------|----------------------------|-------------------------|-------------------------|----------------------------|-------------------------|-------------------------|----------------------------|-------------------------|-------------------------|-------------------------------|
|                              | D (N =388)              | D (N =388)              | D (N =388)                 | T300+D (N=388)          | T300+D (N=388)          | T300+D (N=388)             | T75+D (N =152)          | T75+D (N =152)          | T75+D (N =152)             | S (N =374)              | S (N =374)              | S (N =374)                    |
| Clinical chemistry parameter | ≥1 CTCAE grade changes  | ≥2 CTCAE grade changes  | CTCAE grade changes to3or4 | ≥1 CTCAE grade changes  | ≥2 CTCAE grade changes  | CTCAE grade changes to3or4 | ≥1 CTCAE grade changes  | ≥2 CTCAE grade changes  | CTCAE grade changes to3or4 | ≥1 CTCAE grade changes  | ≥2 CTCAE grade changes  | CTCAE grade changes to 3 or 4 |
| ALT                          | 194/374 (51.9)          | 52/374 (13.9)           | 49/374 (13.1)              | 212/377 (56.2)          | 71/377 (18.8)           | 67/377 (17.8)              | 76/148 (51.4)           | 24/148 (16.2)           | 22/148 (14.9)              | 185/352 (52.6)          | 41/352 (11.6)           | 43/352 (12.2)                 |
| Albumin                      | 89/370 (24.1)           | 62/370 (16.8)           | 2/370 (0.5)                | 116/371 (31.3)          | 66/371 (17.8)           | 2/371 (0.5)                | 42/147 (28.6)           | 26/147 (17.7)           | 1/147 (0.7)                | 130/350 (37.1)          | 81/350 (23.1)           | 6/350 (1.7)                   |
| ALP                          | 145/371 (39.1)          | 22/371 (5.9)            | 30/371 (8.1)               | 154/374 (41.2)          | 34/374 (9.1)            | 31/374 (8.3)               | 70/148 (47.3)           | 11/148 (7.4)            | 18/148 (12.2)              | 156/351 (44.4)          | 17/351 (4.8)            | 19/351 (5.4)                  |
| AST                          | 205/373 (55.0)          | 65/373 (17.4)           | 86/373 (23.1)              | 238/377 (63.1)          | 87/377 (23.1)           | 101/377 (26.8)             | 80/148 (54.1)           | 28/148 (18.9)           | 40/148 (27.0)              | 191/350 (54.6)          | 48/350 (13.7)           | 74/350 (21.1)                 |
| Bilirubin                    | 153/374 (40.9)          | 62/374 (16.6)           | 28/374 (7.5)               | 156/377 (41.4)          | 76/377 (20.2)           | 31/377 (8.2)               | 64/147 (43.5)           | 22/147 (15.0)           | 14/147 (9.5)               | 167/352 (47.4)          | 71/352 (20.2)           | 37/352 (10.5)                 |
| Calcium increased            | 16/367 (4.4)            | 9/367 (2.5)             | 6/367 (1.6)                | 11/367 (3.0)            | 2/367 (0.5)             | 2/367 (0.5)                | 4/146 (2.7)             | 1/146 (0.7)             | 0/146                      | 8/344 (2.3)             | 3/344 (0.9)             | 2/344 (0.6)                   |
| Calcium decreased            | 130/367 (35.4)          | 1/367 (0.3)             | 1/367 (0.3)                | 123/367 (33.5)          | 5/367 (1.4)             | 0/367                      | 50/146 (34.2)           | 2/146 (1.4)             | 0/146                      | 148/344 (43.0)          | 3/344 (0.9)             | 1/344 (0.3)                   |
| Creatinine                   | 70/372 (18.8)           | 6/372 (1.6)             | 1/372 (0.3)                | 78/374 (20.9)           | 10/374 (2.7)            | 5/374 (1.3)                | 25/148 (16.9)           | 7/148 (4.7)             | 0/148                      | 52/352 (14.8)           | 11/352 (3.1)            | 3/352 (0.9)                   |
| Glucose increased            | 142/368 (38.6)          | 63/368 (17.1)           | 31/368 (8.4)               | 144/370 (38.9)          | 70/370 (18.9)           | 50/370 (13.5)              | 55/145 (37.9)           | 22/145 (15.2)           | 21/145 (14.5)              | 101/347 (29.1)          | 43/347 (12.4)           | 13/347 (3.7)                  |
| Glucose decreased            | 16/368 (4.3)            | 6/368 (1.6)             | 3/368 (0.8)                | 22/370 (5.9)            | 12/370 (3.2)            | 4/370 (1.1)                | 5/145 (3.4)             | 3/145 (2.1)             | 2/145 (1.4)                | 19/347 (5.5)            | 8/347 (2.3)             | 3/347 (0.9)                   |
| Magnesium increased          | 0/12                    | 0/12                    | 0/12                       | 0/18                    | 0/18                    | 0/18                       | 0/9                     | 0/9                     | 6/0                        | 0/5                     | 0/5                     | 0/5                           |
| Magnesium decreased          | 0/12                    | 0/12                    | 0/12                       | 2/18 (11.1)             | 1/18 (5.6)              | 0/18                       | 6/0                     | 6/0                     | 6/0                        | 1/5 (20.0)              | 0/5                     | 0/5                           |
| Potassium increased          | 94/369 (25.5)           | 27/369 (7.3)            | 17/369 (4.6)               | 105/370 (28.4)          | 31/370 (8.4)            | 14/370 (3.8)               | 35/147 (23.8)           | 9/147 (6.1)             | 4/147 (2.7)                | 75/352 (21.3)           | 24/352 (6.8)            | 9/352 (2.6)                   |
| Potassium decreased          | 35/369 (9.5)            | 5/369 (1.4)             | 5/369 (1.4)                | 57/370 (15.4)           | 11/370 (3.0)            | 11/370 (3.0)               | 25/147 (17.0)           | 4/147 (2.7)             | 4/147 (2.7)                | 46/352 (13.1)           | 10/352 (2.8)            | 10/352 (2.8)                  |
| Sodium increased             | 17/371 (4.6)            | 0/371                   | 0/371                      | 19/372 (5.1)            | 2/372 (0.5)             | 1/372 (0.3)                | 13/147 (8.8)            | 0/147                   | 0/147                      | 23/352 (6.5)            | 3/352 (0.9)             | 1/352 (0.3)                   |
| Sodium decreased             | 139/371 (37.5)          | 23/371 (6.2)            | 25/371 (6.7)               | 171/372 (46.0)          | 57/372 (15.3)           | 57/372 (15.3)              | 70/147 (47.6)           | 15/147 (10.2)           | 15/147 (10.2)              | 140/352 (39.8)          | 39/352 (11.1)           | 39/352 (11.1)                 |

OnlyworseningofCTCAEgradesarepresented.

Derived from laboratory assessments between the start of treatment and up to and including 90 days following the date of last dose of study treatment or until the initiation of the first subsequent therapy (whichever occurred first).

CTCAE version 4.03.

ALP,alkalinephosphatase;ALT,alanine aminotransferase;AST,aspartate aminotransferase;CTCAE,CommonTerminology CriteriaforAdverseEvents; D, durvalumab monotherapy 1500 mg Q4W; Q4W, every 4 weeks; S, sorafenib 400 mg twice daily; T75+D, tremelimumab 75 mg × 4 doses + durvalumab 1500 mg Q4W; T300+D, tremelimumab 300mg × 1 dose + durvalumab 1500 mg Q4W.

Source: Table 14.3.7.1.2.2.

<div style=\"page-break-after: always\"></div>

Table 63. Clinically Important Changes in Clinical Chemistry Parameters (Safety Analysis Set)

|                         | T300+D (N = 462)       | T300+D (N = 462)             | D (N = 492)            | D (N = 492)                   |
|-------------------------|------------------------|------------------------------|------------------------|-------------------------------|
| Parameter               | >2 CTCAE grade changes | CTCAE grade changes to 3or 4 | >2 CTCAE grade changes | CTCAE grade changes to 3 or 4 |
| AST                     | 101/451 (22.4)         | 121/451 (26.8)               | 87/476 (18.3)          | 112/476 (23.5)                |
| Alkaline  phosphatase   | 38/448 (16.0)          | 35/448 (7.8)                 | 30/474 (6.3)           | 44/474 (9.3)                  |
| ALT                     | 85/451 (18.8)          | 80/451 (17.7)                | 62/477 (13.0)          | 56/477 (11.7)                 |
| Albumin                 | 71/445 (16.0%)         | 2/445 (0.4)                  | 74/473 (15.6)          | 7/473 (1.5)                   |
| Total bilirubin         | 91/451 (20.2%)         | 35/451 (7.8)                 | 81/477 (17.0)          | 40/477 (8.4)                  |
| Creatinine              | 22/448 (4.9)           | 8/448 (1.8)                  | 19/475 (4.0)           | 3/475 (0.6)                   |
| GGT                     | 9/93 (9.7)             | 20/93 (21.5)                 | 8/116 (6.9)            | 20/116 (17.2)                 |
| Lipase                  | 117/423 (27.7)         | 101/423 (23.9)               | 75/460 (16.3)          | 54/460 (11.7)                 |
| Amylase                 | 81/426 (19.0)          | 63/426 (14.8)                | 37/459 (8.1)           | 32/459 (7.0)                  |
| Glucose (high)          | 86/444 (19.4)          | 65/444 (14.6)                | 75/471 (15.9)          | 39/471 (8.3)                  |
| Potassium (high)        | 36/444 (8.1)           | 17/444 (3.8)                 | 38/471 (8.1)           | 21/471 (4.5)                  |
| Sodium (low)            | 64/446 (14.3)          | 64/446 (14.3)                | 35/474 (7.4)           | 37/474 (7.8)                  |
| Corrected Calcium (low) | 5/367 (1.4)            | 0/367 (0)                    | 1/367 (0.3)            | 1/367 (0.3)                   |

Derived from laboratory assessments between the start of treatment and up to and including 90 days following the date of last dose of study medication or until the initiation of the first subsequent therapy (whichever occurred first).Patient's worst (highest CTCAE grade) changes from baseline are used. Percentages had been calculated using the number of patients with a baseline value and a post baseline value. ALT, alanine aminotransferase; AST, aspartate aminotransferase; CTCAE, Common Terminology Criteria for Adverse Events (version 4.03); D, durvalumab 1500 mg (or equivalent); GGT, gamma-glutamyl transferase; HCC, hepatocellular carcinoma; IV, intravenous; Q4W, every 4 weeks; T300+D, tremelimumab 300 mg for a single dose in combination with durvalumab 1500 mg Q4W; T75+D, durvalumab given at a dose of 20 mg/kg Q4W (or equivalent) IV in combination with tremelimumab 1 mg/kg Q4W (or equivalent), for any line of therapy (across tumor types); T750, tremelimumab monotherapy 10 mg/kg Q4W (or equivalent) for any line of therapy (across tumor types).

<div style=\"page-break-after: always\"></div>

Table 64. Hyperglycaemia/new Onset Diabetes Mellitus SMQ AEs in the HCC T300+D Tumour Pool

|                                           |          |          |                 |                | Receivedintervention       | Receivedintervention   | Receivedintervention        | Receivedintervention       |                                              | Eventoutcome        | Eventoutcome   | Eventoutcome   |
|-------------------------------------------|----------|----------|-----------------|----------------|----------------------------|------------------------|-----------------------------|----------------------------|----------------------------------------------|---------------------|----------------|----------------|
| SMQCategory/ MedDRA Preferred Term        | Any AE   | Any SAEa | CTCAE Grade 3-4 | CTCAE Grade ≥3 | Systemic Cortico- Steroids | High Dose Steroid      | Other Immuno Suppre- ssants | Requires Endocrine Therapy | Leading to Dis- contin- uation of Study Drug | Resul- ted in Death | Not Resol- ved | Resol- ved     |
| Hyperglycaemia/newonset diabetes mellitus | 39 (8.4) | 8 (1.7)  | 16 (3.5)        | 16 (3.5)       | 0                          | 0                      | 0                           | 0                          | 2 (0.4)                                      | 0                   | 18 (3.9)       | 21 (4.5)       |
| Diabetes mellitus                         | 11 (2.4) | 4 (0.9)  | 4 (0.9)         | 4 (0.9)        | 0                          | 0                      | 0                           | 0                          | 0                                            | 0                   | 7 (1.5)        | 4 (0.9)        |
| Diabetes mellitus inadequate control      | 2 (0.4)  | 0        | 0               | 0              | 0                          | 0                      | 0                           | 0                          | 0                                            | 0                   | 0              | 2 (0.4)        |
| Diabetic ketoacidosis                     | 1 (0.2)  | 1 (0.2)  | 1 (0.2)         | 1 (0.2)        | 0                          | 0                      | 0                           | 0                          | 0                                            | 0                   | 0              | 1 (0.2)        |
| Hyperglycaemia                            | 22 (4.8) | 2 (0.4)  | 10 (2.2)        | 10 (2.2)       | 0                          | 0                      | 0                           | 0                          | 1 (0.2)                                      | 0                   | 7 (1.5)        | 15 (3.2)       |
| Type 2 diabetes mellitus                  | 6 (1.3)  | 2 (0.4)  | 2 (0.4)         | 2 (0.4)        | 0                          | 0                      | 0                           | 0                          | 1 (0.2)                                      | 0                   | 4 (0.9)        | 2 (0.4)        |

IncludesAEswith an onset date on or after the date offirst dose orpre-treatmentAEs that increase inseverity on or afterdate offirst doseuptoandincluding90daysfollowing thedate of last dose of study medication, orup to and including the date of initiation of thefirst subsequent therapy (whichever occurs first).

MedDRAVersion 23.1

AE = adverse event;CTCAE =CommonTerminology Criteria for Adverse Events;HCC =hepatocellular carcinoma; Q4W = every 4 weeks;SAE= serious adverse event;T300+D = tremelimumab 300 mg for a single dose and durvalumab 1500 mg Q4W; SMQ = Standardised MedDRA Query.

Source:IEMT 0316.2b0.

## Liver chemistry

Table 65 .  Proportion of Patients with Elevated ALT or AST (≥3 x ULN), and Elevated Total Bilirubin (≥ 2 x ULN; Safety Analysis Set)

|                                                        | Nunber (%) of patients   | Nunber (%) of patients   | Nunber (%) of patients   | Nunber (%) of patients   |
|--------------------------------------------------------|--------------------------|--------------------------|--------------------------|--------------------------|
| Category                                               | D (N = 388)              | T300+D (N =388)          | T75+D (N =152)           | S (N =374)               |
| ALT or AST ≥3 x ULN and BILI>2 x ULNa                  | 46 (11.9)                | 51 (13.1)                | 17 (11.2)                | 47 (12.6)                |
| ALT or AST≥3xULN and BILI> 2 x ULN and no ALP≥2 x ULNa | 19 (4.9)                 | 15 (3.9)                 | 3 (2.0)                  | 23 (6.1)                 |

Percentages were calculated based on the number of patients with measurements.

Derived from laboratory assessments between the start of treatment and up to and including 90 days following the date of last dose of IP or until initiation of the first subsequent therapy (whichever occurred first). ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BILI, total bilirubin; D, durvalumab monotherapy 1500 mg Q4W; Q4W, every 4 weeks; IP, investigational product; S, sorafenib 400 mg twice daily; T75+D, tremelimumab 75 mg × 4 doses + durvalumab 1500 mg Q4W; T300+D, tremelimumab 300 mg × 1 dose + durvalumab 1500 mg Q4W; ULN upper limit of normal.

Source:Table 14.3.7.1.4

Table 66. Liver Function Abnormalities (Safety Analysis Set)

|                      | Number (%) of patients   | Number (%) of patients   | Number (%) of patients   | Number (%) of patients   | Number (%) of patients   |
|----------------------|--------------------------|--------------------------|--------------------------|--------------------------|--------------------------|
|                      | HCC-tumor pool           | HCC-tumor pool           | Pan-tumor pool           | Pan-tumor pool           | Pan-tumor pool           |
| Category             | T300+D (N = 462)         | D (N = 492)              | D (N = 4045)             | T75+D (N = 3319)         | T750 (N = 643)           |
| ALT or AST           |                          |                          |                          |                          |                          |
| ≥ 3 × to ≤ 5 × ULN   | 93 (20.1)                | 84 (17.1)                | 242 (6.0)                | 217 (6.5)                | 27 (4.2)                 |
| > 5 × to ≤ 8 × ULN   | 65 (14.1)                | 56 (11.4)                | 127 (3.1)                | 111 (3.3)                | 16 (2.5)                 |
| > 8 × to ≤ 10 × ULN  | 26 (5.6)                 | 31 (6.3)                 | 57 (1.4)                 | 28 (0.8)                 | 7 (1.1)                  |
| > 10 × to ≤ 20 × ULN | 39 (8.4)                 | 33 (6.7)                 | 67 (1.7)                 | 66 (2.0)                 | 4 (0.6)                  |

<div style=\"page-break-after: always\"></div>

|                      | Number (%) of patients   | Number (%) of patients   | Number (%) of patients   | Number (%) of patients   | Number (%) of patients   |
|----------------------|--------------------------|--------------------------|--------------------------|--------------------------|--------------------------|
|                      | HCC-tumor pool           | HCC-tumor pool           | Pan-tumor pool           | Pan-tumor pool           | Pan-tumor pool           |
| Category             | T300+D (N = 462)         | D (N = 492)              | D (N = 4045)             | T75+D (N = 3319)         | T750 (N = 643)           |
| > 20 × ULN           | 14 (3.0)                 | 11 (2.2)                 | 29 (0.7)                 | 36 (1.1)                 | 5 (0.8)                  |
| TBL                  |                          |                          |                          |                          |                          |
| ≥ 2 × to ≤ 3 × ULN   | 29 (6.3)                 | 41 (8.3)                 | 67 (1.7)                 | 39 (1.2)                 | 6 (0.9)                  |
| > 3 × to ≤ 5 × ULN   | 16 (3.5)                 | 18 (3.7)                 | 48 (1.2)                 | 33 (1.0)                 | 1 (0.2)                  |
| > 5 × ULN            | 19 (4.1)                 | 22 (4.5)                 | 56 (1.4)                 | 32 (1.0)                 | 7 (1.1)                  |
| Potential Hy's law a | 57 (12.3)                | 65 (13.2)                | 131 (3.2)                | 85 (2.6)                 | 7 (1.1)                  |

a The onset date of ALT or AST elevation should be prior to or on the date of TBL elevation.

Derived from laboratory assessments between the start of treatment and up to and including 90 days following the date of last dose of study medication or until the initiation of the first subsequent therapy (whichever occurred first).

Patients were counted only once in the worst reported subcategory.

ALT, alanine aminotransferase; AST, aspartate aminotransferase; D, durvalumab 1500 mg (or equivalent); HCC, hepatocellular carcinoma; IV, intravenous; Q4W, every 4 weeks; T300+D, tremelimumab 300 mg for a single dose in combination with durvalumab 1500 mg Q4W; T75+D, durvalumab given at a dose of 20 mg/kg Q4W (or equivalent) IV in combination with tremelimumab 1 mg/kg Q4W (or equivalent), for any line of therapy (across tumor types); T750, tremelimumab monotherapy 10 mg/kg Q4W (or equivalent) for any line of therapy (across tumor types); TBL, total bilirubin; ULN, upper limit of normal.

<!-- image -->

Four patients in Study 22 had liver function test abnormalities meeting the criteria for Hy's Law for whom the role of durvalumab and/or tremelimumab could not be completely excluded. In the HIMALAYA study, 2 patients in the D arm, 4 patients in the T300+D arm, and 3 patients in the T75+D arm had liver function test abnormalities meeting the criteria for Hy's Law for whom the role of durvalumab and/or tremelimumab could not be completely excluded. Narratives for the 4 patients, who met the Hy's law criteria in the T300+D arm have been provided and has not given rise to any concerns

## Thyroid function

<div style=\"page-break-after: always\"></div>

Table 67. Abnormal Thyroid Function (Safety Analysis Set)

|                                                 | Number (%) of patients   | Number (%) of patients   | Number (%) of patients   | Number (%) of patients   |
|-------------------------------------------------|--------------------------|--------------------------|--------------------------|--------------------------|
| Category                                        | D (N =388)               | T300+D (N = 388)         | T75+D (N =152)           | S (N =374)               |
| Elevated TSH> ULN                               | 150 (38.7)               | 157 (40.5)               | 67 (44.1)                | 178 (47.6)               |
| Elevated TSH>ULNwith TSH≤ULN atbaseline         | 94 (24.2)                | 107 (27.6)               | 47 (30.9)                | 114 (30.5)               |
| Elevated TSH>3xULN                              | 40 (10.3)                | 66 (17.0)                | 28 (18.4)                | 30 (8.0)                 |
| Elevated TSH> 3 x ULN with TSH≤ ULN at baseline | 21 (5.4)                 | 42 (10.8)                | 18 (11.8)                | 4 (1.1)                  |
| Elevated TSH>10xULN                             | 15 (3.9)                 | 37 (9.5)                 | 13 (8.6)                 | 6 (1.6)                  |
| Elevated TSH>10 x ULN with TSH≤ ULN at baseline | 8 (2.1)                  | 25 (6.4)                 | 11 (7.2)                 | 1 (0.3)                  |
| Low TSH<LLN                                     | 66 (17.0)                | 129 (33.2)               | 43 (28.3)                | 35 (9.4)                 |
| Low TSH< LLN with TSH≥LLN at baseline           | 60 (15.5)                | 114 (29.4)               | 39 (25.7)                | 31 (8.3)                 |

Derived from laboratory assessments between the start of treatment and up to and including 90 days following the date of last dose of investigational product or until initiation of the first subsequent therapy (whichever occurred first).

D, durvalumab monotherapy 1500 mg Q4W; Q4W, every 4 weeks; LLN, lower limit of normal; S, sorafenib 400 mg twice daily; T75+D, tremelimumab 75 mg × 4 doses + durvalumab 1500 mg Q4W; T300+D, tremelimumab 300 mg × 1 dose + durvalumab 1500 mg Q4W; TSH, thyroid-stimulating hormone; ULN, upper limit of normal.

Source: Table 14.3.7.1.6.

Table 68. Abnormal On-Treatment Thyroid Tests (Safety Analysis Set)

|                                                                              | Number (%) of patients   | Number (%) of patients   | Number (%) of patients   | Number (%) of patients   | Number (%) of patients   |
|------------------------------------------------------------------------------|--------------------------|--------------------------|--------------------------|--------------------------|--------------------------|
|                                                                              | HCC-tumor pool           | HCC-tumor pool           | Pan-tumor pool           | Pan-tumor pool           | Pan-tumor pool           |
| Category                                                                     | T300+D (N = 462)         | D (N = 492)              | D (N = 4045)             | T75+D (N = 3319)         | T750 (N = 64 3)          |
| On-treatment elevated TSH > ULN                                              | 180 (39.0)               | 180 (36.6)               | 1269 (31.4)              | 1152 (34.7)              | 127 (19.8)               |
| On-treatment elevated TSH > ULN with TSH ≤ ULN at baseline *                 | 124                      | 116                      | 780                      | 697                      | 76                       |
| with at least one T3 free/T4 free < LLN a                                    | 73 (58.9)                | 68 (58.6)                | 456 (58.5)               | 420 (60.3)               | 21 (27.6)                |
| with all other T3 free/T4 free ≥ LLN a                                       | 41 (33.1)                | 38 (32.8)                | 270 (34.6)               | 216 (31.0)               | 19 (25.0)                |
| with T3 free/T4 free missing a                                               | 10 (8.1)                 | 10 (8.6)                 | 54 (6.9)                 | 61 (8.8)                 | 36 (47.4)                |
| On-treatment low TSH < LLN                                                   | 154 (33.3)               | 82 (16.7)                | 880 (21.8)               | 896 (27.0)               | 86 (13.4)                |
| On-treatment low TSH < LLN with TSH ≥ LLN at baseline *                      | 136                      | 74                       | 709                      | 778                      | 66                       |
| with at least one T3 free/T4 free > ULN a                                    | 72 (52.9)                | 28 (37.8)                | 310 (43.7)               | 364 (46.8)               | 11 (16.7)                |
| with all other T3 free/T4 free ≤ ULN a                                       | 57 (41.9)                | 36 (48.6)                | 348 (49.1)               | 353 (45.4)               | 19 (28.8)                |
| with T3 free/T4 free missing a                                               | 7 (5.1)                  | 10 (13.5)                | 51 (7.2)                 | 61 (7.8)                 | 36 (54.5)                |
| Number of patients with at least one baseline and post-baseline TSH result * | 437                      | 464                      | 3679                     | 3028                     | 543                      |
| On-treatment elevated TSH > ULN and above baseline a                         | 165 (37.8)               | 162 (34.9)               | 1108 (30.1)              | 1011 (33.4)              | 106 (19.5)               |

<div style=\"page-break-after: always\"></div>

|                                                       | Number (%) of patients   | Number (%) of patients   | Number (%) of patients   | Number (%) of patients   | Number (%) of patients   |
|-------------------------------------------------------|--------------------------|--------------------------|--------------------------|--------------------------|--------------------------|
|                                                       | HCC-tumor pool           | HCC-tumor pool           | Pan-tumor pool           | Pan-tumor pool           | Pan-tumor pool           |
| Category                                              | T300+D (N = 462)         | D (N = 492)              | D (N = 4045)             | T75+D (N = 3319)         | T750 (N = 64 3)          |
| On-treatment decreased TSH < LLN and below baseline a | 148 (33.9)               | 80 (17.2)                | 816 (22.2)               | 848 (28.0)               | 76 (14.0)                |

a

Percentage is based on number of patients in the main category above denoted with a *.

Baseline is defined as the last result obtained prior to the start of study treatment.

Derived from laboratory assessments between the start of treatment and up to and including 90 days following the date of last dose of study medication or until the initiation of the first subsequent therapy (whichever occurred first).

D, durvalumab 1500 mg (or equivalent); HCC, hepatocellular carcinoma; IV, intravenous; LLN, lower limit of normal; Q4W, every 4 weeks; T3, free triiodothyronine; T300+D, tremelimumab 300 mg for a single dose in combination with durvalumab 1500 mg Q4W; T4, free thyroxine; T75+D, durvalumab given at a dose of 20 mg/kg Q4W (or equivalent) IV in combination with tremelimumab 1 mg/kg Q4W (or equivalent), for any line of therapy (across tumor types); T750, tremelimumab monotherapy 10 mg/kg Q4W (or equivalent) for any line of therapy (across tumor types); TSH, thyroid stimulating hormone; ULN, upper limit of normal.

45 patients (9.7%) in the HCC pool had imAEs of hypothyroid events and no grade 3, 4, or 5 events were reported. 1 patient needed high-dose corticosteroid treatment and the median time to onset for the imAE of hypothyroid event was 85 days (range: 26 to 763 days).

21 patients (4.5%) in the HCC pool had imAEs of hyperthyroid events. Grade 3 or 4 events were reported in 1 patient (0.2%) and no grade 5 events were reported. 4 patients (0.9%) received high dose corticosteroid treatment and one patient (0.2%) discontinued study treatment. The median time to onset for the imAE of hyperthyroid events was 30 days (range: 13 to 60 days).

## Safety in special populations

## Intrinsic factors

Age

Table 69. Adverse Events in any Category -Patient Level by Age Group

|                                                  | Number (%) of patients a                         | Number (%) of patients a                         | Number (%) of patients a                         | Number (%) of patients a                         | Number (%) of patients a                         |
|--------------------------------------------------|--------------------------------------------------|--------------------------------------------------|--------------------------------------------------|--------------------------------------------------|--------------------------------------------------|
|                                                  | HCC-tumor pool                                   | HCC-tumor pool                                   | Pan-tumor pool                                   | Pan-tumor pool                                   | Pan-tumor pool                                   |
| AE category                                      | T300+D (N1 = 226) (N2 = 173) (N3 = 63)           | D (N1 = 25 4) (N2 = 16 3) (N3 = 75)              | D (N1 = 22 50) (N2 = 13 56) (N3 = 43 9)          | T75+D (N1 = 18 52) (N2 = 11 26) (N3 = 34 1)      | T750 (N1 = 315 ) (N2 = 253 ) (N3 = 75)           |
| Any AE possibly related to any study treatment b | Any AE possibly related to any study treatment b | Any AE possibly related to any study treatment b | Any AE possibly related to any study treatment b | Any AE possibly related to any study treatment b | Any AE possibly related to any study treatment b |
| < 65 years                                       | 163 (72.1)                                       | 132 (52.0)                                       | 1287 (57.2)                                      | 1223 (66.0)                                      | 214 (67.9)                                       |
| ≥ 65 to < 75 years                               | 138 (79.8)                                       | 93 (57.1)                                        | 804 (59.3)                                       | 781 (69.4)                                       | 182 (71.9)                                       |
| ≥ 75 years                                       | 54 (85.7)                                        | 42 (56.0)                                        | 248 (56.5)                                       | 249 (73.0)                                       | 64 (85.3)                                        |
| Any AE possibly related to durvalumab b          | Any AE possibly related to durvalumab b          | Any AE possibly related to durvalumab b          | Any AE possibly related to durvalumab b          | Any AE possibly related to durvalumab b          | Any AE possibly related to durvalumab b          |
| < 65 years                                       | 162 (71.7)                                       | 132 (52.0)                                       | 1283 (57.0)                                      | 1201 (64.8)                                      | 0                                                |
| ≥ 65 to < 75 years                               | 136 (78.6)                                       | 93 (57.1)                                        | 801 (59.1)                                       | 770 (68.4)                                       | 0                                                |
| ≥ 75 years                                       | 51 (81.0)                                        | 42 (56.0)                                        | 248 (56.5)                                       | 244 (71.6)                                       | 1 (1.3)                                          |
| Any AE possibly related to tremelimumab b        | Any AE possibly related to tremelimumab b        | Any AE possibly related to tremelimumab b        | Any AE possibly related to tremelimumab b        | Any AE possibly related to tremelimumab b        | Any AE possibly related to tremelimumab b        |

<div style=\"page-break-after: always\"></div>

Table 69. Adverse Events in any Category -Patient Level by Age Group

|                                                          | Number (%) of patients a                                 | Number (%) of patients a            | Number (%) of patients a                | Number (%) of patients a                    | Number (%) of patients a               |
|----------------------------------------------------------|----------------------------------------------------------|-------------------------------------|-----------------------------------------|---------------------------------------------|----------------------------------------|
|                                                          | HCC-tumor pool                                           | HCC-tumor pool                      | Pan-tumor pool                          | Pan-tumor pool                              | Pan-tumor pool                         |
| AE category                                              | T300+D (N1 = 226) (N2 = 173) (N3 = 63)                   | D (N1 = 25 4) (N2 = 16 3) (N3 = 75) | D (N1 = 22 50) (N2 = 13 56) (N3 = 43 9) | T75+D (N1 = 18 52) (N2 = 11 26) (N3 = 34 1) | T750 (N1 = 315 ) (N2 = 253 ) (N3 = 75) |
| < 65 years                                               | 102 (45.1)                                               | 0                                   | 0                                       | 1137 (61.4)                                 | 208 (66.0)                             |
| ≥ 65 to < 75 years                                       | 87 (50.3)                                                | 0                                   | 0                                       | 720 (63.9)                                  | 180 (71.1)                             |
| ≥ 75 years                                               | 35 (55.6)                                                | 0                                   | 0                                       | 231 (67.7)                                  | 64 (85.3)                              |
| Any AE with outcome of death                             |                                                          |                                     |                                         |                                             |                                        |
| < 65 years                                               | 9 (4.0)                                                  | 11 (4.3)                            | 112 (5.0)                               | 110 (5.9)                                   | 19 (6.0)                               |
| ≥ 65 to < 75 years                                       | 19 (11.0)                                                | 13 (8.0)                            | 90 (6.6)                                | 80 (7.1)                                    | 20 (7.9)                               |
| ≥ 75 years                                               | 6 (9.5)                                                  | 6 (8.0)                             | 29 (6.6)                                | 39 (11.4)                                   | 5 (6.7)                                |
| Any AE leading to discontinuation of any study treatment | Any AE leading to discontinuation of any study treatment |                                     |                                         |                                             |                                        |
| < 65 years                                               | 19 (8.4)                                                 | 19 (7.5)                            | 188 (8.4)                               | 261 (14.1)                                  | 62 (19.7)                              |
| ≥ 65 to < 75 years                                       | 29 (16.8)                                                | 19 (11.7)                           | 156 (11.5)                              | 200 (17.8)                                  | 69 (27.3)                              |
| ≥ 75 years                                               | 15 (23.8)                                                | 9 (12.0)                            | 53 (12.1)                               | 89 (26.1)                                   | 24 (32.0)                              |
| Any AE leading to discontinuation of durvalumab          | Any AE leading to discontinuation of durvalumab          |                                     |                                         |                                             |                                        |
| < 65 years                                               | 19 (8.4)                                                 | 19 (7.5)                            | 183 (8.1)                               | 235 (12.7)                                  | 0                                      |
| ≥ 65 to < 75 years                                       | 29 (16.8)                                                | 19 (11.7)                           | 151 (11.1)                              | 189 (16.8)                                  | 0                                      |
| ≥ 75 years                                               | 15 (23.8)                                                | 9 (12.0)                            | 53 (12.1)                               | 77 (22.6)                                   | 0                                      |
| Any AE leading to discontinuation of tremelimumab        | Any AE leading to discontinuation of tremelimumab        |                                     |                                         |                                             |                                        |
| < 65 years                                               | 2 (0.9)                                                  | 0                                   | 0                                       | 166 (9.0)                                   | 62 (19.7)                              |
| ≥ 65 to < 75 years                                       | 3 (1.7)                                                  | 0                                   | 0                                       | 128 (11.4)                                  | 68 (26.9)                              |
| ≥ 75 years                                               | 2 (3.2)                                                  | 0                                   | 0                                       | 58 (17.0)                                   | 24 (32.0)                              |

j As assessed by the investigator. Missing responses are counted as related.

Percentages are calculated from N1, N2, and N3 for &lt; 65 years, ≥ 65 to &lt; 75 years, and ≥ 75 years, respectively.

Includes AEs with an onset date on or after the date of first dose or pre-treatment AEs that increase in severity on or after the date of first dose up to and including 90 days following the date of last dose of study medication or up to and including the date of initiation of the first subsequent therapy (whichever occurs first).

Disease progression AEs reported in Study 1108, Study 6, Study 10, and Study 11 are not included in this summary.

AE, adverse event; D, durvalumab 1500 mg (or equivalent); HCC, hepatocellular carcinoma; IV, intravenous; N1, total number of &lt; 65 years patients, N2, total number of ≥ 65 to &lt; 75 years patients, N3, total number of ≥ 75 years patients; Q4W, every 4 weeks; T300+D, tremelimumab 300 mg for a single dose in combination with durvalumab 1500 mg Q4W; T75+D, durvalumab given at a dose of 20 mg/kg Q4W (or equivalent) IV in combination with tremelimumab 1 mg/kg Q4W (or equivalent), for any line of therapy (across tumor types); T750, tremelimumab monotherapy 10 mg/kg Q4W (or equivalent) for any line of therapy (across tumor types).

Table 70. Adverse Events by Age Category in the HCC T300+D Tumour Pool

|                                   | Number (%) of patients   | Number (%) of patients      | Number (%) of patients   |
|-----------------------------------|--------------------------|-----------------------------|--------------------------|
| AE Category or System Organ Class | < 65 years (N = 226)     | ≥ 65 - < 75 years (N = 173) | ≥ 75 years (N = 63)      |
| Any AE                            | 218 (96.5)               | 170 (98.3)                  | 63 (100.0)               |
| Any SAE                           | 91 (40.3)                | 72 (41.6)                   | 26 (41.3)                |

<div style=\"page-break-after: always\"></div>

| AE Category or System Organ Class Hospitalization/prolong existing hospitalization   | Number (%) of patients   | Number (%) of patients      | ≥ 75 years         |
|--------------------------------------------------------------------------------------|--------------------------|-----------------------------|--------------------|
| AE Category or System Organ Class Hospitalization/prolong existing hospitalization   | < 65 years (N = 226)     | ≥ 65 - < 75 years (N = 173) | (N = 63)           |
| Life-threatening                                                                     | 88 (38.9) 14 (6.2)       | 66 (38.2) 18 (10.4)         | 25 (39.7) 9 (14.3) |
| Disability/incapacity                                                                | 3 (1.3)                  | 11 (6.4)                    | 1 (1.6)            |
| Other (medically significant)                                                        | 23 (10.2)                | 29 (16.8)                   | 8 (12.7)           |
| Any AE with outcome of death                                                         | 9 (4.0)                  | 19 (11.0)                   | 6 (19.5)           |
| Any AE leading to discontinuation of study treatment                                 | 19 (8.4)                 | 29 (16.8)                   | 15 (23.8)          |
| Psychiatric disorders                                                                | 24 (10.6)                | 28 (16.2)                   | 10 (15.9)          |
| Nervous system                                                                       | 30 (13.3)                | 39 (22.5)                   | 12                 |
| disorders                                                                            |                          |                             | (19.0)             |
| Cardiac disorders                                                                    | 7 (3.1)                  | 11 (6.4)                    | 5 (7.9)            |
| Vascular                                                                             | 18 (8.0)                 | (16.2)                      | 8 (12.7)           |
| disorders                                                                            |                          | 28                          |                    |
| Cerebrovascular disorders Infections and infestations                                | 0 824 (36.6)             | 0 550 (40.6)                | 0 167 (38.0)       |
| syndrome                                                                             | 0                        | 0                           | 0                  |
| Cholinergic                                                                          |                          |                             |                    |
| Anticholinergic syndrome                                                             | 0                        | 0                           | 0                  |
| Ataxia                                                                               | 0                        | 0                           | 0                  |
| Dizziness                                                                            | 4 (1.8)                  | 9 (5.2)                     | 2 (3.2)            |
| Fall                                                                                 | 1 (0.4)                  | 2 (1.2)                     | 2 (3.2)            |
| Hand fracture                                                                        | 0                        | 0                           | 0                  |
| Multiple fractures                                                                   | 0                        | 0                           | 0                  |
| Orthostatic hypotension                                                              | 0                        | 0                           | 0                  |
| Spinal fracture                                                                      | 0                        | 0                           | 0                  |
| Syncope                                                                              | 1 (0.4)                  | 2 (1.2)                     | 1 (1.6)            |
| Other AEs appearing more frequently in older patients c                              |                          |                             |                    |
| Anaemia                                                                              | 14 (6.2)                 | 17 (9.8)                    | 12 (19.0)          |
| Hypothyroidism                                                                       | 21 (9.3)                 | 23 (13.3)                   | 11 (17.5)          |
| Hyperkalaemia                                                                        | 7 (3.1)                  | 9 (5.2)                     | 6 (9.5)            |
| Pneumonitis                                                                          | 1 (0.4)                  | 4 (2.3)                     | 5 (7.9)            |
| Abdominal pain                                                                       | 35 (15.5)                | 17 (9.8)                    | 6 (9.5)            |
| Constipation                                                                         | 24 (10.6)                | 18 (10.4)                   | 3 (4.8)            |
| Diarrhoea                                                                            | 55 (24.3)                | 48 (27.7)                   | 14 (22.2)          |
| Nausea                                                                               | 24 (10.6)                | 19 (11.0)                   | 14 (22.2)          |
| Pruritus                                                                             | 51 (22.6)                | 54 (31.2)                   | 13 (20.6)          |

<div style=\"page-break-after: always\"></div>

|                                   | Number (%) of patients   | Number (%) of patients      | Number (%) of patients   |
|-----------------------------------|--------------------------|-----------------------------|--------------------------|
| AE Category or System Organ Class | < 65 years (N = 226)     | ≥ 65 - < 75 years (N = 173) | ≥ 75 years (N = 63)      |
| Rash                              | 58 (25.7)                | 44 (25.4)                   | 13 (20.6)                |
| Fatigue                           | 33 (14.6)                | 33 (19.1)                   | 17 (27.0)                |
| Oedema peripheral                 | 14 (6.2)                 | 24 (13.9)                   | 7 (11.1)                 |

AE = adverse event; HCC = hepatocellular carcinoma; Q4W = every 4 weeks; SAE = serious adverse event; T300+D = tremelimumab 300 mg for a single dose and durvalumab 1500 mg Q4W.

a The details of each SAE and the criteria met individually are found in the patient narratives b Patients with multiple AEs are counted once for each category and sub-category.

c &gt;5% difference between the &lt;65, 65 to 74, and ≥75 age categories.

## Body weight

In the HCC D pool, a slight increasing trend for Grade 3 to 4 AEs was observed for patients with body weight ≥ 90 kg  (N=55),  compared  to patients  &lt; 70 kg  (54.5%  vs  36.2%),  and  similarly  for  SAEs (49.1% vs 29.4%). A similar trend was observed in the Pan-tumor D pool.

## ECOG performance status

In  both  of  the  HCC-tumor  pools, patients  with  a baseline ECOG status of  1  experienced  a  higher incidence of Grade 3 to 4 AEs (T300+D pool: 56.6% vs 49.1%) and AEs leading to death (T300+D pool: 10.3% vs 5.6%). In the HCC-tumor pools, no other clinically meaningful differences were observed in the safety profile of T300+D versus D alone with respect to performance status.

## Extrinsic factors

## Geographical region

In the HCC tumor pools, the Applicant claimed that there were no clinically meaningful differences in the safety profile of the T300+D pool compared with the D pool with respect to geographical region .

## Immunological events

<div style=\"page-break-after: always\"></div>

Table 71. Adverse Events in any Category, by ADA Category to Durvalumab (Safety Analysis Set)

|                                                                                        | Nunber (%) of patients   | Nunber (%) of patients   | Nunber (%) of patients   | Nunber (%) of patients   | Nunber (%) of patients   | Nunber (%) of patients   | Nunber (%) of patients   | Nunber (%) of patients   | Nunber (%) of patients   | Nunber (%) of patients   | Nunber (%) of patients   | Nunber (%) of patients   |
|----------------------------------------------------------------------------------------|--------------------------|--------------------------|--------------------------|--------------------------|--------------------------|--------------------------|--------------------------|--------------------------|--------------------------|--------------------------|--------------------------|--------------------------|
|                                                                                        | D (N =388)               | D (N =388)               | D (N =388)               | D (N =388)               | T300+D (N =388)          | T300+D (N =388)          | T300+D (N =388)          | T300+D (N =388)          | T75+D (N = 152)          | T75+D (N = 152)          | T75+D (N = 152)          | T75+D (N = 152)          |
| AE category a                                                                          | TE- ADA+ b               | nAb+                     | ADA+c                    | ADA- d                   | TE- ADA+ b               | nAb+                     | ADA+c                    | ADA-d                    | TE- ADA+ b               | nAb+                     | ADA+c                    | ADA-d                    |
| NumberofdurvalumabADA evaluable patients in the category                               | 8                        | 2                        | 20                       | 262                      | 9                        | 5                        | 24                       | 270                      | 5                        | 0                        | 8                        | 100                      |
| Any AE                                                                                 | 6 (75.0)                 | (100) 2                  | (90.0) 18                | (89.7) 235               | 9 (100)                  | (100) 5                  | (95.8) 23                | (97.8) 264               | 5 (100)                  | 0                        | 8 (100)                  | (97.0) 97                |
| Any AE possibly related to treatmente                                                  | 4 (50.0)                 | 0                        | 9 (45.0)                 | 148 (56.5)               | 5 (55.6)                 | 3 (60.0)                 | 17 (70.8)                | 213 (78.9)               | 4 (80.0)                 | 0                        | 5 (62.5)                 | 76 (76.0)                |
| AnyAEofCTCAEGrade3or 4                                                                 | 2 (25.0)                 | 0                        | 9 (45.0)                 | 89 (34.0)                | 5 (55.6)                 | 3 (60.0)                 | 10 (41.7)                | 135 (50.0)               | 2 (40.0)                 | 0                        | 2 (25.0)                 | 40 (40.0)                |
| Any AE of CTCAE grade 3 or 4, possibly related to treatment e                          | 0                        | 0                        | 2 (10.0)                 | (12.2) 32                | 2 (22.2)                 | (20.0) 1                 | 5 (20.8)                 | (24.4) 66                | 0                        | 0                        | 0                        | (19.0) 19                |
| Any AE with outcome of death                                                           | 0                        | 0                        | 1 (5.0)                  | 9 (3.4)                  | 0                        | 0                        | 2 (8.3)                  | 8 (3.0)                  | 1 (20.0)                 | 0                        | 1 (12.5)                 | 5 (5.0)                  |
| Any AE with outcome of death, possibly related to treatment e                          | 0                        | 0                        | 0                        | 0                        | 0                        | 0                        | 0                        | 2 (0.7)                  | 0                        | 0                        | 0                        | 1 (1.0)                  |
| with outcome of death) Any SAE (including events                                       | 0                        | 0                        | 5 (25.0)                 | (24.8) 65                | 3 (33.3)                 | (40.0) 2                 | 8 (33.3)                 | (38.1) 103               | 3 (60.0)                 | 0                        | 3 (37.5)                 | (30.0) 30                |
| Any SAE (including events with outcome of death), possibly related to treatment e      | 0                        | 0                        | 0                        | 17 (6.5)                 | 0                        | 0                        | 1 (4.2)                  | 43 (15.9)                | 1 (20.0)                 | 0                        | 1 (12.5)                 | 16 (16.0)                |
| Any AE leading to discontinuation of study treatmentf                                  | 0                        | 0                        | 1 (5.0)                  | 13 (5.0)                 | 1 (11.1)                 | (20.0) 1                 | 2 (8.3)                  | 26 (9.6)                 | 0                        | 0                        | 0                        | (15.0) 15                |
| Any AE leading to discontinuation of study treatment, possibly related to treatment ef | 0                        | 0                        | 0                        | 6 (2.3)                  | 1 (11.1)                 | (20.0) 1                 | 1 (4.2)                  | 16 (5.9)                 | 0                        | 0                        | 0                        | 8 (8.0)                  |
| Any AE leading to dose delay/interruption 8                                            | 0                        | 0                        | 4 (20.0)                 | (27.9) 73                | 4 (44.4)                 | 0                        | (45.8) 11                | (36.7) 99                | 1 (20.0)                 | 0                        | 2 (25.0)                 | (39.0) 39                |
| Any AESI                                                                               | 1 (12.5)                 | 0                        | 4 (20.0)                 | (43.1) 113               | 4 (44.4)                 | (40.0) 2                 | (50.0) 12                | (71.5) 193               | 5 (100)                  | 0                        | 6 (75.0)                 | (62.0) 62                |
| treatmente Any AESI, possibly related to                                               | 1 (12.5)                 | 0                        | 1 (5.0)                  | (30.9) 81                | 4 (44.4)                 | (20.0) 1                 | (41.7) 10                | (60.0) 162               | 4 (80.0)                 | 0                        | 5 (62.5)                 | (53.0) 53                |
| Any infusion reaction AEs h                                                            | 0                        | 0                        | 0                        | 5 (1.9)                  | 0                        | 0                        | 0                        | 16 (5.9)                 | 0                        | 0                        | 0                        | 3 (3.0)                  |

- b Treatiment-emergent ADA positive is defined as either treatment-induced or treatment-boosted.
- ADA positive, ie, positive ADA result at any time, baseline or post-baseline.
- p ADA negative, ie, without any ADA positive results (at baseline or post-baseline).
- Possibly related to any of the study treatments,as assessed by the Investigator.Missing responses are counted asrelated.
- f AEs on the AE eCRF with action taken of 'drug permanently discontinued' for at least one treatment.
- g AEs on the AE eCRFwith action taken of'drug interrupted'for either molecule.

h As assessed by theInvestigator.

MedDRAversion23.1.CTCAEversion4.03.

Denominator is the number of ADA evaluable patients (patients in the Safety Analysis Set who have a non-missing baseline ADA and at least one non-missing post-baseline result) in the ADA category.

Includes TEAEs.

ADA, anti-drug antibody; AE, adverse event; AESI, adverse event of special interest; eCRF, electronic case report form; CTCAE, Common Terminology Criteria for Adverse Events; D, durvalumab monotherapy 1500 mg Q4W; MedDRA, Medical Dictionary for Regulatory Activities; N, total number of patients; nAb, neutralizing antibody; Q4W, every 4 weeks; SAE, serious adverse event; T75+D, tremelimumab 75 mg × 4 doses + durvalumab 1500 mg Q4W; T300+D, tremelimumab 300 mg × 1 dose + durvalumab 1500 mg Q4W; TE, treatment-emergent.

Source: Table 14.3.9.3.

<div style=\"page-break-after: always\"></div>

## Table 72. Adverse Events in any Category, by ADA Category to Tremelimumab (Safety Analysis Set)

|                                                                                        | Number (%) of patients   | Number (%) of patients   | Number (%) of patients   | Number (%) of patients   | Number (%) of patients   | Number (%) of patients   | Number (%) of patients   | Number (%) of patients   |
|----------------------------------------------------------------------------------------|--------------------------|--------------------------|--------------------------|--------------------------|--------------------------|--------------------------|--------------------------|--------------------------|
|                                                                                        | T300+D (N=388)           | T300+D (N=388)           | T300+D (N=388)           | T300+D (N=388)           | T75+D (N =152)           | T75+D (N =152)           | T75+D (N =152)           | T75+D (N =152)           |
| AE category a                                                                          | TE- ADA+b                | nAb+                     | ADA+c                    | ADA-d                    | TE- ADA+ b               | nAb+                     | ADA+c                    | ADA-d                    |
| Number of tremelimumabADA-evaluablepatientsin the category                             | 20                       | 8                        | 29                       | 153                      | 23                       | 16                       | 30                       | 72                       |
| Any AE                                                                                 | 19 (95.0)                | 8 (100)                  | 28 (96.6)                | 150 (98.0)               | 23 (100)                 | 16 (100)                 | 30 (100)                 | 70 (97.2)                |
| Any AE possibly related to treatment e                                                 | 15 (75.0)                | 8 (100)                  | 23 (79.3)                | 120 (78.4)               | 18 (78.3)                | 13 (81.3)                | 23 (76.7)                | 54 (75.0)                |
| Any AE of CTCAE Grade 3 or 4                                                           | 9 (45.0)                 | 6 (75.0)                 | 13 (44.8)                | 77 (50.3)                | 10 (43.5)                | 8 (50.0)                 | 12 (40.0)                | 27 (37.5)                |
| Any AE of CTCAE Grade 3 or 4, possibly related to treatment e                          | 4 (20.0)                 | 3 (37.5)                 | 7 (24.1)                 | 37 (24.2)                | 1 (4.3)                  | 1 (6.3)                  | 1 (3.3)                  | 15 (20.8)                |
| Any AE with outcome of death                                                           | 0                        | 0                        | 0                        | 5 (3.3)                  | 2 (8.7)                  | 1 (6.3)                  | 4 (13.3)                 | 2 (2.8)                  |
| AnyAEwithoutcome of death,possiblyrelated to treatmente                                | 0                        | 0                        | 0                        | 2 (1.3)                  | 0                        | 0                        | 1 (3.3)                  | 0                        |
| Any SAE (including events with outcome of death)                                       | 9 (45.0)                 | 5 (62.5)                 | 12 (41.4)                | 58 (37.9)                | 5 (21.7)                 | 3 (18.8)                 | 8 (26.7)                 | 24 (33.3)                |
| Any SAE (including events with outcome of death), possibly related to treatment e      | 6 (30.0)                 | 3 (37.5)                 | 7 (24.1)                 | 25 (16.3)                | 1 (4.3)                  | 1 (6.3)                  | 3 (10.0)                 | 13 (18.1)                |
| Any AE leading to discontinuation of study treatment f                                 | 3 (15.0)                 | 2 (25.0)                 | 4 (13.8)                 | 14 (9.2)                 | 3 (13.0)                 | 3 (18.8)                 | 4 (13.3)                 | 10 (13.9)                |
| Any AE leading to discontinuation of study treatment, possibly related to treatment ef | 2 (10.0)                 | 2 (25.0)                 | 3 (10.3)                 | 11 (7.2)                 | 0                        | 0                        | 1 (3.3)                  | 7 (9.7)                  |
| Any AE leading to dose delay/interruption g                                            | 8 (40.0)                 | 2 (25.0)                 | 10 (34.5)                | 57 (37.3)                | 9 (39.1)                 | 8 (50.0)                 | 10 (33.3)                | 28 (38.9)                |
| Any AESI                                                                               | 16 (80.0)                | 6 (75.0)                 | 20 (69.0)                | 104 (68.0)               | 15 (65.2)                | 9 (56.3)                 | 19 (63.3)                | 46 (63.9)                |
| Any AESI, possibly related to treatment e                                              | 14 (70.0)                | 6 (75.0)                 | 17 (58.6)                | 89 (58.2)                | 12 (52.2)                | 9 (56.3)                 | 16 (53.3)                | 40 (55.6)                |
| Any infusion reaction AEs h                                                            | 2 (10.0)                 | 1 (12.5)                 | 2 (6.9)                  | 10 (6.5)                 | 0                        | 0                        | 0                        | 3 (4.2)                  |

- Positive and negative results are with respect to tremelimumab. Patients with multiple events in the same category are counted only once in that category. Patients with events in more than 1 category are counted once in each of those categories.
- b Treatment-emergent ADA positive is defined as either treatment-induced or treatment-boosted.
- C ADA positive, ie, positive ADA result at any time, baseline or post-baseline.
- P ADA negative,ie,without anyADA positive results (at baseline or post-baseline).
- e Possibly related to any of the study treatments, as assessed by the Investigator. Missing responses are counted as related.

f

AEs on the AE eCRF with action taken of‘drug permanently discontinued’ for at least one treatment.

- g AEs on the AE eCRF with action taken of ^drug interrupted' for either molecule.
- h As assessed by Investigator.

MedDRA version 23.1. CTCAE version 4.03.

Denominator is the number of ADA evaluable patients (patients in the Safety Analysis Set who have a non-missing baseline ADA and at least one non-missing post-baseline result) in the ADA category.

Includes TEAEs.

ADA, antidrug antibody; AE, adverse event; AESI, adverse event of special interest; eCRF, electronic case report form; CTCAE, Common Terminology Criteria for Adverse Events; D, durvalumab monotherapy 1500 mg Q4W; MedDRA, Medical Dictionary for Regulatory Activities; N, total number of patients; nAb, neutralizing antibody; Q4W, every 4 weeks; SAE, serious adverse event; T75+D, tremelimumab 75 mg × 4 doses + durvalumab 1500 mg Q4W;

T300+D,tremelimumab300mg×1dose+durvalumab1500mgQ4W;TE,treatment-emergent.

## Safety related to drug-drug interactions and other interactions

Durvalumab and tremelimumab are immunoglobulins, therefore, no formal pharmacokinetic drug-drug interaction studies have been conducted.

<div style=\"page-break-after: always\"></div>

## Discontinuation due to adverse events

Table 73. Adverse Events leading to discontinuation of study medication by system organ class, preferred term and maximum reported CCAE grade (Safety Analysis Set) -DCO: 27 AUG 2021

|                                       |                            | Number(%)of subjectsa   | Number(%)of subjectsa              | Number(%)of subjectsa              | Number(%)of subjectsa   |
|---------------------------------------|----------------------------|-------------------------|------------------------------------|------------------------------------|-------------------------|
| Systemorganclass/ MedDRAPreferredterm | Maximumreported CTCAEgrade | Durva1500 mg (N=388)    | Treme300mgx1dose+Treme75mgx4doses+ | Treme300mgx1dose+Treme75mgx4doses+ | Sora400mg               |
|                                       |                            |                         | Durva1500mg (N=388)                | Durva1500mg (N=152)                | BID (N=374)             |
| Subjects with any AE                  | Total                      | 32 (8.2)                | 53 (13.7)                          | 23 (15.1)                          | 63 (16.8)               |
|                                       | Grade 1                    | 0                       | 2 (0.5)                            | 0                                  | 2 (0.5)                 |
|                                       | Grade 2                    | 6 (1.5)                 | 7 (1.8)                            | 5 (3.3)                            | 16 (4.3)                |
|                                       | Grade 3                    | 13 (3.4)                | 21 (5.4)                           | 6 (3.9)                            | 27 (7.2)                |
|                                       | Grade4                     | 2 (0.5)                 | 4 (1.0)                            | 5 (3.3)                            | 1 (0.3)                 |
|                                       | Grade5                     | 11 (2.8)                | 19 (4.9)                           | 7 (4.6)                            | 17 (4.5)                |
|                                       | Grade>=3                   | 26 (6.7)                | 44 (11.3)                          | 18 (11.8)                          | 45 (12.0)               |
|                                       | Grade 3-4                  | 15 (3.9)                | 25 (6.4)                           | 11 (7.2)                           | 28 (7.5)                |

Table 74. Adverse Events Leading to Discontinuation by System Organ Class and Preferred Term (≥ 1% Patients in Any Treatment Group) (Safety Analysis Set)

|                                                                        | Number (%) of patients a   | Number (%) of patients a   | Number (%) of patients a   | Number (%) of patients a   | Number (%) of patients a   |
|------------------------------------------------------------------------|----------------------------|----------------------------|----------------------------|----------------------------|----------------------------|
|                                                                        | HCC-tumor pool             | HCC-tumor pool             | Pan-tumor pool             | Pan-tumor pool             | Pan-tumor pool             |
|                                                                        | T300+D                     | D                          | D                          | T75+D                      | T750                       |
| MedDRA preferred term                                                  | (N = 462)                  | (N = 492)                  | (N = 4045)                 | (N = 3319)                 | (N = 643)                  |
| Patients with any AE leading to discontinuation of any study treatment | 63 (13.6)                  | 47 (9.6)                   | 397 (9.8)                  | 550 (16.6)                 | 155 (24.1)                 |
| Respiratory, thoracic and mediastinal disorders                        | 4 (0.9)                    | 2 (0.4)                    | 84 (2.1)                   | 113 (3.4)                  | 9 (1.4)                    |
| Pneumonitis                                                            | 2 (0.4)                    | 1 (0.2)                    | 36 (0.9)                   | 49 (1.5)                   | 2 (0.3)                    |
| Gastrointestinal disorders                                             | 14 (3.0)                   | 9 (1.8)                    | 41 (1.0)                   | 125 (3.8)                  | 98 (15.2)                  |
| Colitis                                                                | 2 (0.4)                    | 1 (0.2)                    | 6 (0.1)                    | 32 (1.0)                   | 26 (4.0)                   |
| Diarrhoea                                                              | 3 (0.6)                    | 2 (0.4)                    | 8 (0.2)                    | 37 (1.1)                   | 63 (9.8)                   |
| Investigations                                                         | 8 (1.7)                    | 6 (1.2)                    | 25 (0.6)                   | 42 (1.3)                   | 11 (1.7)                   |
| Aspartate aminotransferase increased                                   | 5 (1.1)                    | 3 (0.6)                    | 6 (0.1)                    | 8 (0.2)                    | 1 (0.2)                    |

k Number (%) of patients with AEs leading to discontinuation, sorted by international order for system organ class and alphabetically for preferred term.

Patients with multiple AEs are counted once for each system organ class/preferred term.

Includes AEs with an onset date on or after the date of first dose or pre-treatment AEs that increase in severity on or after the date of first dose up to and including 90 days following the date of last dose of study medication, or up to and including the date of initiation of the first subsequent therapy (whichever occurs first).

Disease progression AEs reported in Study 1108, Study 6, Study 10, and Study 11 are not included in this summary.

Percentages are based on the total numbers of patients in the treatment group (N).

MedDRA version 23.1.

AE, adverse event; D, durvalumab 1500 mg (or equivalent); HCC, hepatocellular carcinoma; IV, intravenous; MedDRA, Medical Dictionary for Regulatory Activities; Q4W, every 4 weeks; T300+D, tremelimumab 300 mg for a single dose in combination with durvalumab 1500 mg Q4W; T75+D, durvalumab given at a dose of 20 mg/kg Q4W (or equivalent) IV in combination with tremelimumab 1 mg/kg Q4W (or equivalent), for any line of therapy (across tumor types); T750, tremelimumab monotherapy 10 mg/kg Q4W (or equivalent) for any line of therapy (across tumor types).

<div style=\"page-break-after: always\"></div>

Table 75: Adverse Events Leading to Dose Delay/Interruption by System Organ Class and Preferred Term (≥ 1% Patients in Any Treatment Group) (Safety Analysis Set)

|                                                                                | Number (%) of patients a   | Number (%) of patients a   | Number (%) of patients a   | Number (%) of patients a   | Number (%) of patients a   |
|--------------------------------------------------------------------------------|----------------------------|----------------------------|----------------------------|----------------------------|----------------------------|
|                                                                                | HCC-tumor pool             | HCC-tumor pool             | Pan-tumor pool             | Pan-tumor pool             | Pan-tumor pool             |
|                                                                                | T300+D                     | D                          | D                          | T75+D                      | T750                       |
| MedDRA preferred term                                                          | (N = 462)                  | (N = 492)                  | (N = 4045)                 | (N = 3319)                 | (N = 643)                  |
| Patients with any AE leading to dose delay/interruption of any study treatment | 149 (32.3)                 | 112 (22.8)                 | 1120 (27.7)                | 945 (28.5)                 | 144 (22.4)                 |
| Infections and infestations                                                    | 22 (4.8)                   | 12 (2.4)                   | 255 (6.3)                  | 183 (5.5)                  | 18 (2.8)                   |
| Pneumonia                                                                      | 6 (1.3)                    | 1 (0.2)                    | 88 (2.2)                   | 63 (1.9)                   | 7 (1.1)                    |
| Blood and lymphatic system disorders                                           | 12 (2.6)                   | 11 (2.2)                   | 64 (1.6)                   | 53 (1.6)                   | 9 (1.4)                    |
| Anaemia                                                                        | 6 (1.3)                    | 4 (0.8)                    | 39 (1.0)                   | 28 (0.8)                   | 7 (1.1)                    |
| Endocrine disorders                                                            | 9 (1.9)                    | 6 (1.2)                    | 75 (1.9)                   | 88 (2.7)                   | 7 (1.1)                    |
| Hyperthyroidism                                                                | 5 (1.1)                    | 0                          | 28 (0.7)                   | 34 (1.0)                   | 0                          |
| Respiratory, thoracic and mediastinal disorders                                | 7 (1.5)                    | 5 (1.0)                    | 171 (4.2)                  | 116 (3.5)                  | 12 (1.9)                   |
| Pneumonitis                                                                    | 3 (0.6)                    | 1 (0.2)                    | 48 (1.2)                   | 39 (1.2)                   | 3 (0.5)                    |
| Gastrointestinal disorders                                                     | 23 (5.0)                   | 12 (2.4)                   | 140 (3.5)                  | 186 (5.6)                  | 54 (8.4)                   |
| Colitis                                                                        | 5 (1.1)                    | 0                          | 4 (< 0.1)                  | 25 (0.8)                   | 1 (0.2)                    |
| Diarrhoea                                                                      | 16 (3.5)                   | 4 (0.8)                    | 48 (1.2)                   | 82 (2.5)                   | 43 (6.7)                   |
| Hepatobiliary disorders                                                        | 18 (3.9)                   | 15 (3.0)                   | 44 (1.1)                   | 38 (1.1)                   | 1 (0.2)                    |
| Hepatic function abnormal                                                      | 3 (0.6)                    | 5 (1.0)                    | 8 (0.2)                    | 7 (0.2)                    | 1 (0.2)                    |
| Hepatitis                                                                      | 6 (1.3)                    | 1 (0.2)                    | 6 (0.1)                    | 9 (0.3)                    | 0                          |
| Skin and subcutaneous tissue disorders                                         | 21 (4.5)                   | 12 (2.4)                   | 64 (1.6)                   | 91 (2.7)                   | 19 (3.0)                   |
| Rash                                                                           | 10 (2.2)                   | 3 (0.6)                    | 14 (0.3)                   | 34 (1.0)                   | 7 (1.1)                    |
| General disorders and administration site conditions                           | 13 (2.8)                   | 3 (0.6)                    | 147 (3.6)                  | 112 (3.4)                  | 19 (3.0)                   |
| Pyrexia                                                                        | 9 (1.9)                    | 1 (0.2)                    | 43 (1.1)                   | 25 (0.8)                   | 5 (0.8)                    |
| Investigations                                                                 | 47 (10.2)                  | 45 (9.1)                   | 214 (5.3)                  | 203 (6.1)                  | 19 (3.0)                   |
| Alanine aminotransferase increased                                             | 13 (2.8)                   | 15 (3.0)                   | 47 (1.2)                   | 52 (1.6)                   | 2 (0.3)                    |
| Amylase increased                                                              | 14 (3.0)                   | 1 (0.2)                    | 22 (0.5)                   | 34 (1.0)                   | 2 (0.3)                    |
| Aspartate aminotransferase increased                                           | 12 (2.6)                   | 23 (4.7)                   | 64 (1.6)                   | 53 (1.6)                   | 4 (0.6)                    |
| Lipase increased                                                               | 11 (2.4)                   | 7 (1.4)                    | 27 (0.7)                   | 58 (1.7)                   | 6 (0.9)                    |
| Injury, poisoning and procedural complications                                 | 5 (1.1)                    | 0                          | 73 (1.8)                   | 40 (1.2)                   | 4 (0.6)                    |
| Radiation pneumonitis                                                          | 0                          | 0                          | 41 (1.0)                   | 1 (< 0.1)                  | 0                          |

Number (%) of patients with AE leading to dose delay or interruption, sorted by international order for system organ class and alphabetically for preferred term.

Patients with multiple AEs are counted once for each system organ class/preferred term.

Includes AEs with an onset date on or after the date of first dose or pre-treatment AEs that increase in severity on or after the date of first dose up to and including 90 days following the date of last dose of study medication or up to and including the date of initiation of the first subsequent therapy (whichever occurs first).

Disease progression AEs reported in Study 1108, Study 6, Study 10, and Study 11 are not included in this summary.

MedDRA version 23.1.

AE, adverse event; D, durvalumab 1500 mg (or equivalent); HCC, hepatocellular carcinoma; IV, intravenous; MedDRA, Medical Dictionary for Regulatory Activities; Q4W, every 4 weeks; T300+D, tremelimumab 300 mg for a single dose in combination with durvalumab 1500 mg Q4W; T75+D, durvalumab given at a dose of 20 mg/kg Q4W (or equivalent) IV in combination with tremelimumab 1 mg/kg Q4W (or equivalent), for any line of therapy (across tumor types); T750, tremelimumab monotherapy 10 mg/kg Q4W (or equivalent) for any line of therapy (across tumor types).

<div style=\"page-break-after: always\"></div>

## Post marketing experience

Durvalumab was first  approved  for  marketing  in  the  US  on  01 May 2017.  The  total  post-marketing exposure of durvalumab since launch and until 30 June 2021 is estimated to be 52006 patient-years. No new safety concerns have been identified based on post-marketing safety reports

## 2.5.1. Discussion on clinical safety

The safety population of interest are patients with unresectable HCC (uHCC), who have received the proposed  dosing  regimen  of  a  single  dose  of  tremelimumab  300  mg  +  durvalumab  in  combination followed  by  durvalumab  monotherapy  (T300+D),  which  consists  of  388  patients  from  the  pivotal Himalaya study and 74 patients from the supportive study 22, in total 462 patients.

The median treatment duration in the Himalaya study were 5.5 months, while the median treatment duration  was  4.1  months  in  the  Sorafenib  arm  (n=374).  In  the  HCC  pool,  the  median  duration  of exposure was 20 weeks and approximately 50% of patients received at least 24 weeks of treatment at DCO, while ~28% had 52 weeks of treatment. Hence, the exposure to the proposed regimen and the size of the safety database are considered sufficient for a safety assessment.

Almost all patients in the HCC pool, who received T300+D, experienced at least one adverse event (AE) (97.6%), and 51.9% experienced a grade 3 or 4 AEs. For the Himalaya study, a similar pattern was observed in T300+D arm: 97.4% experienced at least one AE, 50.5% experienced a grade 3 or 4 AE, and SAEs were observed in 40.5% of the patients, noting 7.7% had an SAE leading to death. The discontinuation rate due to AEs was 13.7%. In comparison, 95.5% of the patients in the Sorafenib arm also experienced at least one AE, and 52.4% experienced a grade 3 or 4 AE. SAEs were observed in 29.7% of the patients, of which 7.2% had an SAE leading to death, while the discontinuation rate due to AEs was 16.8%.

Treatment-related AEs in the T300+D arm of the pivotal Himalaya study were rash (19.6%), pruritus (17%), diarrhoea (16.5%), and hypothyroidism (10.8%). In comparison, common treatment-related AEs in the Sorafenib arm were diarrhoea (38.8%), palmar-plantar erythrodysaesthesia (PPE) (43.9%), hypertension (15%), and fatigue (14.7%). The most common grade 3 or 4 treatment-related AEs in the T300+D arm were increased lipase (4.4%), diarrhoea (3.4%), amylase increased (2.6%) and ASAT increased  (2.3%).  Common  grade  3  or  4  treatment-related  AEs  in  the  S  arm  were  PPE  (8.8%), hypertension (5.3%), and diarrhoea (4%), so in comparison there are more high-grade toxicity with sorafenib in favour of T300+D (data not shown).

Adverse  events  of  special  interest for  T300+D  include  immune-mediated  AEs  (imAEs)  and  as expected, the occurrence of imAEs are much more common in the HCC pool vs the Sorafenib arm (36.1% vs 7.5%), and these were of grade 3 or 4 in 13.4% vs 2.4% of the patients, respectively. Serious imAEs are considered common (10.2% vs 1.1%) and 6 patients (1.3%) died from these, while a quarter of the patients need systemic corticosteroids in the HCC pool versus only 4% in the Sorafenib arm. Moreover, many patients needed endocrine therapy, when treated with T300+D vs Sorafenib (14.9% vs 3.5%). It is noted that very few patients had to discontinue treatment due to imAEs (5.6% vs 1.6%), which is reassuring. Other common imAEs with T300+D were hepatic events (7.4%) and diarrhoea/colitis (6.5%). Grade 3 or  4  hepatic  events  (5%)  and  diarrhoea/colitis  (3.7%)  were  the  most  frequent  high-grade events, and these are difficult to manage in the clinic, so it is important that this is clear from the SmPC section 4.4, which is the case. Overall, imAEs were frequently reported and the number of AESIs and imAEs  significantly  differ  for  dermatitis/rash,  pancreatic  events,  hepatic  events,  diarrhoea/colitis, hypothyroid and hyperthyroid events, pneumonitis. Some imAEs such as endocrinopathies, hepatotoxicity, dermatitis/rash are expected to be more manageable than others, such as

<div style=\"page-break-after: always\"></div>

diarrhoea/colitis,  pancreatic  events  and  pneumonitis.  The  latter  are  more  difficult  to  manage,  often require hospitalisation, and might not be assumed as immune-mediated events by clinicians.

Events  of  Stevens-Johnson  Syndrome  or  toxic  epidermal  necrolysis  have  been  reported  in  patients treated with PD-1 inhibitors and CTLA-4 inhibitors. Patients should be monitored for signs and symptoms of  rash  or  dermatitis  and  managed  through  dose  interruption,  treatment  discontinuation  and/or corticoisteroid treatment (see sections 4.2 and 4.4 of the SmPC).

Patients should be monitored for alanine aminotransferase, aspartate aminotransferase, total bilirubin, and alkaline phosphatase levels prior to initiation of treatment and prior to each subsequent infusion. Additional monitoring is to be considered based on clinical evaluation. Patients should be monitored for abnormal  renal  function  tests  prior  to  and  periodically  during  treatment.  Patients  should  also  be monitored for signs and symptoms of immune-mediated pancreatitis and myocarditis. Immune mediated hepatitis,  nephritis,  pancreatitis  and  myocarditis  should  be  managed  through  dose  interruption, treatment discontinuation and/or corticoisteroid treatment (see sections 4.2 and 4.4 of the SmPC).

Patients should be monitored for signs and symptoms of pneumonitis. Suspected pneumonitis should be confirmed with radiographic imaging and other infectious and disease-related aetiologies excluded, and managed  through  dose  interruption,  treatment  discontinuation  and  corticosteroid  treatment  (see sections 4.2 and 4.4 of the SmPC).

Patients should be monitored for signs and symptoms of colitis/diarrhoea and intestinal perforation and managed through dose interruption,  treatment  discontinuation  and/or  corticoisteroid  treatment  (see sections 4.2 and 4.4 of the SmPC).

Patients  should  be  monitored  for  abnormal  thyroid  function  tests  prior  to  and  periodically  during treatment and as indicated based on clinical evaluation. Immune-mediated hypothyroidism, hyperthyroidism, and thyroiditis should be managed through dose interruption, symptomatic treatment or thyroid hormone replacement as clinically indicated (see sections 4.2 and 4.4 of the SmPC).

Immune mediated adrenal insufficiency occurred in patients receiving tremelimumab in combination with durvalumab. Patients should be monitored for clinical signs and symptoms of adrenal insufficiency. For symptomatic adrenal insufficiency, patients should be managed through dose interruption, corticoisteroid treatment and hormone replacement (see sections 4.2 and 4.4 of the SmPC).

Immune mediated type 1 diabetes mellitus, which can first present as diabetic ketoacidosis that can be fatal if not detected early, occurred in patients receiving tremelimumab in combination with durvalumab. Patients  should  be  monitored  for  clinical  signs  and  symptoms  of  type  1  diabetes  mellitus.  For symptomatic type 1 diabetes mellitus, patients should be managed via treatment with insulin as clinically indicated (see sections 4.2, 4.4 and 4.8 of the SmPC).

Patients should be monitored for clinical signs and symptoms of hypophysitis or hypopituitarism. For symptomatic hypophysitis or hypopituitarism, patients should be managed as recommended through dose interruption and corticoisteroid treatment (see sections 4.2 and 4.4 of the SmPC).

Given  the  mechanism  of  action  of  tremelimumab  in  combination  with  durvalumab,  other  potential immune mediated adverse reactions may occur. The following immune-related adverse reactions have been observed in patients treated with tremelimumab in combination with durvalumab: myasthenia gravis,  myositis,  myelitis  transverse,  polymyositis, meningitis, encephalitis, Guillain-Barré syndrome, immune  thrombocytopenia  and  cystitis  noninfective.  Patients  should  be  monitored  for  signs  and symptoms and managed through dose interruption,  treatment  discontinuation  and/or  corticoisteroid treatment (see sections 4.2 and 4.4 of the SmPC).

<div style=\"page-break-after: always\"></div>

Although the rate of imAEs with the T300+D is considered high, these are considered generally clinically manageable.

Patients should also be monitored for signs and symptoms of IRRs. IRRs should be managed through dose interruption, treatment discontinuation, prophylaxis and appropriate treatment (see sections 4.2 and 4.4 of the SmPC).

Serious adverse events (SAEs) were very common in the T300+D arm vs the S arm in Himalaya study (40.5% vs 29.7%) and it is noted that 10% less SAEs were observed with durvalumab monotherapy, suggesting that the addition of the single dose of 300 mg tremelimumab significantly adds toxicity. The most frequent SAEs in the T300+D arm vs the S arm were diarrhoea (2.3% vs 1.6%), sepsis (2.1% vs 0), and pneumonia (1.8% vs 2.1%). Overall, the high level of SAEs with T300+D is worrisome although the targeted patient population is previously untreated patients and this may influence the tolerability in the  general  patient  population  in  the  first-line  setting.  Of  note,  diarrhoea  and  colitis  are  important identified  risks  of  the  anti-CTLA-4  agent  ipilimumab,  which  has  a  similar  mechanism  of  action  as tremelimumab. Moreover, the targeted patient population from the 2L+ setting is expected to have even more serious toxicity.

AEs leading to death occurred in 34 patients (7.4%) in the HCC T300+D pool and 30 patients (7.7%) in the T300+D arm of the Himalaya study.

The overall discontinuation rate due to AEs in the HCC pool was 13.6%, while it was 13.7% of the patients in the pivotal Himalaya study. Most commonly the patients discontinued treatment due to AST increased and diarrhoea, which reflects the safety profile of T300+D. Dose delays were very common in the patients who had T300+D in the HCC pool (32.3%) and mostly due to diarrhoea and increased liver enzymes.

Laboratory findings showed that the changes in haematological parameters were mostly of low grade and pertaining to a decrease in lymphocytes ≥ grade 2 for 20% of the patients and grade 3 or 4 in 11.8%. This is in line with the findings in the pivotal Himalaya study. Laboratory shifts for clinical chemistry parameters were rare and mostly to low grade events. It is noted that increased glucose was common in the HCC pool (19.4%) and that grade 3 or 4 were observed in 14.6% of the patients. New onset diabetes mellitus was identified in 39 (8.4%) of 462 patients in the T300+D HCC pool and 30 (6.1%) of 492 patients in the D monotherapy HCC pool. Eight (1.7%) SAE reports of hyperglycaemia occurred in the T300+D HCC pool and most patients did not receive therapy for the hyperglycaemic event and the reported events were resolved in 21 (4.5%) of the patients in the T300+D HCC pool. One patient with hyperglycaemia  and  one  patient  with  T2DM  discontinued  treatment. Liver  toxicity  was  very  often observed regarding elevated hepatic laboratory parameters in the HCC pool. Potential Hy ' s law cases were reported for 57 patients (12.3%) in the HCC pool and the narratives for the 4 patients, who met the Hy ' s law criteria in the T300+D arm of the pivotal Himalaya study are all agreed.

Increased toxicity with increasing age was observed in the HCC pool, as the incidence of ADRs were 72.1% in the patients of &lt;65 years of age vs 79.8% in patients of 65-75 years of age and 85.7% in those of ≥7 5 years of age. A trend towards more discontinuations with increasing age was also observed.

Safety and tolerability profiles were similar in patients with ADAs and in those without ADAs. According to the Applicant, there were no new types of events or events clearly suggestive or indicative of infusion reactions or immune complex disease.

Overall,  the  toxicity  observed  in  the  first-line  study  Himalaya  was  significantly  less  than  what  was observed for the entire HCC pool, which is to be expected for the included study population, who was previously systemically untreated patients, who are usually more fit and able to tolerate toxicities. The toxicity observed with Sorafenib is similar to the toxicity level observed in the HCC pool and in some

<div style=\"page-break-after: always\"></div>

cases worse than what was observed for the T300+D arm of the Himalaya study. However, the toxicity profiles of T300+D and Sorafenib differs due to different mechanisms of action mainly between immune checkpoint inhibition and a tyrosine kinase inhibitor (TKI).

## 2.5.2. Conclusions on clinical safety

The toxicity of the proposed dosing regimen of T300+D is considerable, since approximately half of the patients experience grade 3 or 4 adverse events and 40% of the patients have serious adverse events, mostly pertaining to diarrhoea and immune-mediated adverse events. The discontinuation rate is however relatively low (~13%) and most of the toxicity observed is clinically manageable and the toxicity profile of T300+D is not considered significantly worse than that of Sorafenib, the current standard of care.

## 2.5.3. PSUR cycle

The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

## 2.6. Risk management plan

The MAH submitted an updated RMP version with this application.

The CHMP received the following PRAC Advice on the submitted Risk Management Plan:

The PRAC considered that the risk management plan version 8 succession 1 is acceptable.

The CHMP endorsed this advice without changes.

The CHMP endorsed the Risk Management Plan version 8 succession 1 with the following content:

## Safety concerns

There are no safety concerns.

## Pharmacovigilance plan

Not applicable as there are no safety concerns.

## Risk minimisation measures

Not applicable as there are no safety concerns.

## 2.7. Update of the Product information

As a consequence of this new indication, sections 4.1, 4.2, 4.4, 4.5, 4.8, 5.1 and 5.2 of the SmPC have been updated. The Package Leaflet has been updated accordingly.

## 2.7.1. User consultation

A justification for not performing a full user consultation with target patient groups on the package leaflet has been submitted by the MAH and has been found acceptable for the following reasons:

<div style=\"page-break-after: always\"></div>

A readability test was performed for the original dossier and provided during the assessment of the initial dossier. This variation aims at extending the indication for durvalumab to be used in combination with tremelimumab for the treatment of adults with unresectable hepatocellular carcinoma. The same route of administration (intravenous use) and age group (adults) is applicable to this variation. The package leaflet is being updated in section 1-4 and are otherwise similar to the text previously tested at the time of the MAA. The changes are not considered too significant and an additional user consultation is not considered necessary for this new indication.

## 2.7.2. Additional monitoring

Pursuant  to  Article  23(1)  of  Regulation  No  (EU)  726/2004,  Imfinzi  (durvalumab)  is  included  in  the additional monitoring list as it contains a new active substance and it is a biological product that is not covered by the previous category and authorised after 1 January 2011.

Therefore, the summary of product characteristics and the package leaflet includes a statement that this medicinal product is subject to additional monitoring and that this will allow quick identification of new safety information. The statement is preceded by an inverted equilateral black triangle.

## 3. Benefit-Risk Balance

## 3.1. Therapeutic Context

## 3.1.1. Disease or condition

The approved therapeutic indication is:

IMFINZI in combination with tremelimumab is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (HCC).

The aim of the applied dosing regimen of tremelimumab plus durvalumab (T300+D) in comparison to Sorafenib (SOC) in the targeted population is to prolong overall survival (OS).

## 3.1.2. Available therapies and unmet medical need

The first-line treatment of uHCC includes sorafenib (a tyrosine-kinase inhibitor - TKI) based on OS benefit when compared to placebo (10.7 vs 7.9 months) and lenvatinib, another TKI, which is non-inferior when compared  to  sorafenib  (median  OS  13.6  vs  12.3  months).  Atezolizumab  (a  PD-L1  inhibitor)  in combination with bevacizumab (a vascular endothelial growth factor receptor inhibitor) has also been approved in the first-line setting, based on the Phase III IMbrave150 study showing improvements of OS  and  PFS  compared  to  sorafenib  i.e.  the  median  OS  was  19.2  months  with  atezolizumab  + bevacizumab vs 13.4 months with Sorafenib (HR, 0.66 [95%CI: 0.52, 0.85]), while the PFS by blinded review was 6.9 vs. 4.3 months (HR 0.65 [95%CI: 0.53, 0.81]).

Despite  recent  advances  in  treatment  options,  patients  with  uHCC  continue  to  have  a  short  life expectancy  and  the  underlying  liver  disease  and  portal  vein  hypertension  increase  the  risk  of gastrointestinal bleeding, which can be potentially life-threatening. Currently available therapies provide only a modest improvement in survival with safety profiles that require management due to adverse events such as diarrhoea, hypertension, and palmar-plantar erythrodysaesthesia (PPE). Treatment with atezolizumab plus bevacizumab also carries a higher incidence of bleeding,  including  fatal  bleeding,

<div style=\"page-break-after: always\"></div>

despite  attempts  to  exclude  patients  at  risk  for  gastrointestinal  bleeding  from  the  pivotal  study. Moreover, the underlying liver cirrhosis may result in moderate liver dysfunction, which may exacerbate the  toxicity  of  systemic  therapies  such  as  TKIs.  Hence,  additional  therapeutic  options  are  needed, including options for patients with uHCC, who are at higher risk of bleeding events, so there exist an unmet medical need for better and more tolerable treatment options for patients with uHCC.

## 3.1.3. Main clinical studies

The pivotal study Himalaya is a randomised, open-label, multicentre Phase III study in patients with unresectable HCC not eligible for locoregional therapy, which compared tremelimumab + durvalumab (T300+D) to standard of care, sorafenib, in the first-line setting. The primary endpoint was OS in the ITT population.

Additional supportive evidence of clinical efficacy was provided from Study 22, a randomised, phase I/II, open-label  study  conducted  in  the  2L+  setting,  comparing  the  efficacy  of  T300+D  and  durvalumab monotherapy.

## 3.2. Favourable effects

The primary endpoint for the Himalaya study was met as treatment with T300+D showed a statistically significant improvement in overall survival (OS) compared to standard of care, Sorafenib.

- At data cutoff 27 August 2021 and after ~33 months of follow up, 66.7% OS events had occurred in  the  T300+D  arm versus 75.3% OS events in the Sorafenib arm, treatment with T300+D showed  a  statistically  significant  survival  benefit  as  compared  with  SoC:  Median  OS  was improved from 13.77 months to 16.43 months, HR 0.78 (96.02% CI: 0.65, 0.93).
- The secondary endpoint of ORR by investigator was 20.1% for the T300+D arm compared to 5.1% in  the  sorafenib  arm,  and  the  median  duration  of  response  was  22.34  months  in  the T300+D arm vs 18.43 months in the sorafenib arm.
- The PFS analyses were not controlled for multiplicity. PFS by investigator was not significantly improved, since the median PFS was 3.78 months in the T300+D arm versus 4.07 months in the S arm; HR 0.90 (95%CI: 0.77, 1.05). The event rates were 85.2% and 84.1% in the T300+D and S arms, respectively.
- Relevant subgroup analyses of the primary endpoint of OS show that the benefit of T300+D vs S is maintained across important subgroups of age of less than or ≥ 65 years, HBV or other reasons  for  liver  disease,  ECOG  performance  status,  macrovascular  invasion  (MVI),  AFP  at baseline and BCLB score C.

## 3.3. Uncertainties and limitations about favourable effects

None.

## 3.4. Unfavourable effects

The safety populations of interest are the 388 patients from the pivotal Himalaya study and the patients included in the HCC pool (n=462), which also contains patients from the supportive study 22. The median

<div style=\"page-break-after: always\"></div>

treatment duration in the Himalaya study were 5.5 months, while the median treatment duration was 4.1 months in the Sorafenib arm (n=374).

Almost all of the patients in the HCC pool, who received T300+D, experienced at least one adverse event (AE)  (97.6%), and 51.9% experienced a grade 3 or 4 AE. For the Himalaya study, a similar pattern was observed.

Adverse drug reactions (ADRs) in the T300+D arm of the pivotal Himalaya study were rash, pruritus, diarrhoea, and abdominal pain. The most common grade 3 or 4 ADRs in the T300+D arm were increased aspartate  aminotransferase/  alanine  aminotransferase,  increased  lipase,  increased  amylase  and diarrhoea.

Adverse  events  of  special  interest for  T300+D  include  immune-mediated  AEs  (imAEs)  and  as expected, the occurrence of imAEs are much more common in the HCC pool vs the Sorafenib arm (36.1% vs 7.5%), and these were of grade 3 or 4 in 13.4% vs 2.4% of the patients, respectively. Serious imAEs were observed in 10.2% vs 1.1% and 6 patients (1.3%) died from these.

The most common serious adverse reactions in the T300+D HCC pool are colitis (2.6%), diarrhoea (2.4%), pneumonia (2.2%), and hepatitis (1.7%).

In the pivotal Himalaya study, 6.1% of the patients in the T300+D arm died from an adverse event , while it was 7.4% in the HCC pool.

The overall discontinuation rate due to ADRs was 6.5%. Most commonly the patients discontinued treatment  due  to  ADRs  of  hepatitis  (1.5%)  and  aspartate  aminotransferase  increased/alanine aminotransferase increased (1.3%).

Laboratory findings showed that the changes in haematological parameters and clinical chemistry were mostly to low grade events. It is noted that increased glucose was common in the HCC pool (19.4%) and that grade 3 or 4 were observed in 14.6% of the patients. Liver toxicity was often observed regarding elevated hepatic laboratory parameters in the HCC pool and potential Hy ' s law cases were reported for 57 patients (12.3%) in the HCC pool.

## 3.5. Uncertainties and limitations about unfavourable effects

There are very limited safety data on elderly aged 75 years and older (see section 4.8 of the SmPC).

## 3.6. Effects Table

Table 76. Effects Table for T300+D in the treatment of uHCC for the Himalaya Study (data cutoff: 27 August 2021)

| Effect     | Short Description          | Unit         | Treatment T300+D   | Control            | Control            | Uncertainties/ Strength of evidence                                    | Re f   |
|------------|----------------------------|--------------|--------------------|--------------------|--------------------|------------------------------------------------------------------------|--------|
| Favourable | Effects                    |              | N=393              | Sorafenib N=389    | Durvalumab N=389   |                                                                        |        |
| OS         | Median overall survival    | Months 95%CI | 16.43 14.16; 19.58 | 13.77 12.25; 16.13 | 16.56 14.06; 19.12 | At 71% events, HR for T300+D vs S 0.78 (96.02%CI: 0.65; 0.93) P=0.0035 |        |
| PFS by INV | Progression- free survival | Months 95%CI | 3.78 3.68; 5.32    | 4.07 3.75; 5.49    | 3.65 3.19, 3.75    | Comparison was not formally tested; no BICR assessment                 |        |
| ORR        | Overall response rate      | %            | 20.1               | 5.1                | 17.0               | Comparison was not formally tested; no BICR assessment                 |        |

<div style=\"page-break-after: always\"></div>

| Effect               | Short Description                | Unit                 | Treatment            | Control              | Control              | Uncertainties/ Strength of evidence                                                                          | Re f                 |
|----------------------|----------------------------------|----------------------|----------------------|----------------------|----------------------|--------------------------------------------------------------------------------------------------------------|----------------------|
| Effect               | Short Description                | Unit                 | T300+D               | Sorafenib            | Durvalumab           | Uncertainties/ Strength of evidence                                                                          | Re f                 |
| DoR                  | Duration of response             | Months               | 22.34                | 18.43                | 16.82                |                                                                                                              |                      |
| Unfavourable Effects | Unfavourable Effects             | Unfavourable Effects | Unfavourable Effects | Unfavourable Effects | Unfavourable Effects | Unfavourable Effects                                                                                         | Unfavourable Effects |
| Any AE               | Any adverse event                | %                    | 97.4                 | 95.5                 | 90.0                 | Incidences from the Himalaya study, except for the Durvalumab monotherapy arm; which are from the HCC D pool |                      |
| Grade 3 or 4 AEs     | High-grade AEs                   | %                    | 50.5                 | 52.4                 | 38.2                 | Incidences from the Himalaya study, except for the Durvalumab monotherapy arm; which are from the HCC D pool |                      |
| Grade 5 AEs          | AEs leading to death             | %                    | 7.7                  | 7.2                  | 6.1                  | Incidences from the Himalaya study, except for the Durvalumab monotherapy arm; which are from the HCC D pool |                      |
| SAEs                 | Serious AEs                      | %                    | 40.5                 | 29.7                 | 32.7                 | Incidences from the Himalaya study, except for the Durvalumab monotherapy arm; which are from the HCC D pool |                      |
| AEs disc.            | AEs leading to dis- continuation | %                    | 13.7                 | 16.8                 | 9.6                  | Incidences from the Himalaya study, except for the Durvalumab monotherapy arm; which are from the HCC D pool |                      |
| ImAEs                | Immune- mediated AEs             | %                    | 36.1                 | 7.5                  | 16.5                 | Incidences from the HCC pool for T300+D group                                                                |                      |
| ImAEs                | Hepatic events                   | %                    | 7.4                  | NA                   | 1.6                  | Incidences from the HCC pool for T300+D group                                                                |                      |
| ImAEs                | Diarrhoea/ colitis               | %                    | 6.5                  | NA                   | 1.4                  | Incidences from the HCC pool for T300+D group                                                                |                      |

Abbreviations: OS: Overall survival; PFS: Progression free survival; INV: Investigator; ORR: Objective response rate; DoR: Duration of response; AE: Adverse event; SAE: Serious adverse event; ImAEs: Immune-mediated adverse events; HCC: hepatocellular carcinoma; BICR: Blinded independent central review.

## 3.7. Benefit-risk assessment and discussion

## 3.7.1. Importance of favourable and unfavourable effects

The proposed dosing regimen of tremelimumab + durvalumab provides a statistically significant and clinically meaningful survival benefit compared to the current standard of care, sorafenib, in a head-tohead  comparison  from  the  pivotal  Himalaya  study,  in  a  population  of  patients  with  unresectable hepatocellular carcinoma, who had not received prior systemic treatment. The ORR was also significantly improved; however, the magnitude of patients who had an objective response with T300+D is still low (~20%).  The  few  objective  responses  were  durable  (~22  months),  which  is  considered  clinically significant. Hence, the efficacy of T300+D in the first-line setting could be considered shown.  Supportive evidence for the application comes from Study 22, which compared T300+D to durvalumab monotherapy in the 2L+ setting.

The safety profiles of T300+D versus sorafenib are distinct as they have different mechanisms of action (immune checkpoint inhibition vs TKI) and the toxicity does not seem worse than sorafenib regarding grade 3 or 4 AEs (50.5% vs 52.4%), AEs leading to discontinuation (13.7% vs 16.8%), and AEs leading to death (7.7% vs 7.2%) as reported in the pivotal Himalaya study. The safety profile of tremelimumab in  combination  with  durvalumab  in  the  HCC  setting  is  serious  and  has  to  be  weighed  against  the seriousness  of  palliative  setting  and  individual  patient  (ECOG  status,  age,  comorbidities).  This  is  of particular importance since a significant proportion of the immune-mediated adverse events observed with the T300+D regimen were serious (e.g. diarrhoea/colitis, pancreatitis and pneumonitis), expected

<div style=\"page-break-after: always\"></div>

to be less manageable and often require hospitalisation. Immune-mediated AEs have therefore been included as important identified risks in the list of safety concerns for durvalumab.

## 3.7.2. Balance of benefits and risks

The shown overall survival benefit and the safety profile of T300+D not worse than that of standard of care, sorafenib, support a positive benefit-risk balance in the first-line treatment setting of advanced, unresectable HCC.

## 3.7.3. Additional considerations on the benefit-risk balance

Not applicable

## 3.8. Conclusions

The overall benefit /risk balance of durvalumab + tremelimumab in the first line treatment of uHCC is positive.

## 4. Recommendations

## Outcome

Based on the review of the submitted data, the CHMP considers the following variation acceptable and therefore recommends by consensus the variation to the terms of the Marketing Authorisation, concerning the following change:

| Variation accepted   | Variation accepted                                                                                                             | Type    | Annexes affected   |
|----------------------|--------------------------------------------------------------------------------------------------------------------------------|---------|--------------------|
| C.I.6.a              | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | Type II | I and IIIB         |

Extension of indication to include IMFINZI in combination with tremelimumab for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (uHCC), based on final results from Study D419CC00002 (HIMALAYA); This was a randomized, open-label, multi-center phase III study of durvalumab and tremelimumab as first-line treatment in patients with unresectable hepatocellular carcinoma. As a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. In addition, the MAH took the opportunity to implement minor editorial changes in the SmPC and Package Leaflet. Version 8.1 of the RMP has also been submitted.

The variation leads to amendments to the Summary of Product Characteristics and Package Leaflet and to the Risk Management Plan (RMP).

## Amendments to the marketing authorisation

In view of the data submitted with the variation, amendments to Annex(es) I and IIIB and to the Risk Management Plan are recommended.

<div style=\"page-break-after: always\"></div>

## 5. EPAR changes

The EPAR will be updated following Commission Decision for this variation. In particular the EPAR module 8 \" steps after the authorisation \" will be updated as follows:

## Scope

Please refer to the Recommendations section above.

## Summary

Please refer to Scientific Discussion ' Imfinzi-II-45 ' .